Document:

<PAGE>

                                                                    Exhibit 10.1

                            ASSET PURCHASE AGREEMENT

                                     BETWEEN

                         XANODYNE PHARMACEUTICALS, INC.,

                                 AAIPHARMA INC.

                                       AND

                                 AAIPHARMA, LLC

                                 --------------

                             Dated as of May 6, 2005

<PAGE>

                                TABLE OF CONTENTS

                                                                            PAGE

Article I         DEFINITIONS..................................................1

         1.1      Certain Definitions..........................................1

         1.2      Terms Defined Elsewhere in this Agreement...................15

         1.3      Other Definitional and Interpretive Matters.................18

Article II        PURCHASE AND SALE OF ASSETS; ASSUMPTION OF LIABILITIES......18

         2.1      Purchase and Sale of Assets.................................19

         2.2      Licenses....................................................19

         2.3      Excluded Assets.............................................27

         2.4      Assumption of Liabilities...................................28

         2.5      Excluded Liabilities........................................28

         2.6      Cure Amounts................................................29

         2.7      Services Agreement, Manufacturing Agreement and
                  Odyssey Co-Development Agreement............................30

         2.8      Further Conveyances and Assumptions.........................30

         2.9      Bulk Sales Law..............................................30

Article III       CONSIDERATION...............................................30

         3.1      Consideration...............................................30

         3.2      Royalties on Lifecycle Products.............................31

         3.3      Products Option.............................................31

         3.4      Option on Purchaser Developed Products......................35

         3.5      Odyssey.....................................................37

         3.6      Disputed Statements.........................................38

         3.7      Closing Date Inventory Adjustment...........................39

         3.8      Adjustment for Excess Shipments.............................41

         3.9      Payment of Purchase Price...................................41

Article IV        CLOSING AND TERMINATION.....................................42

         4.1      Closing Date................................................42

         4.2      Deliveries by Sellers.......................................42

         4.3      Deliveries by Purchaser.....................................43

                                       i

<PAGE>

         4.4      Termination of Agreement....................................43

         4.5      Payment of Development Costs................................45

         4.6      Procedure Upon Termination..................................45

         4.7      Effect of Termination.......................................45

Article V         REPRESENTATIONS AND WARRANTIES OF SELLERS...................46

         5.1      Organization and Good Standing..............................46

         5.2      Authorization of Agreement..................................46

         5.3      Board Approval and Recommendation...........................47

         5.4      Conflicts; Consents of Third Parties........................47

         5.5      Financial Statements; Projections...........................47

         5.6      No Undisclosed Liabilities..................................48

         5.7      Absence of Certain Developments.............................49

         5.8      Taxes.......................................................49

         5.9      Title to Purchased Assets ..................................50

         5.10     Intellectual Property.......................................50

         5.11     Regulatory Status...........................................52

         5.12     Material Contracts..........................................54

         5.13     Labor.......................................................55

         5.14     Litigation..................................................55

         5.15     Compliance with Laws........................................55

         5.16     Environmental Matters.......................................55

         5.17     Insurance...................................................56

         5.18     Inventories.................................................56

         5.19     Customer....................................................56

         5.20     Product Warranty; Product Liability.........................57

         5.21     Financial Advisors..........................................57

         5.22     FDA Indications.............................................57

         5.23     Laboratory Notebooks........................................57

         5.24     No Other Representations and Warranties.....................57

Article VI        REPRESENTATIONS AND WARRANTIES OF PURCHASER.................58

         6.1      Organization and Good Standing..............................58

         6.2      Authorization of Agreement..................................58

                                       ii

<PAGE>

         6.3      Conflicts; Consents of Third Parties........................58

         6.4      Litigation..................................................59

         6.5      Financial Advisors..........................................59

         6.6      Financing...................................................59

Article VII       BANKRUPTCY COURT MATTERS....................................59

         7.1      Approval of Break-Up Fee and Expense Reimbursement..........59

         7.2      Bidding Procedures..........................................60

         7.3      Non-Solicitation Period.....................................61

         7.4      Bankruptcy Court Approval...................................61

Article VIII      COVENANTS...................................................62

         8.1      Access to Information.......................................62

         8.2      Permitted Sellers...........................................63

         8.3      Conduct of the Business Pending the Closing.................63

         8.4      Development of Darvocet-N XR and Lynxorb....................64

         8.5      Rejection of Contracts......................................65

         8.6      Consents....................................................65

         8.7      Regulatory Approvals........................................65

         8.8      Further Assurances..........................................67

         8.9      Non-Competition; Non-Solicitation; Confidentiality..........67

         8.10     Preservation of Records.....................................69

         8.11     Publicity...................................................70

         8.12     aaiPharma Name..............................................70

         8.13     Cooperation with Financing..................................70

         8.14     Returns, Rebates and Chargebacks............................70

         8.15     Adverse Experience Reporting and Product Complaints.........72

         8.16     Recalls.....................................................73

         8.17     Inventory...................................................73

         8.18     Financial Statements........................................73

         8.19     Differentiation of Products.................................74

         8.20     Resale Certificates.........................................74

         8.21     Enforcement of Rights.......................................74

         8.22     Laboratory Notebooks........................................74

                                      iii

<PAGE>

         8.23     Darvocet-N XR IDM...........................................74

Article IX        EMPLOYEES ..................................................75

         9.1      Employment..................................................75

         9.2      Indemnification.............................................75

Article X         CONDITIONS TO CLOSING.......................................75

         10.1     Conditions Precedent to Obligations of Purchaser............75

         10.2     Conditions Precedent to Obligations of Sellers..............76

         10.3     Conditions Precedent to Obligations of Purchaser and
                  Sellers.....................................................77

         10.4     Frustration of Closing Conditions...........................77

Article XI        INDEMNIFICATION.............................................77

         11.1     Survival of Representations and Warranties..................77

         11.2     Indemnification.............................................78

         11.3     Indemnification Procedures..................................79

         11.4     Limitations on Indemnification for Breaches of
                  Representations and Warranties..............................81

         11.5     Indemnity Escrows...........................................81

         11.6     Tax Treatment of Indemnity Payments.........................82

Article XII       TAXES.......................................................83

         12.1     Transfer Taxes..............................................83

         12.2     Prorations..................................................83

         12.3     Purchase Price Allocation...................................83

         12.4     Cooperation on Tax Matters..................................84

Article XIII      MISCELLANEOUS...............................................85

         13.1     Expenses....................................................85

         13.2     Specific Performance........................................85

         13.3     Submission to Jurisdiction; Consent to Service of Process...85

         13.4     Waiver of Right to Trial by Jury............................85

         13.5     Entire Agreement; Amendments and Waivers....................86

         13.6     Governing Law...............................................86

         13.7     Notices.....................................................86

         13.8     Severability................................................87

         13.9     Binding Effect; Assignment..................................87

                                       iv

<PAGE>

         13.10    Non-Recourse................................................88

         13.11    Time of Essence.............................................88

         13.12    Counterparts................................................88

Schedules

1.1(a)            Darvocet-N XR IDM, Darvocet-N XR Product and Lynxorb Product
1.1(b)            Inventory
1.1(c)            Knowledge of Sellers
1.1(d)            Marketed Products
1.1(e)            Marketing Authorizations
1.1(f)            Odyssey Patents and Odyssey Product
1.1(g)            Pipeline Products
1.1(h)            ProSorb Patents
1.1(i)            Purchased Contracts
1.1(j)            Purchased DMFs
1.1(k)            Purchased INDs
1.1(l)            Purchased Intellectual Property
2.7(i)            Additional Manufacturing Agreement Terms
2.7(ii)           Additional Services Agreement Terms
5.1               Good Standing
5.4(b)            Consents
5.5(c)            Exceptions to SEC Filings
5.7               Absence of Certain Developments
5.8               Taxes
5.9               Title to Purchased Assets
5.11              Regulatory Status
5.10              Intellectual Property
5.12              Material Contracts
5.14              Litigation
5.15              Compliance with Laws
5.16              Environmental Matters
5.17              Insurance
5.18              Inventory Estimate
5.19(a)           Customers
5.19(b)           Negative Customer Events
5.20              Product Warranty
5.21              Sellers Financial Advisors
6.5               Purchaser Financial Advisors
8.3               Conduct of the Business
8.5               Rejection of Contracts
8.14(a)(ii)       Returned Marketed Products
9.1               Employees
10.3(e)           Closing Consents

                                       v

<PAGE>

Exhibits

A                 Bill of Sale
B                 Assumption Agreement
C                 Indemnity Escrow Agreement
D                 Trademark Assignment Agreement
E                 Manufacturing Agreement Term Sheet
F                 Bidding Procedures
G                 Services Agreement Term Sheet
H                 Sale Order
I                 Bidding Procedures Order
J                 Product Transfer of Ownership Letters to the FDA

                                       vi

<PAGE>

                            ASSET PURCHASE AGREEMENT

                  ASSET PURCHASE AGREEMENT, dated as of May 6, 2005 (this
"Agreement"), between Xanodyne Pharmaceuticals, Inc., a Delaware corporation
("Purchaser"), aaiPharma Inc., a Delaware corporation ("Parent"), and aaiPharma,
LLC, a Delaware limited liability company ("LLC" and, together with Parent,
"Sellers").

                              W I T N E S S E T H:

                  WHEREAS, Sellers intend to commence chapter 11 cases in the
United States Bankruptcy Court for the District of Delaware (the "Bankruptcy
Court") (such cases, the "Chapter 11 Case") and shall be debtors-in-possession
under chapter 11 of title 11 of the United States Code, 11 U.S.C. Section 101 et
seq. (the "Bankruptcy Code");

                  WHEREAS, Sellers desire to sell, transfer and assign to
Purchaser or its designated Affiliate or Affiliates, and Purchaser desires to
(or to cause its designated Affiliate or Affiliates to) acquire and assume from
Sellers, pursuant to Sections 363 and 365 of the Bankruptcy Code, all of the
Purchased Assets and Assumed Liabilities, all as more specifically provided
herein; and

                  WHEREAS, certain terms used in this Agreement are defined in
Section 1.1;

                  NOW, THEREFORE, in consideration of the premises and the
mutual covenants and agreements hereinafter contained, the parties hereby agree
as follows:

                                   ARTICLE I

                                  DEFINITIONS

         1.1      Certain Definitions.

                  For purposes of this Agreement, the following terms shall have
the meanings specified in this Section 1.1:

                  "AAI DS" means AAI Development Services, a division of Parent.

                  "AAI IP" means all Intellectual Property owned and primarily
used by Sellers or their Affiliates in connection with any business other than
the Business, the Pipeline Products or the New Products, but exclusive of the
Purchased Intellectual Property.

                  "AAI Trademarks" means the trademarks "aaiPharma," "AAI
Development Services," and "AAI," the aaiPharma and AAI DS corporate logos and
the trade names of Sellers, including the words "AAI" and "AAI Development
Services"

<PAGE>

together with variations and derivatives thereof and any other logos, symbols,
trademarks, trade names or service marks of Sellers or their respective
Affiliates including, except for the licenses granted thereto, the ProSorb
Trademark, but excluding the Purchased Trademarks.

                  "Accountant" means an accounting firm of national reputation
(excluding each of Purchaser's and Sellers' respective regular outside
accounting firms) as may be mutually acceptable to Purchaser and Sellers;
provided, however, that in the event that Purchaser and Sellers are unable to
agree on such an accounting firm within ten (10) Business Days after the date
the Accountant is required to be engaged pursuant to Section 3.6, then Sellers
shall within ten (10) Business Days thereafter deliver to Purchaser a listing of
three other accounting firms of national reputation and Purchaser shall, within
ten (10) Business Days after receipt of such list, select one of such three
accounting firms as the Accountant.

                  "Affiliate" means, with respect to any Person, any other
Person that, directly or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, such Person, and
the term "control" (including the terms "controlled by" and "under common
control with") means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of such Person,
whether through ownership of voting securities, by contract or otherwise.

                  "Alternative Transaction" means (a) the sale (whether by stock
sale, merger, consolidation or otherwise) of all or a substantial portion of the
capital stock of Sellers, (b) the sale of all or any of the Purchased Assets
pursuant to the Bidding Procedures, or (c) a transaction or series of
transactions outside or independent of the Bidding Procedures that result in the
Sellers realizing not less than an aggregate of $75,000,000 in cash and/or fair
market value of debt and/or equity securities (such fair market value to be
determined by the Bankruptcy Court or, if Sellers shall not then be the subjects
of a Chapter 11 Case, then jointly by Sellers and Purchaser or, failing such
joint determination, by an independent nationally recognized investment banking
firm jointly selected by Sellers and Purchaser or, failing such joint selection,
by such an independent nationally recognized investment banking firm selected by
two other investment banking firms selected one each by Sellers and Purchaser)
from the sale or transfer of Purchased Assets, in each case to a Person other
than Purchaser, excluding the sale of Inventory in the Ordinary Course of
Business.

                  "ANDA" means an abbreviated new drug application.

                  "APAP" means acetaminophen.

                  "Applicable Laws" means all binding laws, treaties, statutes,
ordinances, decrees, rules, injunctions, writs, regulations, Orders,
authorizations and permits as all of the preceding may be in effect and
interpreted on the date of this Agreement, in each case relating to, or of any
Governmental Body having jurisdiction over, the Business the Purchased Assets,
the Licensed Assets, Sellers or Purchaser, as the case may be.

                                       2

<PAGE>

                  "Approval Motion" means the motion, acceptable to Purchaser in
its reasonable discretion, to be filed with the Bankruptcy Court by Sellers no
later than one (1) day following the commencement of the Chapter 11 Case seeking
approval of the (a) the Bidding Procedures Order (including the Bidding
Procedures) and (b) the Sale Order.

                  "Azathioprine ANDA" means ANDA 75-252.

                  "Azathioprine Copyrights" means Copyrights in all advertising,
marketing and promotional materials in any stage of development owned by Sellers
that are used or intended for use in connection with the Azathioprine Product.

                  "Azathioprine Know How" means all Know How necessary or useful
in connection with the Azathioprine Product.

                  "Azathioprine Product" means the 50 mg azathioprine product
marketed pursuant to the Azathioprine ANDA, including bioequivalents.

                  "Azathioprine Product Assets" means the Azathioprine ANDA,
Azathioprine Copyrights (but exclusive of any portions of advertising or
marketing and promotional materials describing the business of Sellers or
incorporating the AAI Trademarks and any variations thereof and related logos or
symbols), and the Azathioprine Know How.

                  "Bidding Procedures" means those bidding procedures set forth
in Exhibit F attached hereto.

                  "Bidding Procedures Order" means the order of the Bankruptcy
Court in the form attached hereto as Exhibit I, including such changes thereto
requested or approved by Purchaser in its reasonable discretion, which changes
shall in no event be adverse to Purchaser.

                  "Business" means the business of Sellers, as currently
conducted, of marketing, promoting, distributing, and selling the Marketed
Products, but excluding all other business of Sellers and their Affiliates,
including AAI DS.

                  "Business Day" means any day of the year on which national
banking institutions in New York are open to the public for conducting business
and are not required or authorized to close.

                  "Break-Up Fee" means the fee to be paid by Sellers to
Purchaser in accordance with the provisions of Section 7.1 hereof.

                  "Calcitriol ANDA" means ANDA 75-766.

                  "Closing Date Inventory" means the quantities of each item of
Inventory as of the Closing Date.

                                       3
<PAGE>

                  "Code" means the Internal Revenue Code of 1986, as amended.

                  "Contract" means any contract, agreement, indenture, note,
bond, loan, instrument, lease, commitment or other arrangement or agreement,
whether written or oral.

                  "Copyrights" means all copyrights, works of authorship, and
copyrightable works, and all registrations, applications, and renewals therefor.

                  "Darvocet-N Suspension Know How" means all Know How necessary
or useful in connection with the Darvocet-N Suspension Product and owned by
Sellers, which, for the avoidance of doubt, excludes any Know How licensed from
Eli Lilly and Company that is the subject of the Assignment, Transfer and
Assumption Agreement dated as of February 18, 2002 between NeoSan
Pharmaceuticals, Inc. and Eli Lilly and Company referenced on Schedule 1.1(i).

                  "Darvocet-N Suspension Product" means the product identified
as such in Schedule 1.1(a).

                  "Darvocet-N XR IDM" means the invention disclosure memorandum
identified in Schedule 1.1(a) and the invention described therein.

                  "Darvocet-N XR Know How" means all Know How necessary or
useful in connection with the Darvocet-N XR Product and owned by Sellers, which,
for the avoidance of doubt, excludes any Know How licensed from Eli Lilly and
Company that is the subject of the Assignment, Transfer and Assumption Agreement
dated as of February 18, 2002 between NeoSan Pharmaceuticals, Inc. and Eli Lilly
and Company referenced on Schedule 1.1(i).

                  "Darvocet-N XR Product" means the product identified as such
in Schedule 1.1(a).

                  "DEA" means the United States Drug Enforcement Administration.

                  "Derivative Darvocet Product" means the product identified as
such in Schedule 1.1(a).

                  "Derivative Lynxorb Product" means the product identified as
such in Schedule 1.1(a).

                  "Employee" means all individuals, as of the date hereof, who
are employed by Sellers in connection with the Business, together with
individuals who are hired in respect of the Business after the date hereof.

                  "Environmental Costs and Liabilities" means, with respect to
any Person, all liabilities, obligations, responsibilities, Remedial Actions,
losses, damages, punitive damages, consequential damages, treble damages, costs
and expenses (including all

                                       4
<PAGE>

reasonable fees, disbursements and expenses of counsel, experts and consultants
and costs of investigation and feasibility studies), fines, penalties, sanctions
and interest incurred as a result of any claim or demand by any other Person or
in response to any violation of Environmental Law, whether known or unknown,
accrued or contingent, whether based in contract, tort, implied or express
warranty, strict liability, criminal or civil statute, to the extent based upon,
related to, or arising under or pursuant to any Environmental Law, Environmental
Permit, order or agreement with any Governmental Body or other Person, which
relates to any environmental, health or safety condition, violation of
Environmental Law or a Release or threatened Release of Hazardous Materials.

                  "Environmental Law" means any applicable foreign, federal,
state or local statute, regulation, ordinance, rule of common law or other legal
requirement as now or hereafter in effect in any way relating to the protection
of human health and safety, the environment or natural resources, including,
without limitation, the Comprehensive Environmental Response, Compensation and
Liability Act (42 U.S.C. Section 9601 et seq.), the Hazardous Materials
Transportation Act (49 U.S.C. App. Section 1801 et seq.), the Resource
Conservation and Recovery Act (42 U.S.C. Section 6901 et seq.), the Clean Water
Act (33 U.S.C. Section 1251 et seq.), the Clean Air Act (42 U.S.C. Section 7401
et seq.) the Toxic Substances Control Act (15 U.S.C. Section 2601 et seq.), the
Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. Section 136 et
seq.), and the Occupational Safety and Health Act (29 U.S.C. Section 651 et
seq.), as each has been or may be amended and the regulations promulgated
pursuant thereto.

                  "Environmental Permit" means any Permit required by
Environmental Laws for the operation of the Business.

                  "Escrow Agent" means Wilmington Trust Company in its capacity
as Escrow Agent under the Indemnity Escrow Agreement.

                  "Excluded Contracts" means those Contracts of Sellers which
are not set forth in Schedule 1.1(i).

                  "Expense Reimbursement" means the reimbursement of Purchaser's
expenses to be paid by Sellers to Purchaser in accordance with the provisions of
Section 7.1 hereof.

                  "Extended Units" means the number of tablets, capsules, or
milliliters of liquid, as applicable, of the Marketed Products.

                  "FDA" means the United States Food and Drug Administration.

                  "Final Order" means any order or judgment which has not been
reversed, vacated, or stayed, and as to which (i) the time to appeal, petition
for certiorari, or move for a new trial, reargument, or rehearing has expired,
and as to which no appeal, petition for certiorari, or other proceedings for a
new trial, reargument, or rehearing shall then be pending, or (ii) if an appeal,
writ of certiorari, new trial, reargument, or rehearing thereof

                                       5
<PAGE>

has been sought, such order or judgment shall have been affirmed by the highest
court to which such order was appealed, or certiorari shall have been denied, or
a new trial, reargument, or rehearing shall have been denied or resulted in no
modification of such order, and the time to take any further appeal, petition
for certiorari or move for a new trial, reargument, or rehearing shall have
expired; provided, however, that the possibility that a motion under Rule 59 or
Rule 60 of the Federal Rules of Civil Procedure, or any analogous rule under the
Bankruptcy Rules, may be filed relating to such order shall not cause such order
to not be a Final Order.

                  "GAAP" means generally accepted accounting principles,
consistently applied in the United States in effect at the relevant time.

                  "Governmental Body" means any court (including the Bankruptcy
Court), tribunal, arbitrator (public or private), authority, agency, commission,
official or other instrumentality of the United States or any state, county,
city or other political subdivision thereof.

                  "Hazardous Material" means any substance, material or waste
that is regulated, classified, or otherwise characterized under or pursuant to
any Environmental Law as "hazardous," "toxic," "pollutant," "contaminant,"
"radioactive," or words of similar meaning or effect, including, without
limitation, petroleum and its by-products, asbestos, polychlorinated biphenyls,
radon, mold or other fungi, and urea formaldehyde insulation.

                  "HSR Act" means the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended.

                  "IDM" means invention disclosure memorandum.

                  "IMS" means IMS Health Inc.

                  "IMS National Sales Perspective" means the monthly audit
prepared by IMS and usually available 27 days after the closing of the month.
All available channels of distribution to be included.

                  "IMS Product Demand Average Value" means, with respect to each
Marketed Product, the three (3) month rolling average of the latest available
IMS National Sales Perspective data at the time of Closing in Extended Units
(prorated for any partial months) for such Marketed Product times the actual
monthly Net Selling Price for such Marketed Product.

                  "Included Books and Records" shall mean all of the books,
records, files, documents, information and correspondences (including Marketing
and Pricing Data) owned by either Seller or any of their Subsidiaries as of the
Closing Date necessary for, or to the extent solely related to, selling,
promoting, manufacturing, advertising, marketing or distributing the Products,
and necessary for, or to the extent related to, all other books, records, files,
documents, information and correspondences that are used in,

                                       6

<PAGE>

held for use in or intended to be used in, or that arise primarily out of, the
Business, Pipeline Products or New Products, including documents relating to
Products, services, Purchased Intellectual Property, personnel files for
Transferred Employees and all customer files and documents (including credit
information), supplier lists, records, literature and correspondences, but
excluding the Excluded Books and Records.

                  "Indebtedness" of any Person means, without duplication, (i)
the principal of and premium (if any) in respect of (A) indebtedness of such
Person for money borrowed and (B) indebtedness evidenced by notes, debentures,
bonds or other similar instruments for the payment of which such Person is
responsible or liable; (ii) all obligations of such Person issued or assumed as
the deferred purchase price of property, all conditional sale obligations of
such Person and all obligations of such Person under any title retention
agreement (but excluding trade accounts payable and other accrued liabilities
arising in the Ordinary Course of Business); (iii) all obligations of such
Person under leases required to be capitalized in accordance with GAAP; (iv) all
obligations of such Person for the reimbursement of any obligor on any letter of
credit, banker's acceptance or similar credit transaction; (v) the liquidation
value of all redeemable preferred stock of such Person; (vi) all obligations of
the type referred to in clauses (i) through (v) of any Persons for the payment
of which such Person is responsible or liable, directly or indirectly, as
obligor, guarantor, surety or otherwise, including guarantees of such
obligations; and (vii) all obligations of the type referred to in clauses (i)
through (vi) of other Persons secured by any Lien on any property or asset of
such Person (whether or not such obligation is assumed by such Person).

                  "Indemnity Escrow Agreement" means the Indemnity Escrow
Agreement to be dated as of the Closing Date by and among Sellers, Purchaser and
the Escrow Agent substantially in the form of Exhibit C hereto.

                  "Intellectual Property" means: (i) all patents and patent
applications, including continuations, divisionals, continuations-in-part,
re-examinations, extensions, and/or reissues or foreign counterparts of patent
applications and patents issuing thereon (collectively, "Patents"); (ii) all
trademarks, service marks, trade names, service names, brand names, trade dress
rights, logos, and corporate names and general intangibles of a like nature,
together with the goodwill associated with any of the foregoing, and all
applications, registrations, and renewals thereof (collectively, "Trademarks");
(iii) all Internet domain names; (iv) all Copyrights; and (v) all Know How.

                  "Intellectual Property Licenses" means (i) any grant to a
third Person of any right to use any of the Purchased Intellectual Property, and
(ii) any grant to Sellers of a right to use a third Person's Intellectual
Property rights which is necessary or useful for the use of any Purchased
Intellectual Property or the development, manufacture, use, sale, offer for
sale, distribution, marketing or promotion of Products.

                  "Inventory" means all inventory of finished Marketed Products
and propoxyphene bulk active ingredient owned by Sellers as of the Closing Date,
excluding all other active ingredients, raw materials, or work in progress. For
purposes of "Parent

                                       7
<PAGE>

Closing Date Inventory Adjustment Amount" and "Purchaser Closing Date Inventory
Adjustment Amount," "Inventory" means all items of inventory with an expiration
date of no less than six (6) months following the Closing Date for Schedule II
Marketed Products and with an expiration date of no less than twelve (12) months
following the Closing Date for all other Marketed Products and in quantities no
less than the minimum quantities set forth on Schedule 1.1(b).

                  "IRS" means the United States Internal Revenue Service.

                  "Know How" means any and all product specifications, product
formulations, compositions, product designs, plans, technology, ideas, concepts,
trade secrets, manufacturing and packaging processes, technical information,
expertise, skill, practice, inventions, procedures, manufacturing formulae,
manufacturing directions, manufacturing specifications, manufacturing validation
data, component specifications, test methods, preclinical, clinical, toxicology
and stability data, validation data of analytical methods and know how, whether
or not patentable.

                  "Knowledge of Sellers" means the actual knowledge, after due
inquiry, of the Persons listed on Schedule 1.1(c).

                  "Law" means any foreign, federal, state or local law
(including common law), statute, code, ordinance, rule, regulation or other
requirement (including the Bankruptcy Code).

                  "Legal Proceeding" means any judicial, administrative or
arbitral actions, suits, proceedings (public or private) or claims or any
proceedings by or before a Governmental Body.

                  "Liability" means any debt, loss, damage, adverse claim,
liability or obligation (whether direct or indirect, known or unknown, asserted
or unasserted, absolute or contingent, accrued or unaccrued, liquidated or
unliquidated, or due or to become due, and whether in contract, tort, strict
liability or otherwise), and including all costs and expenses relating thereto.

                  "Licensed Assets" means the Azathioprine ANDA and the Licensed
Intellectual Property.

                  "Licensed Intellectual Property" means the Azathioprine Know
How, the Azathioprine Copyrights, the ProSorb Know How, the ProSorb Patents, the
ProSorb Trademark, the Darvocet-N XR IDM and the Darvocet-N XR Patents.

                  "Lien" means any lien, pledge, mortgage, deed of trust,
security interest, claim, lease, charge, option, right of first refusal,
easement, proxy, voting trust or agreement, transfer restriction under any
shareholder or similar agreement, encumbrance or any other restriction or
limitation whatsoever.

                                       8
<PAGE>

                  "Lifecycle Products" means Pipeline Products, Derivative
Darvocet Products, and Derivative Lynxorb Products.

                  "Lynxorb Licensed Assets" means the ProSorb Patents, the
ProSorb Trademark and the ProSorb Know How.

                  "Lynxorb Know How" means all Know How necessary or useful in
connection with the Lynxorb Product other than the ProSorb Know How.

                  "Lynxorb Product" means the product identified in Schedule
1.1(a).

                  "Manufacturing Agreement" means the agreement between
Purchaser and Sellers to manufacture those Products identified on Schedule
2.7(i), in form and substance mutually agreed upon by each of Purchaser and
Sellers and containing the terms set forth on Schedule 2.7(i) and Exhibit E
attached hereto.

                  "Marketed Products" means those products identified as
currently marketed products on Schedule 1.1(d).

                  "Marketed Products Know How" means all Know How necessary or
useful in connection with the Marketed Products, except for the Azathioprine
Product.

                  "Marketing Authorizations" means those NDAs and ANDAs set
forth in Schedule 1.1(e).

                  "Marketing and Pricing Data" shall mean (i) copies of all
market research, marketing plans, media plans, advertising, promotional and
marketing books and records, customer lists, sales data, price lists, sales
training materials, and all other pricing, advertising and promotional
information owned by and in the possession or control of Sellers as of the
Closing Date and used solely in connection with the Marketed Products, and (ii)
originals of all Marketed Product labels and inserts and all films, artwork,
photography and other graphic materials related thereto, but excluding any such
items in clauses (i) and (ii) to the extent that (a) any Applicable Law
prohibits their transfer or disclosure to Purchaser or (b) any transfer or
disclosure to Purchaser thereof would subject Sellers to any contractual
liability.

                  "Material Adverse Effect" means (a) any event, change,
condition (financial or otherwise) or matter that, individually or in the
aggregate, results in or would be reasonably expected to result in a material
adverse effect on the Purchased Assets and the Licensed Assets taken as a whole;
(b) any written indication by the FDA that a factorial design study (being a
study in which the Darvocet-N XR Product is required to be compared against one
or more of its ingredients alone) will be required for FDA approval of the
Darvocet-N XR Product (it being understood that the results of bioequivalence
studies or the clinical trial results for the Darvocet-N XR Product shall not be
deemed to be a Material Adverse Effect); or (c) a material adverse effect on the
ability of Sellers to consummate the transactions contemplated by this Agreement
or perform their obligations under this Agreement or the Seller Documents,
excluding any

                                       9
<PAGE>

such effect to the extent resulting from or arising in connection with (i)
general economic or market changes or changes that generally affect businesses
of the same type as the Business, but only if, in each case, the Purchased
Assets or Licensed Assets are not disproportionately affected; (ii) the filing
of the Chapter 11 Case; or (iii) the public announcement of the transactions
contemplated hereunder. Any determination as to whether any event, change,
circumstance or effect has a Material Adverse Effect shall be made only after
taking into account all effective insurance coverages and third-party
indemnifications with respect to such event, change, circumstance or effect.
Purchaser acknowledges that Seller has ceased actively marketing and promoting
the Marketed Products through a sales force or otherwise and that the cessation
of such marketing and promotion shall not, in and of itself, constitute a
Material Adverse Effect.

                  "Modification" means, with respect to any item, any
modification, translation, conversion, compilation, upgrade or other derivative
version of, or change or addition to, such item. "Modified" and "Modify" shall
have corollary meanings.

                  "NDA" means a new drug application.

                  "Net Sales" means with respect to a Lifecycle Product or New
Product, as the case may be, the gross amount invoiced by a Permitted Seller of
such Lifecycle Product or New Product, to third Persons, less

                  (a)      trade, quantity and/or cash discounts actually
allowed;

                  (b)      discounts, refunds, rebates, chargebacks, retroactive
price adjustments and any other allowances, credits or payments which
effectively reduce the net selling price; and

                  (c)      actual Lifecycle Product or New Product returns and
allowances, as the case may be;

provided that in no event shall Net Sales equal less than zero. For the
avoidance of doubt, all licensing fees not based on product sales, milestone
payments and other similar payments derived from any sublicense, assignment or
transfer of the rights to sell or otherwise market a Lifecycle Product or New
Product, as the case may be, shall be deemed to be Net Sales. Net Sales shall be
determined from books and records maintained in accordance with GAAP and shall
be deemed to have been made as of the recorded sale date according to GAAP for
such product.

                  "Net Selling Price" means, with respect to a Marketed Product,
the gross amount invoiced by a Seller or a Subsidiary of a Seller for such
Marketed Product, to third Persons, less

                  (a)      trade, quantity and/or cash discounts actually
allowed;

                                       10
<PAGE>

                  (b)      discounts, refunds, rebates, chargebacks, retroactive
price adjustments and any other allowances, credits or payments (other than
commissions) which effectively reduce the net selling price; and

                  (c)      actual Marketed Product returns and allowances, as
the case may be.

                  "New Licensed Intellectual Property" means any Intellectual
Property necessary or useful in connection with a New Product that Purchaser has
elected to acquire under Section 3.3 other than the New Purchased Intellectual
Property associated with that New Product.

                  "New Purchased Intellectual Property" means any Intellectual
Property necessary or useful in connection with a New Product that Purchaser has
elected to acquire under Section 3.3 that does not have general applicability to
products other than the New Product.

                  "NSAID" means any non-steroidal anti-inflammatory drug.

                  "Odyssey Co-Development Agreement" means the co-development
agreement referenced in Section 3.5, in form and substance mutually agreed upon
by Purchaser and Sellers.

                  "Odyssey Ingredient" means the ingredient identified in
Schedule 1.1(f).

                  "Odyssey Know How" means all Know How necessary or useful in
connection with the Odyssey Product.

                  "Odyssey Patents" means those Patents set forth in Schedule
1.1(f).

                  "Odyssey Product" means the product identified in Schedule
1.1(f).

                  "Order" means any order, injunction, judgment, decree, ruling,
writ, assessment or arbitration award.

                  "Ordinary Course of Business" means the ordinary and usual
course of normal day-to-day operations of the Business since January 1, 2005
through the date hereof.

                  "Pain Product" means a prescription pharmaceutical product for
which the FDA labeling in the Indication and Usage section of such product's
package insert could reasonably be expected to include the words "relief" or
"management" plus the word "pain."

                  "Parent Closing Date Inventory Adjustment Amount" means, with
respect to each item of Inventory, the product of (i) Sellers' actual cost of
such item of Inventory

                                       11
<PAGE>

and (ii) the difference between the quantities of such item of Inventory listed
in Schedule 1.1(b) and the quantities included in the Final Closing Date
Inventory.

                  "Permits" means any approvals, authorizations, consents,
licenses, permits or certificates.

                  "Permitted Seller" means Purchaser and its Affiliates and any
assignee, licensee or sublicensee having the right to sell Marketed Products,
Lifecycle Products or New Products.

                  "Person" means any individual, corporation, partnership, firm,
joint venture, association, joint-stock company, trust, unincorporated
organization, Governmental Body or other entity.

                  "Pipeline Products" means those products identified as
pipeline products on Schedule 1.1(g).

                  "PK Study" means a pharmacokinetics study.

                  "Post-Signing Shipment Value" means, with respect to each
Marketed Product, the total monthly Extended Units (prorated for any partial
month) of such Marketed Product times the actual monthly Net Selling Price of
such Marketed Product shipped to a customer by or on behalf of either Seller
from the date hereof through and including the Closing Date, as reported by SPS
Cord.

                  "Product Registration Data" shall mean, to the extent solely
related to a Product and owned by and in the possession and control of Sellers
as of the Closing Date, the following (including electronic copies where no hard
copies exist): (i) all regulatory files relating thereto, other than the
Marketing Authorizations, Purchased DMFs and Purchased INDs, including, but not
limited to, any Permits (to the extent transferable), and minutes of meetings
and telephone conferences with the FDA, validation data, preclinical and
clinical studies and tests related to the applicable Product, and all audit
reports of clinical studies, plus all annual reports and safety reports
associated therewith, drug master files, FDA approvals for export, documents
relating to Phase IV studies and pediatric studies, and all correspondence with
the FDA regarding the marketing status of such applicable Product; and (ii) all
records maintained under current good manufacturing practices or other record
keeping or reporting requirements of the FDA, the DEA, the Occupational Safety
and Health Administration or any other Governmental Body, including, but not
limited to, FDA warning letters, FDA Notices of Adverse Finding Letters, FDA
audit reports (including any comments on such reports), all other correspondence
and communications with regulatory agencies in connection with such Product
(including any advertising and promotion documents and 2253 forms), adverse
event files, complaint files and manufacturing records.

                  "Products" means the Marketed Products set forth in
Schedule 1.1(d), and the Pipeline Products set forth in Schedule 1.1(g).

                                       12
<PAGE>

                  "ProSorb Know How" means the Know How necessary or useful in
connection with the Lynxorb Product, which Know How has general applicability
beyond that product.

                  "ProSorb Patents" means the Patents set forth in Schedule
1.1(h).

                  "ProSorb Trademark" means the common law rights in the United
States to use the phrase "ProSorb" as a trademark and the rights arising under
the United States registration of the trademark for "ProSorb," registration
number 2,346,573.

                  "Purchased Contracts" means the Contracts set forth in
Schedule 1.1(i). Purchaser shall have the right, by written notice delivered to
Sellers at any time during the period from and after the date hereof and until
the Closing Date to delete any Contract from Schedule 1.1(i) (it being
understood that any such Contract deleted by Purchaser from such schedule may
subsequently be rejected by Sellers in the Chapter 11 Case and, if so rejected,
Purchaser shall reimburse Sellers for any administrative expenses incurred by
Sellers after the commencement of the Chapter 11 Case as a result of the
rejection of such Contract). Purchaser shall also have the right by written
notice delivered to Sellers at any time during the period from and after the
date hereof and until the Closing Date to add any Contract to Schedule 1.1(i)
that was not disclosed to Purchaser prior to the date hereof. Schedule 1.1(i)
also sets forth the estimated amounts (as of the date hereof) of all amounts
which Sellers expect will be payable pursuant to Section 365(b) of the
Bankruptcy Code on account of the assumption and assignment of any Purchased
Contract.

                  "Purchased DMFs" means those drug master files set forth in
Schedule 1.1(j).

                  "Purchased INDs" means those investigational new drug
applications set forth in Schedule 1.1(k).

                  "Purchased Intellectual Property" means all right, title, and
interest in and to the following Intellectual Property which is owned (and not
licensed) by Sellers: (i) all the Trademarks set forth on Schedule 1.1(l) (the
"Purchased Trademarks"); (ii) all the Internet domain names set forth on
Schedule 1.1(l) (the "Purchased Domain Names"); (iii) all the Copyrights in all
advertising, marketing, promotional and packaging materials relating to the
Products (other than the Azathioprine Copyrights), exclusive of any portions of
advertising, marketing, promotional and packaging materials describing the
business of Sellers or incorporating the AAI Trademarks and any variations
thereof and related logos or symbols (the "Purchased Copyrights"); (iv) all
Patents set forth in Schedule 1.1(l) (the "Purchased Patents"); (v) the Marketed
Product Know How; (vi) the Darvocet-N XR Know How; (vii) the Darvocet-N
Suspension Know How; and (viii) the Lynxorb Know How.

                  "Purchaser Closing Date Inventory Adjustment Amount" means,
with respect to each item of Inventory, the product of (i) Sellers' actual cost
of such item of

                                       13
<PAGE>

Inventory as of the Closing Date and (ii) the difference between the quantities
of such item of Inventory listed in Schedule 1.1(b) and the quantities included
in the Final Closing Date Inventory.

                  "Purchaser's Indemnity Escrow Amount" means $2,000,000.

                  "Purchaser's Indemnity Escrow Fund" means the Purchaser's
Indemnity Escrow Amount together with all interest or income actually earned
thereon pursuant to the Indemnity Escrow Agreement.

                  "Release" means any release, spill, emission, leaking,
pumping, injection, deposit, disposal, discharge, dispersal, or leaching into
the indoor or outdoor environment, or into or out of any property.

                  "Remedial Action" means all actions to (i) clean up, remove,
treat or in any other way remediate any Hazardous Material; (ii) prevent the
Release of any Hazardous Material so it does not endanger or threaten to
endanger public health or welfare or the indoor or outdoor environment; (iii)
perform pre-remedial studies and investigations or post-remedial monitoring and
care; or (iv) to correct a condition of noncompliance with Environmental Laws.

                  "Restructuring Transaction" means (a) a recapitalization
transaction involving, in whole or in part, Sellers and its existing security
holders or creditors, or (b) a transaction or series of transactions, including
by way of a plan of reorganization, in connection with a liquidation or
reorganization or other continuation of Seller's business relating to some or
all of the Purchased Assets.

                  "Sale Order" means the order of the Bankruptcy Court in the
form attached hereto as Exhibit H, including such changes thereto requested or
approved by Purchaser in its sole discretion.

                  "Sellers' Indemnity Escrow Amount" means $8,000,000.

                  "Sellers' Indemnity Escrow Fund" means the Sellers' Indemnity
Escrow Amount together with all interest or income actually earned thereon
pursuant to the Indemnity Escrow Agreement.

                  "Services Agreement" means the agreement to provide services
with respect to the Marketed Products, Purchaser Developed Products, Lifecycle
Products, and New Products, in form and substance mutually agreed upon by
Purchaser and Sellers and containing the terms set forth on Schedule 2.7(ii) and
Exhibit G attached hereto.

                  "Shipping Adjustment Amount" means the cash value of the
difference between the sum of the Post-Signing Shipment Values for all Marketed
Products minus the sum of the IMS Product Demand Average Values for all Marketed
Products, in the event that the sum of the Post-Signing Shipment Values is
greater than the sum of the IMS Product Demand Average Values.

                                       14
<PAGE>

                  "Split Lot" means any lot of Marketed Product that Sellers
have sold some, but not all, of the applicable Marketed Product in such lot
prior to the Closing Date.

                  "SPS Cord" means Cardinal Health 105, Inc. (formerly known as
Cord Logistics, Inc.), an Ohio corporation.

                  "Subsidiary" means any Person of which a majority of the
outstanding voting securities or other voting equity interests are owned,
directly or indirectly, by such Person.

                  "Tax" or "Taxes" means (i) any and all federal, state, local
or foreign taxes, charges, fees, imposts, levies or other assessments,
including, without limitation, all net income, gross receipts, capital, sales,
use, ad valorem, value added, transfer, franchise, profits, inventory, capital
stock, license, withholding, payroll, employment, social security, unemployment,
excise, severance, stamp, occupation, property and estimated taxes, customs
duties, fees, assessments and charges of any kind whatsoever, (ii) all interest,
penalties, fines, additions to tax or additional amounts imposed by any Taxing
Authority in connection with any item described in clause (i), and (iii) any
liability in respect of any items described in clauses (i) and/or (ii) payable
by reason of contract, assumption, transferee liability, operation of law,
Treasury Regulation section 1.1502-6(a) (or any predecessor or successor thereof
or any analogous or similar provision under law) or otherwise.

                  "Taxing Authority" means the IRS and any other Governmental
Body responsible for the administration of any Tax.

                  "Tax Return" means any return, report or statement required to
be filed with respect to any Tax (including any attachments thereto, and any
amendment thereof) including, but not limited to, any information return, claim
for refund, amended return or declaration of estimated Tax, and including, where
permitted or required, combined, consolidated or unitary returns for any group
of entities that includes the Sellers or any of their Subsidiaries.

                  "Territory" means worldwide.

                  "WARN" means the Worker Adjustment and Retraining Notification
Act of 1988, as amended.

         1.2      Terms Defined Elsewhere in this Agreement. For purposes of
this Agreement, the following terms have meanings set forth in the sections
indicated:

      Term                                              Section
      ----                                              -------

      AAI Packaging                                     8.12
      Agreement                                         Recitals
      Adjustment Deadline                               3.1

                                       15
<PAGE>

      Term                                              Section
      ----                                              -------

      Allocation Objection Notice                       12.3
      Allocation Response Period                        12.3
      Antitrust Division                                8.7(a)
      Antirust Laws                                     8.7(b)
      Asset Acquisition Statement                       12.3
      Assumed Liabilities                               3.1
      Audit Termination Date                            3.6(a)
      Balance Sheet                                     5.5(a)
      Balance Sheet Date                                5.5(a)
      Bankruptcy Code                                   Recitals
      Bankruptcy Court                                  Recitals
      Basket                                            11.4(a)
      Chapter 11 Case                                   Recitals
      Chargeback Termination Date                       8.14(c)
      Closing                                           4.1
      Closing Date                                      4.1
      Closing Date Inventory Statement                  3.7(a)
      Commitment Letters                                6.6
      Confidential Information                          8.9(d)
      Confidentiality Agreement                         8.9(d)
      Cure Amounts                                      2.6
      Cure Deadline                                     3.5(d)
      Darvocet-N XR Patents                             2.2(f)(ii)
      Development Costs                                 8.4
      Disclosing Party                                  8.9(d)
      Domain Name Transfer Agreement                    4.2(i)
      Excess Cure Amount                                2.6
      Exchange Act                                      5.5(c)
      Excluded Assets                                   2.3
      Excluded Books and Records                        2.3(d)
      Excluded Liabilities                              2.5
      Expenses                                          11.2(a)(vi)
      Final Closing Date Inventory                      3.7(e)
      Financial Statement of the Business               5.5(b)
      Financial Statements                              5.5(a)
      Five Year Period                                  3.3(c)
      FTC                                               8.7(a)
      Indemnification Claim                             11.3(a)
      Lifecycle Product Statement                       3.2
      LLC                                               Recitals
      Losses                                            11.2(a)(i)
      New Combo Product                                 3.3(b)
      New Internal Product                              3.3(c)
      New P/D Product                                   3.3(a)

                                       16
<PAGE>

      Term                                              Section
      ----                                              -------

      New Product                                       3.3(a)
      New Product Statement                             3.3(h)
      Net Cash Proceeds                                 3.5(b)
      Net Sale Proceeds                                 3.5(c)
      Net Sales Statement                               3.6(a)
      Non-Solicitation Period                           7.3(a)
      Notebooks                                         2.1(f)
      Parent                                            Recitals
      Parent Inventory Payment                          3.7(e)
      Patents                                           1.1 (in Intellectual
                                                          Property definition)
      Period of Election                                3.3(a)
      Post-Signing Shipments Statement                  3.8
      Purchased Assets                                  2.1
      Purchase Price                                    3.1
      Purchase Price Adjustment                         3.1
      Purchaser                                         Recitals
      Purchaser Developed Product                       3.3(b)
      Purchaser Documents                               6.2
      Purchaser Indemnified Parties                     11.2(a)
      Purchaser Inventory Payment                       3.7(e)
      Rebates Termination Date                          8.14(b)
      Recalls                                           8.16
      Receiving Party                                   8.9(d)
      Rejected Pain Products                            2.2(c)(ii)
      Restricted Business                               8.9(a)
      Restrictive Agreements                            8.21
      Revised Statements                                12.2
      SEC                                               5.5(c)
      Securities Act                                    8.18
      Sellers                                           Recitals
      Seller Documents                                  5.2
      Seller Indemnified Parties                        11.2(b)
      Seller Representatives                            7.3(a)
      Seven Year Period                                 3.3(a)
      Survival Period                                   11.1
      Ten Year Period                                   3.3(d)(i)
      Trademark Assignment Agreement                    4.2(b)
      Transferred Employees                             9.1(a)
      Transfer Taxes                                    12.1
      Unresolved Claims                                 11.5
      WAC                                               8.14(e)

                                       17
<PAGE>

         1.3      Other Definitional and Interpretive Matters

                  (a)      Unless otherwise expressly provided, for purposes of
this Agreement, the following rules of interpretation shall apply:

                  Calculation of Time Period. When calculating the period of
time before which, within which or following which any act is to be done or step
taken pursuant to this Agreement, the date that is the reference date in
calculating such period shall be excluded. If the last day of such period is a
non-Business Day, the period in question shall end on the next succeeding
Business Day.

                  Dollars. Any reference in this Agreement to $ means U.S.
dollars.

                  Exhibits/Schedules. The Exhibits and Schedules to this
Agreement are hereby incorporated by reference and made a part hereof and are an
integral part of this Agreement. All Exhibits and Schedules annexed hereto or
referred to herein are hereby incorporated in and made a part of this Agreement
as if set forth in full herein. Any capitalized terms used in any Schedule or
Exhibit but not otherwise defined therein shall be defined as set forth in this
Agreement.

                  Gender and Number. Any reference in this Agreement to gender
shall include all genders, and words imparting the singular number only shall
include the plural and vice versa.

                  Headings. The provision of a Table of Contents, the division
of this Agreement into Articles, Sections and other subdivisions and the
insertion of headings are for convenience of reference only and shall not affect
or be utilized in construing or interpreting this Agreement. All references in
this Agreement to any "Section" are to the corresponding Section of this
Agreement unless otherwise specified.

                  Herein. The words such as "herein," "hereinafter," "hereof,"
and "hereunder" refer to this Agreement as a whole and not merely to a
subdivision in which such words appear unless the context otherwise requires.

                  Including. The word "including" or any variation thereof means
"including, without limitation" and shall not be construed to limit any general
statement that it follows to the specific or similar items or matters
immediately following it.

                  (b)      The parties hereto have participated jointly in the
negotiation and drafting of this Agreement and, in the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as jointly drafted by the parties hereto and no presumption or burden of proof
shall arise favoring or disfavoring any party by virtue of the authorship of any
provision of this Agreement.

                                   Article II

             PURCHASE AND SALE OF ASSETS; ASSUMPTION OF LIABILITIES

                                       18
<PAGE>

         2.1      Purchase and Sale of Assets. On the terms and subject to the
conditions set forth in this Agreement, at the Closing Purchaser shall (or shall
cause its designated Affiliate or Affiliates to) purchase, acquire and accept
from Sellers, and Sellers shall (and shall cause its Subsidiaries to) sell,
transfer, assign, convey and deliver to Purchaser (or its designated Affiliate
or Affiliates) all of Sellers' right, title and interest in, to and under the
Purchased Assets, free and clear of all Liens, claims (as defined in Section
101(5) of the Bankruptcy Code) and interests. "Purchased Assets" means each of
the following assets:

                  (a)      the Purchased DMFs;

                  (b)      the Purchased INDs;

                  (c)      the Marketing Authorizations;

                  (d)      the Inventory;

                  (e)      the Purchased Intellectual Property;

                  (f)      subject to the terms of Section 8.22, copies of
laboratory notebooks to the extent relating to the Purchased Intellectual
Property and the Licensed Assets ("Notebooks"), it being understood that such
Notebooks are included in Excluded Assets other than the Purchaser's right to
receive copies thereof;

                  (g)      all rights of Sellers under the Purchased Contracts;

                  (h)      the Included Books and Records;

                  (i)      all rights of Sellers under non-disclosure or
confidentiality, non-compete, or non-solicitation agreements relating to
Transferred Employees;

                  (j)      the Calcitriol ANDA;

                  (k)      the Product Registration Data;

                  (l)      all goodwill associated with the Purchased Assets;
and

                  (m)      all amounts recoverable or recovered in connection
with Legal Proceedings relating to the Purchased Assets or Licensed Assets
commenced after the Closing Date, subject to Section 2.2(j).

         2.2      Licenses.

                  (a)      All the licenses granted in this Section 2.2 are
subject to the terms and conditions set forth herein and, in the case of the
licenses granted from Sellers to Purchaser, the terms and conditions set forth
in the Services Agreement and the Manufacturing Agreement.

                                       19
<PAGE>

                  (b)      Development Cross-License.

                           (i)      Purchaser to Sellers:

                                    (A) From and after the Closing Date,
                           Purchaser hereby grants to Sellers, and Sellers
                           accept, a worldwide, perpetual, irrevocable
                           royalty-free license to the Patents and Know How
                           contained within the Purchased Intellectual Property
                           and the New Purchased Intellectual Property to
                           develop any pharmaceutical products other than the
                           Darvocet-N XR Product or the Lynxorb Product.

                                    (B) The license granted in Section
                           2.2(b)(i)(A) is exclusive outside the field of Pain
                           Products and shall become exclusive for all products
                           other than Lifecycle Products at the end of the Seven
                           Year Period. It is otherwise nonexclusive.

                                    (C) Sellers shall use all reasonable efforts
                           to maintain the confidentiality of all confidential
                           Know How licensed under this Section 2.2(b) and shall
                           not disclose it to any third party other than as
                           reasonably warranted in connection with Sellers'
                           licensed development activities or sublicenses or
                           assignments as contemplated in Section 2.2(l) and in
                           any event pursuant to appropriate terms of
                           confidentiality.

                           (ii)     Sellers to Purchaser:

                                    (A) From and after the Closing Date, Sellers
                           hereby grant to Purchaser, and Purchaser accepts, a
                           worldwide irrevocable license to the Patents and Know
                           How contained within the Licensed Intellectual
                           Property and New Licensed Intellectual Property to
                           develop any pharmaceutical products in the field of
                           Pain Products. This license shall not include fields
                           to the extent and for the time covered by other
                           licenses granted in this Section 2.2 with the
                           intention of the parties being that after taking all
                           such licenses into account, Purchaser has the sum of
                           the license rights specified in all the relevant
                           sections but for each activity of Purchaser, only the
                           license most specific to that activity applies.

                                    (B) The license granted in Section
                           2.2(b)(ii)(A) shall expire at the end of the Seven
                           Year Period, except (x) as otherwise granted in this
                           Section 2.2, for which it shall survive; and (y) for
                           products that have reached the stage of development
                           by or for Purchaser of a prototype and dissolution
                           profile by the end of the Seven Year Period, as to
                           which specific products it will survive.

                                       20
<PAGE>

                                    (C) Purchaser shall have the right, upon
                           request, to receive a copy of any written or
                           electronic embodiments of Know How contained within
                           the Licensed Intellectual Property and New Licensed
                           Intellectual Property that are necessary or useful
                           for the development of Pain Products, provided that
                           Purchaser shall agree in writing to maintain the
                           confidentiality of such information pursuant to
                           appropriate terms of confidentiality; provided,
                           further, to the extent not precluded by agreements
                           between Sellers and third parties, Purchaser may
                           disclose confidential portions of such Know How to
                           third parties developing Pain Products on Purchaser's
                           behalf, under appropriate written terms of
                           confidentiality. Purchaser shall reimburse Sellers at
                           cost for such materials. All such copies will be
                           returned to Sellers at the end of the Seven Year
                           Period.

                  (c)      Exploitation License Back.

                           (i) Outside Field of Pain Products. From and after
         the Closing Date, Purchaser hereby grants to Sellers, and Sellers
         accept, a worldwide, exclusive, perpetual, royalty-free, transferable
         license to the Patents and Know How contained within the Purchased
         Intellectual Property and New Purchased Intellectual Property to make,
         have made, distribute, use, sell, offer to sell, have sold, market,
         co-market, import, promote and co-promote products other than Pain
         Products and Marketed Products.

                           (ii) Rejected Pain Products. From and after the
         Closing Date, Purchaser hereby grants to Sellers, and Sellers accept a
         worldwide, exclusive, perpetual, royalty-free, transferable license
         (with a right to sublicense without consent) to the Patents and Know
         How contained within the Purchased Intellectual Property and New
         Purchased Intellectual Property to make, have made, distribute, use,
         sell, offer to sell, have sold, market, co-market, import, promote and
         co-promote Pain Product(s) that under the terms of Sections 3.3(a)
         3.3(b) or 3.3(c), Sellers developed and Sellers offered to Purchaser,
         and that Purchaser declined ("Rejected Pain Products"), thereby
         entitling Sellers to market such Rejected Pain Product(s) themselves or
         through a licensee, in which case the license shall be exclusive but
         only as to the specific Rejected Pain Product(s) offered, provided that
         in the case of rejected New P/D Products, the license shall only be
         effective after the Seven Year Period.

                           (iii) Non-Offered Pain Products. Purchaser grants to
         Sellers an exclusive license under the Patents and Know How contained
         within the Purchased Intellectual Property and New Purchased
         Intellectual Property of scope equivalent to that granted under Section
         2.2(c)(ii) with respect to each product that under the terms of Section
         3.3, Sellers are entitled to develop and market without offering to
         Purchaser once such products have reached the stage of development of a
         prototype and dissolution profile upon delivery by Sellers of a

                                       21
<PAGE>

         written notice describing in reasonable detail the product that will be
         the subject of the exclusive license, provided that in no event will
         any license granted pursuant to this Section 2.2(c)(iii) under the
         Purchased Intellectual Property or New Purchased Intellectual Property
         restrict Purchaser's rights to any Product, any New Product Purchaser
         has elected to acquire under Section 3.3, any Derivative Lynxorb
         Product, any Derivative Darvocet Product, the Odyssey Product or any
         product that Purchaser is legally authorized to develop under the
         license granted in Section 2.2(b)(ii)(A). The scope of the exclusive
         license shall be automatically conformed to apply only to the specific
         product marketed once that product has reached final formulation.

                           (iv) Sellers shall use all reasonable efforts to
         maintain the confidentiality of all confidential Know How licensed
         under this Section 2.2(c) and shall not disclose it to any third party
         other than as reasonably warranted and pursuant to appropriate terms of
         confidentiality.

                  (d)      General License.

                           (i) Sellers hereby grant Purchaser a license under
         the Licensed Intellectual Property and New Licensed Intellectual
         Property to make, have made, distribute, use, sell, offer to sell, have
         sold, market, co-market, import, promote and co-promote any Pain
         Products. Purchaser covenants, however, not to make, have made,
         distribute, use, sell, offer to sell, have sold, market, co-market,
         import, promote or co-promote any Pain Products using the Licensed
         Intellectual Property or New Licensed Intellectual Property other than
         the Lynxorb Product (as to the Lynxorb Licensed Assets), Derivative
         Lynxorb Products (as to the Lynxorb Licensed Assets), Darvocet-N XR
         Product (as to the Darvocet-N XR Know How, the Darvocet-N XR IDM and
         the Darvocet-N XR Patents), Derivative Darvocet Products (as to the
         Darvocet-N XR Know How, the Darvocet-N XR IDM and the Darvocet-N XR
         Patents), Darvocet-N Suspension Product, any New Products that
         Purchaser has elected to acquire under Section 3.3 and any products
         that Purchaser is legally authorized to develop under the license
         granted in Section 2.2(b)(ii)(A).

                           (ii) Rejected Pain Products. The license granted in
         Section 2.2(d)(i) shall terminate with respect to Rejected Pain
         Products upon Sellers' entitlement to market a Rejected Pain Product,
         but only with respect to the particular Rejected Pain Product offered.

                           (iii) Non-Offered Pain Products. The license granted
         in Section 2.2(d)(i) shall terminate with respect to Pain Products that
         under the terms of Section 3.3 Sellers are entitled to develop and
         market without offering to Purchaser once such products have reached
         the stage of development of a prototype and dissolution profile upon
         delivery by Sellers of a written notice describing in reasonable detail
         the product that will be the subject of the termination, provided that
         in no event will the termination with respect to the

                                       22
<PAGE>

         Purchased Intellectual Property or New Purchased Intellectual Property
         restrict Purchaser's rights to any Product, any New Product Purchaser
         has elected to acquire under Section 3.3, any Derivative Lynxorb
         Product, any Derivative Darvocet Product, the Odyssey Product or any
         product that Purchaser is legally authorized to develop under the
         license granted in Section 2.2(b)(ii)(A). The scope of the termination
         shall be automatically conformed to apply only to the specific product
         marketed once that product has reached final formulation.

                  (e)      Lynxorb License.

                           (i) Sellers hereby grant to Purchaser, and Purchaser
         accepts a worldwide, exclusive, perpetual, transferable license under
         the Lynxorb Licensed Assets and New Licensed Intellectual Property
         necessary or useful for the Lynxorb Product or Derivative Lynxorb
         Products in order to develop, make, have made, distribute, use, sell,
         offer to sell, have sold, market, co-market, import, promote and
         co-promote the Lynxorb Product and Derivative Lynxorb Products, which
         license is irrevocable for all assets other than the ProSorb Trademark,
         but which as to the ProSorb Trademark may be terminated as set forth in
         Section -------- 2.2(e)(ii). For the avoidance of doubt, Sellers retain
         all rights to exploit the ProSorb Trademark for products other than
         with respect to the Lynxorb Product and Derivative Lynxorb Products and
         Purchaser is prohibited from exploiting its trademark rights under this
         Section 2.2(e)(i) except with respect to the Lynxorb Product and
         Derivative Lynxorb Products.

                           (ii) All uses by Purchaser, its Affiliates and their
         respective sublicensees and assigns of the ProSorb Trademark (whether
         on Lynxorb Products or Derivative Lynxorb Products, in marketing
         materials or otherwise) shall be in an appropriate manner, without
         jeopardizing the significance, distinctiveness or validity of such
         trademarks; shall use the designation "(R)" with such trademarks and
         labeled as a registered trademark of Parent; and shall only be in such
         form and manner as approved in writing by Sellers. Purchaser shall only
         use the ProSorb Trademark on products of high quality that do not
         tarnish, dilute or diminish the current value of such trademarks. All
         trademark rights from the use of the ProSorb Trademark by Purchaser,
         its Affiliates and their respective sublicensees and assigns will inure
         to the benefit of Sellers. Neither Purchaser, its Affiliates nor their
         respective sublicensees and assigns shall contest or challenge the
         validity of, or Sellers' ownership of, the ProSorb Trademark. All
         Lynxorb Products and Derivative Lynxorb Products and related marketing
         materials featuring the ProSorb Trademark must be manufactured,
         labeled, sold, distributed and advertised in accordance with all
         Applicable Laws. Once each calendar year upon the written request of
         Sellers, in order that Sellers can assure themselves of the maintenance
         of the above-described quality standards, Purchaser and its Affiliates
         will, and shall cause their respective sublicensees and assigns to: (i)
         provide to Sellers at cost (not to exceed $10.00) two (2) then-current
         production samples of each Lynxorb Product or Derivative Lynxorb
         Product featuring the ProSorb Trademark (with the current packaging) to
         the extent not

                                       23
<PAGE>

         manufactured by AAI DS, together with two (2) copies of all marketing
         materials, and (ii) permit Sellers to inspect the manufacturing process
         for each Lynxorb Product and Derivative Lynxorb Product not
         manufactured by AAI DS featuring the ProSorb Trademark upon five (5)
         Business Days prior notice, which inspection shall be scheduled during
         normal business hours. If Sellers reasonably determine that Purchaser
         has breached the provisions of this Section 2.2(e)(ii) with respect to
         the ProSorb Trademark and such breach is not materially cured within
         sixty (60) days after Purchaser's receipt of written notice thereof,
         Sellers may terminate the license granted in Section 2.2(e)(i) above
         with respect to the ProSorb Trademark subject to such violation
         immediately upon written notice to Purchaser.

                  (f)      Darvocet-N XR License.

                           (i) Sellers hereby grant to Purchaser, and Purchaser
         accepts a worldwide, exclusive, perpetual, irrevocable, transferable
         license under the Darvocet-N XR Know How, Darvocet-N XR IDM and New
         Licensed Intellectual Property necessary or useful for Darvocet-N XR
         Product or Derivative Darvocet Products in order to develop, make, have
         made, distribute, use, sell, offer to sell, have sold, market,
         co-market, import, promote and co-promote the Darvocet-N XR Product and
         Derivative Darvocet Products.

                           (ii) Sellers hereby grant to Purchaser, and Purchaser
         accepts a worldwide, exclusive, perpetual, irrevocable, transferable
         license under any patent that solely and exclusively relates to the
         Darvocet-N XR Product (the "Darvocet-N XR Patents") with respect to the
         full scope of rights provided by such patent.

                  (g)      Azathioprine Product License. Sellers hereby grant to
Purchaser, and Purchaser accepts a worldwide, exclusive, perpetual, irrevocable,
transferable license under the Azathioprine Product Assets in order to develop,
make, have made, distribute, use, sell, offer to sell, have sold, market,
co-market, import, promote and co-promote the Azathioprine Product. For the
avoidance of doubt, no right is granted hereunder to use the Azathioprine
Product Assets in connection with any dosages other than the 50 mg dose of the
Azathioprine Product.

                  (h)      Patent Prosecution.

                           (i) Platform Patents. Sellers shall prepare and file,
         at Sellers' expense, subject to the review and approval of Purchaser,
         one or more patent applications claiming the invention disclosed in the
         Darvocet-N XR IDM or as further developed to the final Darvocet-N XR
         Product. Once filed, prosecution of that patent application shall be
         under the control and the expense of Sellers. Purchaser agrees to
         coordinate with Sellers in the prosecution of those applications to
         ensure consistency with Sellers' other patent filing efforts regarding
         similar and "platform" inventions. Sellers shall give due consideration
         to Purchaser's input in the prosecution of these applications.

                                       24
<PAGE>

                           (ii) Lynxorb. Purchaser shall prepare and file, to
         the extent possible, at Purchaser's expense, subject to the review of
         Sellers, one or more patent applications claiming potentially
         patentable subject matter to the extent solely and directly related to
         the Lynxorb Product.

                           (iii) Other Licensed Patents. Sellers shall prepare
         and file, at Sellers' expense, to the extent practicable, subject to
         the review, but not approval, of Purchaser, all other patent
         applications that are contained within the Licensed Intellectual
         Property with a scope that allows at a minimum for protection of the
         final Darvocet-N XR Product and Lynxorb Product. Once filed,
         prosecution of these applications shall be under the control of and at
         the expense of Sellers. Sellers agree to coordinate with Purchaser in
         the prosecution of those applications to ensure consistency with
         Purchaser's other patent filing efforts and the development of the
         products acquired hereunder. Sellers shall give due consideration to
         Purchaser's input in the prosecution of these applications.

                           (iv) Purchaser Prosecution Rights. Sellers hereby
         appoint Purchaser its agent to file patent applications claiming the
         inventions contained within the Licensed Intellectual Property and
         prosecute such applications and any other patent applications contained
         within the Licensed Intellectual Property that solely pertain to Pain
         Products. Purchaser covenants, however, not to exercise its right to so
         file and prosecute while Sellers are making commercially reasonable
         efforts to file and prosecute such inventions.

                  (i)      Orange Book. Purchaser hereby agrees that if Sellers
request that any Patents contained in the Purchased Intellectual Property or New
Purchased Intellectual Property be listed in the Orange Book and such listing
would protect products of Sellers other than those acquired hereunder, it will
consent to such listing so long as it does not reasonably believe, in good
faith, that such listing would give rise to a claim of patent misuse. Sellers
hereby agree that if Purchaser requests that any Patents contained in the
Licensed Intellectual Property or New Licensed Intellectual Property be listed
in the Orange Book and such listing would protect products acquired hereunder,
it will consent to such listing so long as it does not reasonably believe, in
good faith, that such listing would give rise to a claim of patent misuse.

                  (j)      Third Party Infringement.

                           (i) If either party learns of any actual or
         threatened infringement, misappropriation, dilution, tarnishment, or
         unauthorized use of the Purchased Intellectual Property or Licensed
         Intellectual Property by any third Person, such party shall notify the
         other party of such infringement in writing. Either party shall have
         the right, but not the obligation, to take any action against such
         third Person to stop the same, or otherwise enforce Purchaser's rights
         in the Purchased Intellectual Property and Seller's rights in the
         Licensed Intellectual Property. If a party initiates suit as
         contemplated in this Section 2.2(j)(i), such party shall have the
         exclusive right to employ counsel of its own selection and to

                                       25
<PAGE>

         direct and control the litigation or any settlement thereof. The party
         that initiates suit shall notify the other party in writing. In the
         event either party initiates suit, (A) the other party shall cooperate
         in such action, (B) the other party shall have the right to retain
         separate counsel in connection with any such action (the costs of such
         separately-retained counsel at that party's expense, provided, that if
         the other party is a necessary party to such action, the costs of such
         separately retained counsel shall be at the expense of the party
         bringing the action), and (C) the party bringing the action shall
         reimburse the other party for all reasonable costs, attorneys' fees and
         other expenses incurred by the other party in connection with such
         action, including appropriate reimbursement for time of that party's
         personnel involved in discovery, trial and other related matters,
         except as provided in Section 2.2(j)(i)(B). Nothing herein shall be
         construed to prevent Sellers and Purchaser from taking action jointly
         in any infringement suit or other action with respect to the Purchased
         Intellectual Property.

                           (ii) Each party shall be entitled to any recovery of
         damages (including payments received in any settlement) resulting from
         a lawsuit brought solely in its own name and, in the event both Sellers
         and Purchaser are joint parties to any lawsuit, Sellers and Purchaser
         shall share in any recovery, after reimbursement of each party's
         expenses in connection with the action, including appropriate
         reimbursement for time of that party's personnel involved in discovery,
         trial and other related matters, in proportion to the expenses it
         incurred. Neither party may settle with an infringer in a manner which
         could reasonably be considered to negatively impact any rights of the
         other without the other's prior written approval, which approval shall
         not be unreasonably withheld or delayed.

                  (k)      Sellers agree that they will not, during or after the
term of this Agreement, in any way challenge the validity of the Purchased
Intellectual Property or Purchaser's ownership thereof. Purchaser agrees that if
Purchaser challenges the validity of the Licensed Intellectual Property,
Purchaser will pay Sellers' expenses in connection therewith.

                  (l)      Any license granted pursuant to this Section 2.2
shall be freely transferable and sub licensable, and may be assumed and/or
assigned in whole or in part without the consent of any Party, so long as the
transfer, sublicense, assumption and/or assignment is subject to the obligation
and restrictions contained in this Agreement.

                  (m)      Purchaser acknowledges and agrees that a breach of
Sections 2.2(d)(i) (second sentence) or 3.4(b) (last paragraph) would cause
irreparable damage to Sellers not compensable by monetary damages and that
Sellers will not have an adequate remedy at law. Therefore, Purchaser's
obligations under Section 2.2(d)(i) (second sentence) or 3.4(b) (last paragraph)
shall be enforceable by, and Sellers shall be entitled to seek, temporary,
preliminary and/or permanent equitable or injunctive relief (including a decree
of specific performance) from any court of competent jurisdiction, without the
necessity of posting bond. Sellers' remedies under this Section 2.2(m) shall,

                                       26
<PAGE>

however, be cumulative and not exclusive and shall be in addition to any other
remedies which any party may have under this Agreement or otherwise.

         2.3      Excluded Assets. Nothing herein contained shall be deemed to
transfer, assign or convey the Excluded Assets to Purchaser, and Sellers shall
retain all right, title and interest to, in and under the Excluded Assets.
"Excluded Assets" means each of the following assets:

                  (a)      the Excluded Contracts;

                  (b)      cash, cash equivalents, all prepayments (including
all prepayments made to third party manufacturers, suppliers and contractors),
deferred assets, refunds, credits or overpayments or other receivables for
Taxes;

                  (c)      all accounts receivable of Sellers;

                  (d)      all books and records to the extent related to or
constituting (i) human resources and any other employee-related files and
records for employees that are not Transferred Employees or any other books and
records Sellers are required by law to retain, (ii) original (but not copies of)
financial and accounting records; (iii) any tax files, returns, documents,
instruments, papers, books and records not related to the Purchased Assets or
Assumed Liabilities; (iv) original (but not copies of, to the extent relating to
the Purchased Intellectual Property and the Licensed Assets) laboratory
notebooks and (v) Excluded Assets or Excluded Liabilities (collectively, the
"Excluded Books and Records");

                  (e)      the AAI Trademarks;

                  (f)      the AAI IP;

                  (g)      all rights of Sellers under or pursuant to all
warranties, representations and guarantees made by suppliers, manufacturers and
contractors to the extent relating to Products sold by, or services provided to,
Sellers or to the extent affecting any Purchased Assets in respect of matters
occurring prior to the Closing Date;

                  (h)      any refund or credit of (i) Taxes that relate to the
Purchased Assets or the Assumed Liabilities attributable to any period or
portion thereof ending prior to the Closing Date, including any Taxes allocated
to Sellers pursuant to Section 12.2 and (ii) Taxes of Sellers that are not
Assumed Liabilities;

                  (i)      all deposits (including customer deposits and
security deposits for rent, electricity, telephone or otherwise) and prepaid
charges and expenses of Sellers and its Subsidiaries;

                  (j)      all amounts recoverable or recovered by Sellers or
their Affiliates in connection with any Legal Proceedings commenced prior to the
Closing Date, or after

                                       27
<PAGE>

the Closing Date to the extent not related to the Purchased Assets or the
Licensed Assets subject to Section 2.2(j).

                  (k)      all manufacturing and laboratory facilities;

                  (l)      all computers, software and office equipment,
personal property, furniture, fixtures and equipment;

                  (m)      all real estate and leasehold interests of Sellers;
and

                  (n)      all businesses of Sellers and their Affiliates other
than the Business.

         2.4      Assumption of Liabilities. On the terms and subject to the
conditions set forth in this Agreement, at the Closing Purchaser shall (or shall
cause its designated Affiliate or Affiliates to) assume, effective as of the
Closing, only the following liabilities of Sellers (collectively, the "Assumed
Liabilities"):

                  (a)      all Liabilities of Sellers under the Purchased
Contracts that arise out of or relate to the period on and after the Closing
Date;

                  (b)      all Liabilities for (i) Purchaser's portion of the
Transfer Taxes pursuant to Section 12.1 and (ii) Taxes that relate to the
Purchased Assets or the Assumed Liabilities for taxable periods (or portions
thereof) beginning on or after the Closing Date, including any Taxes allocated
to Purchaser pursuant to Section 12.2; and

                  (c)      all Liabilities relating to amounts required to be
paid by Purchaser hereunder.

         2.5      Excluded Liabilities. Notwithstanding anything in this
Agreement to the contrary, Purchaser shall not assume, and shall be deemed not
to have assumed, any Liabilities relating to the Business of Sellers or any
Affiliate of Sellers except as expressly provided in Section 2.4 hereof or
elsewhere in this Agreement, and Sellers and their Affiliates shall be solely
and exclusively liable with respect to all such Liabilities, other than the
Assumed Liabilities (collectively, the "Excluded Liabilities"), including
without limitation, those Liabilities set forth below:

                  (a)      all Liabilities in respect of any and all Products
sold and/or services performed by Sellers before the Closing Date, including
product liability claims;

                  (b)      all Environmental Costs and Liabilities, to the
extent arising out of or otherwise related to (i) the ownership or operation by
Sellers of the Business on or prior to the Closing Date, (ii) the manufacture by
Sellers' or their Subsidiaries at any time of the Products set forth in Exhibit
E and (iii) the Excluded Assets or any other real property presently or formerly
owned, operated, leased or otherwise used by Seller;

                                       28
<PAGE>

                  (c)      except to the extent specifically provided in
Article IX, all Liabilities arising out of, relating to or with respect to (i)
the employment or performance of services, or termination of employment or
services by Sellers or any of its Affiliates of any individual before the
Closing Date, (ii) workers' compensation claims against Sellers or any of their
Subsidiaries that relate to the period before the Closing Date, irrespective of
whether such claims are made prior to or after the Closing or (iii) any employee
benefit plan of Sellers or their Affiliates;

                  (d)      all Liabilities arising out of, under or in
connection with Contracts that are not Purchased Contracts and, with respect to
Purchased Contracts, Liabilities in respect of a breach by or default of Sellers
accruing under such Contracts with respect to any period prior to Closing and
all Cure Amounts;

                  (e)      all Liabilities arising out of, under or in
connection with any Indebtedness of Sellers or any of their Subsidiaries;

                  (f)      all Liabilities for (i) Sellers' portion of the
Transfer Taxes pursuant to Section 12.1, (ii) Taxes of Sellers that are not
Assumed Liabilities, (iii) Taxes that relate to the Purchased Assets or the
Assumed Liabilities for taxable periods (or portions thereof) ending before the
Closing Date, including any Taxes allocated to Sellers pursuant to Section 12.2,
and (iv) payments under any Tax allocation, sharing or similar agreement
(whether oral or written) with respect to which Sellers or any Affiliates are
liable;

                  (g)      all Liabilities in respect of any pending or
threatened Legal Proceeding, or any claim arising out of, relating to or
otherwise in respect of (i) the operation of the Business to the extent such
Legal Proceeding or claim relates to such operation prior to the Closing Date,
or (ii) any Excluded Asset; and

                  (h)      all Liabilities relating to amounts required to be
paid by Sellers hereunder.

         2.6      Cure Amounts. At Closing and pursuant to Section 365 of the
Bankruptcy Code, Sellers shall assume and assign to Purchaser the Purchased
Contracts. The cure amounts, as determined by the Bankruptcy Court, if any (the
"Cure Amounts"), necessary to cure all defaults, if any, and to pay all actual
or pecuniary losses that have resulted from such defaults under the Purchased
Contracts, shall be paid by Sellers, on or before Closing, and not by Purchaser
and Purchaser shall have no liability therefor. Notwithstanding the foregoing,
in the event the actual Cure Amounts for all Purchased Contracts required to be
paid by Sellers on the Closing Date in accordance with this Section 2.6 exceed
the aggregate of the estimated Cure Amounts set forth on Schedule 1.1(i) for
such Purchased Contracts (such excess, the "Excess Cure Amount") by $6,000,000
or more, then Purchaser may, by written notice to Sellers, elect to (i) pay the
amount by which the Excess Cure Amount exceeds $6,000,000 and/or (ii) cause
Sellers to reject any Purchased Contract or (iii) to the extent the failure to
assume the Purchased Contract would result in a Material Adverse Effect,
terminate this Agreement

                                       29
<PAGE>

in accordance with Section 4.4(f). If Purchaser elects to proceed pursuant to
clause (i) and/or (ii) above, then Sellers shall pay, in addition to the
aggregate Cure Amounts specified in Schedule 1.1(i), the first $6,000,000 of the
Excess Cure Amount.

         2.7      Services Agreement, Manufacturing Agreement and Odyssey
Co-Development Agreement. At the Closing, Purchaser and Sellers shall enter into
and deliver to each other the (i) Services Agreement, (ii) Manufacturing
Agreement and (iii) Odyssey Co-Development Agreement.

         2.8      Further Conveyances and Assumptions. From time to time
following the Closing, Sellers and Purchaser shall, and shall cause their
respective Affiliates to, execute, acknowledge and deliver all such further
conveyances, notices, assumptions, releases and acquaintances and such other
instruments, and shall take such further actions, as may be necessary or
appropriate to assure fully to Purchaser and its respective successors or
assigns, all of the properties, rights, titles, interests, estates, remedies,
powers and privileges intended to be conveyed to Purchaser under this Agreement
and the Seller Documents and to assure fully to Sellers and their Affiliates and
their successors and assigns, the assumption of the liabilities and obligations
intended to be assumed by Purchaser under this Agreement and the Seller
Documents, and to otherwise make effective the transactions contemplated hereby
and thereby.

         2.9      Bulk Sales Law. Purchaser hereby waives compliance by Sellers
with the requirements and provisions of any "bulk-transfer" Laws of any
jurisdiction that may otherwise be applicable with respect to the sale of any or
all of the Purchased Assets to Purchaser. Pursuant to Section 363(f) of the
Bankruptcy Code, the transfer of the Purchased Assets shall be free and clear of
any security interests in the Purchased Assets, including any Liens or claims
arising out of the bulk transfer laws, and the parties shall take such steps as
may be necessary or appropriate to so provide in the Sale Order.

                                  ARTICLE III

                                 CONSIDERATION

         3.1      Consideration. The aggregate consideration for the Purchased
Assets shall be (i) the payment by Purchaser to Seller, in the manner provided
in Section 3.9 hereof, of $170,000,000, less the Development Costs, if any (the
"Purchase Price"), provided that if the Closing Date does not occur within the
ninetieth (90th) day following the commencement of the Chapter 11 Case (the
"Adjustment Deadline"), the Purchase Price shall be reduced by $1,500,000 on
each weekly anniversary of the Adjustment Deadline prior to the Closing Date
(the "Purchase Price Adjustment"), provided that the Purchase Price Adjustment
shall not be applicable to any week (or portion thereof) after the Adjustment
Deadline in which (A) there shall be an uncured breach by Purchaser of covenant
or agreement contained in this Agreement which would result in a failure of a
condition set forth in Section 10.2 or 10.3 and all other conditions set forth
in Article X (other than conditions that by their nature are to be satisfied at
the Closing) to have been satisfied or (B) the waiting period under the HSR Act
shall not have expired or early

                                       30
<PAGE>

termination shall not have been granted; provided, further, that in no event,
shall the Purchase Price Adjustment exceed $6,000,000 in the aggregate, (ii) the
assumption by Purchaser of the Assumed Liabilities, and (iii) the payment by
Purchaser to Sellers of royalty payments pursuant to Section 3.2. Commencing on
the one hundred twentieth (120th) day following the commencement of the Chapter
11 Case and provided that the Closing Date has not yet occurred, Purchaser shall
have the right to terminate this Agreement pursuant to Section 4.4; provided,
however, that in the event Purchaser terminates this Agreement pursuant to
Section 4.4, Purchaser shall be paid the Expense Reimbursement on the first
(1st) Business Day after such termination and Purchaser shall remain entitled to
receive the Break-Up Fee in accordance with Section 7.1 upon the satisfaction of
the conditions set forth therein.

         3.2      Royalties on Lifecycle Products. From the Closing Date through
December 31, 2011, Purchaser shall pay to Parent royalties on the aggregate Net
Sales of the Lifecycle Products as follows:

                  (a)      0% of Net Sales under $25,000,000 per calendar
quarter,

                  (b)      5% of Net Sales between $25,000,000 and $50,000,000
per calendar quarter and

                  (c)      10% of Net Sales over $50,000,000 per calendar
quarter.

Within ten (10) Business Days after the end of each calendar quarter, Purchaser
shall provide to Parent a written statement (each, a "Lifecycle Products
Statement"), which shall set forth the aggregate Net Sales of the Lifecycle
Products for such quarter and the calculation of the corresponding royalty
payment. Purchaser shall pay to Parent such royalty payment reflected in such
Lifecycle Products Statement within twenty (20) Business Days after the end of
each calendar quarter.

         3.3      Products Option.

                  (a)      If at any time between the Closing Date and the
seventh (7th) anniversary of the Closing Date (the "Seven Year Period") Sellers
or any of their Subsidiaries develop to the stage of creation of a prototype and
dissolution profile any new Pain Product (a "New Product") that contains
propoxyphene and/or diclofenac (a "New P/D Product"), then Sellers shall, or
shall cause their Subsidiaries to, offer in writing to Purchaser prior to any
other Person the option for a sixty (60) day period (as such time period may be
extended as provided for in Section 3.3(e), the "Period of Election") to acquire
any such New P/D Product. Purchaser shall accept or reject such offer by Sellers
during the Period of Election. If Purchaser notifies Sellers in writing within
the Period of Election that Purchaser declines to exercise such option to
acquire any such New P/D Product, then Sellers shall not sell, license,
transfer, assign, convey or deliver such New P/D Product to any third party for
the remainder of the Seven Year Period; provided, however, that Purchaser
acknowledges that Sellers may continue to develop (but not commercialize) such
New P/D Product during the Seven Year Period.

                                       31
<PAGE>

                  (b)      If during the Seven Year Period Sellers or any of
their Subsidiaries develop to the stage of creation of a prototype and
dissolution profile any New Product that (i) does not contain propoxyphene
and/or diclofenac, and (ii) is an opioid/APAP combination or an opioid/NSAID
combination (a "New Combo Product"), then Sellers shall, or shall cause their
Subsidiaries to, offer in writing to Purchaser prior to any other Person the
option for a Period of Election to acquire any such New Combo Product. Purchaser
shall accept or reject such offer by Sellers during the Period of Election. If
Purchaser notifies Sellers in writing within this Period of Election that
Purchaser declines to exercise such option to acquire any such New Combo
Product, then Purchaser shall have no further rights with respect to the New
Combo Product, and Sellers shall have no further obligation to notify Purchaser
with respect to such New Combo Product and may continue to develop, make, have
made, distribute, use, sell, offer to sell, have sold, market, co-market,
import, promote and co-promote such New Combo Product or sublicense such New
Combo Product to a third party.

                  (c)      If at any time between the Closing Date and the
fifth (5th) anniversary of the Closing Date (the "Five Year Period") Sellers or
any of their Subsidiaries develop to the stage of creation of a prototype and
dissolution profile any New Product for their own internal business purpose and
not for any third party, and such New Product (i) does not contain propoxyphene
and/or diclofenac and (ii) is not an opioid/APAP combination or an opioid/NSAID
combination (a "New Internal Product"), then Sellers shall, or shall cause their
Subsidiaries to, offer in writing to Purchaser prior to any other Person the
option for a Period of Election to acquire any such New Internal Product.
Purchaser shall respond to such offer by Sellers during the Period of Election.
If Purchaser notifies Sellers that Purchaser declines to exercise such option to
acquire any such New Internal Product, then Purchaser shall have no further
rights with respect to the New Internal Product, and Sellers shall have no
further obligation to notify Purchaser with respect to such New Internal Product
and may continue to develop, make, have made, distribute, use, sell, offer to
sell, have sold, market, co-market, import, promote and co-promote such New
Internal Product or sublicense such New Internal Product to a third party.

                  (d)      If Purchaser notifies Sellers in writing that it
elects to acquire any New Product, within the applicable Period of Election,
pursuant to Sections 3.3(a), 3.3(b) or 3.3(c), then:

                           (i) Sellers will develop such New Product and, during
         the period of time between the commercial launch of such New Product
         and the tenth (10th) anniversary of such commercial launch (the "Ten
         Year Period"), Purchaser shall pay to Sellers or their Subsidiaries, as
         the case may be, the amounts specified in the Services Agreement in
         connection with the development of such New Product and royalties on
         the aggregate Net Sales of such New Product as follows:

                            (x)     7.5% of Net Sales up to and including
         $25,000,000 per calendar quarter, and

                                       32
<PAGE>

                            (y)     10% of the portion of Net Sales, if any,
         over $25,000,000 per calendar quarter;

         or

                           (ii) Sellers shall notify Purchaser within
         twenty (20) Business Days after their receipt of Purchaser's notice if
         Sellers are unable or unwilling to continue development and production
         of any such New Product, and Sellers shall promptly grant to Purchaser
         a license to utilize any and all intellectual property of Sellers
         necessary or useful to any such New Product to enable Purchaser to
         either develop such New Product internally or utilize a third party to
         develop such New Product, and during the Ten Year Period Purchaser
         shall pay to Sellers or their Subsidiary, as the case may be, royalties
         on the aggregate Net Sales of such New Product as follows:

                            (x)      3.75% of Net Sales up to and including
         $25,000,000 per calendar quarter, and

                            (y)      5% of the portion of Net Sales, if any,
         over $25,000,000 per calendar quarter;

provided that for each Derivative Darvocet Product and each Derivative Lynxorb
Product that Sellers develop and license to Purchaser in accordance with the
terms of this Section 3.3, Purchaser shall pay to Sellers or their Subsidiaries,
as the case may be, royalties pursuant to Section 3.2 prior to December 31, 2011
and royalties pursuant to Section 3.3(d)(i) from the period January 1, 2012
through the end of the Ten Year Period for that product. For each Derivative
Darvocet Product and each Derivative Lynxorb Product that Purchaser develops and
offer to Sellers and that Sellers decline in accordance with the terms of this
Section 3.3, or that Purchaser otherwise develops on its own, Purchaser shall
pay to Sellers or their Subsidiaries, as the case may be, royalties pursuant to
Section 3.2 prior to December 31, 2011 and royalties pursuant to Section
3.3(d)(ii) from the period January 1, 2012 through the end of the Ten Year
Period for that product.

                  (e)      Notwithstanding the foregoing, with regard to the
Period of Election for an option of Purchaser to acquire a New Product pursuant
to Section 3.3(a), Section 3.3(b) or Section 3.3(c), no Period of Election shall
expire less than six (6) months after the expiration of the Period of Election
for the immediately preceding New Product (if any) in the event that Purchaser
has exercised its option to acquire such immediately preceding New Product;
provided, however, that in the event that Purchaser has declined such
immediately preceding New Product, the Period of Election for the then-current
New Product shall expire sixty (60) days after the later of the date that
Purchaser declined such immediately preceding New Product and the date of
submission of the then-current New Product.

                  (f)      If Sellers or any of their Subsidiaries are
contracted to develop any New Product by and for any unaffiliated third party
and not for Sellers' own internal

                                       33
<PAGE>

business purpose, and such New Product (i) does not contain propoxyphene and/or
diclofenac and (ii) is not an opioid/APAP combination or an opioid/NSAID
combination, then Purchaser shall have no rights with respect to the New Product
and Sellers shall have no obligation to notify Purchaser with respect to such
New Product and may develop, make, have made, distribute, use, sell, offer to
sell, have sold, market, co-market, import, promote and co-promote such New
Product or sublicense such New Product to a third party.

                  (g)      To the extent Purchaser exercises an option under
this Section 3.3, if Purchaser notifies Sellers in writing that (y) it elects to
develop any such New Product internally or to utilize a third party to develop
such New Product and (z) it has determined that Sellers are or reasonably could
be impaired in their ability to perform in accordance with Section 3.3 in a
timely manner with respect to any such New Product, Sellers shall promptly grant
to Purchaser a license to utilize any and all intellectual property of Sellers
applicable to any such New Product to enable Purchaser to either develop such
product internally or utilize a third party to develop such product, and during
the Ten Year Period Purchaser shall pay to Sellers or their Subsidiaries, as the
case may be, royalties on the aggregate Net Sales of such New Product as
follows:

                           (i)      3.75% of Net Sales up to and including
         $25,000,000 per calendar quarter, and

                           (ii)     5% of the portion of Net Sales, if any, over
         $25,000,000 per calendar quarter.

                  (h)      Within ten (10) Business Days after the end of each
calendar quarter, Purchaser shall provide to Parent a written statement (each, a
"New Product Statement"), which shall set forth the aggregate Net Sales of each
such New Product for such calendar quarter and the calculation of the
corresponding royalty payment. Purchaser shall pay to Parent such royalty
payment reflected in such New Product Statement within twenty (20) Business Days
after the end of each calendar quarter.

                  (i)      With respect to each New Product that Purchaser
elects to acquire, all royalty payments by Purchaser with respect to such New
Product pursuant to this Section 3.3 shall be reduced by 50% upon the commercial
launch of a generic version of such New Product.

                  (j)      Upon submission of a notice that Purchaser elects to
acquire a New Product, Sellers shall immediately assign to Purchaser all New
Purchased Intellectual Property associated with the New Product.

                  (k)      In the event that Purchaser elects to acquire a New
Product pursuant to Section 3.3(a), Section 3.3(b) or Section 3.3(c), Purchaser
agrees to use commercially reasonable efforts to develop or have developed, as
applicable, market such New Product; provided, however, that Purchaser shall
have the right to terminate its license to such New Product provided that
Purchaser assigns back the New Purchased

                                       34
<PAGE>

Intellectual Property. If Purchaser terminates its license to such New Product,
then Purchaser shall have no further rights or obligations with respect to the
New Product (including, but not limited to, the obligation to market such New
Product), and Sellers may make, have made, distribute, use, sell, offer to sell,
have sold, market, co-market, import, promote and co-promote such New Product or
sublicense such New Product to a third party (subject to the restrictions
regarding New P/D Products during the Seven Year Period).

                  (l)      Sellers and Purchaser shall negotiate in good faith
the focus of Sellers' development efforts regarding the New Products that may be
submitted under this Section 3.3 for Purchaser's option, which negotiation is
anticipated to include the planned identity and order of the first several New
Products.

                  (m)      Notwithstanding anything herein to the contrary, any
Pain Product that has been developed to the state of creation of a prototype and
dissolution profile (i) prior to the date hereof, (ii) during the period of time
between the date hereof and the Closing Date, or (iii) after the Closing Date,
which is owned by Sellers or their Subsidiaries and has not been licensed to a
third party prior to the date hereof, shall be considered a New Product which
Sellers shall, or shall cause their Subsidiaries to, offer in writing to
Purchaser prior to any other Person the option for a Period of Election to
acquire any such New Product pursuant to Section 3.3(a), Section 3.3(b) or
Section 3.3(c), provided that such new Pain Product contains or does not
contain, as applicable, the chemical ingredients or compounds required by such
sections.

                  (n)      Notwithstanding anything herein to the contrary,
including this Section 3.3 and Section 8.9, this Agreement shall not prevent
Sellers or their Affiliates from providing any routine services to third
parties, where Sellers or their Affiliates are merely implementing such third
parties' instructions and Sellers or their Affiliates are not engaged in
providing formulating services to such parties or otherwise performing inventive
work (including conceiving inventions for the third party or reducing the third
party's inventions to practice). Illustrative examples of such non-precluded
routine services include (i) chemical structure analysis and elucidation of
compounds or chemicals independently provided by third parties (without
formulation by Sellers or their Affiliates) (ii) clinical supply manufacturing
on a contract basis of compounds or chemicals independently provided by third
parties; (iii) clinical studies; (iv) validation services with respect to
processes and methods; (v) regulatory services; (vi) method development; and
(vii) stability testing.

                  (o)      For the avoidance of doubt, the terms of Sellers'
right to develop New Products as set forth herein shall be subject to the
Services Agreement.

         3.4      Option on Purchaser Developed Products. If at any time during
the Seven Year Period Purchaser wants to internally develop, or wants to utilize
a third party to develop, any Pain Product containing (i) propoxyphene and/or
diclofenac or (ii) an opioid/APAP combination or an opioid/NSAID combination (a
"Purchaser Developed Product"), then Purchaser shall offer in writing to Sellers
prior to any other Person the

                                       35
<PAGE>

option for a Period of Election to develop any such Purchaser Developed Product.
Sellers shall respond to such offer by Purchaser during the Period of Election.
If Sellers notify Purchaser that Sellers decline to exercise such option to
develop any such Purchaser Developed Product, then Sellers shall have no further
rights with respect to the Purchaser Developed Product, and Purchaser shall have
no further obligation to notify Sellers with respect to such Purchaser Developed
Product and may develop, or may utilize a third party to develop, such Purchaser
Developed Product. If Seller notifies Purchaser in writing that it elects to
develop any Purchaser Developed Product within such Period of Election, then:

                  (a)      Sellers will develop such Purchaser Developed Product
and, during the Ten Year Period, Purchaser shall pay to Sellers or their
Subsidiaries, as the case may be, the amounts specified in the Services
Agreement in connection with the development of such New Product and royalties
on the aggregate Net Sales of such Purchaser Developed Product as follows:

                           (i)      7.5% of Net Sales up to and including
$25,000,000 per calendar quarter, and

                           (ii)     10% of the portion of Net Sales, if any,
over $25,000,000 per calendar quarter;

                  or

                  (b)      Sellers shall notify Purchaser within sixty (60)
Business Days after their receipt of Purchaser's notice if Sellers are unable or
unwilling to develop and produce any such Purchaser Developed Product; provided,
however, that Sellers shall have no right to any royalty payments with respect
to such Purchaser Developed Product pursuant to this Section 3.4(b).

                  Notwithstanding the foregoing, with regard to the Period of
Election for an option of Sellers to develop a Purchaser Developed Product
pursuant to this Section 3.4, no Period of Election shall expire less than six
(6) months after the expiration of the Period of Election for the immediately
preceding Purchaser Developed Product (if any) in the event that Sellers have
exercised their option to develop such immediately preceding Purchaser Developed
Product; provided, however, that in the event that Sellers have failed to elect
to develop such immediately preceding Purchaser Developed Product, the Period of
Election for the then-current Purchaser Developed Product shall expire sixty
(60) days after the end of the Period of Election in which Sellers failed to
make such election and the date of submission of the then-current Purchaser
Developed Product.

                  Purchaser covenants not to develop any pharmaceutical products
using the Patents and Know How contained within the Licensed Assets and
Purchased Assets during the Seven Year Period except with respect to Lifecycle
Products that Purchaser requested Sellers to develop and Sellers were unable or
unwilling to develop, in which case Purchaser may develop such Lifecycle
Products itself or retain a third party to do the

                                       36
<PAGE>

same using, in the case of Derivative Darvocet Products, the Darvocet-N Know How
and the Darvocet-N XR IDM and, in the case of Derivative Lynxorb Products, the
ProSorb Patents and the ProSorb Know How.

         3.5      Odyssey.

                  (a)      On the Closing Date, Purchaser and Sellers shall
enter into the Odyssey Co-Development Agreement for the development and
commercialization of the Odyssey Product. Pursuant to the Odyssey Co-Development
Agreement, Sellers shall grant to Purchaser an exclusive license to the Odyssey
Patents and Odyssey Know How for all pharmaceutical products containing the
Odyssey Ingredient as the sole active ingredient. The Odyssey Co-Development
Agreement shall further provide that Purchaser shall pay for all costs and
expenses relating to the development and commercialization of the Odyssey
Product, including costs arising from the defense and prosecution of the Odyssey
Patent application filed on May 26, 2004 and Odyssey Know How, in each case
solely as it relates to products containing the Odyssey Ingredient.

                  (b)      Each party shall retain fifty percent (50%) of any
cash proceeds from the development and commercial exploitation of the Odyssey
Product (net of Purchaser's and Sellers' aggregate costs and expenses incurred
in connection with the development and commercial exploitation of the Odyssey
Product) (the "Net Cash Proceeds").

                  (c)      If Purchaser and Sellers mutually agree to sell the
rights to the Odyssey Product, then each party shall retain fifty percent (50%)
of the sale proceeds (net of Purchaser's and Sellers' aggregate costs and
expenses incurred in connection with the development and commercial exploitation
of the Odyssey Product) (the "Net Sale Proceeds"). To the extent there is any
deferred consideration in such sale, including, but not limited to, milestone
payments and royalties, each party shall retain fifty percent (50%) of any such
deferred compensation.

                  (d)      Notwithstanding the foregoing, in the event that
Purchaser has not enrolled at least one (1) subject in a PK Study on or prior to
the later of six (6) months (i) from the Closing Date, or (ii) after the date
upon which delivery of the Odyssey Product formulation and clinical supply
thereof is made by Sellers to Purchaser, then thereafter Purchaser shall only
retain twenty-five percent (25%), rather than fifty percent (50%), of any of the
Net Sale Proceeds, deferred compensation and Net Cash Proceeds referred to in
Section 3.5(b) and Section 3.5(c); provided, however, that in the event that
Purchaser has enrolled at least one (1) subject in a PK Study on or prior to the
later of twelve (12) months (x) from the Closing Date or (y) after the date upon
which delivery of the Odyssey Product formulation and clinical supply thereof is
made (the "Cure Deadline"), Purchaser shall regain its right to receive fifty
percent (50%) by Sellers to Purchaser of any of the Net Sale Proceeds, deferred
compensation and Net Cash Proceeds referred to in Section 3.5(b) and Section
3.5(c); provided, further, however, if Purchaser fails to enroll at least one
(1) subject in a PK Study on or prior to the Cure Deadline, then Purchaser's
rights to the Odyssey Patents and Odyssey Know How shall revert to Parent,

                                       37
<PAGE>

provided that (notwithstanding such reversion) Purchaser shall retain the right
to receive twenty-five percent (25%), of any of the Net Sale Proceeds, deferred
compensation and Net Cash Proceeds referred to in Section 3.5(b) and Section
3.5(c) and Purchaser shall thereafter pay for all costs and expenses relating to
the development and commercialization of the Odyssey Product.

                  (e)      During any period Purchaser retains the rights to the
Odyssey Product in accordance with the foregoing, Purchaser shall pursue the
development and commercialization, including any litigation, relating to the
Odyssey Product and Purchaser shall bear all costs and expenses in connection
therewith; provided, however, that in the event that Parent determines in good
faith that Purchaser is not aggressively pursuing the development,
commercialization, and any litigation, Parent shall have the right, upon five
(5) Business Days written notice to Purchaser, to assume the pursuit of all or
any part of such development, commercialization, or litigation at Sellers'
costs.

                  (f)      Purchaser shall have the right to assign its rights
under the Odyssey Co-Development Agreement to a third party without consent,
provided that the third party agrees to be bound by the obligations of Purchaser
and perform Purchaser's obligations under that agreement. Purchaser may, at any
time, terminate the Odyssey Co-Development Agreement, in which case Purchaser
shall have no further obligations regarding the Odyssey Product or that
agreement, but shall also waive all rights it received under that agreement.

         3.6      Disputed Statements.

                  (a)      Purchaser will keep full and accurate books and
records relating to the performance required with respect to its obligations to
pay royalties under this Agreement and its Net Sales. For one (1) year after
receipt of a Lifecycle Products Statement or New Product Statement delivered
pursuant to Section 3.2 or Section 3.2(a) (each, a "Net Sales Statement"), as
applicable (the "Audit Termination Date"), Sellers shall have the right, during
regular business hours and upon reasonable advance notice, to have the books and
records of Purchaser relating to such Net Sales and royalty payments audited no
more frequently than once per year so as to verify the accuracy of Purchaser's
calculation of such Net Sales or royalty payment. If, upon the inspection of the
books and records of Purchaser, Sellers disagree with Purchaser's calculation of
Net Sales or royalty payments set forth in any Net Sales Statement, Sellers may,
prior to the expiration of the Audit Termination Date, deliver written notice to
Purchaser disagreeing with such calculation and setting forth Sellers'
calculation of such amount. Any such notice of disagreement shall specify those
items or amounts as to which Sellers disagree, and Sellers shall be deemed to
have agreed with all other items and amounts contained in the Net Sales
Statement and the calculation of Net Sales included in such Net Sales Statement.
If Sellers do not deliver to Purchaser a written notice of disagreement prior to
the expiration of the Audit Termination Date, then Sellers shall be deemed to
have agreed to such Net Sales Statement.

                                       38
<PAGE>

                  (b)      If a notice of disagreement shall be duly delivered
pursuant to Section 3.6(a), Purchaser and Sellers shall, during the ten (10)
Business Days following such delivery, use their commercially reasonable efforts
to reach agreement on the disputed items or amounts in order to determine, as
may be required, the amount of Net Sales of the Lifecycle Products, or New
Products, as applicable, and the royalty payments in connection therewith, which
amount shall not be less than the amount thereof shown in Purchaser's
calculation set forth in the Net Sales Statement nor more than the amount
thereof set forth in Sellers' calculation delivered pursuant to Section 3.6(a).
If during such period, Purchaser and Sellers are unable to reach such agreement,
they shall promptly thereafter cause the Accountant to review this Agreement and
the disputed items or amounts for the purpose of calculating Net Sales of the
Lifecycle Products, or New Products, as applicable, and the amount of the
royalty payments in connection therewith included in such Net Sales Statement
(it being understood that in making such calculation, the Accountant shall be
functioning as an expert and not as an arbitrator). In making such calculation,
the Accountant shall consider only those items or amounts in the Net Sales
Statement and Sellers' calculation of Net Sales included in such Net Sales
Statement as to which Sellers have disagreed. The Accountant shall deliver to
Purchaser and Sellers, as promptly as practicable (but in any case no later than
twenty (20) Business Days from the date of engagement of the Accountant), a
report setting forth such calculation. Such report shall be final and binding
upon Purchaser and Sellers. The cost of such review and report shall be borne
equally by Purchaser on one hand and Sellers on the other hand; provided,
however, that if the Accountant's report is in agreement with either party's
calculations included in the Net Sales Statement, the cost of such review and
report shall be borne solely by the other party.

                  (c)      Purchaser and Sellers shall, and shall cause their
respective representatives to, cooperate and assist in the preparation of the
Net Sales Statement and the calculation of the amount of Net Sales of the
Lifecycle Products, or New Products, as applicable, and the amount of the
royalty payments in connection therewith and in the conduct of the review
referred to in this Section 3.6(a), including making available, to the extent
necessary, books, records, work papers and personnel.

                  (d)      If the amount of Net Sales of the Lifecycle Products,
or New Products, as applicable, and the royalty payments in connection
therewith, as determined by the Accountant pursuant to Section 3.6(a), is
greater than the calculation provided for by Purchaser in the applicable Net
Sales Statement, then Purchaser shall promptly pay to Parent an amount equal to
the difference between the Accountant's calculation of such royalty payments and
Purchaser's calculation of such royalty payments.

         3.7      Closing Date Inventory Adjustment.

                  (a)      As promptly as practicable, but no later than
sixty (60) days after the Closing Date, Purchaser shall cause to be prepared and
delivered to Sellers a statement calculating the Closing Date Inventory (the
"Closing Date Inventory Statement"), including copies of any and all back-up or
supporting data used in the preparation of the Closing Date Inventory Statement.

                                       39
<PAGE>

                  (b)      If Sellers disagree with Purchaser's calculation of
the Closing Date Inventory delivered pursuant to Section 3.7(a), Sellers may,
within ten (10) Business Days after delivery of the Closing Date Inventory
Statement, deliver a written notice to Purchaser disagreeing with such
calculation and setting forth Sellers' calculation of the Closing Date
Inventory. Any such notice of disagreement shall specify those items or amounts
as to which Sellers disagree, and Sellers shall be deemed to have agreed with
all other items and amounts contained in the Closing Date Inventory Statement
and the calculation of Closing Date Inventory delivered pursuant to Section
3.7(a). If Sellers do not deliver to Purchaser a written notice of disagreement
within such ten (10) Business Day period, then Sellers shall be deemed to have
agreed to such the Closing Date Inventory Statement.

                  (c)      If a notice of disagreement shall be duly delivered
pursuant to Section 3.7(b), Purchaser and Sellers shall, during the ten (10)
Business Days following such delivery, use their commercially reasonable efforts
to reach agreement on the disputed items or amounts in order to determine, as
may be required, the Closing Date Inventory. If during such period, Purchaser
and Sellers are unable to reach such agreement, they shall promptly thereafter
cause the Accountant to review this Agreement and the disputed items or amounts
for the purpose of calculating Closing Date Inventory. In making such
calculation, the Accountant shall consider only those items or amounts in the
Closing Date Inventory Statement and Sellers' calculation of Closing Date
Inventory as to which Sellers have disagreed. The Accountant shall deliver to
Purchaser and Sellers, as promptly as practicable (but in any case no later than
twenty (20) Business Days from the date of engagement of the Accountant), a
report setting forth such calculation. Such report shall be final and binding
upon Purchaser and Sellers. The cost of such review and report shall be borne
equally by Purchaser on one hand and Sellers on the other hand; provided,
however, that if the Accountant's report is substantially in agreement with
either party's calculations included in the Closing Date Inventory Statement,
the cost of such review and report shall be borne solely by the other party.

                  (d)      Purchaser and Sellers shall, and shall cause their
respective representatives to, cooperate and assist in the preparation of the
Closing Date Inventory Statement and the calculation of Closing Date Inventory
and in the conduct of the review referred to in this Section 3.7, including the
making available to the extent necessary of books, records, work papers and
personnel.

                  (e)      "Final Closing Date Inventory" means Closing Date
Inventory (i) as shown in Purchaser's calculation delivered pursuant to Section
3.7(a) if no notice of disagreement with respect thereto is duly delivered
pursuant to Section 3.7(b); or (ii) if such a notice of disagreement is
delivered, (A) as agreed by Purchaser and Sellers pursuant to Section 3.7(c) or
(B) in the absence of such agreement, as shown in the Accountant's calculation
delivered pursuant to Section 3.7(c). If the Final Closing Date Inventory does
not include each item of Inventory and in the minimum quantities listed in
Schedule 1.1(b), then Parent shall be obligated to pay to Purchaser an amount in
cash equal to the Purchaser Closing Date Inventory Adjustment Amount (the
"Purchaser Inventory Payment") within three (3) Business Days after the Final
Closing Date

                                       40
<PAGE>

Inventory is determined; provided, however, that if the Final Closing Date
Inventory reflects any item of Inventory in quantities exceeding the minimum
quantities listed in Schedule 1.1(b), then the Purchaser Inventory Payment shall
be offset by an amount equal to the Parent Closing Date Inventory Adjustment
Amount (the "Parent Inventory Payment"); provided, further, however, that if the
Parent Inventory Payment exceeds the Purchaser Inventory Payment, then Purchaser
shall not be entitled to the Purchaser Inventory Payment and Purchaser shall pay
to Parent, within three (3) Business Days after the Final Closing Date Inventory
is determined, an amount in cash equal to the amount that the Parent Inventory
Payment exceeds the Purchaser Inventory Payment. Any payment that any party is
obligated to make to the other party pursuant to this Section 3.7 shall be paid
by wire transfer of immediately available funds into an account designated by
such other party; provided, however, that such other party may (but shall not be
obligated to) elect, at any time, to withdraw the amount of any such payment
from the Purchaser's Indemnity Escrow Fund or the Sellers' Indemnity Escrow
Fund, as applicable.

         3.8 Adjustment for Excess Shipments. As promptly as practical, but no
later than sixty (60) days after the Closing Date, Sellers shall cause to be
prepared and delivered to Purchaser a statement calculating the Post-Signing
Shipment Values for each Marketed Product (the "Post-Signing Shipments
Statement"), including any and all back-up or supporting data used in the
preparation of the Post-Signing Shipments Statement. If the sum of the
Post-Signing Shipment Values of all of the Marketed Products is greater than the
sum of applicable IMS Product Demand Average Values, then the Sellers shall pay
to the Purchaser an amount in cash equal to the Shipping Adjustment Amount
within three (3) Business Days after the Post-Signing Shipment Statement is
delivered. Any payment Sellers are obligated to make to Purchaser pursuant to
this Section 3.8 shall be paid by Sellers by wire transfer of immediately
available funds into an account designated by Purchaser; provided, however, that
Purchaser may (but shall not be obligated to) elect, at any time, to withdraw
the amount of any such payment from the Sellers' Indemnity Escrow Fund.

         3.9      Payment of Purchase Price.

                  (a)      On the Closing Date, Purchaser shall pay the Purchase
Price (less Sellers' Indemnity Escrow Amount) to Sellers, which shall be paid by
wire transfer of immediately available funds into an account designated by
Sellers.

                  (b)      On the Closing Date, Purchaser, Sellers and the
Escrow Agent shall enter into the Indemnity Escrow Agreement and Purchaser shall
deliver to the Escrow Agent under the Indemnity Escrow Agreement, by wire
transfer of immediately available funds, Sellers' Indemnity Escrow Amount and
Purchaser's Indemnity Escrow Amount.

                                       41
<PAGE>

                                   ARTICLE IV

                             CLOSING AND TERMINATION

         4.1      Closing Date. Subject to the satisfaction of the conditions
set forth in Sections 10.1 and 10.2 hereof (or the waiver thereof by the party
entitled to waive that condition), the closing of the purchase and sale of the
Purchased Assets and the assumption of the Assumed Liabilities provided for in
Article II hereof (the "Closing") shall take place at the offices of Weil,
Gotshal & Manges LLP located at 767 Fifth Avenue, New York, New York 10153 (or
at such other place as the parties may designate in writing) at 10:00 a.m. (New
York City time) on a date to be specified by the parties, which date shall be no
later than the second (2nd) Business Day after satisfaction or waiver of the
conditions set forth in Article X (other than conditions that by their nature
are to be satisfied at the Closing, but subject to the satisfaction or waiver of
such conditions), unless another time or date, or both, are agreed to in writing
by the parties hereto. The date on which the Closing shall be held is referred
to in this Agreement as the "Closing Date." Unless otherwise agreed by the
parties in writing, the Closing shall be deemed effective and all right, title
and interest of Sellers to be acquired by Purchaser hereunder shall be
considered to have passed to Purchaser as of 12:01 a.m. (New York City time) on
the Closing Date.

         4.2      Deliveries by Sellers.  At the Closing, Sellers shall deliver
to Purchaser:

                  (a)      a duly executed bill of sale in the form of
Exhibit A hereto;

                  (b)      duly executed assumption agreement in the form of
Exhibit B hereto and duly executed assignments of the U.S. trademark
registrations and applications included in the Purchased Intellectual Property,
in the form attached hereto as Exhibit D (the "Trademark Assignment Agreement"),
and general assignments of all other Purchased Intellectual Property;

                  (c)      copies of all consents, waivers and approvals
referred to in Section 10.3(e);

                  (d)      duly executed affidavits of non-foreign status for
each Seller that comply with Section 1445 of the Code;

                  (e)      a copy of the Sale Order;

                  (f)      the officer's certificate required to be delivered
pursuant to Sections 10.1(a) and 10.1(b);

                  (g)      a duly executed Manufacturing Agreement;

                  (h)      a duly executed Services Agreement;

                                       42
<PAGE>

                  (i)      a duly executed domain name transfer agreement
substantially in a form and substance reasonably satisfactory to Purchase and
Sellers (the "Domain Name Transfer Agreement");

                  (j)      a duly executed Indemnity Escrow Agreement;

                  (k)      a duly executed Odyssey Co-Development Agreement;

                  (l)      product transfer of ownership letters to the FDA
substantially in the form attached hereto as Exhibit J; and

                  (m)      such other documents, instruments and certificates as
Purchaser may reasonably request.

         4.3      Deliveries by Purchaser. At the Closing, Purchaser shall
deliver to Seller:

                  (a)      the Purchase Price (less Sellers' Indemnity Escrow
Amount);

                  (b)      evidence of the wire transfers referred to in
Section 3.9 hereof;

                  (c)      a duly executed assumption agreement in the form
attached hereto as Exhibit B hereto;

                  (d)      the officer's certificate required to be delivered
pursuant to Sections 10.2(a) and 10.2(b);

                  (e)      a duly executed Manufacturing Agreement;

                  (f)      a duly executed Domain Name Transfer Agreement in a
form and substance reasonably satisfactory to Purchaser and Sellers;

                  (g)      a duly executed Trademark Assignment Agreement;

                  (h)      a duly executed Indemnity Escrow Agreement;

                  (i)      a duly executed Services Agreement;

                  (j)      a duly executed Odyssey Co-Development Agreement;

                  (k)      product transfer of ownership letters to the FDA
substantially in the form attached hereto as Exhibit J; and

                  (l)      such other documents, instruments and certificates as
Sellers may reasonably request.

         4.4      Termination of Agreement. This Agreement may be terminated
prior to the Closing as follows:

                                       43
<PAGE>

                  (a)      by mutual written consent of Sellers and Purchaser;

                  (b)      by Purchaser, if any of the conditions to the
obligations of Purchaser set forth in Sections 10.1 and 10.3 shall have become
incapable of fulfillment, other than as a result of a breach by Purchaser of any
covenant or agreement contained in this Agreement, and such condition is not
waived by Purchaser;

                  (c)      by Sellers, if any condition to the obligations of
Sellers set forth in Sections 10.2 and 10.3 shall have become incapable of
fulfillment, other than as a result of a breach by Sellers of any covenant or
agreement contained in this Agreement, and such condition is not waived by
Sellers;

                  (d)      by Sellers or Purchaser if there shall be in effect a
final nonappealable Order of a Governmental Body of competent jurisdiction
restraining, enjoining or otherwise prohibiting the consummation of the
transactions contemplated hereby; it being agreed that Sellers and Purchaser, as
the case may be, shall promptly appeal any adverse determination which is not
nonappealable (and Sellers and Purchaser, as the case may be, shall use their
commercially reasonable efforts to pursue such appeal);

                  (e)      by Purchaser, in accordance with Section 3.1;

                  (f)      by Purchaser, if there is a Material Adverse Effect;

                  (g)      by Purchaser or Sellers, if the Bankruptcy Court
approves a Restructuring Transaction or an Alternative Transaction;

                  (h)      by Purchaser, if Sellers have not commenced the
Chapter 11 Case within four (4) Business Days after the date hereof;

                  (i)      by Purchaser, if the Sellers have not filed with the
Bankruptcy Court the Approval Motion within one (1) Business Day after the date
of commencement of the Chapter 11 Case;

                  (j)      by Purchaser, if the Bidding Procedures Order has not
been entered by the Bankruptcy Court within thirty-five (35) days after the date
of commencement of the Chapter 11 Case;

                  (k)      by Purchaser, if the Sale Order has not been entered
by the Bankruptcy Court within seventy (70) days after the date of commencement
of the Chapter 11 Case;

                  (l)      by Purchaser, if the Bidding Procedures Order
(including the Bidding Procedures) or the Sale Order is modified in any respect
without the consent of Purchaser; provided, however, in the case of the Bidding
Procedures Order, Purchaser shall exercise its reasonable discretion, provided
that no such modification shall be adverse to Purchaser;

                                       44
<PAGE>

                  (m)      by Purchaser, if (i) the Bankruptcy Court enters an
order appointing a trustee, examiner with expanded powers or responsible officer
in the Chapter 11 Case, (ii) the Chapter 11 Case is converted to a case under
chapter 7 of the Bankruptcy Code or (iii) the Chapter 11 Case is dismissed;

                  (n)      by Purchaser, if Purchaser shall have sent written
notice to Sellers at least three (3) Business Days prior to the hearing to
approve the Bidding Procedures Order that the condition set forth in Section
10.1(d) has not been satisfied; or

                  (o)      by Purchaser, if any secured creditor of either
Seller obtains relief from the stay to foreclose on a significant portion of the
Purchased Assets or Licensed Assets, the effect of which would cause a Material
Adverse Effect.

         Notwithstanding the foregoing, if the Closing shall not have occurred
by the close of business on one hundred eighty (180) days after the date hereof,
this Agreement shall automatically terminate.

         4.5      Payment of Development Costs. If this Agreement is terminated,
Sellers shall pay to Purchaser the Development Costs, if any, on the fifth (5th)
Business Day after such termination, which payment obligation of Sellers shall
be an administrative priority expense under Sections 503(b) and 507(a)(1) of the
Bankruptcy Code. The payment by Sellers to Purchaser of the Development Costs
shall be in addition to the payment of the Expense Reimbursement and shall not
be included in the calculation of the Expense Reimbursement.

         4.6      Procedure Upon Termination. In the event of termination and
abandonment by Purchaser or Sellers, or both, pursuant to Section 4.4 hereof,
written notice thereof shall forthwith be given to the other party or parties,
and this Agreement shall terminate, and the purchase of the Purchased Assets
hereunder shall be abandoned, without further action by Purchaser or Sellers. If
this Agreement is terminated as provided herein each party shall redeliver all
documents, work papers and other material of any other party relating to the
transactions contemplated hereby, whether so obtained before or after the
execution hereof, to the party furnishing the same.

         4.7      Effect of Termination. In the event that this Agreement is
validly terminated as provided herein, then each of the parties shall be
relieved of its duties and obligations arising under this Agreement after the
date of such termination and such termination shall be without liability to
Purchaser or Seller; provided, however, that the obligations of the parties set
forth in Article XIII and Sections 4.6, 4.7 and 7.1 hereof shall survive any
such termination and shall be enforceable hereunder; provided, further, however,
that nothing in this Section 4.7 shall relieve Purchaser or Sellers of any
liability for a breach of this Agreement prior to the effective date of such
termination.

                                       45
<PAGE>

                                   ARTICLE V

                    REPRESENTATIONS AND WARRANTIES OF SELLERS

                  Sellers hereby, jointly and severally, represent and warrant
to Purchaser that:

         5.1      Organization and Good Standing.

                  Each Seller is duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all requisite power and
authority to own, lease and operate its properties and to carry on its business
as now conducted. Except as set forth in Schedule 5.1 each Seller is duly
qualified or authorized to do business as a foreign company and is in good
standing under the laws of each jurisdiction in which it owns or leases real
property and each other jurisdiction in which the conduct of its business or the
ownership of its properties requires such qualification or authorization, except
where the failure to be so qualified, authorized or in good standing would not
have a Material Adverse Effect. Each Seller has delivered to Purchaser true,
complete and correct copies of its certificate of incorporation and by-laws or
comparable organizational documents as in effect on the date hereof.

         5.2      Authorization of Agreement. Subject to obtaining Bankruptcy
Court approval pursuant to the Sale Order, Sellers have all requisite power,
authority and legal capacity to execute and deliver this Agreement and Sellers
and each of their Subsidiaries have all requisite power, authority and legal
capacity to execute and deliver each other agreement, document, or instrument or
certificate contemplated by this Agreement or to be executed by Sellers in
connection with the consummation of the transactions contemplated by this
Agreement (the "Seller Documents"), to perform their respective obligations
hereunder and thereunder and to consummate the transactions contemplated hereby
and thereby. Subject to obtaining Bankruptcy Court approval pursuant to the Sale
Order, the execution and delivery of this Agreement and the Seller Documents and
the consummation of the transactions contemplated hereby and thereby have been
duly authorized by all requisite corporate action on the part of Sellers and
each of their Subsidiaries. This Agreement has been, and each of the Seller
Documents will be at or prior to the Closing, duly and validly executed and
delivered by Sellers and each of their Subsidiaries which is a party thereto and
(assuming the due authorization, execution and delivery by the other parties
hereto and thereto) following the approval of this Agreement and the
transactions contemplated hereby by the Bankruptcy Court pursuant to the Sale
Order, this Agreement, constitutes, and each of the Seller Documents when so
executed and delivered will constitute, legal, valid and binding obligations of
Sellers, or, as the case may be, their Subsidiaries enforceable against Sellers
or, as the case may be, their Subsidiaries in accordance with their respective
terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium
and similar laws affecting creditors' rights and remedies generally, and
subject, as to enforceability, to general principles of equity, including
principles of commercial reasonableness, good faith and fair dealing (regardless
of whether enforcement is sought in a proceeding at law or in equity).

                                       46
<PAGE>

         5.3     Board Approval and Recommendation. The Board of Directors of
Parent has (i) determined that this Agreement and the transactions contemplated
hereby, including the purchase of the Purchased Assets by Purchaser in
accordance with the Bidding Procedures, are advisable, fair to and in the best
interests of the Sellers' chapter 11 estates, (ii) determined that an immediate
sale of the Purchased Assets pursuant to Section 363 of the Bankruptcy Code is
necessary to preserve the value of the Purchased Assets, and (iii) approved this
Agreement and the transactions contemplated hereby.

         5.4      Conflicts; Consents of Third Parties.

                  (a) Except as a result of the Chapter 11 Case, none of the
execution and delivery by Sellers of this Agreement or by Sellers of the Seller
Documents, the consummation of the transactions contemplated hereby or thereby,
or compliance by Sellers with any of the provisions hereof or thereof will
conflict with, or result in any violation of or default (with or without notice
or lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation or to loss of a material benefit
under, or give rise to any obligation of Sellers to make any payment under, or
to the increased, additional, accelerated or guaranteed rights or entitlements
of any Person under, or result in the creation of any Liens upon any of the
properties or assets of Sellers under any provision of (i) the certificate of
incorporation and by-laws or comparable organizational documents of Sellers or
any Subsidiary; (ii) subject to entry of the Sale Order, any Purchased Contract;
(iii) subject to entry of the Sale Order, any Order of any court, Governmental
Body or arbitrator applicable to Sellers or any Subsidiary or any of the
properties or assets of Sellers or any Subsidiary as of the date hereof; or (iv)
subject to entry of the Sale Order, any Applicable Law except as set forth on
Schedule 5.4(b).

                  (b)      Other than in connection with the commencement of the
Chapter 11 Case, entry of the Bidding Procedures Order and entry of the Sale
Order, no consent, waiver, approval, Order or authorization of, or declaration
or filing with, or notification to, any Person or Governmental Body is required
on the part of Sellers or any Subsidiary (i) in connection with the execution
and delivery of this Agreement or the Seller Documents, the compliance by
Sellers or any Subsidiary with any of the provisions hereof or thereof, the
consummation of the transactions contemplated hereby or the taking by Sellers or
any Subsidiary of any other action contemplated hereby, or (ii) for the
continuing validity and effectiveness immediately following the Closing of any
of the Purchased Assets or Licensed Assets, except for compliance with the
applicable requirements of the HSR Act or as set forth in Schedule 5.4(b).

         5.5      Financial Statements; Projections.

                  (a)      Sellers have delivered to Purchaser copies of the
audited consolidated balance sheets of Parent as at December 31, 2003 and 2004
and the related audited consolidated statements of income and of cash flows of
Parent for the fiscal years then ended (such audited statements, including the
related notes and schedules thereto, are referred to herein as the "Financial
Statements"). The Financial Statements have been

                                       47
<PAGE>

prepared in accordance with GAAP consistently applied and present fairly in all
material respects the consolidated financial position, results of operations and
cash flows of Parent as at the dates and for the periods indicated.

                  For the purposes hereof, the audited consolidated balance
sheet of Parent as at December 31, 2004 is referred to as the "Balance Sheet"
and December 31, 2004 is referred to as the "Balance Sheet Date."

                  (b)      Sellers have delivered to Purchaser the unaudited
statement of gross revenues, net revenues and direct costs of the Business for
the fiscal year ended December 31, 2004 and the interim period ended March 31,
2005 (collectively, the "Financial Statements of the Business"). The gross
revenues, net revenues and direct costs included in the Financial Statements of
the Business were prepared in accordance with Parent's applicable accounting
policies, which are consistent with and based upon GAAP, via Parent's compliance
with GAAP, and present fairly in all material respects the gross revenues, net
revenues and direct costs of the Business for the periods indicated.

                  (c)      Except as disclosed in Schedule 5.5(c), Parent has
made all required filings with the U.S. Securities and Exchange Commission (the
"SEC") since January 1, 2004 through the date hereof. Except as disclosed in
Schedule 5.5(c), to the Knowledge of Sellers, as of their respective dates, all
such filings complied as to form in all material respects with the requirements
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
rules and regulations of the SEC promulgated thereunder applicable to such SEC
filings, and such SEC filings did not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they
were made, not misleading. Except as disclosed in Schedule 5.5(c), to the
Knowledge of Sellers, the financial statements set forth in such SEC filings
comply as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC promulgated
under the Exchange Act, including Regulation S-X. Except as disclosed in
Schedule 5.5(c), to the Knowledge of Sellers, with respect to each Annual Report
on Form 10-K and each Quarterly Report on Form 10-Q included in such SEC
filings, the financial statements and other financial information included in
such reports fairly present in all material respects the financial condition and
results of operations of Parent as of, and for, the periods presented in the SEC
filings. The reports of Parent's independent auditors regarding Parent's
consolidated financial statements in the SEC filings have not been withdrawn,
supplemented or modified, and none of Parent or any of its Subsidiaries has
received any written communication from its independent auditors concerning any
such withdrawal, supplement or modification.

         5.6      No Undisclosed Liabilities. Except as disclosed in
Schedule 5.6, neither Sellers nor any of their Subsidiaries have any
Indebtedness, obligations or Liabilities of any kind related to the Business
other than those (i) fully reflected in, reserved against or otherwise described
in the Financial Statements or the notes thereto; (ii) immaterial to Sellers or
any Subsidiary and incurred in the Ordinary Course of Business since

                                       48
<PAGE>

December 31, 2004; or (iii) which would not have or would not reasonably be
expected to have a Material Adverse Effect.

         5.7      Absence of Certain Developments. Except as expressly
contemplated by this Agreement or as set forth in Schedule 5.7, since the
Balance Sheet Date (i) Sellers have conducted the Business only in the Ordinary
Course of Business and (ii) there has not occurred any Material Adverse Effect.
Except as set forth in Schedule 5.7, without limiting the generality of the
foregoing, since the Balance Sheet Date, with respect to only the Business,
Purchased Assets and Licensed Assets:

                           (i)      Sellers have not made or rescinded any
         election relating to Taxes or settled or compromised any claim, action,
         suit, litigation, proceeding, arbitration, investigation, audit or
         controversy relating to Taxes to the extent such election, settlement
         or compromise would have any material post Closing effect that would be
         binding on Purchaser for taxable periods (or portions thereof)
         beginning on or after the Closing Date;

                           (ii)     neither Sellers nor any Subsidiary has
         amended, modified, canceled, terminated, relinquished, waived or
         released any Purchased Contract or right except in the Ordinary Course
         of Business and which, in the aggregate, would not have a Material
         Adverse Effect;

                           (iii)    neither Sellers nor any Subsidiary has
         instituted or settled any material Legal Proceeding relating to the
         Purchased Assets or the Licensed Assets that would result in a Material
         Adverse Effect;

                           (iv)     Sellers have not granted any license or
         sublicense of any rights under or with respect to any Purchased
         Intellectual Property; or

                           (v)      Sellers have not agreed, committed, arranged
         or entered into any understanding to do anything set forth in this
         Section 5.7.

         5.8      Taxes.

                  (a)      With respect to the Business, the Purchased Assets
and the Licensed Assets, (i) all material Tax Returns required to be filed by or
on behalf of Sellers or any affiliated group of which Sellers are or were a
member have been duly and timely filed with the appropriate Taxing Authority in
all jurisdictions in which such Tax Returns are required to be filed (after
giving effect to any valid extensions of time in which to make such filings),
and all such Tax Returns are true, complete and correct in all material
respects; and (ii) all material Taxes payable by or on behalf of Sellers or any
Affiliated Group of which Sellers are or were a member have been fully and
timely paid.

                  (b)      Sellers have timely paid or caused to be paid all
Taxes due with respect to the Purchased Assets, Licensed Assets or the Business,
the non-payment of which would result in a Lien on any Purchased Asset or
Licensed Assets or would result in Purchaser becoming liable or responsible
therefor.

                                       49
<PAGE>

                  (c)      All deficiencies asserted or assessments made as a
result of any examinations by any Taxing Authority of the Tax Returns related to
the Purchased Assets, the Licensed Assets or the Business have been fully paid,
and, to the knowledge of Sellers, there are no other audits or investigations by
any Taxing Authority in progress, nor have Sellers received any written notice
from any Taxing Authority that it intends to conduct such an audit or
investigation related to the Purchased Assets or the Business.

                  (d)      There is no Purchased Contract covering any Person
that, individually or collectively, could give rise to the payment of any amount
that would not be deductible by Purchaser, Sellers or any of their respective
Affiliates by reason of Section 280G of the Code.

                  (e)      Neither Seller is a foreign person within the meaning
of Section 1445 of the Code.

                  (f)      No power of attorney with respect to any Tax matter
is currently in force with respect to the Purchased Assets, the Licensed Assets
or the Business that would, in any manner, bind, obligate, or restrict
Purchaser.

                  (g)      Sellers have not executed or entered into any
agreement with, or obtained any consents or clearances from, any Taxing
Authority, or have been subject to any ruling guidance specific to any Seller,
that would be binding on Purchaser for any taxable period (or portion thereof)
ending on or after the Closing Date.

         5.9      Title to Purchased Assets . Sellers own and have good title to
each of the Purchased Assets and the Licensed Assets, and at the Closing,
Sellers shall convey each of the Purchased Assets free and clear of all Liens.

         5.10     Intellectual Property.

                  (a)      Schedule 5.10 sets forth an accurate and complete
list of all Patents, registered Trademarks, pending applications for
registrations of any Trademarks, registered Copyrights, and pending applications
for registration of Copyrights, owned or filed by Sellers or any of their
Subsidiaries included in the Purchased Intellectual Property, including the
jurisdictions in which each such item has been issued or registered or in which
any such application for such issuance and registration has been filed.

                  (b)      To the actual knowledge of Sellers: (i) the Purchased
Intellectual Property does not; (ii) the manufacturing, licensing, importation,
offer for sale, sale, use, marketing, co-marketing, promotion and co-promotion
of the Marketed Products as such products are currently manufactured, licensed,
imported, offered for sale, sold, used, marketed, co-marketed, promoted and
co-promoted does not; (iii) the manufacturing, licensing, importation, offer for
sale, sale, use, marketing, co-marketing, promotion and co-promotion of the
Pipeline Products as they exist as of the date hereof will not; and (iv) the
manufacturing, licensing, importation, offer for sale, sale, use, marketing,
co-marketing, promotion and co-promotion of the Lynxorb Product and the
Darvocet-N

                                       50
<PAGE>

Suspension Product as they are currently contemplated to be developed will not
constitute an infringement, unauthorized use or misappropriation of any patent,
copyright, trademark, trade secret or other similar right, of any Person
(including, without limitation, pursuant to any non-disclosure agreements or
obligations to which Sellers or any of their present or former employees is a
party). To the actual knowledge of Sellers, the manufacturing, licensing,
importation, offer for sale, sale, use, marketing, co-marketing, promotion and
co-promotion of the Darvocet-N XR Product and the Odyssey Product as they each
are currently contemplated to be developed does not and will not constitute
infringement, unauthorized use or misappropriation of any copyright, trademark,
trade secret or similar non-patent right of any Person (including, without
limitation, pursuant to any non-disclosure agreements or obligations to which
Sellers or any of their present or former employees is a party). Subject to the
consents referred to in Section 5.4(b) being obtained for the Purchased
Contracts, the Purchased Intellectual Property, the Licensed Assets, the
Purchased Assets, and the transactions contemplated by the Manufacturing
Agreement and the Services Agreement include all of the Intellectual Property
rights necessary to enable Sellers to conduct the Business in the manner in
which such Business is currently being conducted as of the date hereof. The
consummation of the transactions contemplated hereby will not result in the loss
or impairment of Purchaser's right to own or use any of the Purchased
Intellectual Property.

                  (c)      Except as set forth in Schedule 5.10, other than the
Purchased Intellectual Property and Licensed Assets, neither Sellers nor any of
their Subsidiaries own or are exclusive licensees under any Intellectual
Property necessary for the manufacturing, licensing, importation, offer for
sale, sale, use, marketing, co-marketing, promotion and co-promotion of the
Marketed Products, the Pipeline Products or the Odyssey Product and, to the
actual knowledge of Sellers, there are no Intellectual Property rights owned by
or exclusively licensed to Sellers useful in connection with the same.

                  (d)      Except as set forth in Schedule 5.10, neither Sellers
nor any of their Subsidiaries are obligated to pay any royalties, fees or
similar obligations to any owner, licensor of, or other claimant for the use of
the Purchased Intellectual Property.

                  (e)      Schedule 5.10 sets forth a complete and accurate list
of all: (i) Intellectual Property Licenses; and (ii) material Contracts to which
Sellers or any of their Subsidiaries are a party containing an agreement to
indemnify any other Person against any claim of infringement by the Purchased
Intellectual Property.

                  (f)      Except as set forth in Schedule 5.10 or except as
would not have or would not reasonably be expected to have a Material Adverse
Effect, (i) each of the Intellectual Property Licenses is in full force and
effect and constitutes a valid and binding obligation of Sellers and/or their
Subsidiaries, enforceable against them in accordance with its terms, subject to
applicable bankruptcy, insolvency, reorganization, moratorium and similar laws
affecting creditors' rights and remedies generally and subject, as to
enforceability, to general principles of equity (regardless of whether
enforcement is sought in a proceeding at law or in equity), (ii) except as a
result of the

                                       51

<PAGE>

Chapter 11 Case, neither Sellers nor any Subsidiary is in default under any
Intellectual Property License, nor, to the Knowledge of Sellers, is any other
party to an Intellectual Property License in default thereunder, (iii) to the
Knowledge of Sellers, no event has occurred that with the lapse of time or the
giving of notice or both would constitute a default thereunder, and (iv) no
party to any of the Intellectual Property Licenses has exercised any termination
rights with respect thereto.

                  (g)       Except as set forth in Schedule 5.10, no trade
secret or any other non-public, proprietary information material to the Marketed
Products, the Pipeline Products or the Odyssey Product has been authorized to be
disclosed or, to the Knowledge of Sellers, has been actually disclosed by
Sellers or any of their Subsidiaries to any employee or any third party other
than pursuant to a non-disclosure agreement restricting the disclosure and use
of the Purchased Intellectual Property. Sellers have taken commercially
reasonable security measures to protect the secrecy, confidentiality and value
of all material trade secrets and other confidential information included in the
Purchased Intellectual Property, including invention disclosures not covered by
any patents owned or patent applications filed by Sellers.

                  (h)      To the actual knowledge of Sellers, no Person is
infringing, violating, misusing or misappropriating any Purchased Intellectual
Property.

                  (i)      Except as set forth in the Parent's SEC filings or
Schedule 5.10, as of the date hereof, no Legal Proceedings are pending or, to
the actual knowledge of Sellers, threatened in writing (i) against the Sellers
or any of their Subsidiaries (A) claiming infringement, unauthorized use, or
violation of any other Person's Intellectual Property with respect to the
Marketed Products or the Pipeline Products, (B) challenging the ownership, use,
validity or enforceability of, any Purchased Intellectual Property or Licensed
Assets, or (ii) against any third Person charging that such third Person is
infringing, violating, misusing or misappropriating any Purchased Intellectual
Property or Licensed Assets of Sellers. To the Knowledge of Sellers, all Patents
and applications or registrations for Trademarks included in the Purchased
Intellectual Property or Licensed Assets have been appropriately prosecuted,
registered, filed, and maintained consistent with all applicable US patent and
trademark laws and rules, including determination of inventorship and citation
of material prior art references.

                  (j)      Schedule 5.10 sets forth the true and complete list
of all contributors to the science of all potentially claimed subject matter
contained within the Darvocet-N XR IDM and Lynxorb Know How, together with the
identity of their respective inventions. Except as set forth in Schedule 5.10,
to the Knowledge of Sellers, no present or former employee has any right, title,
or interest, directly or indirectly, in whole or in part, in any Purchased
Intellectual Property.

         5.11     Regulatory Status.

                  (a)      Sellers are the lawful holder of the Marketing
Authorizations, Azathioprine ANDA, Purchased INDs and Purchased DMFs.

                                       52
<PAGE>

                  (b)      Except as otherwise set forth in Schedule 5.11, all
of the Marketing Authorizations and the Azathioprine ANDA are in full force and
effect and, to the Knowledge of Sellers, all of the Marketing Authorizations and
the Azathioprine ANDA have been duly and validly issued. Except as otherwise set
forth in Schedule 5.11, there is no Legal Proceeding by any Governmental Body
pending or, to the Knowledge of Sellers, threatened seeking the revocation or
suspension of any of the Marketing Authorizations or the Azathioprine ANDA.

                  (c)      Except as set forth in Schedule 5.11, to the
Knowledge of Sellers there is no information suggesting that the Marketed
Products that are the subject of an NDA or ANDA cannot be marketed in the
Territory pursuant to the applicable Marketing Authorization or the Azathioprine
ANDA. Sellers do not represent and warrant that the FDA will not, at some future
date, require the submission of a new drug application, abbreviated new drug
application, other regulatory approval or additional information for Marketed
Products marketed without an approved new drug application or abbreviated new
drug application, or require the submission of additional information for any
other Marketed Products.

                  (d)      Except as set forth in Schedule 5.11, to the
Knowledge of Sellers there are no facts which are reasonably likely to cause (i)
market withdrawal, recall or suspension of any of the Marketed Products, (ii) a
change in the marketing classification of any of the Marketed Products, (iii) a
material change in the labeling of any of the Marketed Products or (iv) a
termination or suspension of marketing of any of the Marketed Products.

                  (e)      Except as set forth in Schedule 5.11, Sellers have
made available to Purchaser all (i) outstanding post-approval commitments to the
FDA; (ii) adverse drug experience information, (iii) customer complaints, (iv)
files with respect to investigations of complaints, (v) FDA adverse event
reports and (vi) reports of trends of adverse events, in each case to the extent
relating to the Marketed Products and to the extent that any of the foregoing is
in Sellers' possession. Sellers have made available to Purchaser all
preclinical, clinical and validation data and any risk assessments in each
Sellers' possession that have been generated to demonstrate the safety and/or
effectiveness of each of the Marketed Products.

                  (f)      Except as set forth in Schedule 5.11, Sellers (only
with respect to the operation of the Business), and the Marketed Products
(including the labeling thereof) are in compliance with Applicable Law, except
where the failure to be in compliance would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. Except as
set forth in Schedule 5.11, to the Knowledge of Sellers there are no facts which
furnish any reasonable basis for any notice of adverse findings, warning or
other regulatory letters or sanctions, Section 305 notices, or other similar
communication. Except as set forth in Schedule 5.11, to the Knowledge of Sellers
there are no misstatements or material omissions relating to the Marketed
Products in any regulatory submission or other document required to be
maintained by Applicable Law

                                       53
<PAGE>

and the accuracy of its regulatory submissions has not been contested by any
Governmental Body.

                  (g)      No employee or officer of Sellers, or to the
Knowledge of Sellers, any other Person, including any clinical investigator,
involved in any services in connection with the Products was debarred or
otherwise deemed to be ineligible to provide services in connection with any of
the Products at the time such services were provided to Sellers.

                  (h)      Sellers and their respective employees, and, to the
Knowledge of Sellers, all contract manufacturers, packagers, and other Persons
involved in the manufacture, processing, testing, promoting or advertising of
the Marketed Products are in compliance with all applicable FDA regulations with
respect to the Marketed Products, except to the extent any noncompliance with
such applicable FDA regulations would not reasonably be expected to have a
Material Adverse Effect.

                  (i)      Except as otherwise set forth in Schedule 5.11, all
filings and notices required to be delivered to any Governmental Body with
respect to any of the Marketed Products have been made on a timely basis, except
where the failure to make such filings and notices on a timely basis would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.

                  (j)      Sellers (with respect to the Business) and the
Marketed Products are in compliance with the Federal Controlled Substances Act
and applicable DEA and state regulations, including, but not limited to, record
keeping, reporting, registration, security, labeling, and quota requirements,
except where the failure to be in compliance would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.

         5.12     Material Contracts. Schedule 5.12 sets forth each material
Contract to which either Seller is currently a party that (i) relates to the
manufacture, marketing, distribution, licensing or sale of any of the Marketed
Products; (ii) has been entered into with any Governmental Body with respect to
the manufacture, marketing, distribution, licensing or sale of the Marketed
Products; (iii) contains covenants not to compete or otherwise restricts
Sellers' rights to manufacture, market, distribute, license or sell the Marketed
Products, the Odyssey Products or any Pain Products; or (iv) provides for
coupons, rebates, chargebacks, promotions, discounts or advertising of any of
the Products. Except as set forth in Schedule 5.12, each such Purchased Contract
is in full force and effect, constitutes a valid and binding obligation of each
Seller party thereto and, to the Knowledge of Sellers, the other parties
thereto, and is legally enforceable against the applicable Seller party thereto
and, to the Knowledge of Sellers, the other parties thereto, in accordance with
its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, moratorium, reorganization, or similar laws from time to
time in effect which affect the enforcement of creditors' rights generally.
Except as disclosed in Schedule 5.12, neither Seller is in material breach or
default under any such Purchased Contract to which it is a party and, to the
Knowledge of Sellers, no other

                                       54
<PAGE>

party to any of such Purchased Contracts is in material breach or default in any
material respect thereunder. To the Knowledge of Sellers, no party to any of the
Purchased Contracts has exercised any termination rights with respect thereto.
Sellers have delivered or otherwise made available to Purchaser true, correct
and complete copies of all of the Purchased Contracts, together with all
amendments, modifications or supplements thereto.

         5.13     Labor. Neither Sellers nor any of their Subsidiaries is a
party to any labor or collective bargaining agreement and there are no labor or
collective bargaining agreements which pertain to employees of Sellers or any of
their Subsidiaries.

         5.14     Litigation. Except as set forth in Schedule 5.14 and except
for the contemplated Chapter 11 Case, there is no suit, action, proceeding,
investigation (to the Knowledge of Sellers as of the date hereof), claim or
order pending or, to the Knowledge of Sellers, threatened against Sellers or any
of their Subsidiaries (or to the Knowledge of Sellers, pending or threatened,
against any of the officers, directors, members or key employees of Sellers or
any of their Subsidiaries with respect to their business activities on behalf of
Seller), or to which any Seller or any of their Subsidiaries is otherwise a
party, which, if adversely determined, would have a Material Adverse Effect,
before any Governmental Body; nor to the Knowledge of Sellers is there any
reasonable basis for any such action, proceeding, or investigation. Other than
the Chapter 11 Case, neither Sellers nor any Subsidiary is subject to any Order
of any Governmental Body except to the extent the same could not reasonably be
expected to have a Material Adverse Effect.

         5.15     Compliance with Laws. Except as set forth in Schedule
5.15, Sellers are in compliance in all material respects with all Applicable
Laws of any Governmental Body applicable to the Business. Neither Sellers nor
any of their Subsidiaries has received any written notice of or been charged
with the violation of any Applicable Laws which would reasonably be expected to
have a Material Adverse Effect. To the Knowledge of Sellers, neither Sellers nor
any of their Subsidiaries is under investigation with respect to the violation
of any Applicable Laws that would reasonably be expected to have a Material
Adverse Effect and there are no facts or circumstances which could form the
basis for any such violation.

         5.16     Environmental Matters.  Except as set forth in Schedule 5.16
hereto or as would individually or in the aggregate, not have a Material Adverse
Effect:

                  (a)      the operations of Sellers and each of their
Subsidiaries, with respect to the Business, are and have been in compliance with
all applicable Environmental Laws, which compliance includes obtaining,
maintaining in good standing and complying with all Environmental Permits
necessary to operate the Business and no action or proceeding is pending or, to
the Knowledge of Sellers, threatened to revoke, modify or terminate any such
Environmental Permit, and, to the Knowledge of Sellers, no facts, circumstances
or conditions currently exist that could adversely affect such continued
compliance with Environmental Laws and Environmental Permits;

                                       55
<PAGE>

                  (b)      with respect to the Business, neither Sellers nor
any of their Subsidiaries is the subject of any outstanding written order or
Contract with any Governmental Body or Person respecting (i) Environmental Laws,
(ii) Remedial Action or (iii) any Release or threatened Release of a Hazardous
Material;

                  (c)      no claim has been made or is pending or, to the
Knowledge of Sellers, threatened against Sellers nor any of its Subsidiaries,
alleging, with respect to the Business, that either or both Sellers, or any of
its Subsidiaries, may be in violation of any Environmental Law or any
Environmental Permit or may have any liability under any Environmental Law; and

                  (d)      the transactions contemplated hereunder do not
require the consent of or filings with any Governmental Body with jurisdiction
over Sellers with respect to environmental matters.

         5.17     Insurance. Set forth in Schedule 5.17 is a list of all product
liability insurance relating to the Business, setting forth, in respect of each
such policy, the policy name, policy number, carrier, term, type of coverage and
annual premium. Except as noted on Schedule 5.17, to Seller's Knowledge all such
product liability insurance will remain in full force and effect.

         5.18     Inventories. The Inventory has been manufactured in material
compliance with United States current good manufacturing practices (as set forth
in 21 C.F.R. 210 and 211) and in accordance with relevant product specifications
used by Sellers at the date of manufacture. The inventories of the Business set
forth in the Balance Sheet were properly stated therein in accordance with GAAP
consistently applied. Adequate reserves have been reflected in the Balance Sheet
for obsolete, excess, damaged or otherwise unusable inventory, which reserves
were calculated in a manner consistent with past practice and in accordance with
GAAP consistently applied. Schedule 5.18 sets forth the quantities of Inventory
that the Sellers in good faith estimate will be on hand at June 30, July 31,
August 31, and September 30, 2005. The inventories and related reserves were
prepared from Sellers' books and records, which books and records are correct
and complete in all material respects.

         5.19     Customer.

                  (a)      Schedule 5.19(a) sets forth a list of the ten (10)
largest customers with respect to the Marketed Products, as measured by the
dollar amount of invoices therefrom or thereby, during each of the fiscal years
ended December 31, 2003 and December 31, 2004, showing the approximate total
sales by Sellers to each such customer during such period.

                  (b)      Except as set forth in Schedule 5.19(b) since
December 31, 2004 through the date hereof, no customer listed on Schedule
5.19(a) has terminated its relationship with Sellers or any of their
Subsidiaries or materially reduced or changed the pricing or other terms of its
business with Sellers or any of their Subsidiaries and, to the

                                       56
<PAGE>

Knowledge of Sellers, no customer listed on Schedule 5.19(a) has notified
Sellers that it intends to terminate or materially reduce or change the pricing
or other terms of its business with Sellers or any of their Subsidiaries, in
each case which termination or notification would reasonably be expected to have
a Material Adverse Effect.

         5.20     Product Warranty; Product Liability.

                  (a)      Except as set forth in Schedule 5.20, each product
manufactured, sold or delivered by Sellers or any of their Subsidiaries in
conducting the Business has been in material conformity with applicable product
specifications and all express warranties. Neither Sellers nor any of their
Subsidiaries has any liability for replacement of any such products or other
damages in connection therewith or any other customer or product obligations not
reserved against on the Balance Sheet. Neither Sellers nor any of their
Subsidiaries has sold any products in connection with the Business that included
a warranty for a period of longer than the applicable expiration date for such
products.

                  (b)      Neither Sellers nor any of their Subsidiaries have
committed any act or failed to commit any act, which would result in, and there
has been no occurrence which would give rise to or form the basis of, any
product liability or liability for breach of warranty (whether covered by
insurance or not) on the part of Sellers or any of their Subsidiaries with
respect to Marketed Products.

         5.21     Financial Advisors. Except as set forth in Schedule 5.21, no
Person has acted, directly or indirectly, as a broker, finder or financial
advisor for Sellers or any of their Subsidiaries in connection with the
transactions contemplated by this Agreement and no Person is entitled to any fee
or commission or like payment in respect thereof.

         5.22     FDA Indications. Sellers have not received any written or oral
indication from the FDA that a factorial design study (being a study in which
the Darvocet-N XR Product is required to be compared against one or more of its
ingredients alone) will be required for FDA approval of the Darvocet-N XR
Product.

         5.23     Laboratory Notebooks. The copies of the Notebooks included in
the Purchased Assets, which shall be provided at Purchaser's expense, shall be
identical copies of the portions of the Notebooks for which copies are provided
by Sellers to Purchaser and no information has been removed or deleted from such
copies with respect to any Purchased Intellectual Property or Licensed Assets as
they relate to the Marketed Products, Pipeline Products and Odyssey Products.

         5.24     No Other Representations and Warranties. Purchaser
acknowledges that except as expressly provided in this Agreement, (A) Sellers
make no representation or warranty of any kind whatsoever or by operation of
law, by statute or otherwise, and specifically disclaim any representation or
warranty with respect to any forward-looking projections, forecasts, budgets,
financial data or any other information (written or oral) with respect to the
Business, the Purchased Assets, the Licensed Assets, or any other matter,
including those supplied in the Confidential Information Memorandum

                                       57
<PAGE>

distributed by Rothschild, Inc. or presented in due diligence, and the Purchaser
takes full responsibility for making its own evaluation of such matters, and (b)
Sellers specifically disclaim any and all implied or statutory warranties,
including, without limitation, any warranty of merchantability, warranty of
fitness for a particular purpose, warrant of noninfringement or warranty of
title.

                                   ARTICLE VI

                   REPRESENTATIONS AND WARRANTIES OF PURCHASER

                  Purchaser hereby represents and warrants to Sellers that:

         6.1      Organization and Good Standing. Purchaser is a corporation
duly organized, validly existing and in good standing under the laws of the
State of Delaware.

         6.2      Authorization of Agreement. Purchaser has full corporate power
and authority to execute and deliver this Agreement and each other agreement,
document, instrument or certificate contemplated by this Agreement or to be
executed by Purchaser in connection with the consummation of the transactions
contemplated hereby and thereby (the "Purchaser Documents"), and to consummate
the transactions contemplated hereby and thereby. The execution, delivery and
performance by Purchaser of this Agreement and each Purchaser Document have been
duly authorized by all necessary corporate action on behalf of Purchaser. This
Agreement has been, and each Purchaser Document will be at or prior to the
Closing, duly executed and delivered by Purchaser and (assuming the due
authorization, execution and delivery by the other parties hereto and thereto)
this Agreement constitutes, and each Purchaser Document when so executed and
delivered will constitute, legal, valid and binding obligations of Purchaser,
enforceable against Purchaser in accordance with their respective terms, subject
to applicable bankruptcy, insolvency, reorganization, moratorium and similar
laws affecting creditors' rights and remedies generally, and subject, as to
enforceability, to general principles of equity, including principles of
commercial reasonableness, good faith and fair dealing (regardless of whether
enforcement is sought in a proceeding at law or in equity).

         6.3      Conflicts; Consents of Third Parties.

                  (a)      Except as set forth in Schedule 6.3 hereto, neither
of the execution and delivery by Purchaser of this Agreement and of the
Purchaser Documents, nor the compliance by Purchaser with any of the provisions
hereof or thereof will (i) conflict with, or result in the breach of, any
provision of the certificate of incorporation or by-laws of Purchaser, (ii)
conflict with, violate, result in the breach of, or constitute a default under
any note, bond, mortgage, indenture, license, agreement or other obligation to
which Purchaser is a party or by which Purchaser or its properties or assets are
bound or (iii) violate any statute, rule, regulation or Order by which Purchaser
is bound, except, in the case of clauses (ii) and (iii), for such violations,
breaches or defaults as would not,

                                       58
<PAGE>

individually or in the aggregate, have a material adverse effect on the ability
of Purchaser to consummate the transactions contemplated by this Agreement.

                  (b)      No consent, waiver, approval, Order, Permit or
authorization of, or declaration or filing with, or notification to, any Person
or Governmental Body is required on the part of Purchaser in connection with the
execution and delivery of this Agreement or Purchaser Documents or the
compliance by Purchaser with any of the provisions hereof or thereof, except for
compliance with the applicable requirements of the HSR Act.

         6.4      Litigation. There are no Legal Proceedings pending or, to the
knowledge of Purchaser, threatened that are reasonably likely to prohibit or
restrain the ability of Purchaser to enter into this Agreement or consummate the
transactions contemplated hereby.

         6.5      Financial Advisors. Except as set forth in Schedule 6.5, no
Person has acted, directly or indirectly, as a broker, finder or financial
advisor for Purchaser in connection with the transactions contemplated by this
Agreement and no Person is entitled to any fee or commission or like payment in
respect thereof.

         6.6      Financing. On the date hereof, Purchaser has obtained an
executed commitment letter or executed commitment letters (collectively, the
"Commitment Letters") for the financing of the consummation of the transactions
contemplated hereunder. The obligations to fund the commitments under the
Commitment Letters are not subject to any condition, other than the conditions
in the Commitment Letters. Copies of such Commitment Letters, which have been
provided to Sellers, have been duly executed by Purchaser and each other Person
party thereto, and have not been amended, modified, withdrawn, terminated or
replaced. There are no fees, expense reimbursement obligations, or other amounts
that are required to be paid by Purchaser prior to the Closing under or in
respect of the Commitment Letters that are unpaid. None of the lenders or
investors thereunder have notified Purchaser of its intention to terminate its
commitment under its Commitment Letter or not to provide in full the financing
contemplated thereby. Purchaser has provided to Sellers a chart showing a
reasonably detailed breakdown of the contemplated sources and uses of such
financing as of the date of this Agreement.

                                  ARTICLE VII

                            BANKRUPTCY COURT MATTERS

         7.1      Approval of Break-Up Fee and Expense Reimbursement.

                  (a)      Sellers acknowledge and agree that Purchaser has
expended considerable time and expense in connection with this Agreement and the
negotiation thereof and the identification and quantification of assets of
Sellers. In consideration therefor, Sellers shall file with and seek the
approval of the Bankruptcy Court of the

                                       59
<PAGE>

Approval Motion, including the Break-Up Fee and Expense Reimbursement, and the
entry by the Bankruptcy Court of the Bidding Procedures Order approving the
payment of the Break-Up Fee in an amount equal to Five Million Two Hundred Fifty
Thousand Dollars ($5,250,000) and the Expense Reimbursement in an amount not to
exceed One Million Five Hundred Thousand Dollars ($1,500,000) (not including any
amounts previously paid by Sellers) for Purchaser's reasonable out-of-pocket
documented expenses incurred in connection with the transactions contemplated
hereby and the financing thereof and deeming the Break-Up Fee and the Expense
Reimbursement as administrative priority expenses under Sections 503(b) and
507(a)(1) of the Bankruptcy Code.

                  (b)      Sellers shall pay to Purchaser the Expense
Reimbursement on the first (1st) Business Day after the earlier to occur of (i)
Purchaser's termination of this Agreement pursuant to Section 4.4(e) through
Section 4.4(m) or Section 4.4(o) and (ii) any of the events specified in Section
7.1(c).

                  (c)      Sellers shall pay to Purchaser the Expense
Reimbursement (unless previously paid to Purchaser in accordance with Section
7.1(b)) and the Break-Up Fee on the first (1st) Business Day after the earlier
to occur of:

                           (i)      the Bankruptcy Court enters an order
         approving an Alternative Transaction;

                           (ii)     Outside of the Bidding Procedures, Sellers
         consummate an Alternative Transaction, provided that Sellers have
         entered into an agreement for such Alternative Transaction on or prior
         to twelve (12) months following the date of termination of this
         Agreement.

                  (d)      If on or prior to twelve (12) months following the
date of termination of this Agreement Sellers file with the Bankruptcy Court a
Restructuring Transaction or enter into a Restructuring Transaction, Sellers
shall pay to Purchaser, on the first (1st) Business Day after consummation of
such Restructuring Transaction, the Expense Reimbursement and 50% of the
Break-Up Fee (in each case if not previously paid to Purchaser in accordance
with Section 7.1(b)).

         7.2      Bidding Procedures. Not later than the date that is one (1)
Business Day following commencement of the Chapter 11 Case, Sellers shall file
the Approval Motion seeking approval of the Bidding Procedures Order, including
the Bidding Procedures, and the Sale Order with the Bankruptcy Court. No later
than thirty-five (35) days after the date of the commencement of the Chapter 11
Case, Sellers shall obtain entry by the Bankruptcy Court of the Bidding
Procedures Order (with such changes thereto as Purchaser shall approve or
request in its reasonable discretion, which changes shall not be adverse to
Purchaser). Sellers shall comply with all of the terms and conditions contained
in the Bidding Procedures, including the occurrence of the events by the dates
and times listed therein which are expressly incorporated by reference herein as
if set forth at length. Sellers agree to make promptly any filings, to take all
actions and to

                                       60
<PAGE>

obtain entry of the Bidding Procedures Order and the Sale Order and any and all
other approvals and orders necessary or appropriate for the consummation of the
transactions contemplated hereby.

         7.3      Non-Solicitation Period.

                  (a)      From the time of Sellers' and Purchaser's execution
and delivery of this Agreement until the Bankruptcy Court's entry of the Bidding
Procedures Order (the "Non-Solicitation Period"), Sellers shall not, nor shall
they authorize or permit any Affiliate to, nor shall they authorize or permit
any officer, director, manager or employee of, or any investment banker,
attorney or other advisor, agent or representative of, Sellers or any Subsidiary
(collectively, "Seller Representatives") to solicit or otherwise encourage any
entity with respect to the submission of an Alternative Transaction or negotiate
the terms of an Alternative Transaction. Sellers shall not execute any
Alternative Transaction prior to the Bankruptcy Court's entry of the Bidding
Procedures Order.

                  (b)      Following entry of the Bidding Procedures Order until
the bid deadline set forth therein, Sellers and Seller Representatives shall not
be subject to any restrictions with respect to the solicitation or encouragement
of any entity concerning the potential or actual submission of a qualified bid
in accordance with the Bidding Procedures; provided, however, that within
twenty-four (24) hours after Sellers' receipt of any offer for an Alternative
Transaction, Sellers must deliver to Purchaser by facsimile transmission or same
day courier service true and complete copies of all documents related to any
such Alternative Transaction.

                  (c)      To the extent the Bidding Procedures Order is
inconsistent with the terms of this Agreement, the Bidding Procedures Order
shall control.

         7.4      Bankruptcy Court Approval.

                  (a)      At least twenty-five (25) days prior to the hearing
approving the Sale Order, Sellers shall serve a copy of the Approval Motion
(along with a copy of the proposed Sale Order and the Bidding Procedures Order)
on each jurisdiction where the Purchased Assets are subject to Tax.

                  (b)      Sellers shall obtain entry by the Bankruptcy Court of
the Sale Order no later than seventy (70) days after the date of commencement of
the Chapter 11 Case.

                  (c)      If the Bidding Procedures Order or Sale Order or any
other orders of the Bankruptcy Court relating to this Agreement shall be
appealed by any party (or a petition for certiorari or motion for
reconsideration, amendment, clarification, modification, vacation, stay,
rehearing or reargument shall be filed with respect to any such order), Sellers
shall diligently defend against such appeal, petition or motion and shall use
their reasonable best efforts to obtain an expedited resolution of any such
appeal, petition or motion.

                                       61
<PAGE>

                  (d)      Sellers shall not make any filing with the Bankruptcy
Court or any other court or Governmental Body with respect to the Bidding
Procedures Order or Sale Order without the consent of Purchaser, which consent
shall not be unreasonably withheld or delayed.

                  (e)      Sellers shall cooperate with Purchaser and its
representatives in connection with the Sale Order, the Bidding Procedures Order
and the bankruptcy proceedings in connection therewith. Such cooperation shall
include, but not be limited to, consulting with Purchaser at Purchaser's
reasonable request concerning the status of such proceedings and providing
Purchaser with copies of requested pleadings, notices, proposed orders and other
documents relating to such proceedings as soon as reasonably practicable prior
to any submission thereof to the Bankruptcy Court. Sellers further covenant and
agree that the terms of any plan it submits to the Bankruptcy Court for
confirmation shall not conflict with, supersede, abrogate, nullify or restrict
the terms of this Agreement, or in any way prevent or interfere with the
consummation or performance of the transactions contemplated by this Agreement,
including, without limitation, any transaction contemplated by or approved
pursuant to the Sale Order or the Bidding Procedures Order.

                  (f)      Notwithstanding anything to the contrary herein,
neither Purchaser nor Sellers shall be prohibited or otherwise restrained from
making any filing with the Bankruptcy Court to challenge or object to the entry
of an order by the Bankruptcy Court approving the entry by Sellers into an
Alternative Transaction or Restructuring Transaction; provided, that nothing
herein shall grant Purchaser standing to the extent that Purchaser would not
otherwise have standing under Applicable Law.

                                  ARTICLE VIII

                                    COVENANTS

         8.1      Access to Information. Sellers agree that, prior to the
Closing Date, Purchaser shall be entitled, through its officers, employees and
representatives (including, without limitation, its legal advisors and
accountants), to make such investigation of the properties, businesses and
operations of Sellers and such examination of the books, records and financial
condition of Sellers as it reasonably requests and to make extracts and copies
of such books and records. Any such investigation and examination shall be
conducted during regular business hours and under reasonable circumstances, and
Sellers shall cooperate fully therein. No investigation by Purchaser prior to or
after the date of this Agreement shall diminish or obviate any of the
representations, warranties, covenants or agreements of Sellers contained in
this Agreement or the Seller Documents. In order that Purchaser may have full
opportunity to make such physical, business, accounting and legal review,
examination or investigation as it may reasonably request of the affairs of
Sellers, Sellers shall use their commercially reasonable efforts to cause the
officers, employees, consultants, agents, accountants, attorneys and other
representatives of Sellers to cooperate fully with such representatives in
connection with such review and examination. Sellers shall promptly deliver to
Purchaser such copies of all pleadings,

                                       62
<PAGE>

motions, notices, statements, schedules, applications, reports and other papers
filed by Sellers in the Chapter 11 Case. Sellers shall promptly provide to
Purchaser all documents and materials relating to the proposed sale of the
Purchased Assets, or any portion thereof, and otherwise cooperate with
Purchaser, to the extent reasonably necessary in connection with Purchaser's
preparation for or participation in any part of the Chapter 11 Case in which
Purchaser's participation is necessary, required or reasonably appropriate.
Sellers shall promptly deliver to Purchaser all pleadings, motions, notices,
statements, schedules, applications, reports and other papers filed in any other
judicial or administrative proceeding as Purchaser may reasonably request.

         8.2      Permitted Sellers. To the extent any Permitted Seller assigns,
licenses, or sublicenses the rights to sell Marketed Products, Lifecycle
Products, or New Products, such Permitted Seller must notify Sellers in writing
no later than three (3) Business Days after such assignment, license, or
sublicense of the identity of the new Permitted Seller and provide Sellers with
a copy of such assignment, license, or sublicense agreement.

         8.3      Conduct of the Business Pending the Closing.

                  (a)      Except as otherwise expressly contemplated by this
Agreement (including the prosecution of the Chapter 11 Case) or with the prior
written consent of Purchaser, Sellers shall, and shall cause their Subsidiaries
to, with respect to the Business only:

                           (i)      except as set forth in Schedule 8.3, conduct

         the Business only in the Ordinary Course of Business as debtors in
         possession;

                           (ii)     use their commercially reasonable efforts,
         as debtors in possession, to (A) preserve their present business
         operations, organization (including employees) and goodwill of Sellers
         and (B) preserve the present relationships with Persons having business
         dealings with Sellers (including without limitation customers and
         suppliers);

                           (iii)    maintain (A) all of the Purchased Assets and
         Licensed Assets in their current condition, ordinary wear and tear
         excepted and (B) insurance upon all of the Purchased Assets and
         Licensed Assets in such amounts and of such kinds comparable to that in
         effect on the date of this Agreement;

                           (iv)     (A) maintain the books, accounts and records
         of Sellers in the Ordinary Course of Business, (B) continue to pay,
         with respect to the Purchased Contracts, post-petition accounts payable
         when due and without discounting or accelerating payment of such
         accounts, and (C) subject to existing defaults and future payment
         defaults, comply with all obligations under the Purchased Contracts;

                           (v)      comply in all material respects with
         Applicable Laws; and

                                       63
<PAGE>

                           (vi)     not take any action which would adversely
         affect the ability of the parties to consummate the transactions
         contemplated by this Agreement.

                  (b)      Except as otherwise expressly contemplated by this
Agreement (including the prosecution of the Chapter 11 Case) or with the prior
written consent of Purchaser, Sellers shall not, and shall not permit their
Subsidiaries to, with respect to the Business only:

                           (i)      with respect to the Employees set forth in
         Schedule 9.1, enter into any non-competition or similar agreement to
         which Sellers or any of their Subsidiaries is a party;

                           (ii)     make or rescind any election relating to
         Taxes or settle or compromise any claim, action, suit, litigation,
         proceeding, arbitration, investigation, audit or controversy relating
         to Taxes to the extent that such election, settlement or compromise
         would have any material post-Closing effect that would be binding on
         Purchaser for taxable periods (or portions thereof) beginning on or
         after the Closing Date;

                           (iii)    sell, assign, license, transfer, convey,
         lease or otherwise dispose of any of the Purchased Assets (except for
         fair consideration in the Ordinary Course of Business) of Sellers;

                           (iv)     with respect to the Employees set forth in
         Schedule 9.1, enter into any labor or collective bargaining agreement
         or, through negotiation or otherwise, make any commitment or incur any
         liability to any labor organization;

                           (v)      except as set forth in Schedule 8.3,
         introduce any material change with respect to the operation of the
         Business, including any material change in the types, nature,
         composition (except as required by the FDA) or quality of the Products
         or services, or make any change in Product specifications or prices or
         terms of distributions of such Products;

                           (vi)     enter into any Contract, understanding or
         commitment that restrains, restricts, limits or impedes the ability of
         the Business, or the ability of Purchaser, to compete with or conduct
         any business or line of business in any geographic area;

                           (vii)    terminate, amend, restate, supplement or
         waive any rights under any Purchased Contract or Intellectual Property
         License; or

                           (viii)   agree to do anything prohibited by this
         Section 8.3 or anything which would make any of the representations and
         warranties of Sellers in this Agreement untrue or incorrect in any
         material respect.

         8.4      Development of Darvocet-N XR and Lynxorb. Upon the entry of
the Bidding Procedures Order and prior to the Closing Date, upon Purchaser's
written notice

                                       64
<PAGE>

to Sellers, Sellers shall continue to develop the Darvocet-N XR Product and the
Lynxorb Product in accordance with a development plan mutually agreed upon by
Sellers and Purchaser, with such costs and expenses of development to be funded
by Purchaser (the "Development Costs") up to $1,000,000; provided, that nothing
contained herein shall be deemed an affirmative obligation, absent Purchaser's
written notice, to develop the Darvocet-N XR Product or the Lynxorb Product in
the Ordinary Course of Business.

         8.5      Rejection of Contracts. Except as set forth in Schedule 8.5,
Sellers shall not seek to have any Contract related to the Business rejected in
the Chapter 11 Case until after the Closing Date.

         8.6      Consents. Sellers and Purchaser shall use (and shall cause
each of their Subsidiaries to use) their commercially reasonable efforts, and
Purchaser shall cooperate with Sellers, to obtain at the earliest practicable
date all consents and approvals required to consummate the transactions
contemplated by this Agreement, including, without limitation, the consents and
approvals referred to in Section 5.4(b) hereof.

         8.7      Regulatory Approvals.

                  (a)      Each of Purchaser and Sellers shall (i) make or cause
to be made all filings required of each of them or any of their respective
Subsidiaries or Affiliates under the HSR Act or other Antitrust Laws with
respect to the transactions contemplated hereby as promptly as practicable and,
in any event, within five (5) Business Days after approval of the Bidding
Procedures by the Bankruptcy Court in the case of all filings required under the
HSR Act and within ten (10) Business Days in the case of all other filings
required by other Antitrust Laws, (ii) comply at the earliest practicable date
with any request under the HSR Act or other Antitrust Laws for additional
information, documents, or other materials received by each of them or any of
their respective Subsidiaries from the Federal Trade Commission (the "FTC"), the
Antitrust Division of the United States Department of Justice (the "Antitrust
Division") or any other Governmental Body in respect of such filings or such
transactions, and (iii) cooperate with each other in connection with any such
filing (including, to the extent permitted by Applicable Law, and at Purchaser's
cost providing copies of all such documents to the non-filing parties prior to
filing and considering all reasonable additions, deletions or changes suggested
in connection therewith) and in connection with resolving any investigation or
other inquiry of any of the FTC, the Antitrust Division or other Governmental
Body under any Antitrust Laws with respect to any such filing or any such
transaction. Each such party shall use commercially reasonable efforts to
furnish to each other all information required for any application or other
filing to be made pursuant to any applicable law in connection with the
transactions contemplated by this Agreement. Each such party shall promptly
inform the other parties hereto of any oral communication with, and provide
copies of written communications with, any Governmental Body regarding any such
filings or any such transaction. No party hereto shall independently participate
in any formal meeting with any Governmental Body in respect of any such filings,
investigation, or other inquiry without giving the other parties hereto prior
notice of the meeting and, to the extent permitted by such Governmental Body,
the opportunity

                                       65
<PAGE>

to attend and/or participate. Subject to applicable law, the parties hereto will
consult and cooperate with one another in connection with any analyses,
appearances, presentations, memoranda, briefs, arguments, opinions and proposals
made or submitted by or on behalf of any party hereto relating to proceedings
under the HSR Act or other Antitrust Laws. Sellers and Purchaser may, as each
deems advisable and necessary, reasonably designate any competitively sensitive
material provided to the other under this Section 8.7 as "outside counsel only."
Such materials and the information contained therein shall be given only to the
outside legal counsel of the recipient and will not be disclosed by such outside
counsel to employees, officers, or directors of the recipient, unless express
written permission is obtained in advance from the source of the materials
(Sellers or Purchaser, as the case may be). Notwithstanding anything to the
contrary provided herein, none of Sellers, Purchaser nor any of their respective
Affiliates shall be required (i) to hold separate (including by trust or
otherwise) or divest any of its businesses, product lines or assets, or any of
the Purchased Assets, (ii) to agree to any limitation on the operation or
conduct of the Business, or (iii) to waive any of the conditions to this
Agreement set forth in Section 10.1.

                  (b)      Each of Purchaser and Sellers shall use commercially
reasonable efforts to resolve such objections, if any, as may be asserted by any
Governmental Body with respect to the transactions contemplated by this
Agreement under the HSR Act, the Sherman Act, as amended, the Clayton Act, as
amended, the Federal Trade Commission Act, as amended, and any other United
States federal or state or foreign statutes, rules, regulations, orders,
decrees, administrative or judicial doctrines or other laws that are designed to
prohibit, restrict or regulate actions having the purpose or effect of
monopolization or restraint of trade (collectively, the "Antitrust Laws"). In
connection therewith, if any Legal Proceeding is instituted (or threatened to be
instituted) challenging any transaction contemplated by this Agreement is in
violation of any Antitrust Law, Sellers shall use reasonable best efforts, and
Purchaser shall cooperate with Sellers, to contest and resist any such Legal
Proceeding, and to have vacated, lifted, reversed, or overturned any decree,
judgment, injunction or other order whether temporary, preliminary or permanent,
that is in effect and that prohibits, prevents, or restricts consummation of the
transactions contemplated by this Agreement, including by pursuing all available
avenues of administrative and judicial appeal and all available legislative
action, unless, by mutual agreement, Purchaser and Sellers decide that
litigation is not in their respective best interests. Each of Purchaser and
Sellers shall use commercially reasonable efforts to take such action as may be
required to cause the expiration of the notice periods under the HSR Act or
other Antitrust Laws with respect to such transactions as promptly as possible
after the execution of this Agreement. Notwithstanding anything to the contrary
provided herein, none of Sellers, Purchaser nor any of their respective
Affiliates shall be required (i) to hold separate (including by trust or
otherwise) or divest any of its businesses, product lines or assets, or any of
the Purchased Assets, (ii) to agree to any limitation on the operation or
conduct of the Business, or (iii) to waive any of the conditions to this
Agreement set forth in Section 10.1.

                                       66
<PAGE>

                  (c)      All filings fees related to this Agreement incurred
in connection with the HSR Act or other Antitrust Laws shall be borne by the
parties in accordance with their respective legal obligations.

         8.8      Further Assurances. Subject to Section 8.7, each of Sellers
and Purchaser shall use its commercially reasonable efforts to (i) take all
actions reasonably necessary or appropriate to consummate the transactions
contemplated by this Agreement including actively pursuing and securing the
financing as set forth in the Commitment Letters and (ii) cause the fulfillment
at the earliest practicable date of all of the conditions to their respective
obligations to consummate the transactions contemplated by this Agreement.
Without limiting the foregoing, Purchaser or Sellers, as applicable, shall
cooperate in transferring Excluded Assets to Sellers or Purchased Assets
(including assets of Sellers intended to be Purchased Assets) to Purchaser,
including turning over any payments received by the other party, and assisting
in the collection of any Excluded Assets. Sellers shall take all necessary
actions to enforce all rights of Sellers with respect to employees, consultants
and agents of Sellers and their Subsidiaries, who are contributors to the
science of patentable inventions of the Darvocet-N XR Product, the Lynxorb
Product, the Darvocet-N Suspension Product, and the New Products to effectuate
the transactions contemplated herein.

         8.9      Non-Competition; Non-Solicitation; Confidentiality.

                  (a)      Except with respect to Sellers' manufacturing
Products for Purchaser pursuant to the Manufacturing Agreement or as otherwise
provided for in Section 3.3, for a period from the Closing Date until the
seventh (7th) anniversary of the Closing Date, Sellers shall not and shall cause
their Subsidiaries not to directly or indirectly, own, manage, operate, control
or participate in the ownership, management, operation or control of any
business, whether in corporate, proprietorship or partnership form or otherwise,
engaged in the marketing, promoting, distributing and selling of pharmaceutical
products competitive with any of the Products (a "Restricted Business") in the
Territory; provided, however, that the restrictions contained in this Section
8.9(a) shall not restrict the acquisition by Sellers, directly or indirectly, of
less than 2% of the outstanding capital stock of any publicly traded company
engaged in a Restricted Business; provided, further, however, that, except as
otherwise provided for in Section 3.3, nothing contained herein shall preclude
Sellers or their Affiliates from developing or manufacturing products for third
parties.

                  (b)      For a period of one (1) year from the Closing Date,
Sellers shall not and shall cause their Subsidiaries not to: (i) cause, solicit,
induce or encourage any employees of Sellers who are or become employees of
Purchaser or its Affiliates to leave such employment or hire, employ or
otherwise engage any such individual; or (ii) cause, induce or encourage any
material client, customer, supplier, or licensor of the Business (including any
existing customer of Sellers and any Person that becomes a client or customer of
the Business after the Closing) or any other Person who has a material business
relationship with the Business, to terminate or modify any such relationship;

                                       67
<PAGE>

provided that the foregoing shall not apply to general advertisements in
newspapers, newsletters, magazines, commercials, billboards, or other media
outlets.

                  (c)      For the period commencing on the date hereof and
continuing until one (1) year from the Closing Date, Purchaser shall not and
shall cause its Affiliates not to: (i) cause, solicit, induce or encourage any
employees of Sellers or their Affiliates, except as set forth in Schedule 9.1,
to become employees of Purchaser or its Affiliates to leave such employment or
hire, employ or otherwise engage any such individual without the prior written
consent of Sellers; or (ii) cause, induce or encourage any material actual
client, customer, supplier, or licensor of Sellers or their Affiliates, except
as set forth in Schedule 9.1 (including any existing customer of Sellers, their
Affiliates, or the Business and any Person that becomes a client or customer of
the Business after the Closing) or any other Person who has a material business
relationship with the Sellers, their Affiliates or the Business, to terminate or
modify any such actual or prospective relationship.

                  (d)      The confidentiality agreement between Purchaser and
Parent dated November 12, 2004 (the "Confidentiality Agreement") shall remain in
effect and terminate upon the earlier to occur of the Closing and as otherwise
provided in the Confidentiality Agreement. From and after the Closing Date, none
of Sellers or Purchaser shall, and each shall cause their respective Affiliates,
officers and directors (collectively, with Sellers or Purchaser, as applicable,
a "Receiving Party") not to, directly or indirectly, without the prior written
consent of the other (the "Disclosing Party"), disclose any Confidential
Information (as defined below) of the Disclosing Party to any Person, except to
a Receiving Party's or its Affiliates' employees or representatives who need to
know such information for any reason contemplated by this Agreement (and then
only to the extent that such Persons are under an obligation to maintain the
confidentiality of the Confidential Information), or use any Confidential
Information of the Disclosing Party for any reason other than contemplated by
this Agreement unless such Receiving Party has (i) consulted with the Disclosing
Party and obtained the Disclosing Party's prior written consent or (ii) been
advised by counsel that disclosure is required to be made under Applicable Law,
legal process, subpoena, litigation, discovery requests or demands from a
Governmental Body or other legal compulsion, or the requirements of a national
securities exchange or another similar regulatory body. In the event that the
Receiving Party is required by subpoena, civil investigative demand,
interrogatories, requests for information, or other similar process, as provided
for in the preceding sentence, to disclose any Confidential Information, the
Receiving Party shall provide the Disclosing Party with prompt written notice of
such demands so that the Disclosing Party may seek an appropriate protective
order; provided, however, to the extent that the Disclosing Party does not seek
a protective order or it is denied a protective order, such disclosure of
Confidential Information by the Receiving Party shall not constitute a breach of
this Agreement. Notwithstanding the foregoing, Sellers shall not make any
filings with the Bankruptcy Court or otherwise permit any filings to be made
with respect to any Confidential Information of Purchaser without the reasonable
prior written consent of Purchaser, and Sellers further agree that any such
filings shall be made under seal pursuant to section 107(b) of the Bankruptcy
Code and Bankruptcy Rule 9018 to the extent reasonably requested by Purchaser.
For purposes of

                                       68
<PAGE>

this Section 8.9(d), "Confidential Information" means any confidential
information with respect to the Business, including, Licensed Assets, methods of
operation, customers, customer lists, Products, prices, fees, costs, technology,
inventions, trade secrets, know how, software, marketing methods, plans,
personnel, suppliers, competitors, markets or other specialized information or
proprietary matters. "Confidential Information" does not include, and there
shall be no obligation hereunder with respect to, information that (i) is
generally available to the public on the date of this Agreement or (ii) becomes
generally available to the public other than as a result of a disclosure not
otherwise permissible hereunder. This Section 8.9 shall not in any way limit the
disclosure of information (x) by Sellers in connection with the prosecution of
the Chapter 11 Case or (y) regarding Sellers to other bidders or potential
bidders, to the extent specifically permitted by this Agreement. Notwithstanding
the generality of the foregoing, Sellers agree that, without Purchaser's prior
written consent, Sellers shall not disclose the identity of Purchaser's
financing sources or the amount or terms of financing proposed to be supplied by
an such source, except as otherwise required by Applicable Law or by the
Bankruptcy Court with respect to filings to be made with the Bankruptcy Court in
connection with this Agreement.

                  (e)      The covenants and undertakings contained in this
Section 8.9 relate to matters which are of a special, unique and extraordinary
character and a violation of any of the terms of this Section 8.9 will cause
irreparable injury to the parties, the amount of which will be impossible to
estimate or determine and which cannot be adequately compensated. Therefore,
Purchaser will be entitled to an injunction, restraining order or other
equitable relief from any court of competent jurisdiction in the event of any
breach of this Section 8.9. The rights and remedies provided by this Section 8.9
are cumulative and in addition to any other rights and remedies which Purchaser
may have hereunder or at law or in equity. In the event that Purchaser were to
seek damages for any breach of this Section 8.9, the portion of the Purchase
Price which is allocated by the parties to the foregoing covenant shall not be
considered a measure of or limit on such damages.

                  (f)      The parties hereto agree that, if any court of
competent jurisdiction in a final nonappealable judgment determines that a
specified time period, a specified geographical area, a specified business
limitation or any other relevant feature of this Section 8.9 is unreasonable,
arbitrary or against public policy, then a lesser time period, geographical
area, business limitation or other relevant feature which is determined to be
reasonable, not arbitrary and not against public policy may be enforced against
the applicable party.

         8.10     Preservation of Records. Sellers and Purchaser agree that each
of them shall preserve and keep the records held by it or their Affiliates
relating to the Business for a period of seven (7) years from the Closing Date
and shall make such records and personnel available to the other as may be
reasonably required by such party in connection with, among other things, any
insurance claims by, legal proceedings against or governmental investigations of
Sellers or Purchaser or any of their Affiliates or in order to enable Sellers or
Purchaser to comply with their respective obligations under this Agreement and
each other agreement, document or instrument contemplated hereby or

                                       69
<PAGE>

thereby. To the extent that any party provides the other with records relating
to the Business, such party providing the files shall have the right to
duplicate and maintain copies of such files. In the event Sellers or Purchaser
wishes to destroy such records before or after that time, such party shall first
give ninety (90) days prior written notice to the other and such other party
shall have the right at its option and expense, upon prior written notice given
to such party within such ninety (90) day period, to take possession of the
records within one hundred and eighty (180) days after the date of such notice.

         8.11     Publicity. Neither Sellers nor Purchaser shall issue any press
release or public announcement concerning this Agreement or the transactions
contemplated hereby without obtaining the prior written approval of the other
party hereto, which approval will not be unreasonably withheld or delayed,
unless, in the sole judgment of Purchaser or Sellers, disclosure is otherwise
required by Applicable Law or by the Bankruptcy Court with respect to filings to
be made with the Bankruptcy Court in connection with this Agreement or by the
applicable rules of any stock exchange on which Purchaser or Sellers lists
securities, provided that the party intending to make such release shall use
commercially reasonable efforts consistent with such Applicable Law or
Bankruptcy Court requirement to consult with the other party with respect to the
text thereof.

         8.12     aaiPharma Name. From the earlier to occur of (i) one (1) year
following the Closing Date or (ii) until exhaustion of packaging and promotional
materials existing as of the Closing Date ("AAI Packaging"), Purchaser shall
have the right to use, in connection with the AAI Packaging, the name
"aaiPharma" or similar names or any service marks, trademarks, trade names,
identifying symbols, logos, emblems or signs containing or comprising the
foregoing, only to the extent that such right is reasonably necessary or
required for the limited use of the AAI Packaging.

         8.13     Cooperation with Financing. In order to assist with obtaining
Purchaser's acquisition financing in connection with this Agreement, Sellers
shall, and shall cause their Subsidiaries to, provide such reasonable assistance
and cooperation as Purchaser and its Affiliates may reasonably request.

         8.14     Returns, Rebates and Chargebacks.

                  (a)      (i) Sellers shall be financially responsible for
returned Marketed Products sold by Sellers prior to the Closing Date and
Purchaser shall be financially responsible for returned Marketed Products sold
by Purchaser on or after the Closing Date, provided that Sellers and Purchaser
shall be financially responsible for their own allocated percentage of Split
Lots of returned Marketed Products that will be set forth on a schedule of Split
Lots to be provided by Sellers within ten (10) Business Days after the Closing
Date; provided, however, that Sellers' financial obligation for such returns
shall terminate two hundred seventy (270) days after the Closing Date. Such
allocated percentage of a Split Lot that Purchaser shall be responsible for
under this Section 8.14(a)(i) shall be equal to the percentage of such Split Lot
located at SPS Cord on the Closing Date and such allocated percentage of a Split
Lot that Sellers shall be

                                       70
<PAGE>

responsible for under this Section 8.14(a)(i) shall equal the percentage of such
Split Lot not located at SPS Cord on the Closing Date.

                           (ii)     As of the Closing, Purchaser and Sellers
         will use commercially reasonable efforts in requesting that customers
         direct all returned Marketed Products to Purchaser; provided, however,
         that except as set forth on Schedule 8.14(a)(ii), returned Marketed
         Products received by Purchaser or Sellers after the Closing Date will
         be handled by such party at its respective returns handling facility.
         Neither Purchaser nor Sellers shall issue credits or make any cash
         payments for returned Marketed Products for which the other party is
         financially responsible as set forth in Section 8.14(a)(i) above;
         provided, however, that such party shall destroy such returned Marketed
         Product and invoice the other party for the reasonable cost of
         destruction. Each such invoice shall set forth information as shall be
         necessary to support the invoice. Sellers and Purchaser shall, within
         thirty (30) days of such party's receipt of invoice, pay the other
         party for the full invoiced amount. Notwithstanding anything else
         contained herein, if either Purchaser or Sellers issue financial credit
         or other reimbursement for returned Marketed Products and related
         administrative fees for which the other party was financially
         responsible as set forth in this Section 8.14(a), such party shall
         invoice the other party for such amount setting forth information as
         shall be reasonably necessary to support the invoice. Purchaser and
         Sellers shall, within thirty (30) days of Purchaser's or Sellers'
         receipt of invoice, pay the other party for the full invoiced amount.

                           (iii)    Neither Purchaser nor Sellers shall
         encourage Marketed Product returns or accept Marketed Product returns
         outside of its normal course of business without the prior written
         approval of the other party.

                  (b)      Sellers shall be financially responsible for all
rebates pursuant to any rebate programs, including government rebate programs,
with respect to claims for the Marketed Products dispensed (the dispense date
contained in any report from a rebate program shall be used for purposes of
determining the date of such rebate) on or before thirty (30) days after the
Closing Date; provided, however, that Sellers' financial obligation for such
rebates shall terminate one-hundred eighty (180) days after the Closing Date
(the "Rebates Termination Date"). Purchaser shall assume financial
responsibility for all rebates pursuant to any such rebate programs with respect
to claims for the Marketed Products dispensed after the Rebates Termination
Date. Purchaser and Sellers acknowledge that government rebates are billed on a
calendar quarter basis and to the extent that the periods set forth in this
Section 8.14(b) do not end on a calendar quarter, the Purchaser and Seller shall
make payments for such fractional periods of any applicable quarter on a
pro-rata basis based on the number of days for which such party is responsible
for rebates in the applicable quarter. Purchaser acknowledges that Sellers will
require certain information from Purchaser in order to calculate the Medicaid
rebate for Marketed Products bearing Sellers' NDC number. Accordingly, Purchaser
agrees that, from and after the Closing Date until the date which is one (1)
calendar year after the expiration date of the last lot of Marketed Products
produced with Sellers' NDC

                                       71
<PAGE>

number, Purchaser will provide to Sellers, concurrently with its timely delivery
of related information to the Centers for Medicare and Medicaid Services (or any
successor agency), the following information: (a) the "best price" (as defined
under the Social Security Act, 42 U.S.C. Section 1396r-8(c)(1)(C)) for each
Marketed Product identified by NDC number, (b) on the twentieth (20th) day after
the end of each calendar quarter during such one (1) year period, all
information reasonably necessary for Sellers to calculate the "average
manufacturer price" (as defined under the Social Security Act, 42 U.S.C.
Sections 1396r-8(k)(1)) for each Marketed Product identified by NDC number, and
(c) any additional data or other information related to such Medicaid issues
reasonably requested by Sellers.

                  (c)      Sellers shall be financially responsible for all
chargeback claims and related administrative service fees for the Marketed
Products with a chargeback invoice dated (i.e., the date of sale from the
wholesaler to the wholesaler customer) on or before forty-five (45) days after
the Closing Date; provided, however, that Sellers' maximum financial obligation
for chargeback claims and related administrative service fees for the Marketed
Products shall terminate one-hundred eighty (180) days after the Closing Date
(the "Chargeback Termination Date"). Purchaser shall be financially responsible
for all chargeback claims and related administrative service fees for the
Marketed Products with a chargeback invoice dated after the Chargeback
Termination Date. If either Purchaser or Sellers issues financial credit or
other reimbursement for chargeback claims and related administrative fees for
which the other party was financially responsible as set forth in this Section
8.14(c), such party shall invoice the other party for such amount setting forth
information as shall be reasonably necessary to support the invoice. Purchaser
and Sellers shall, within thirty (30) days of Purchaser's or Sellers' receipt of
invoice, pay the other party for the full invoiced amount.

                  (d)      After the Closing Date, the Purchaser and Sellers
shall use commercially reasonable efforts and cooperate in good faith to notify
the wholesale trade customers that Purchaser will begin marketing the Marketed
Products, which notification shall include letters or other communication as
Purchaser and Sellers may mutually agree.

                  (e)      In the event that Purchaser increases the published
Wholesaler Acquisition Cost ("WAC") of any of the Marketed Products prior to the
last to expire of the Rebates Termination Date or the Chargeback Termination
Date, Purchaser shall (i) promptly notify Sellers of such increase and (ii)
reimburse Sellers the increase in amounts associated with returns, rebates or
chargebacks as a result of such increase in WAC. Purchaser and Sellers
acknowledge that a percentage increase in WAC may result in a greater percentage
increase in rebates, in which case Sellers would invoice Purchaser for the full
increase in the rebate. Sellers shall invoice Purchaser on a monthly basis for
amounts due pursuant to this Section 8.14(e) and Purchaser shall pay such
invoices within thirty (30) days after receipt of same.

         8.15     Adverse Experience Reporting and Product Complaints. Sellers
shall promptly submit to Purchaser all adverse drug experience information and
product

                                       72
<PAGE>

complaints brought to the attention of Sellers in writing following the Closing
in respect of any of the Products, as well as any material events and matters
concerning or affecting the safety or efficacy of any of the Products. Without
limiting the foregoing, Sellers shall notify Purchaser of any adverse or
unexpected event brought to the attention of Sellers in writing following the
Closing in respect of any of the Products within three (3) Business Days from
the date Sellers receive written notice of such event.

         8.16     Recalls. Purchaser shall be solely responsible and liable for
conducting all voluntary recalls, stop sales, field alerts, market withdrawals
or other related actions (collectively "Recalls") of units of any Products after
the Closing Date relating to Products sold by or on behalf of Sellers prior to
the Closing Date; provided, however, that, subject to Purchaser's compliance
with this Section 8.16, Sellers shall reimburse Purchaser for all of its
reasonable out-of-pocket costs and expenses, including notification, shipping
and handling charges and amounts refunded or credited to customers incurred in
respect of any Recalls relating to the Products sold by or on behalf of Sellers
prior to the Closing Date and deemed necessary by Purchaser in Purchaser's
commercially reasonable judgment. Purchaser shall reasonably consult with
Sellers and take into consideration Sellers' reasonable recommendations
regarding such Recalls; provided, that Purchaser shall not be required to
consult with Sellers in advance to the extent circumstances preclude prior
consultation. In addition, Purchaser shall use commercially reasonable efforts
to mitigate the costs and expenses associated with any such Recall.

         8.17     Inventory. Sellers shall deliver the Inventory to Purchaser
FOB Sellers' third party distribution center. Sellers shall invoice Purchaser
for reasonable storage fees with respect to Inventory not picked up by Purchaser
within ten (10) Business Days after the Closing Date. Purchaser shall pay any
such invoiced amounts within thirty (30) days of its receipt of invoice.

         8.18     Financial Statements. At Purchaser's cost (and with Purchaser
making direct arrangements with certified public accountants), Sellers shall use
their commercially reasonable efforts to furnish Purchaser and its
representatives as soon as practicable, but no later than sixty (60) days after
the Closing Date, audited balance sheets of the Purchased Assets, Licensed
Assets and Assumed Liabilities as at December 31, 2002 , 2003 and 2004 and the
audited statements of gross revenue, net revenues and direct costs for the three
(3) years ended December 31, 2004. No later than September 30, 2005, Sellers
shall furnish Purchaser and its representatives with a balance sheet of the
Purchased Assets, Licensed Assets and Assumed Liabilities as at June 30, 2005
and the statement of gross revenues, net revenues and direct costs of the
Business for the six-month period ended June 30, 2004. At Purchaser's expense,
Sellers shall also make reasonable efforts to furnish Purchaser with such other
financial, business and operating data of the Business as may be required or
reasonably requested by Purchaser for inclusion in, or in connection with, any
private placement memoranda or filings with the U.S. Securities and Exchange
Commission and registration statement (including, without limitation, any
prospectus supplement) of Purchaser under the Securities Act of 1933, as amended
(the "Securities Act"), including using commercially reasonable efforts

                                       73
<PAGE>

to furnish Purchaser, with financial information of the Business for any period
ending on or before the Closing Date that complies with any requirements of the
staff of the SEC applicable to the balance sheets and statements of gross
revenue, net revenues and direct costs described above and using reasonable
commercial efforts to cause Sellers' certified public accountants to provide
their opinion, consents for the inclusion thereof in any such registration
statement and comfort letters that are customary for registration statements or
private placement memoranda.

         8.19     Differentiation of Products. Not later than three (3) months
following the Closing, Purchaser shall use commercially reasonable efforts to
ensure that Marketed Products manufactured, finished or sold by, or on behalf
of, Purchaser bear an NDC code different than that used by the Sellers for the
Marketed Products.

         8.20     Resale Certificates. Purchaser shall use commercially
reasonable efforts to deliver to Sellers at the Closing resale certificates with
respect to the Inventory, in form and substance mutually acceptable to Purchaser
and Sellers, but in no event shall the failure to deliver such resale
certificates delay the Closing or the delivery of such resale certificates be
deemed a condition to the Closing.

         8.21     Enforcement of Rights. Sellers shall enforce all rights of
Sellers under non-disclosure or confidentiality, non-compete, or
non-solicitation agreements (collectively, the "Restrictive Agreements") with
employees and agents of Sellers or with third parties to the extent relating to
the Business, the Purchased Assets (or any portion thereof) or the Licensed
Assets (or any portion thereof) and Sellers shall aggressively pursue all
litigation in connection with any breach of such Restrictive Agreements. If
Sellers fail to aggressively pursue any such litigation, then, at Purchaser's
option, Purchaser may send written notice to Sellers indicating Purchaser's
desire to take over such litigation, and Sellers shall, upon receipt of such
written notice, promptly assign their right to pursue such litigation to
Purchaser and Purchaser shall have the right pursue such litigation, at
Purchaser's cost.

         8.22     Laboratory Notebooks. Within a commercially reasonable time
after the Closing Date, Sellers shall, at Purchaser's expense, create and
deliver copies of the Notebooks to Purchaser, provided that prior to the
delivery of copies of the Notebooks relating to the Licensed Assets, Purchaser
and Sellers shall enter into a mutually acceptable
confidentiality/non-disclosure or similar agreement protecting the
confidentiality of, and any applicable privilege or protection in, the
information contained in such Notebooks.

         8.23     Darvocet-N XR IDM. Prior to the Closing Date, Sellers shall
update the Darvocet-N XR IDM to reflect the then-current formulation of the
Darvocet-N XR Product to the extent the relevant formulation exists or is
available.

                                       74
<PAGE>

                                   ARTICLE IX

                                    EMPLOYEES

         9.1      Employment.

         (a)      Except as otherwise provided herein, at any time immediately
prior to or after the Closing, Purchaser shall be permitted to offer employment
to those employees listed on Schedule 9.1. Such individuals who accept such
offer are referred to herein as the "Transferred Employees." Subject to
Applicable Laws, Purchaser shall have the right to dismiss any or all
Transferred Employees at any time, with or without cause, and to change the
terms and conditions of their employment (including compensation and employee
benefits provided to them).

         (b)      To the extent permitted by Applicable Law, from time to time
following the Closing, Sellers shall, or shall cause their Subsidiaries to, make
available to Purchaser such non-confidential data in personnel records of
Transferred Employees as is reasonably necessary for Purchaser to transition
such employees into Purchaser's records.

         9.2      Indemnification. Sellers shall indemnify and hold Purchaser
and its Affiliates harmless with respect to any Transferred Employee from (i)
any employment-related liability with respect to employment on or prior to the
date any such Transferred Employee was hired by Purchaser and (ii) any liability
under WARN.

                                   ARTICLE X

                              CONDITIONS TO CLOSING

         10.1     Conditions Precedent to Obligations of Purchaser. The
obligation of Purchaser to consummate the transactions contemplated by this
Agreement is subject to the fulfillment, on or prior to the Closing Date, of
each of the following conditions (any or all of which may be waived by Purchaser
in whole or in part to the extent permitted by Applicable Law):

                  (a)      the representations and warranties of Sellers set
forth in this Agreement qualified as to materiality shall be true and correct,
and those not so qualified shall be true and correct in all material respects,
as of the date of this Agreement and as of the Closing as though made at and as
of the Closing, except to the extent such representations and warranties
expressly relate to an earlier date (in which case such representations and
warranties qualified as to materiality shall be true and correct, and those not
so qualified shall be true and correct in all material respects, on and as of
such earlier date) and Purchaser shall have received a certificate signed by an
authorized officer of Sellers (in form and substance reasonably satisfactory to
Purchaser), dated the Closing Date, to such effect;

                  (b)      Sellers shall have performed and complied in all
material respects with all obligations and agreements required in this Agreement
to be performed or

                                       75
<PAGE>

complied with by it prior to the Closing Date, and Purchaser shall have
received a certificate signed by an authorized officer of Sellers (in form and
substance reasonably satisfactory to Purchaser), dated the Closing Date, to such
effect;

                  (c)      there shall not have been or occurred any event,
change, occurrence or circumstance that has had or which could reasonably be
expected to have a Material Adverse Effect since the Balance Sheet Date,
provided that if there is an oral indication by the FDA that a factorial design
study (being a study in which the Darvocet-N XR Product is required to be
compared against one or more of its ingredients alone) may or will be required
for FDA approval of the Darvocet-N XR Product, Purchaser shall not be obligated
to consummate the transactions contemplated by this Agreement unless there is a
subsequent written indication by the FDA that no such factorial design study is
required, and if there is a written indication by the FDA that such factorial
design study is required, then such written indication shall be a Material
Adverse Effect; and

                  (d)      Purchaser shall have received the financing set forth
in the Commitment Letters, which condition shall be deemed satisfied if
Purchaser does not provide written notice to Sellers on or prior to three (3)
Business Days before the Bankruptcy Court's hearing with respect to the Bidding
Procedures that such condition has not been satisfied.

         10.2     Conditions Precedent to Obligations of Sellers. The
obligations of Sellers to consummate the transactions contemplated by this
Agreement are subject to the fulfillment, prior to or on the Closing Date, of
each of the following conditions (any or all of which may be waived by Sellers
in whole or in part to the extent permitted by applicable law):

                  (a)      The representations and warranties of Purchaser set
forth in this Agreement qualified as to materiality shall be true and correct,
and those not so qualified shall be true and correct in all material respects,
as of the date of this Agreement and as of the Closing as though made at and as
of the Closing, except to the extent such representations and warranties
expressly relate to an earlier date (in which case such representations and
warranties qualified as to materially shall be true and correct, and those not
so qualified shall be true and correct in all material respects, on and as of
such earlier date) and Sellers shall have received a certificate signed by an
authorized officer of Purchaser (in form and substance reasonably satisfactory
to Purchaser), dated the Closing Date, to such effect;

                  (b)      Purchaser shall have performed and complied in all
material respects with all obligations and agreements required by this Agreement
to be performed or complied with by Purchaser on or prior to the Closing Date
and Sellers shall have received a certificate signed by an authorized officer of
Purchaser (in form and substance reasonably satisfactory to Sellers), dated the
Closing Date, to such effect; and

                  (c)      Purchaser shall have paid the Purchase Price in
accordance with Section 3.9.

                                       76
<PAGE>

         10.3     Conditions Precedent to Obligations of Purchaser and Sellers.
The respective obligations of Purchaser and Sellers to consummate the
transactions contemplated by this Agreement are subject to the fulfillment, on
or prior to the Closing Date, of each of the following conditions (any or all of
which may be waived by Purchaser and Sellers in whole or in part to the extent
permitted by Applicable Law):

                  (a)      no Legal Proceedings (including any proceeding over
which the Bankruptcy Court has jurisdiction under 28 U.S.C. Section 157(b))
shall have been instituted or threatened or claim or demand made against Sellers
or Purchaser seeking to restrain or prohibit or to obtain substantial damages
with respect to the consummation of the transactions contemplated hereby, and
there shall not be in effect any Order by a Governmental Body of competent
jurisdiction restraining, enjoining or otherwise prohibiting the consummation of
the transactions contemplated hereby;

                  (b)      the Bankruptcy Court shall have entered the Bidding
Procedures Order and the Sale Order shall be a Final Order;

                  (c)      the waiting period under the HSR Act shall have
expired or early termination shall have been granted and Sellers shall have
obtained any other consent, approval, order or authorization of, or
registration, declaration or filing with, any Governmental Body required to be
obtained or made in connection with the execution and delivery of this Agreement
or the performance of the transactions contemplated herein and no Governmental
Body shall have instituted, or announced an intention to institute, any
proceeding against Purchaser or either Seller arising out of or based upon an
antitrust, competition or similar Applicable Law in connection with the
transactions contemplated herein:

                  (d)      each of Sellers on the one hand and Purchaser on the
other hand shall have executed and delivered to each other the (i) Services
Agreement, (ii) the Manufacturing Agreement and (iii) the Odyssey Co-Development
Agreement; and

                  (e)      Sellers shall have obtained those consents, waivers
and approvals referred to Schedule 10.3(e) hereof in a form satisfactory to
Purchaser.

         10.4     Frustration of Closing Conditions. Neither Sellers nor
Purchaser may rely on the failure of any condition set forth in Section 10.1,
10.2, 10.3, or, as the case may be, if such failure was caused by such party's
failure to comply with any provision of this Agreement.

                                   ARTICLE XI

                                 INDEMNIFICATION

         11.1     Survival of Representations and Warranties. The
representations and warranties of the parties contained in Articles V and VI of
this Agreement shall survive the Closing through and including twelve (12)
months following the Closing Date (the "Survival Period"); provided, however,
that any obligations to indemnify and hold

                                       77
<PAGE>

harmless shall not terminate with respect to any Losses as to which the Person
to be indemnified shall have given notice (stating in reasonable detail the
basis of the claim for indemnification) to the indemnifying party in accordance
with Section 13.3(a) before the termination of the Survival Period.

         11.2     Indemnification.

                  (a)      Subject to Section 11.4 hereof, Sellers hereby agree
to indemnify and hold Purchaser and its directors, officers, employees,
Affiliates, stockholders, agents, attorneys, representatives, successors and
assigns (collectively, the "Purchaser Indemnified Parties") harmless from and
against:

                           (i)      any and all losses, liabilities,
         obligations, damages, costs and expenses (collectively, "Losses") based
         upon, attributable to or resulting from the failure of any
         representation or warranty of Sellers set forth in this Agreement or in
         any Sellers Document, to be true and correct in all respects at the
         date hereof and at the Closing Date (except where Sellers
         representations and warranties are given as of any other applicable
         date in which case such representation and warranty shall be correct as
         of such date);

                           (ii)     any and all Losses based upon, attributable
         to or resulting from the breach of any covenant or other agreement on
         the part of Sellers under this Agreement or any Sellers Document;

                           (iii)    any and all Losses arising out of, based
         upon or relating to any Excluded Asset or any Excluded Liability;

                           (iv)     any recall, warranty claim, product
         liability claim or other claim which arises from or relates to any
         Products sold by or on behalf of Sellers prior to the Closing Date;

                           (v)      any amounts owed by Sellers to Purchaser
         pursuant to Section 8.14; and

                           (vi)     any and all notices, actions, suits,
         proceedings, claims, demands, assessments, judgments, costs, penalties
         and expenses, including reasonable attorneys' and other professionals'
         fees and disbursements (collectively, "Expenses") incident to any and
         all Losses with respect to which indemnification is provided hereunder.

                  (b)      Subject to Section 11.4, Purchaser hereby agrees to
         indemnify and hold Sellers and their Affiliates, stockholders, agents,
         attorneys, representatives, successors and permitted assigns
         (collectively, the "Seller Indemnified Parties") harmless from and
         against:

                           (i)      any and all Losses based upon, attributable
         to or resulting from the failure of any representation or warranty of
         Purchaser set forth in this

                                       78
<PAGE>

         Agreement or any Purchaser Document, to be true and correct at the date
         hereof and at the Closing Date;

                           (ii)     any and all Losses based upon, attributable
         to or resulting from the breach of any covenant or other agreement on
         the part of Purchaser under this Agreement or any Purchaser Document;

                           (iii)    any and all Losses arising out of, based
         upon or relating to any Assumed Liability;

                           (iv)     any and all Losses arising in connection
         with the conduct and operation of Purchaser's business on and after the
         Closing Date;

                           (v)      any recall, warranty claim, product
         liability claim or other claim which arises from or relates to any
         Products sold by or on behalf of Purchaser after the Closing Date;

                           (vi)     any amounts owed by Purchaser to Sellers
         pursuant to Section 8.14; and

                           (vii)    any and all Expenses incident to any and all
         Losses with respect to which indemnification is provided hereunder.

         11.3     Indemnification Procedures.

                  (a)      In the event that any Legal Proceedings shall be
instituted or that any claim or demand shall be asserted by any Person in
respect of which payment may be sought under Section 11.2 hereof (regardless of
the limitations set forth in Section 11.4) "Indemnification Claim"), the
indemnified party shall reasonably and promptly cause written notice of the
assertion of any Indemnification Claim of which it has knowledge which is
covered by this indemnity to be forwarded to the indemnifying party. The
indemnifying party shall have the right, at its sole expense, to be represented
by counsel of its choice, which must be reasonably satisfactory to the
indemnified party, and to defend against, negotiate, settle or otherwise deal
with any Indemnification Claim which relates to any Losses indemnified against
hereunder; provided that the indemnifying party shall have acknowledged in
writing to the indemnified party its unqualified obligation to indemnify the
indemnified party as provided hereunder. If the indemnifying party elects to
defend against, negotiate, settle or otherwise deal with any Indemnification
Claim which relates to any Losses indemnified against hereunder, it shall within
fifteen (15) Business Days (or sooner, if the nature of the Indemnification
Claim so requires) notify the indemnified party of its intent to do so. If the
indemnifying party elects not to defend against, negotiate, settle or otherwise
deal with any Indemnification Claim which relates to any Losses indemnified
against hereunder, fails to notify the indemnified party of its election as
herein provided or contests its obligation to indemnify the indemnified party
for such Losses under this Agreement, the indemnified party may defend against,
negotiate, settle or otherwise deal with such Indemnification Claim. If the
indemnified party defends any Indemnification Claim, then the indemnifying party
shall reimburse the

                                       79
<PAGE>

indemnified party for the Expenses of defending such Indemnification Claim upon
submission of periodic bills. If the indemnifying party shall assume the defense
of any Indemnification Claim, the indemnified party may participate, at his or
its own expense, in the defense of such Indemnification Claim; provided,
however, that such indemnified party shall be entitled to participate in any
such defense with separate counsel at the expense of the indemnifying party if
(i) so requested by the indemnifying party to participate or (ii) in the
reasonable opinion of counsel to the indemnified party a conflict or potential
conflict exists between the indemnified party and the indemnifying party that
would make such separate representation advisable; and provided, further, that
the indemnifying party shall not be required to pay for more than one such
counsel for all indemnified parties in connection with any Indemnification
Claim. The parties hereto agree to cooperate fully with each other in connection
with the defense, negotiation or settlement of any such Indemnification Claim.
Notwithstanding anything in this Section 11.3 to the contrary, neither the
indemnifying party nor the indemnified party shall, without the written consent
of the other party, settle or compromise any Indemnification Claim or permit a
default or consent to entry of any judgment unless the claimant and such party
provide to such other party an unqualified release from all liability in respect
of the Indemnification Claim. Notwithstanding the foregoing, if a settlement
offer solely for money damages is made by the applicable third party claimant,
and the indemnifying party notifies the indemnified party in writing of the
indemnifying party's willingness to accept the settlement offer and, subject to
the applicable limitations of Section 11.4, pay the amount called for by such
offer, and the indemnified party declines to accept such offer, the indemnified
party may continue to contest such Indemnification Claim, free of any
participation by the indemnifying party, and the amount of any ultimate
liability with respect to such Indemnification Claim that the indemnifying party
has an obligation to pay hereunder shall be limited to the lesser of (A) the
amount of the settlement offer that the indemnified party declined to accept
plus the Losses of the indemnified party relating to such Indemnification Claim
through the date of its rejection of the settlement offer or (B) the aggregate
Losses of the indemnified party with respect to such Indemnification Claim. If
the indemnifying party makes any payment on any Indemnification Claim, the
indemnifying party shall be subrogated, to the extent of such payment, to all
rights and remedies of the indemnified party to any insurance benefits or other
claims of the indemnified party with respect to such Indemnification Claim.

                  (b)      After any final judgment or award shall have been
rendered by a Governmental Body of competent jurisdiction and the expiration of
the time in which to appeal therefrom, or a settlement shall have been
consummated, or the indemnified party and the indemnifying party shall have
arrived at a mutually binding agreement with respect to an Indemnification Claim
hereunder, the indemnified party shall forward to the indemnifying party notice
of any sums due and owing by the indemnifying party pursuant to this Agreement
with respect to such matter and the indemnifying party shall be required to pay
all of the sums so due and owing to the indemnified party by wire transfer of
immediately available funds within ten (10) Business Days after the date of such
notice.

                                       80
<PAGE>

                  (c)      The failure of the indemnified party to give
reasonably prompt notice of any Indemnification Claim shall not release, waive
or otherwise affect the indemnifying party's obligations with respect thereto
except to the extent that the indemnifying party can demonstrate actual loss and
prejudice as a result of such failure.

         11.4     Limitations on Indemnification for Breaches of Representations
and Warranties.

                  (a)      An indemnifying party shall not have any liability
under Section 11.2(a)(i) or Section 11.2(b)(i) hereof unless and until the
aggregate amount of Losses and Expenses to the indemnified parties finally
determined to arise thereunder based upon, attributable to or resulting from the
failure of any representation or warranty to be true and correct (unless such
failure is the result of the indemnifying party's fraud or willful misconduct),
other than the representations and warranties set forth in Sections 5.1, 5.2,
5.8, 5.16 and 6.1, 6.2 and 6.5 hereof, exceeds $1,700,000 (the "Basket"), in
which case, only the Losses in excess of such amount of Loss shall be covered.

                  (b)      Sellers shall not be required to indemnify any Person
for an aggregate amount of Losses and Expenses above the amount of Sellers'
Indemnity Escrow Fund, which shall be the sole source of payment of such
amounts, and Purchaser shall not be required to indemnify any Person for an
aggregate amount of Expenses and Losses under Section 11.2(b)(i) above the
amount of Purchaser's Indemnity Escrow Fund.

                  (c)      For purposes of calculating Losses hereunder with
respect to determining whether the Losses and Expenses exceed $1,700,000 for
purposes of Section 11.4(a), any materiality or material adverse effect
qualifications in the representations, warranties, covenants and agreements
shall be ignored.

         11.5     Indemnity Escrows.

                  (a)      Purchaser's Indemnity Escrow Amount. On the Closing
Date, Purchaser shall pay to the Escrow Agent, in immediately available funds,
to the account designated by the Escrow Agent, the Purchaser's Indemnity Escrow
Amount in accordance with the terms of this Agreement and the Indemnity Escrow
Agreement. Six (6) months after the Closing Date, the Escrow Agent shall release
fifty percent (50%) of (i) the then existing amount of the Purchaser's Indemnity
Escrow Fund to Purchaser, less (ii) the amount of claims for indemnification
under this Article XI asserted by Sellers prior to the expiration of such six
(6) month period but not yet resolved ("Unresolved Claims"), and any unreleased
amount shall be retained by the Escrow Agent. Twelve (12) months after the
Closing Date, the Escrow Agent shall release the remaining amount of Purchaser's
Indemnity Escrow Fund to Purchaser, except that the Escrow Agent shall retain an
amount equal to the amount of the Unresolved Claims asserted prior to the
expiration of such twelve (12) month period. The Purchaser's Indemnity Escrow
Fund retained for Unresolved Claims shall be released by the Escrow Agent (to
the extent not

                                       81
<PAGE>

utilized to pay Sellers for any such claims resolved in favor of Sellers) upon
their resolution in accordance with this Article XI.

                  (b)      Sellers' Indemnity Escrow Amount. On the Closing
Date, Purchaser shall pay to the Escrow Agent, in immediately available funds,
to the account designated by the Escrow Agent, the Sellers' Indemnity Escrow
Amount (which shall be deducted from the Purchase Price) in accordance with the
terms of this Agreement and the Indemnity Escrow Agreement. Any payment Sellers
are obligated to make to any Purchaser Indemnified Party pursuant to this
Article XI shall be paid from the Sellers' Indemnity Escrow Fund. Six (6) months
after the Closing Date, the Escrow Agent shall release fifty percent (50%) of
(i) the then existing amount of the Sellers' Indemnity Escrow Fund to Sellers,
less (ii) the amount of the Unresolved Claims asserted by Sellers prior to the
expiration of such six (6) month period, and any unreleased amount shall be
retained by the Escrow Agent. Twelve (12) months after the Closing Date, the
Escrow Agent shall release the remaining amount of the Seller's Indemnity Escrow
Fund to Sellers, except that the Escrow Agent shall retain an amount equal to
the amount of the Unresolved Claims asserted prior to the expiration of such
twelve (12) month period. The Sellers' Indemnity Escrow Fund retained for
Unresolved Claims shall be released by the Escrow Agent (to the extent not
utilized to pay Purchaser for any such claims resolved in favor of Purchaser)
upon their resolution in accordance with this Article XI.

         11.6     Tax Treatment of Indemnity Payments. Sellers and Purchaser
agree to treat any indemnity payment made pursuant to this Article XI as an
adjustment to the Purchase Price for all Tax purposes. If, notwithstanding the
treatment required by the preceding sentence, any indemnification payment is
determined to be taxable to the party receiving such payment by any Taxing
Authority, the paying party shall also indemnify the party receiving such
payment for any Taxes incurred by reason of the receipt of such payment and any
Expenses incurred by the party receiving such payment in connection with such
Taxes (or any asserted deficiency, claim, demand, action, suit, proceeding,
judgment or assessment, including the defense or settlement thereof, relating to
such Taxes). The amount of any Loss shall be reduced on account of any Tax
benefit actually realized by the party incurring such Loss.

NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL
ANY PARTY OR THEIR AFFILIATES BE LIABLE UNDER ANY THEORY, INCLUDING NEGLIGENCE,
FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR INDIRECT DAMAGES
OR LOST PROFITS, DAMAGE TO REPUTATION, LOST BUSINESS OPPORTUNITIES, INTERFERENCE
WITH BUSINESS OPPORTUNITIES OR DIMINUTION OF VALUE.

                                       82
<PAGE>

                                  ARTICLE XII

                                      TAXES

         12.1     Transfer Taxes. (i) Purchaser and Sellers shall each be
responsible for (and shall indemnify and hold harmless each other against) half
of any and all Liabilities for any sales, use, stamp, documentary, filing,
recording, transfer, real estate transfer, stock transfer, gross receipts,
registration, duty, securities transactions or similar fees or taxes or
governmental charges (together with any interest or penalty, addition to tax or
additional amount imposed) as levied by any Taxing Authority in connection with
the transactions contemplated by this Agreement (collectively, "Transfer
Taxes"), regardless of the Person liable for such Transfer Taxes under
Applicable Law and (ii) Sellers or Purchaser, as required by Applicable Law,
shall timely file or caused to be filed all necessary documents (including all
Tax Returns) with respect to Transfer Taxes. Notwithstanding the foregoing, the
Sellers shall seek to include in the Sale Order a provision that Sellers' sale,
transfer, assignment and conveyance of the Purchased Assets to Purchaser
hereunder shall be entitled to the protections afforded under Section 1146(c) of
the Bankruptcy Code. The parties will reasonably cooperate to minimize any such
taxes, including with respect to delivery location.

         12.2     Prorations. All personal property taxes, or ad valorem
obligations and similar recurring taxes and fees on the Purchased Assets for
taxable periods beginning before, and ending after, the Closing Date, shall be
prorated between Purchaser and Sellers as of 12:01 a.m. eastern standard time on
the Closing Date. With respect to Taxes described in this Section 12.2, Sellers
shall timely file all Tax Returns due before the Closing Date with respect to
such Taxes and Purchaser shall prepare and timely file all Tax Returns due after
the Closing Date with respect to such Taxes. If one party remits to the
appropriate Taxing Authority payment for Taxes, which are subject to proration
under this Section 12.2 and such payment includes the other party's share of
such Taxes, such other party shall promptly reimburse the remitting party for
its share of such Taxes.

         12.3     Purchase Price Allocation. Not later than sixty (60) days
after the Closing Date, Purchaser shall prepare and deliver to Sellers copies of
Form 8594 and any required exhibits thereto (the "Asset Acquisition Statement")
allocating the purchase price (including the Assumed Liabilities) among the
Purchased Assets in accordance with Section 1060 of the Code and the Treasury
regulations thereunder. Purchaser shall prepare and deliver to Sellers from time
to time revised copies of the Asset Acquisition Statement (the "Revised
Statements") so as to report any matters on the Asset Acquisition Statement that
need updating (including purchase price adjustments, if any). Sellers shall have
a period of ten (10) days after the delivery of the Asset Acquisition Statement
or, if applicable, the last Revised Statement (the "Allocation Response Period")
to present in writing to Purchaser notice of any objections Sellers may have to
the allocations set forth therein (an "Allocation Objections Notice"). Unless
Sellers object within such period, the Asset Allocation Statement or, if
applicable, the last Revised Statement shall be binding on the parties. If
Sellers shall raise any objections within the Allocation Response Period,
Purchaser and Sellers shall negotiate in good faith

                                       83
<PAGE>

and use their commercially reasonable efforts to resolve such dispute. If the
parties fail to agree within fifteen (15) days after the delivery of the
Allocation Objections Notice, then Purchaser shall submit the Asset Acquisition
Statement or, if applicable, the last Revised Statement, including
modifications, if any, that Purchaser chooses to make as a result of its
negotiations with Sellers, to the Accountant for resolution by it. The disputed
items shall be submitted to the Accountant within fifteen (15) days following
such failure to agree. The determination of the Accountant shall be final and
binding on the parties and shall not be subject to appeal. The Accountant shall
resolve the dispute by selecting the proposed allocation submitted by either
Purchaser or Sellers which in the sole judgment of the Accountant most
accurately allocates the purchase price and the Assumed Liabilities among the
Purchased Assets in accordance with their relative fair market values, but not
by choosing any other formulation. The Accountant shall render such decision and
report to Purchaser and Sellers in writing, specifying the reasons for its
decision in reasonable detail, not later than thirty (30) days after the item
has been referred to it. The costs, fees and expenses of the Accountant shall be
borne equally by Sellers and Purchaser. The purchase price for the Purchased
Assets shall be allocated in accordance with the Asset Acquisition Statement or,
if applicable, the last Revised Statements, as finally determined, and all
income Tax Returns and reports filed by Purchaser and Sellers shall be prepared
consistently with such allocation.

         12.4     Cooperation on Tax Matters.

         (a)      Purchaser and Sellers shall furnish or cause to be furnished
to each other, as promptly as practicable, such information and assistance
relating to the Purchased Assets and the Assumed Liabilities as is reasonably
necessary for the preparation and filing of any Tax Return, claim for refund or
other required or optional filings relating to Tax matters, for the preparation
for any Tax audit, for the preparation for any Tax protest, or for the
prosecution or defense of any suit or other proceeding relating to Tax matters.

                  (b)      Purchaser shall retain possession of all accounting,
business, financial and Tax records and information relating to the Purchased
Assets or the Assumed Liabilities that are in existence on the Closing Date and
transferred to Purchaser hereunder for a period of at least three (3) years from
the Closing Date. Purchaser shall give Sellers notice and an opportunity to
retain any such records in the event that Purchaser determines to destroy or
dispose of them after such period. In addition, from and after the Closing Date,
Purchaser shall provide access to Sellers (after reasonably detailed prior
notice and during normal business hours), to the books, records, documents and
other information relating to the Purchased Assets or the Assumed Liabilities as
is reasonably necessary for Sellers to properly prepare for, file, prove,
answer, prosecute and/or defend any Tax Return, claim, filing, tax audit, tax
protest, suit, proceeding or answer.

                                       84
<PAGE>

                                  ARTICLE XIII

                                  MISCELLANEOUS

         13.1     Expenses. Except for the Expense Reimbursement and as
otherwise expressly provided in this Agreement, each of Sellers and Purchaser
shall bear its own expenses incurred in connection with the negotiation and
execution of this Agreement and each other agreement, document and instrument
contemplated by this Agreement and the consummation of the transactions
contemplated hereby and thereby.

         13.2     Specific Performance. Sellers and Purchaser acknowledge and
agree that the breach of this Agreement would cause irreparable damage to the
other and that neither Sellers nor Purchaser will have an adequate remedy at
law. Therefore, the obligations of Sellers and Purchaser under this Agreement
shall be enforceable by a decree of specific performance issued by any court of
competent jurisdiction, and appropriate injunctive relief may be applied for and
granted in connection therewith. Such remedies shall, however, be cumulative and
not exclusive and shall be in addition to any other remedies which any party may
have under this Agreement or otherwise.

         13.3     Submission to Jurisdiction; Consent to Service of Process.

                  (a)      The parties hereto hereby irrevocably submit to the
exclusive jurisdiction of the Bankruptcy Court over any dispute arising out of
or relating to this Agreement or any of the transactions contemplated hereby and
each party hereby irrevocably agrees that all claims in respect of such dispute
or any suit, action proceeding related thereto may be heard and determined in
the Bankruptcy Court; provided, however, that in the event the Bankruptcy Court
abstains from exercising or declines to exercise jurisdiction with respect to
any matter provided for in this sentence or is without jurisdiction, such
abstention, refusal or lack of jurisdiction shall have no effect upon and shall
not control, prohibit or limit the exercise of jurisdiction of any other court
having competent jurisdiction with respect to any such matter. The parties
hereby irrevocably waive, to the fullest extent permitted by Applicable Law, any
objection which they may now or hereafter have to the laying of venue of any
such dispute brought in such court or any defense of inconvenient forum for the
maintenance of such dispute. Each of the parties hereto agrees that a judgment
in any such dispute may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by law.

                  (b)      Each of the parties hereto hereby consents to process
being served by any party to this Agreement in any suit, action or proceeding by
the mailing of a copy thereof in accordance with the provisions of Section 13.7.

         13.4     Waiver of Right to Trial by Jury. Each party to this Agreement
waives any right to trial by jury in any action, matter or proceeding regarding
this Agreement or any provision hereof.

                                       85
<PAGE>

         13.5     Entire Agreement; Amendments and Waivers. This Agreement
(including the schedules and exhibits hereto) and the Confidentiality Agreement
represent the entire understanding and agreement between the parties hereto with
respect to the subject matter hereof. This Agreement can be amended,
supplemented or changed, and any provision hereof can be waived, only by written
instrument making specific reference to this Agreement signed by the party
against whom enforcement of any such amendment, supplement, modification or
waiver is sought. No action taken pursuant to this Agreement, including without
limitation, any investigation by or on behalf of any party, shall be deemed to
constitute a waiver by the party taking such action of compliance with any
representation, warranty, covenant or agreement contained herein. The waiver by
any party hereto of a breach of any provision of this Agreement shall not
operate or be construed as a further or continuing waiver of such breach or as a
waiver of any other or subsequent breach. No failure on the part of any party to
exercise, and no delay in exercising, any right, power or remedy hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of such
right, power or remedy by such party preclude any other or further exercise
thereof or the exercise of any other right, power or remedy. All remedies
hereunder are cumulative and are not exclusive of any other remedies provided by
law.

         13.6     Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to
contracts made and performed in such State.

         13.7     Notices. All notices and other communications under this
Agreement shall be in writing and shall be deemed given (i) when delivered
personally by hand (with written confirmation of receipt), (ii) when sent by
facsimile (with written confirmation of transmission) or (iii) one business day
following the day sent by overnight courier (with written confirmation of
receipt), in each case at the following addresses and facsimile numbers (or to
such other address or facsimile number as a party may have specified by notice
given to the other party pursuant to this provision):

                  If to Sellers, to:

                  aaiPharma Inc.
                  2320 Scientific Park Drive
                  Wilmington, NC 28405
                  Facsimile:  (910) 815-2387
                  Attention:  Ludo Reynders

                  With a copy to:

                  Fried, Frank, Harris, Shriver & Jacobson LLP
                  One New York Plaza
                  New York, NY 10004
                  Facsimile:  (212) 859-4000
                  Attention:  Jean Hanson, Esq.

                                       86
<PAGE>

                  If to Purchaser, to:

                  Xanodyne Pharmaceuticals, Inc.
                  7300 Turfway Road
                  Suite 300
                  Florence, KY 41042
                  Facsimile:  (859) 371-7692
                  Attention:  Thomas P. Jennings, Esq.

                  With a copy to:

                  Weil, Gotshal & Manges LLP
                  767 Fifth Avenue
                  New York, NY  10153
                  Facsimile: (212) 310-8007
                  Attention:  Lori R. Fife, Esq.
                              Simeon Gold, Esq.

         13.8     Severability. If any term or other provision of this Agreement
is invalid, illegal, or incapable of being enforced by any law or public policy,
all other terms or provisions of this Agreement shall nevertheless remain in
full force and effect so long as the economic or legal substance of the
transactions contemplated hereby is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision
is invalid, illegal, or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in an acceptable manner in order
that the transactions contemplated hereby are consummated as originally
contemplated to the greatest extent possible.

         13.9     Binding Effect; Assignment. This Agreement shall be binding
upon and inure to the benefit of the parties and their respective successors and
permitted assigns. Nothing in this Agreement shall create or be deemed to create
any third party beneficiary rights in any person or entity not a party to this
Agreement except as provided below. No assignment of this Agreement or of any
rights or obligations hereunder may be made by either Sellers or Purchaser (by
operation of law or otherwise) without the prior written consent of the other
parties hereto and any attempted assignment without the required consents shall
be void; provided, however, that Purchaser may assign this Agreement and any or
all rights or obligations hereunder (including, without limitation, Purchaser's
rights to purchase the Purchased Assets and assume the Assumed Liabilities and
Purchaser's rights to seek indemnification hereunder) to any wholly-owned
Subsidiary of Purchaser); provided, further, however, in such event, Purchaser
shall remain bound by the terms of this Agreement. Upon any such permitted
assignment, the references in this Agreement to Purchaser shall also apply to
any such assignee unless the context otherwise requires.

                                       87
<PAGE>

         13.10    Non-Recourse. No past, present or future director, officer,
employee, incorporator, member, partner, equityholder, Affiliate, agent,
attorney or representative of Purchaser or Sellers or their respective
Affiliates shall have any liability for any obligations or liabilities of
Purchaser or Sellers, as the case may be, under this Agreement or the Purchaser
Documents of or for any claim based on, in respect of, or by reason of, the
transactions contemplated hereby and thereby.

         13.11    Time of Essence. With regard to all dates and time periods set
forth or referred to in this Agreement, including, without limitation, the
deadline by which the Approval Motion must be filed, the deadlines by which the
Bidding Procedures Order and Sale Order must be entered, and the deadline by
which the Closing Date must occur, each of the parties hereto acknowledge that
time is of the essence. The failure to meet the foregoing deadlines shall
constitute a default under this Agreement.

         13.12    Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed to be an original copy of this
Agreement and all of which, when taken together, will be deemed to constitute
one and the same agreement.

                                       88
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be executed by their respective officers thereunto duly authorized,
as of the date first written above.

                                      XANODYNE PHARMACEUTICALS, INC.

                                      By:  /s/ William A. Nuerge
                                           -------------------------------------
                                           Name: William A. Nuerge
                                           Title: Chief Executive Officer

                                      AAIPHARMA INC.

                                      By:  /s/ Ludo J. Reynders
                                           -------------------------------------
                                           Ludo J. Reynders, Ph. D.
                                           President and Chief Executive Officer

                                      AAIPHARMA, LLC

                                      By:  /s/ Ludo J. Reynders
                                           -------------------------------------
                                           Ludo J. Reynders, Ph. D.
                                           President and Chief Executive Officer

                                       89<PAGE>
                               FINANCING AGREEMENT

                            DATED AS OF MAY 11, 2005

                                  BY AND AMONG

                                 AAIPHARMA INC.,
                       AS DEBTOR AND DEBTOR-IN-POSSESSION,
                                    AS PARENT

                                       AND

  EACH SUBSIDIARY OF PARENT LISTED AS A BORROWER ON THE SIGNATURE PAGES HERETO,
                       AS DEBTOR AND DEBTOR-IN-POSSESSION,
                                  AS BORROWERS,

           THE FINANCIAL INSTITUTIONS FROM TIME TO TIME PARTY HERETO,
                                   AS LENDERS,

                           SILVER POINT FINANCE, LLC,
                              AS COLLATERAL AGENT,

                                       AND

                              BANK OF AMERICA, N.A.
                             AS ADMINISTRATIVE AGENT
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
ARTICLE I DEFINITIONS; CERTAIN TERMS.....................................      2
   Section 1.01    Definitions...........................................      2
   Section 1.02    Terms Generally.......................................     30
   Section 1.03    Accounting and Other Terms............................     31
   Section 1.04    Time References.......................................     31

ARTICLE II THE LOANS.....................................................     31
   Section 2.01    Commitments...........................................     31
   Section 2.02    Making the Loans......................................     32
   Section 2.03    Repayment of Loans; Evidence of Debt..................     35
   Section 2.04    Interest..............................................     36
   Section 2.05    Reduction of Commitment; Prepayment of Loans..........     37
   Section 2.06    Fees..................................................     42
   Section 2.07    Securitization........................................     42
   Section 2.08    Taxes.................................................     43
   Section 2.09    LIBOR Option..........................................     45

ARTICLE III LETTERS OF CREDIT............................................     47
   Section 3.01    Letters of Credit.....................................     47
   Section 3.02    Letter of Credit Fees.................................     53

ARTICLE IV SECURITY AND ADMINISTRATIVE PRIORITY..........................     54
   Section 4.01    Pre-Petition Obligations..............................     54
   Section 4.02    Acknowledgment of Security Interests..................     54
   Section 4.03    Binding Effect of Documents...........................     54
   Section 4.04    Collateral; Grant of Lien and Security Interest.......     55
   Section 4.05    Administrative Priority...............................     55
   Section 4.06    Grants, Rights and Remedies...........................     56
   Section 4.07    No Filings Required...................................     56
   Section 4.08    Survival..............................................     56

ARTICLE V FEES, PAYMENTS AND OTHER COMPENSATION..........................     57
   Section 5.01    Audit and Collateral Monitoring Fees..................     57
   Section 5.02    Payments; Computations and Statements.................     57
   Section 5.03    Sharing of Payments, Etc..............................     58
   Section 5.04    Apportionment of Payments.............................     59
   Section 5.05    Increased Costs and Reduced Return....................     60
   Section 5.06    Joint and Several Liability of the Borrowers..........     61

ARTICLE VI CONDITIONS TO LOANS...........................................     62
   Section 6.01    Conditions Precedent to Interim Facility..............     62
   Section 6.02    Conditions Precedent to Final Facility
                      Effectiveness......................................     66
   Section 6.03    Conditions Precedent to All Loans and Letters of
                      Credit.............................................     68
   Section 6.04    Conditions Subsequent to Effectiveness................     69
</TABLE>

                                       -i-
<PAGE>
<TABLE>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
ARTICLE VII REPRESENTATIONS AND WARRANTIES...............................     70
   Section 7.01    Representations and Warranties........................     70

ARTICLE VIII COVENANTS OF THE LOAN PARTIES...............................     79
   Section 8.01    Affirmative Covenants.................................     79
   Section 8.02    Negative Covenants....................................     90

ARTICLE IX MANAGEMENT, COLLECTION AND STATUS OF ACCOUNTS RECEIVABLE
              AND OTHER COLLATERAL.......................................     97
   Section 9.01    Collection of Accounts Receivable; Management of
                      Collateral.........................................     97
   Section 9.02    Accounts Receivable Documentation.....................    100
   Section 9.03    Status of Accounts Receivable and Other Collateral....    100
   Section 9.04    Collateral Custodian..................................    101

ARTICLE X EVENTS OF DEFAULT..............................................    101
   Section 10.01   Events of Default.....................................    101

ARTICLE XI AGENTS........................................................    106
   Section 11.01   Appointment...........................................    106
   Section 11.02   Nature of Duties......................................    107
   Section 11.03   Rights, Exculpation, Etc..............................    107
   Section 11.04   Reliance..............................................    108
   Section 11.05   Indemnification.......................................    108
   Section 11.06   Agents Individually...................................    109
   Section 11.07   Successor Agent.......................................    109
   Section 11.08   Collateral Matters....................................    110
   Section 11.09   Agency for Perfection.................................    111
   Section 11.10   Senior Subordinated Note Intercreditor Agreement......    112
   Section 11.11   Other Agents; Arrangers and Manager...................    112

ARTICLE XII MISCELLANEOUS................................................    112
   Section 12.01   Notices, Etc..........................................    112
   Section 12.02   Amendments, Etc.......................................    115
   Section 12.03   No Waiver; Remedies, Etc..............................    115
   Section 12.04   Expenses; Taxes; Attorneys' Fees......................    116
   Section 12.05   Right of Set-off......................................    117
   Section 12.06   Severability..........................................    117
   Section 12.07   Assignments and Participations........................    117
   Section 12.08   Counterparts..........................................    121
   Section 12.09   GOVERNING LAW.........................................    122
   Section 12.10   CONSENT TO JURISDICTION; SERVICE OF PROCESS AND
                      VENUE..............................................    122
   Section 12.11   WAIVER OF JURY TRIAL, ETC.............................    122
   Section 12.12   Consent by the Agents, the L/C Issuer and Lenders.....    123
   Section 12.13   No Party Deemed Drafter...............................    123
   Section 12.14   Reinstatement; Certain Payments.......................    123
   Section 12.15   Indemnification.......................................    123
</TABLE>

                                      -ii-
<PAGE>
<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                         <C>
   Section 12.16   Parent as Agent for Borrowers.........................    124
   Section 12.17   Records...............................................    125
   Section 12.18   Binding Effect........................................    125
   Section 12.19   Interest..............................................    126
   Section 12.20   Confidentiality.......................................    127
   Section 12.21   Integration...........................................    127
   Section 12.22   USA Patriot Act Notice................................    128
</TABLE>

                                     -iii-
<PAGE>
                              SCHEDULE AND EXHIBITS

<TABLE>
<S>                   <C>
Schedule 1.01(A)      Lenders and Lenders' Commitments
Schedule 1.01(B)      Licensing Agreements
Schedule 1.01(C)      Long-Term Budget
Schedule 1.01(D)      Carry-Forward Amount
Schedule 1.01(E)      Material Contracts
Schedule 1.01(F)      Net Cash Proceeds
Schedule 1.01(G)      Supplemental Disclosure
Schedule 3.01         Existing Letters of Credit
Schedule 7.01(e)      Subsidiaries
Schedule 7.01(f)      Litigation; Commercial Tort Claims
Schedule 7.01(g)(i)   Financial Condition
Schedule 7.01(h)      Compliance with Laws
Schedule 7.01(i)      ERISA
Schedule 7.01(o)      Real Property
Schedule 7.01(r)      Environmental Matters
Schedule 7.01(s)      Insurance
Schedule 7.01(u)      Bank Accounts
Schedule 7.01(v)      Intellectual Property
Schedule 7.01(w)      Material Contracts
Schedule 7.01(aa)     Name; Jurisdiction of Organization; Organizational ID
                      Number; Chief Place of Business; Chief Executive Office;
                      FEIN
Schedule 7.01(bb)     Tradenames
Schedule 7.01(cc)     Collateral Locations
Schedule 7.01(ff)     FDA and Other Governmental Notices
Schedule 8.02(a)      Existing Liens
Schedule 8.02(e)      Existing Investments
Schedule 8.02(j)      Transactions With Affiliates
Schedule 8.02(k)      Limitations on Dividends and Other Payment Restrictions
Schedule 8.02(o)      Compromise of Accounts Receivable
Schedule 8.02(v)      Pre-Petition Payments
Schedule 9.01         Lockbox Banks and Lockbox Accounts
</TABLE>

<TABLE>
<S>         <C>
Exhibit A   Form of Notice of Borrowing
Exhibit B   Form of LIBOR Notice
Exhibit C   Form of Opinion of Counsel
Exhibit D   Form of Assignment and Acceptance
Exhibit E   Form of Interim Facility Bankruptcy Court Order
</TABLE>

                                      -iv-
<PAGE>
                               FINANCING AGREEMENT

          Financing Agreement, dated as of May 11, 2005, by and among aaiPharma
Inc., a Delaware corporation, as debtor and debtor-in-possession (the "Parent"),
Applied Analytical Industries Learning Center, Inc., a Delaware corporation, as
debtor and debtor-in-possession ("Applied Analytical"), AAI Technologies, Inc.,
a Delaware corporation, as debtor and debtor-in-possession ("AAI Technologies"),
AAI Properties, Inc., a North Carolina corporation, as debtor and
debtor-in-possession ("AAI Properties"), AAI Japan, Inc., a Delaware
corporation, as debtor and debtor-in-possession ("AAI Japan"), Kansas City
Analytical Services, Inc., a Kansas corporation, as debtor and
debtor-in-possession ("Analytical Services"), AAI Development Services, Inc., a
Massachusetts corporation, as debtor and debtor-in-possession ("AAI
Development-MA"), aaiPharma LLC, a Delaware limited liability company, as debtor
and debtor-in-possession ("Pharma LLC") and AAI Development Services, Inc., a
Delaware corporation, as debtor and debtor-in-possession ("AAI Development-DE",
and together with Parent, Applied Analytical, AAI Technologies, AAI Properties,
AAI Japan, Analytical Services, AAI Development-MA and Pharma LLC, each a
"Borrower" and collectively, the "Borrowers"), the financial institutions from
time to time party hereto (each a "Lender" and collectively, the "Lenders"),
Silver Point Finance, LLC, a Delaware limited liability company ("Silver
Point"), as collateral agent for the Lenders (in such capacity, and any
successor in such capacity, the "Collateral Agent"), and Bank of America, N.A.
("Bank of America"), administrative agent for the Lenders (in such capacity, and
any successor in such capacity, the "Administrative Agent" and together with the
Collateral Agent, each an "Agent" and collectively, the "Agents").

                                    RECITALS

          The Borrowers have commenced voluntary cases (the "Chapter 11 Cases")
under Chapter 11 of the Bankruptcy Code (as hereinafter defined) in the United
States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"),
and the Borrowers continue to operate their businesses and manage their
properties as debtors-in-possession pursuant to sections 1107 and 1108 of the
Bankruptcy Code.

          The Borrowers have asked the Lenders to make post-petition loans and
advances to the Borrowers consisting of (a) a term loan in the aggregate
principal amount of $180,000,000 and (b) a revolving credit facility in an
aggregate principal amount not to exceed $30,000,000 at any time outstanding,
which will include a subfacility for the issuance of letters of credit, provided
that until the Final Bankruptcy Court Order (as hereinafter defined) shall have
been entered by the Bankruptcy Court, no loans or advances under the term loan
or revolving credit facilities shall be made, and no letters of credit shall be
issued, other than revolving credit loans in an aggregate principal amount not
to exceed $15,000,000. The Lenders have severally, and not jointly, agreed to
extend such credit to the Borrowers subject to the terms and conditions
hereinafter set forth.

          In consideration of the premises and the covenants and agreements
contained herein, the parties hereto agree as follows:
<PAGE>
                                    ARTICLE I

                           DEFINITIONS; CERTAIN TERMS

          Section 1.01 Definitions. As used in this Agreement, the following
terms shall have the respective meanings indicated below, such meanings to be
applicable equally to both the singular and plural forms of such terms:

          "Account Debtor" means each debtor, customer or obligor in any way
obligated on or in connection with any Account Receivable.

          "Account Receivable" means, with respect to any Person, any and all
rights of such Person to payment for goods sold and/or services rendered,
including accounts, general intangibles and any and all such rights evidenced by
chattel paper, instruments or documents, whether due or to become due and
whether or not earned by performance, and whether now or hereafter acquired or
arising in the future, and any supporting obligations in respect of the
foregoing and any proceeds arising from or relating to the foregoing.

          "Acquisition" means the acquisition of (i) all of the Capital Stock of
any Person, (ii) all or substantially all of the assets of any Person or (iii)
all or substantially all of the intellectual property rights to a pharmaceutical
product or product line of any Person, whether or not involving a merger or
consolidation with such Person.

          "Action" has the meaning specified therefor in Section 12.12.

          "Administrative Agent" has the meaning specified therefor in the
preamble hereto.

          "Administrative Agent's Account" means an account at a bank designated
by the Administrative Agent from time to time as the account into which the Loan
Parties shall make all payments to the Administrative Agent for the benefit of
the Agents, L/C Issuer and the Lenders under this Agreement and the other Loan
Documents.

          "Administrative Borrower" has the meaning specified therefor in
Section 12.16.

          "Affiliate" means, with respect to any Person, any other Person that
directly or indirectly through one or more intermediaries, controls, is
controlled by, or is under common control with, such Person. For purposes of
this definition, "control" of a Person means the power, directly or indirectly,
either to (i) vote 10% or more of the Capital Stock having ordinary voting power
for the election of directors of such Person or (ii) direct or cause the
direction of the management and policies of such Person whether by contract or
otherwise. Notwithstanding anything herein to the contrary, in no event shall
any Agent, the L/C Issuer or any Lender be considered an "Affiliate" of any Loan
Party.

          "After Acquired Property" has the meaning specified therefor in
Section 8.01(n).

          "Agent" has the meaning specified therefor in the preamble hereto.

                                       -2-
<PAGE>
          "Agent-Related Persons" means the Administrative Agent and the
Collateral Agent, together with their Affiliates, and the officers, directors,
employees, agents and attorneys-in-fact of such Persons and Affiliates.

          "Agreed Administrative Expense Priorities" means that administrative
expenses with respect to the Loan Parties and, with respect to sub-clause (ii)
of clause "first", any official committee appointed by the Bankruptcy Court,
shall have the following order of priority:

               first, (i) amounts then due and payable pursuant to 28 U.S.C.
          Section 1930(a)(6) and (ii) amounts then due and payable in respect of
          Carve-Out Expenses, provided that the amount entitled to priority
          under this sub-clause (ii) of this clause first ("Priority
          Professional Expenses") shall not exceed the lesser of (a) (1) during
          the Interim Period, $2,000,000 and (2) during the Final Period,
          $3,600,000 (in each case, inclusive of any holdbacks required by the
          Bankruptcy Court) and (b) the sum of (1) the aggregate amount of
          professional fees, costs and expenses (only to the extent approved and
          allowed as a claim by the Bankruptcy Court and not incurred in
          connection with any action or claim against the Existing Agents, the
          Existing Lenders, the Agents or the Lenders, including, without
          limitation, any claim challenging the amount, validity, priority or
          enforceability of the Pre-Petition Obligations or the Obligations)
          accrued and not paid immediately prior to the commencement of a
          Carve-Out Expense Reduction Period and (2) $1,000,000 (such lesser
          amount, the "Professional Expense Cap"); provided, further, however,
          that (A) during any Carve-Out Expense Reduction Period, any payments
          actually made in respect of Carve-Out Expenses shall reduce the
          Professional Expense Cap on a dollar-for-dollar basis, and (B) for the
          avoidance of doubt, so long as no Carve-Out Expense Reduction Period
          shall be continuing, the payment of Carve-Out Expenses shall not
          reduce the Professional Expense Cap,

               second, solely from the Net Cash Proceeds of the Pharma Sale, the
          Rothschild Success Fee (to the extent then due and payable),

               third, all Obligations then due and payable, and

               fourth, all other allowed administrative expenses (including
          Carve-Out Expenses other than Priority Professional Expenses) to the
          extent then due and payable.

          "Agreement" means this Financing Agreement, including all amendments,
modifications and supplements and any exhibits or schedules to any of the
foregoing, and shall refer to the Agreement as the same may be in effect at the
time such reference becomes operative.

          "Assignment and Acceptance" means an assignment and acceptance entered
into by an assigning Lender and an assignee, and accepted by the Collateral
Agent (and the Administrative Agent, if applicable), in accordance with Section
12.07 hereof and substantially in the form of Exhibit D hereto or such other
form acceptable to the Collateral Agent.

                                       -3-
<PAGE>
          "Authorized Officer" means, with respect to any Person, the chief
executive officer, chief operating officer, chief financial officer, president,
executive vice president, controller or treasurer of such Person.

          "Availability" means, at any time, the difference between (i) the
Total Revolving Credit Commitment and (ii) the sum of (A) the aggregate
outstanding principal amount of all Revolving Loans, (B) all Letter of Credit
Obligations and (C) the aggregate amount of all reserves established by the
Administrative Agent at the direction of the Collateral Agent pursuant to the
terms of this Agreement and the other Loan Documents, including, without
limitation, a reserve solely during the Final Period in respect of the
Professional Expense Cap in an amount equal to $3,600,000.

          "Avoidance Actions" means all causes of action arising under Sections
542, 544, 545, 547, 548, 550, 551, 553(b) or 724(a) of the Bankruptcy Code
and any proceeds therefrom.

          "Avoided Payments" has the meaning specified therefor in Section
2.05(c)(vi).

          "Bank of America" has the meaning specified therefor in the preamble
hereto.

          "Bankruptcy Code" means the United States Bankruptcy Code (11
U.S.C. Section 101, et seq.), as amended, and any successor statute.

          "Bankruptcy Court" has the meaning specified therefor in the recitals
hereto.

          "Bankruptcy Court Orders" means the Interim Bankruptcy Court Order and
the Final Bankruptcy Court Order.

          "Board" means the Board of Governors of the Federal Reserve System of
the United States.

          "Board of Directors" means, with respect to any Person, the board of
directors (or comparable managers) of such Person or any committee thereof duly
authorized to act on behalf of the board.

          "Borrower" has the meaning specified therefor in the preamble hereto.

          "Budget" means the Short Term Budget or the Long Term Budget, as the
context requires.

          "Budget Period" means each 4-week period set forth in the Long-Term
Budget commencing with the 4-week period ending June 3, 2005.

          "Business Day" means any day other than a Saturday, Sunday or other
day on which commercial banks in New York City or the state where the Payment
Office is located are authorized or required to close, except that, if a
determination of a Business Day shall relate to a LIBOR Rate Loan, the term
"Business Day" also shall exclude any day on which banks are closed for dealings
in Dollar deposits in the London interbank market.

                                       -4-
<PAGE>
          "Capital Expenditures" means, with respect to any Person for any
period, the aggregate of all expenditures by such Person and its Subsidiaries
during such period that in accordance with GAAP are or should be included in
"property, plant and equipment" or in a similar fixed asset account on its
balance sheet, whether such expenditures are paid in cash or financed and
including all Capitalized Lease Obligations paid or payable during such period.

          "Capital Stock" means (i) with respect to any Person that is a
corporation, any and all shares, interests, participations or other equivalents
(however designated and whether or not voting) of corporate stock, and (ii) with
respect to any Person that is not a corporation, any and all partnership,
membership or other equity interests of such Person.

          "Capitalized Lease" means, with respect to any Person, any lease of
real or personal property by such Person as lessee which is (i) required under
GAAP to be capitalized on the balance sheet of such Person or (ii) a transaction
of a type commonly known as a "synthetic lease" (i.e. a lease transaction that
is treated as an operating lease for accounting purposes but with respect to
which payments of rent are intended to be treated as payments of principal and
interest on a loan for Federal income tax purposes).

          "Capitalized Lease Obligations" means, with respect to any Person,
obligations of such Person and its Subsidiaries under Capitalized Leases, and,
for purposes hereof, the amount of any such obligation shall be the capitalized
amount thereof determined in accordance with GAAP.

          "Carve-Out Expense Reduction Period" means any period during which an
Event of Default under this Agreement or a default by any Loan Party in any of
its obligations under any of the Bankruptcy Court Orders, in either such case,
shall have occurred and be continuing, and as to which the Collateral Agent has
provided written notice of the commencement thereof to the Administrative
Borrower (it being understood and agreed that a Carve-Out Expense Reduction
Period shall commence on the date of such notice).

          "Carve-Out Expenses" means any payments permitted to be made by the
Bankruptcy Court in respect of (i) fees, costs and expenses of attorneys,
accountants and other professionals retained in the Chapter 11 Cases pursuant to
Sections 327, 328, 330, 331 and 1103 of the Bankruptcy Code, (ii) the hourly
wages of employees of FTI Consulting Inc. retained by the Borrowers in the
Chapter 11 Cases (or any other advisors retained by the Borrowers in compliance
with Section 8.01(q)) and payable pursuant to Section 363(b)(i) of the
Bankruptcy Code and (iii) from and after the Final Facility Effective Date, any
restructuring fee payable by the Borrowers to FTI Consulting Inc. pursuant to
that certain Engagement Letter, dated as of March 18, 2004 (as amended by an
amendment dated as of February 24, 2005), between the Parent and FTI Consulting,
Inc. in an aggregate amount not to exceed $750,000; provided, however, that
nothing herein shall limit FTI Consulting Inc.'s right to receive any
restructuring fee pursuant to the foregoing Engagement Letter after termination
of the Total Commitment, payment in full in cash of all Obligations and the
termination or cash collateralization of all outstanding Letters of Credit. For
the avoidance of doubt, Carve-Out Expenses shall not include the fees, costs and
expenses of attorneys, accountants and other professionals retained by the
Agents, the Lenders or the L/C Issuer in connection with the Loan Documents or
the Chapter 11 Cases.

                                      -5-
<PAGE>
          "Cash and Cash Equivalents" means all cash and any presently existing
or hereafter arising deposit account balances, certificates of deposit or other
financial instruments properly classified as cash equivalents under GAAP.

          "Change in Law" has the meaning specified therefor in Section 5.05(a).

          "Change of Control" means each occurrence of any of the following:

          (a) during any period of two consecutive years, individuals who at the
beginning of such period constituted the Board of Directors of the Parent
(together with any new directors whose election by such Board of Directors or
whose nomination for election by the shareholders of the Parent was approved by
a vote of at least a majority the directors of the Parent then still in office
who were either directors at the beginning of such period, or whose election or
nomination for election was previously approved) cease for any reason to
constitute a majority of the Board of Directors of the Parent;

          (b) except as otherwise permitted by Section 8.02(c), the Parent shall
cease to have beneficial ownership (as defined in Rule 13d-3 under the Exchange
Act) of 100% of the aggregate voting power of the Capital Stock (other than
directors' qualifying shares) of each other Loan Party, free and clear of all
Liens (other than Permitted Liens); or

          (c) (i) any Loan Party consolidates or amalgamates with or merges into
another entity or conveys, transfers or leases all or substantially all of its
property and assets to another Person, except as otherwise permitted in Section
8.02(c)(i) or 8.02(c)(iii), or (ii) any entity consolidates or amalgamates with
or merges into any Loan Party in a transaction pursuant to which the outstanding
voting Capital Stock of such Loan Party is reclassified or changed into or
exchanged for cash, securities or other property, other than any such
transaction described in this clause (ii) in which either (A) in the case of any
such transaction involving the Parent, no person or group (within the meaning of
Section 13(d)(3) of the Exchange Act) other than a Permitted Holder has,
directly or indirectly, acquired beneficial ownership of more than 33% of the
aggregate outstanding voting Capital Stock of the Parent or (B) in the case of
any such transaction involving a Loan Party other than the Parent, the Parent
has direct or indirect beneficial ownership of 100% of the aggregate voting
power of all Capital Stock (other than director's qualifying shares) of the
resulting, surviving or transferee entity.

          "Chapter 11 Cases" has the meaning specified therefor in the recitals
hereto.

          "Collateral" has the meaning specified therefor in Section 4.04(a).

          "Collateral Agent" has the meaning specified therefor in the preamble
hereto.

          "Collateral Agent Advances" has the meaning specified therefor in
Section 11.08(a).

          "Collection Account" and "Collection Accounts" have the meanings
specified therefor in Section 9.01(a).

                                       -6-
<PAGE>
          "Commitments" means, with respect to each Lender, such Lender's
Revolving Credit Commitment and Term Loan Commitment.

          "Contingent Obligation" means, with respect to any Person, any
obligation of such Person (other than endorsements in the ordinary course of
business of negotiable instruments for deposit or collection) guaranteeing or
intended to guarantee any Indebtedness ("primary obligations") of any other
Person (the "primary obligor") in any manner, whether directly or indirectly,
including, without limitation, (i) the direct or indirect guaranty, endorsement
(other than for collection or deposit in the ordinary course of business) or
co-making by such Person of the obligation of a primary obligor, (ii) the
obligation to make take-or-pay or similar payments, if required, regardless of
nonperformance by any other party or parties to an agreement, (iii) any
obligation of such Person, whether or not contingent, (A) to purchase any such
primary obligation or any property constituting direct or indirect security
therefor, (B) to advance or supply funds (1) for the purchase or payment of any
such primary obligation or (2) to maintain working capital or equity capital of
the primary obligor or otherwise to maintain the net worth or solvency of the
primary obligor, (C) to purchase property, assets, securities or services
primarily for the purpose of assuring the owner of any such primary obligation
of the ability of the primary obligor to make payment of such primary obligation
or (D) otherwise to assure or hold harmless the holder of such primary
obligation against loss in respect thereof; provided, however, that the term
"Contingent Obligation" shall not include any product or service warranties
extended in the ordinary course of business. The amount of any Contingent
Obligation shall be deemed to be an amount equal to the stated or determinable
amount of the primary obligation with respect to which such Contingent
Obligation is made (or, if less, the maximum amount of such primary obligation
for which such Person may be liable pursuant to the terms of the instrument
evidencing such Contingent Obligation) or, if not stated or determinable, the
maximum reasonably anticipated liability with respect thereto (assuming such
Person is required to perform thereunder), as determined by such Person in good
faith.

          "Current Value" has the meaning specified therefor in Section 8.01(n).

          "Default" means an event which, with the giving of notice or the lapse
of time or both, would constitute an Event of Default.

          "Disposition" means any transaction, or series of related
transactions, pursuant to which any Person or any of its Subsidiaries sells,
assigns, transfers or otherwise disposes of any property or assets, whether now
owned or hereafter acquired, to any other Person, in each case, whether or not
the consideration therefor consists of cash, securities or other assets owned by
the acquiring Person, excluding the sales, transfers or other dispositions set
forth in Section 8.02(c)(ii)(A), (B), (D), (E), (G) and (H). Notwithstanding the
foregoing, (x) Investments permitted by Section 8.02(e) and (y) Extraordinary
Receipts shall not constitute "Dispositions" under this Agreement.

          "Dollar," "Dollars" and the symbol "$" each means lawful money of the
United States of America.

          "Domestic Subsidiary" means a Subsidiary organized under the laws of
the United States, any of the states thereof or the District of Columbia.

                                       -7-
<PAGE>
          "Employee Plan" means an employee benefit plan (other than a
Multiemployer Plan) covered by Title IV of ERISA and maintained (or that was
maintained at any time during the six (6) calendar years preceding the date of
any borrowing hereunder) for employees of any Loan Party or any of its ERISA
Affiliates.

          "Environmental Actions" means any complaint, summons, citation,
notice, directive, order, claim, litigation, investigation, judicial or
administrative proceeding, judgment, letter or other communication from any
Person or Governmental Authority involving violations of Environmental Laws or
Releases of Hazardous Materials (i) from any assets, properties or businesses
owned or operated by any Loan Party or any of its Subsidiaries or any
predecessor in interest; (ii) from adjoining properties or businesses; or (iii)
onto any facilities which received Hazardous Materials generated by any Loan
Party or any of its Subsidiaries or any predecessor in interest.

          "Environmental Laws" means the Comprehensive Environmental Response,
Compensation and Liability Act (42 U.S.C. Section 9601, et seq.), the Hazardous
Materials Transportation Act (49 U.S.C. Section 1801, et seq.), the Resource
Conservation and Recovery Act (42 U.S.C. Section 6901, et seq.), the Federal
Clean Water Act (33 U.S.C. Section 1251 et seq.), the Clean Air Act (42 U.S.C.
Section 7401 et seq.), the Toxic Substances Control Act (15 U.S.C. Section 2601
et seq.) and the Occupational Safety and Health Act (29 U.S.C. Section 651 et
seq.), as such laws may be amended or otherwise modified from time to time, and
any other present or future federal, state, local or foreign statute, ordinance,
rule, regulation, order, judgment, decree, permit, license or other binding
determination of any Governmental Authority imposing liability or establishing
standards of conduct for protection of the environment or other government
restrictions relating to the protection of the environment or the Release,
deposit or migration of any Hazardous Materials into the environment.

          "Environmental Liabilities and Costs" means all liabilities, monetary
obligations, Remedial Actions, losses, damages, punitive damages, consequential
damages, treble damages, costs and expenses (including all reasonable fees,
disbursements and expenses of counsel, experts and consultants and costs of
investigations and feasibility studies), fines, penalties, sanctions and
interest incurred as a result of any claim or demand by any Governmental
Authority or any third party, and which relate to any environmental condition or
a Release of Hazardous Materials from or onto (i) any property presently or
formerly owned by any Loan Party or any of its Subsidiaries or (ii) any facility
which received Hazardous Materials generated by any Loan Party or any of its
Subsidiaries.

          "Environmental Lien" means any Lien in favor of any Governmental
Authority for Environmental Liabilities and Costs.

          "ERISA" means the Employee Retirement Income Security Act of 1974, as
amended, and any successor statute of similar import, and regulations
thereunder, in each case, as in effect from time to time. References to sections
of ERISA shall be construed also to refer to any successor sections.

          "ERISA Affiliate" means, with respect to any Person, any trade or
business (whether or not incorporated) which is a member of a group of which
such Person is a member

                                       -8-
<PAGE>
and which would be deemed to be a "controlled group" within the meaning of
Sections 414(b), (c), (m) and (o) of the Internal Revenue Code.

          "Event of Default" means any of the events set forth in Section 10.01.

          "Exchange Act" means the Securities Exchange Act of 1934, as amended.

          "Existing Agents" means Silver Point, as collateral agent for the
Existing Lenders, and Bank of America, as administrative agent for the Existing
Lenders.

          "Existing Credit Agreement" means that certain Financing Agreement,
dated as of April 23, 2004, by and among the Parent and each subsidiary of the
Parent listed as a borrower on the signature pages thereto, the Existing Agents
and the Existing Lenders, as amended, restated, supplemented or otherwise
modified from time to time prior to the Interim Facility Effective Date.

          "Existing Lenders" means the lenders party to the Existing Credit
Agreement, including the L/C Issuer under and as defined in the Existing Credit
Agreement.

          "Existing Letters of Credit" means the letter(s) of credit outstanding
on the Filing Date and identified on Schedule 3.01.

          "Extraordinary Receipts" means any cash received by the Parent or any
of its Subsidiaries not in the ordinary course of business (and not consisting
of proceeds described in Section 2.05(c)(iii), (iv) or (vi) hereof or proceeds
of any Permitted Indebtedness), including, without limitation, (i) foreign,
United States, state or local tax refunds, (ii) pension plan reversions, (iii)
proceeds of insurance, (iv) judgments, proceeds of settlements or other
consideration of any kind in connection with any cause of action, (v)
condemnation awards (and payments in lieu thereof), (vi) indemnity payments and
(vii) any purchase price adjustments or deferred purchase price payments
(including, without limitation, in the form of royalties and licensing fees)
received in connection with any purchase agreement (it being understood that
royalties and progress payments received by the Parent or any of its
Subsidiaries in the ordinary course of business shall not constitute
"Extraordinary Receipts").

          "Facility" means each parcel of real property identified on Schedule
7.01(o) that is identified with an asterisk (*), including, without limitation,
the land on which such facility is located, all buildings and other improvements
thereon, all fixtures located at or used in connection with such facility, all
whether now or hereafter existing.

          "FDA" means the United States Food and Drug Administration and any
successor agency.

          "FDA Notice" has the meaning set forth in Section 7.01(ff).

          "FDA Regulation" means any rule, regulation or administrative order
promulgated or issued by the FDA.

                                       -9-
<PAGE>
          "Federal Funds Rate" means, for any day, the rate per annum (rounded
upward, if necessary, to a whole multiple of 1/100 of 1%) equal to the weighted
average of the rates on overnight Federal funds transactions with members of the
Federal Reserve System arranged by Federal funds brokers on such day, as
published by the Federal Reserve Bank of New York on the Business Day next
succeeding such day; provided that (a) if such day is not a Business Day, the
Federal Funds Rate for such day shall be such rate on such transactions on the
next preceding Business Day as so published on the next succeeding Business Day,
and (b) if no such rate is so published on such next succeeding Business Day,
the Federal Funds Rate for such day shall be the average rate charged to Bank of
America on such day on such transactions as determined by the Administrative
Agent.

          "Fee Letter" means that certain fee letter, dated as of the Interim
Facility Effective Date, by and among the Borrowers and the Agents, in form and
substance satisfactory to the Agents, which Fee Letter supersedes the
Fee/Expense Side Letter, dated as of April 29, 2005, between the Parent and
Silver Point.

          "Field Survey and Audit" means a field survey and audit of the Loan
Parties and an appraisal of the Collateral performed by auditors, examiners
and/or appraisers selected by the Collateral Agent, at the sole cost and expense
of the Borrowers.

          "Filing Date" means May 10, 2005.

          "Final Bankruptcy Court Order" means the final order of the Bankruptcy
Court with respect to the Borrowers, in form and substance reasonably
satisfactory to the Agents and in any event providing for the repayment in full
of the Pre-Petition Obligations, as the same may be amended, modified or
supplemented from time to time with the express written joinder or consent of
the Agents and the Borrowers.

          "Final Bankruptcy Court Order Entry Date" means the date on which the
Final Bankruptcy Court Order shall have been entered by the Bankruptcy Court.

          "Final Facility Effective Date" has the meaning specified therefor in
Section 6.02.

          "Final Maturity Date" means the date which is the earliest of (i) the
date which is 30 days following the date of entry of the Interim Bankruptcy
Court Order, if the Final Bankruptcy Court Order has not been entered by the
Bankruptcy Court on or prior to such date, (ii) May 11, 2006, (iii) the earlier
of the effective date and the date of the substantial consummation (as defined
in Section 1101(2) of the Bankruptcy Code), in each case, of a plan of
reorganization in any of the Chapter 11 Cases that has been confirmed by an
order of the Bankruptcy Court, and (iv) such earlier date on which all Loans and
other Obligations for the payment of money shall become due and payable in
accordance with the terms of this Agreement and the other Loan Documents.

          "Final Period" means the period commencing on the Final Facility
Effective Date and ending on the Final Maturity Date.

                                      -10-
<PAGE>
          "Financial Statements" means the audited consolidated balance sheet of
the Parent and its Subsidiaries for the Fiscal Year ended December 31, 2004, and
the related consolidated statement of operations, shareholders' equity and cash
flows for the Fiscal Year then ended.

          "Fiscal Year" means the fiscal year of the Parent and its Subsidiaries
ending on December 31st of each year.

          "Food and Drug Act" means the Federal Food, Drug and Cosmetic Act, 21
USC Section 1 et seq. and any successor act.

          "Foreign Subsidiary" means a Subsidiary organized under the laws of a
jurisdiction other than the United States, any of the states thereof or the
District of Columbia.

          "Funding Losses" has the meaning set forth in Section 2.09(b)(ii).

          "GAAP" means generally accepted accounting principles in effect from
time to time in the United States, applied on a consistent basis.

          "German Subsidiary" has the meaning specified therefor in Section
6.02(e)(v).

          "Government Acts" has the meaning specified therefor in Section
3.01(i)(i).

          "Governmental Authority" means any nation or government, any Federal,
state, city, town, municipality, county, local or other political subdivision
thereof or thereto and any department, commission, board, bureau,
instrumentality, agency or other entity exercising executive, legislative,
judicial, taxing, regulatory or administrative powers or functions of or
pertaining to government.

          "Guarantor" means each Person which guarantees, pursuant to Section
8.01(b) or otherwise, all or any part of the Obligations.

          "Guaranty" means each guaranty, in form and substance satisfactory to
the Collateral Agent, made by any Guarantor in favor of the Collateral Agent for
the benefit of the Agents, L/C Issuer and the Lenders pursuant to Section
8.01(b) or otherwise.

          "Hazardous Material" means (a) any element, compound or chemical that
is defined, listed or otherwise classified as a contaminant, pollutant, toxic
pollutant, toxic or hazardous substance, extremely hazardous substance or
chemical, hazardous waste, special waste, or solid waste under Environmental
Laws or that is likely to cause immediately, or at some future time, harm to or
have an adverse effect on, the environment or risk to human health or safety,
including, without limitation, any pollutant, contaminant, waste, hazardous
waste, toxic substance or dangerous good which is defined or identified in any
Environmental Law and which is present in the environment in such quantity or
state that it violates any Environmental Law; (b) petroleum and its refined
products; (c) polychlorinated biphenyls; (d) any substance exhibiting a
hazardous waste characteristic, including, without limitation, corrosivity,
ignitability, toxicity or reactivity as well as any radioactive or explosive
materials; and (e) any raw materials, building components (including, without
limitation, asbestos-containing

                                      -11-
<PAGE>
materials) and manufactured products containing hazardous substances listed or
classified as such under Environmental Laws.

          "Hedging Agreement" means any interest rate, foreign currency,
commodity or equity swap, collar, cap, floor or forward rate agreement, or other
agreement or arrangement designed to protect against fluctuations in interest
rates or currency, commodity or equity values (including, without limitation,
any option with respect to any of the foregoing and any combination of the
foregoing agreements or arrangements), and any confirmation executed in
connection with any such agreement or arrangement.

          "HHS" means the United States Department of Health and Human Services,
or any successor agency thereof.

          "HHS Regulation" means any rule, regulation or administrative order
promulgated or issued by the HHS.

          "Highest Lawful Rate" means, with respect to any Agent, the L/C Issuer
or any Lender, the maximum non-usurious interest rate, if any, that at any time
or from time to time may be contracted for, taken, reserved, charged or received
on the Obligations under laws applicable to such Agent, the L/C Issuer or such
Lender which are currently in effect or, to the extent allowed by law, under
such applicable laws which may hereafter be in effect and which allow a higher
maximum non-usurious interest rate than applicable laws now allow.

          "Indebtedness" means, with respect to any Person, without duplication,
(i) all indebtedness of such Person for borrowed money; (ii) all obligations of
such Person for the deferred purchase price of property or services (other than
(x) accrued expenses (including salaries, accrued vacation and other
compensation), trade payables, other accounts payable, royalty and licensing fee
payables and other similar payment obligations incurred in the ordinary course
of such Person's business and, to the extent that enforcement thereof is not
stayed by virtue of the filing of the Chapter 11 Cases, not outstanding for more
than 90 days after the date created and (y) contingent obligations for the
deferred purchase price of property that mature or become fixed based upon the
financial performance of the property acquired and that have not matured or
become fixed); (iii) all obligations of such Person evidenced by bonds,
debentures, notes or other similar instruments or upon which interest payments
are customarily made; (iv) all reimbursement, payment or other obligations and
liabilities of such Person created or arising under any conditional sales or
other title retention agreement with respect to property used and/or acquired by
such Person (other than customary reservations of rights (other than retentions
of title) under agreements with suppliers entered into in the ordinary course of
business); (v) all Capitalized Lease Obligations of such Person; (vi) all
obligations and liabilities, contingent or otherwise, of such Person, in respect
of letters of credit, acceptances and similar facilities; (vii) the net
termination obligations, calculated on any date, on a basis satisfactory to the
Collateral Agent and in accordance with accepted practice as if the Hedging
Agreement was terminated on such date, of such Person under Hedging Agreements;
(viii) all monetary obligations under any receivables factoring, receivable
sales or similar transactions and all monetary obligations under any synthetic
lease, tax ownership/operating lease, off-balance sheet financing or similar
financing; (ix) all Contingent Obligations; (x) liabilities incurred under Title
IV of ERISA with respect to any plan (other than a Multiemployer Plan) covered
by

                                      -12-
<PAGE>
Title IV of ERISA and maintained for employees of such Person or any of its
ERISA Affiliates; (xi) withdrawal liability incurred under ERISA by such Person
or any of its ERISA Affiliates with respect to any Multiemployer Plan; and (xii)
all obligations referred to in clauses (i) through (xi) of this definition of
another Person secured by (or for which the holder of such Indebtedness has an
existing right, contingent or otherwise, to be secured by) a Lien upon property
owned by such Person, even though such Person has not assumed or become liable
for the payment of such Indebtedness. The Indebtedness of any Person shall
include the Indebtedness of any partnership of or joint venture in which such
Person is a general partner or a joint venturer.

          "Indemnified Matters" has the meaning specified therefor in Section
12.15.

          "Indemnitees" has the meaning specified therefor in Section 12.15.

          "Interim Bankruptcy Court Order" means the order of the Bankruptcy
Court with respect to the Borrowers, substantially in the form of Exhibit E
hereto, as the same may be amended, modified or supplemented from time to time
with the express written joinder or consent of the Agents and the Borrowers.

          "Interim Bankruptcy Court Order Entry Date" means the date on which
the Interim Bankruptcy Court Order shall have been entered by the Bankruptcy
Court.

          "Interim Facility Effective Date" means the date, on or before May 11,
2005, on which all of the conditions precedent set forth in Section 6.01 are
satisfied.

          "Interim Period" means the period commencing on the Interim Facility
Effective Date and ending on the earlier to occur of (i) the Final Facility
Effective Date and (ii) the Final Maturity Date.

          "Interest Period" means, with respect to each LIBOR Rate Loan, a
period commencing on the date of the making of such LIBOR Rate Loan (or the
continuation of a LIBOR Rate Loan or the conversion of a Reference Rate Loan to
a LIBOR Rate Loan) and ending 1, 2 or 3 months thereafter; provided, however,
that (a) if any Interest Period would end on a day that is not a Business Day,
such Interest Period shall be extended (subject to clauses (c)-(e) below) to the
next succeeding Business Day, (b) interest shall accrue at the applicable rate
based upon the LIBOR Rate from and including the first day of each Interest
Period to, but excluding, the day on which any Interest Period expires, (c) any
Interest Period that would end on a day that is not a Business Day shall be
extended to the next succeeding Business Day unless such Business Day falls in
another calendar month, in which case such Interest Period shall end on the next
preceding Business Day, (d) with respect to an Interest Period that begins on
the last Business Day of a calendar month (or on a day for which there is no
numerically corresponding day in the calendar month at the end of such Interest
Period), the Interest Period shall end on the last Business Day of the calendar
month that is 1, 2 or 3 months after the date on which the Interest Period
began, as applicable, and (e) Borrowers (or Administrative Borrower on behalf
thereof) may not elect an Interest Period which will end after the Final
Maturity Date.

          "Internal Revenue Code" means the Internal Revenue Code of 1986, as
amended (or any successor statute thereto) and the regulations thereunder.

                                      -13-
<PAGE>
          "Inventory" means, with respect to any Person, all goods and
merchandise of such Person, including, without limitation, all raw materials,
work-in-process, packaging, supplies, materials and finished goods of every
nature used or usable in connection with the shipping, storing, advertising or
sale of such goods and merchandise, whether now owned or hereafter acquired, and
all such other property the sale or other disposition of which in the ordinary
course of business would give rise to an Account Receivable or cash.

          "Investment" in any Person means (a) the acquisition (whether for
cash, property, services, assumption of Indebtedness, securities or otherwise)
of assets (other than equipment, Inventory, supplies or other property in the
ordinary course of business and other than any acquisition of assets
constituting a Capital Expenditure), Capital Stock, bonds, notes, debentures,
partnership, joint ventures or other ownership interests or other securities of
such other Person, (b) any deposit with, or advance, loan or other extension of
credit to, such Person (other than security deposits under a lease, deposits
made in connection with the purchase or manufacture of equipment, inventory and
supplies in the ordinary course of business) or (c) any other capital
contribution to or investment in such Person, including, without limitation, any
Contingent Obligations (including any support for a letter of credit issued on
behalf of such Person) incurred for the benefit of such Person and any
Disposition to such Person for consideration less than fair market value of the
property disposed in such transaction, but excluding any payment to such Person
permitted by Section 8.02(h). Investments which are capital contributions or
purchases of Capital Stock which have a right to participate in the profits of
the issuer thereof shall be valued at the amount actually contributed or paid to
purchase such Capital Stock as of the date of such contribution or payment.
Investments which are loans, advances, extensions of credit or Contingent
Obligations shall be valued at the principal amount of such loan, advance or
extension of credit outstanding as of the date of determination or, as
applicable, the principal amount of the loan or advance outstanding as of the
date of determination actually guaranteed by such Contingent Obligation.

          "ISP98" has the meaning specified therefor in Section 3.01(h).

          "L/C Issuer" means Bank of America or such other bank as the
Administrative Agent may select in its sole and absolute discretion.

          "Lease" means any lease of real property to which any Loan Party or
any of its Subsidiaries is a party as lessor or lessee.

          "Lender" has the meaning specified therefor in the preamble hereto.

          "Letter of Credit" means any Existing Letter of Credit and any letter
of credit issued by the L/C Issuer for the account of a Borrower in accordance
with the terms of Section 3.01(a).

          "Letter of Credit Application" has the meaning specified therefor in
Section 3.01(b).

          "Letter of Credit Committed Amount" has the meaning specified therefor
in Section 3.01(a).

                                      -14-
<PAGE>
          "Letter of Credit Documents" means, with respect to any Letter of
Credit, such Letter of Credit, any amendments thereto, any documents delivered
in connection therewith, any application therefor, and any agreements,
instruments, guarantees or other documents (whether general in application or
applicable only to such Letter of Credit) governing or providing for (i) the
rights and obligations of the parties concerned or at risk or (ii) any
collateral security for such obligations.

          "Letter of Credit Fee" has the meaning specified therefor in Section
3.02(a).

          "Letter of Credit Obligations" means, at any time, without
duplication, the sum of (i) the maximum amount which is, or at any time
thereafter may become, available to be drawn under Letters of Credit then
outstanding, assuming compliance with all requirements for drawings referred to
in such Letters of Credit plus (ii) the aggregate amount of all drawings under
Letters of Credit honored by the L/C Issuer but not theretofore reimbursed by
the Borrowers.

          "Liabilities" has the meaning specified therefor in Section 2.07.

          "LIBOR" means for any Interest Period with respect to a LIBOR Rate
Loan:

          (a) the rate per annum equal to the rate determined by the
Administrative Agent to be the offered rate that appears on the page of the
Telerate screen (or any successor thereto) that displays an average British
Bankers Association Interest Settlement Rate for deposits in Dollars (for
delivery on the first day of such Interest Period) with a term equivalent to
such Interest Period, determined as of approximately 11:00 a.m. (London time)
two Business Days prior to the first day of such Interest Period, or

          (b) if the rate referenced in the preceding clause (a) does not appear
on such page or service or such page or service shall not be available, the rate
per annum equal to the rate determined by the Administrative Agent to be the
offered rate on such other page or other service that displays an average
British Bankers Association Interest Settlement Rate for deposits in Dollars
(for delivery on the first day of such Interest Period) with a term equivalent
to such Interest Period, determined as of approximately 11:00 a.m. (London time)
two Business Days prior to the first day of such Interest Period, or

          (c) if the rates referenced in the preceding clauses (a) and (b) are
not available, the rate per annum determined by the Administrative Agent as the
rate of interest at which deposits in Dollars for delivery on the first day of
such Interest Period in same day funds in the approximate amount of the LIBOR
Rate Loan being made, continued or converted by the Reference Bank and with a
term equivalent to such Interest Period would be offered by the Reference Bank's
London Branch to major banks in the London interbank eurodollar market at their
request at approximately 4:00 p.m. (London time) two Business Days prior to the
first day of such Interest Period.

          "LIBOR Deadline" has the meaning set forth in Section 2.09(b)(i).

          "LIBOR Notice" means a written notice in the form of Exhibit B.

                                      -15-
<PAGE>
          "LIBOR Option" has the meaning set forth in Section 2.09(a).

          "LIBOR Rate" means, for each Interest Period for each LIBOR Rate Loan,
the rate per annum determined by the Administrative Agent (rounded upwards if
necessary, to the next 1/100%) by dividing (a) LIBOR for such Interest Period by
(b) 100% minus the Reserve Percentage. The LIBOR Rate shall be adjusted on and
as of the effective day of any change in the Reserve Percentage.

          "LIBOR Rate Loan" means each portion of a Loan that bears interest at
a rate determined by reference to the LIBOR Rate.

          "Licensing Agreements" means each of the licensing agreements
constituting a Material Contract set forth on Schedule 1.01(B) hereto between
any Loan Party or any of its Subsidiaries and any licensor with respect to the
rights to manufacture, sell and/or distribute Inventory.

          "Lien" means any mortgage, deed of trust, pledge, lien (statutory or
otherwise), security interest, charge or other encumbrance or security or
preferential arrangement of any nature, including, without limitation, any
conditional sale or title retention arrangement, any Capitalized Lease and any
assignment, deposit arrangement or financing lease intended as, or having the
effect of, security.

          "Loan" means the Term Loan or any Revolving Loan made by an Agent or a
Lender to the Borrowers pursuant to Article II hereof.

          "Loan Account" means an account maintained hereunder by the
Administrative Agent on its books of account at the Payment Office, and with
respect to the Borrowers, in which the Borrowers will be charged with all Loans
made to, and all other Obligations incurred by, the Borrowers.

          "Loan Document" means this Agreement, the Fee Letter, any Guaranty,
any Security Agreement, any Pledge Agreement, any Mortgage, any Letter of Credit
Application, the Interim Bankruptcy Court Order, the Final Bankruptcy Court
Order and any other agreement, instrument, certificate, report and other
document executed and delivered pursuant hereto or thereto or otherwise
evidencing or securing any Loan, any Letter of Credit Obligation or any other
Obligation.

          "Loan Party" means any Borrower and any Guarantor.

          "Lockbox Bank" has the meaning specified therefor in Section 9.01(a).

          "Lockboxes" has the meaning specified therefor in Section 9.01(a).

          "Long Term Budget" means the cash receipts and disbursements and
Revolving Loan and Letter of Credit projections of the Loan Parties attached
hereto as Schedule 1.01(C), and any supplement thereto delivered by the Parent
to the Agents and the Lenders pursuant to Section 8.01(a)(vi), which is in form
consistent with the Long-Term Budget attached hereto as

                                      -16-
<PAGE>
Schedule 1.01(C) and in substance reasonably satisfactory to the Agents at the
time of delivery thereof.

          "Material Adverse Deviation" means, as of any date of determination,
an adverse deviation of more than the Permitted Deviation from the amount set
forth for any Budget Period in the line item of the Long-Term Budget entitled
"Total Payments" or the line item of the Long-Term Budget entitled "Total Cash
Generation/(Use)"; provided, that the Borrowers may carry forward amounts for
any Budget Period under each such line item in the Long-Term Budget in an amount
not greater than 25% of (i) in the case of "Total Payments", the difference
between (A) the aggregate amount of total payments projected for such Budget
Period under such line item in the Long-Term Budget plus the Permitted Deviation
for such Budget Period and (B) the actual aggregate amount of total payments for
such Budget Period (to the extent less than the projected amount therefor and
after giving effect to the Permitted Deviation from the projected amount for
such Budget Period) and (ii) in the case of "Total Cash Generation/(Use)", the
difference between (A) the aggregate amount of cash generation or the aggregate
amount of cash (use), as the case may be, projected for such Budget Period under
such line item in the Long-Term Budget plus the Permitted Deviation for such
Budget Period and (B) the actual aggregate amount of cash generation (to the
extent more than the projected amount therefor and after giving effect to the
Permitted Deviation from the projected amount for such Budget Period) or the
actual aggregate amount of cash (use) (to the extent less than the projected
amount therefor and after giving effect to the Permitted Deviation from the
projected amount for such Budget Period), as the case may be, for such Budget
Period (such amount, in each case, the "Carry-Forward Amount") from one Budget
Period to succeeding Budget Periods (each a "Carry-Forward Period"), which
Carry-Forward Amount shall be deemed to increase the amount of total payments or
cash (use), or decrease the amount of cash generation, as the case may be,
permitted in any Carry-Forward Period (after giving effect to the Permitted
Deviation from the projected amount for such Carry-Forward Period) by the
aggregate Carry-Forward Amount. Notwithstanding the foregoing, the calculation
of the Permitted Deviation and the Carry-Forward Amount for any Budget Period
shall, for purposes of this definition, exclude the line items entitled
"Negotiated/Finance Payments" and "Transaction Costs" related to the Pharma Sale
and the plan of reorganization projected in the Long-Term Budget. For
illustrative purposes, a sample calculation of Carry-Forward Amounts is set
forth on Schedule 1.01(D) hereto.

          "Material Adverse Effect" means a material adverse effect on any of
(i) the operations, business, assets, properties, condition (financial or
otherwise) or prospects of the Loan Parties taken as a whole, except for the
occurrence of the Pharma Sale, the commencement of the Chapter 11 Cases and the
events resulting from the commencement of the Chapter 11 Cases, (ii) the ability
of any Loan Party to perform any of its obligations under any Loan Document to
which it is a party, (iii) the legality, validity or enforceability of this
Agreement or any other Loan Document, (iv) the rights and remedies of any Agent,
the L/C Issuer or any Lender under any Loan Document, or (v) the validity,
perfection or priority of a Lien in favor of the Collateral Agent for the
benefit of the Agents, the L/C Issuer and the Lenders on any of the Collateral
with an aggregate value in excess of $500,000 (it being understood that the
grant by a Loan Party in favor of any Person of a Lien on any of the Collateral
that is a Permitted Priority Lien would not have a material adverse effect on
the priority of a Lien in favor of the Collateral Agent on such Collateral).

                                      -17-
<PAGE>
          "Material Contract" means, with respect to any Person, (i) each
contract or agreement to which such Person or any of its Subsidiaries is a party
involving aggregate consideration payable to or by such Person or such
Subsidiary of $500,000 per year or more (other than purchase orders in the
ordinary course of the business of such Person or such Subsidiary and other than
contracts that by their terms may be terminated by such Person or Subsidiary in
the ordinary course of its business upon less than 60 days' notice without
penalty or premium) and (ii) all other contracts or agreements material to the
business, operations, condition (financial or otherwise), performance, prospects
or properties of such Person and its Subsidiaries, taken as a whole; provided,
that the contracts and agreements set forth on Schedule 1.01(E) shall not be
Material Contracts for purposes of this Agreement.

          "Moody's" means Moody's Investors Service, Inc. and any successor
thereto.

          "Mortgage" means a mortgage (including, without limitation, a
leasehold mortgage), deed of trust or deed to secure debt, in form and substance
reasonably satisfactory to the Collateral Agent, made by a Loan Party in favor
of the Collateral Agent for the benefit of the Agents, the L/C Issuer and the
Lenders, securing the Obligations and delivered to the Collateral Agent pursuant
to Section 6.01(e), Section 8.01(b), Section 8.01(n) or otherwise.

          "Multiemployer Plan" means a "multiemployer plan" as defined in
Section 4001(a)(3) of ERISA to which any Loan Party or any of its ERISA
Affiliates has contributed to, or has been obligated to contribute, at any time
during the preceding six (6) years.

          "Net Cash Proceeds" means, (a) with respect to any Disposition by any
Person or any of its Subsidiaries, an amount equal to the result of (i) the
aggregate amount of cash received (directly or indirectly) from time to time
(whether as initial consideration or through the payment or disposition of
deferred consideration (it being understood that payments received by such
Person in respect of services provided by it in the ordinary course of business,
for fair consideration and on ordinary business terms shall not constitute
deferred consideration for purposes of this definition)) by or on behalf of such
Person or such Subsidiary in connection therewith, minus (ii) the sum of (A) the
amount of any Indebtedness secured by any Lien permitted by Section 8.02(a) on
any asset (other than Indebtedness assumed by the purchaser of such asset) which
is required to be, and is, repaid in connection with such Disposition (other
than Indebtedness under this Agreement), (B) costs and expenses related thereto
incurred by such Person or such Subsidiary in connection therewith (including,
without limitation, legal, accounting and investment banking fees, and
underwriting discounts and commissions), (C) transfer taxes paid to any taxing
authorities by such Person or such Subsidiary in connection therewith, (D) net
income taxes to be paid in connection with such Disposition (after taking into
account any tax credits or deductions and any tax sharing arrangements) and (E)
reasonable reserves for indemnification obligations in connection with such
Disposition in an aggregate amount not to exceed $500,000 during the term of
this Agreement, (b) with respect to any Extraordinary Receipts received by any
Person or any of its Subsidiaries, an amount equal to the result of (i) the
aggregate amount of cash received (directly or indirectly) from time to time by
or on behalf of such Person or such Subsidiary in connection therewith, minus
(ii) the sum of (A) reasonable expenses related to the collection thereof
incurred by such Person or such Subsidiary and (B) net income taxes to be paid
in connection with such Extraordinary Receipts (after taking into account any
tax credits or deductions and any tax sharing arrangements) and (c) with respect

                                      -18-
<PAGE>
to the Pharma Sale, an amount equal to the result of (i) the aggregate amount of
cash received (directly or indirectly) from time to time (whether as initial
consideration or through the payment or disposition of deferred consideration
(it being understood that payments received by such Person in respect of
services provided by it in the ordinary course of business, for fair
consideration and on ordinary business terms shall not constitute deferred
consideration for purposes of this definition)) by or on behalf of such Person
or such Subsidiary in connection therewith, minus (ii) the fees, costs and
expenses set forth on Schedule 1.01(F) hereto to the extent that such costs and
expenses are (A) required to be paid pursuant to the Pharma Purchase Agreement
or, with respect to cure amounts and certain other liabilities, deemed by the
Borrowers to be in the best interests of the Borrowers to be paid and (B)
actually paid in connection with the Pharma Sale; in the case of each of clauses
(a), (b) and (c), to the extent, but only to the extent, that the amounts so
deducted are (xx) actually paid to a Person that, except in the case of
reasonable out-of-pocket expenses, is not an Affiliate of such Person or any of
its Subsidiaries and (yy) properly attributable to such transaction or to the
asset that is the subject thereof, as the case may be.

          "Non-Consenting Lender" has the meaning specified therefor in Section
12.07(j).

          "Notice of Borrowing" has the meaning specified therefor in Section
2.02(a).

          "Obligations" means all present and future indebtedness, obligations,
and liabilities of each Loan Party to the Agents, the L/C Issuer and the Lenders
arising under this Agreement or any other Loan Document, whether or not the
right of payment in respect of such claim is reduced to judgment, liquidated,
unliquidated, fixed, contingent, matured, disputed, undisputed, legal,
equitable, secured, unsecured, and whether or not such claim is discharged,
stayed or otherwise affected by any proceeding referred to in Section 10.01.
Without limiting the generality of the foregoing, the Obligations of each Loan
Party under the Loan Documents include (a) the obligation to pay principal,
interest, charges, expenses, fees, attorneys' fees and disbursements,
indemnities and other amounts payable by such Person under the Loan Documents,
(b) the obligation of such Person to reimburse any amount in respect of any of
the foregoing that any Agent, the L/C Issuer or any Lender (in its sole
discretion) may elect to pay or advance on behalf of such Person in accordance
with the terms of the Loan Documents, (c) any Hedging Agreement of the Borrower
to which a Lender or Agent-Related Person is a party, and (d) all obligations
under any Treasury Management Agreement between any Loan Party and any
Agent-Related Person.

          "Operating Lease Obligations" means all obligations for the payment of
rent for any real or personal property under leases or agreements to lease,
other than Capitalized Lease Obligations.

          "Parent" has the meaning specified therefor in the preamble hereto.

          "Participant Register" has the meaning specified therefor in Section
12.07(g).

          "Participation Interest" means a purchase by a Revolving Loan Lender
of a participation in Letters of Credit or Letter of Credit Obligations as
provided in Section 3.01.

                                      -19-
<PAGE>
          "Payment Office" means the Administrative Agent's office located at 90
Main Street, 14th Floor, Dallas, Texas 75202-3714, or at such other office or
offices of the Administrative Agent as may be designated in writing from time to
time by the Administrative Agent to the Collateral Agent and the Administrative
Borrower.

          "PBGC" means the Pension Benefit Guaranty Corporation or any successor
thereto.

          "Period" means the Interim Period or the Final Period, as the context
requires.

          "Permitted Deviation" means (i) prior to the 4 month anniversary of
the Interim Bankruptcy Court Order Entry Date, 20%, and (ii) thereafter, 25%.

          "Permitted Holder" means Frederick D. Sancilio and any of his Related
Parties.

          "Permitted Indebtedness" means:

          (a) any Indebtedness owing to any Agent or any Lender under this
Agreement or any other Loan Document;

          (b) any Indebtedness existing on the Filing Date;

          (c) Indebtedness evidenced by Capitalized Lease Obligations entered
into after the Filing Date in order to finance Capital Expenditures made by the
Loan Parties in accordance with the provisions of Section 8.02(g), which
Indebtedness, when aggregated with the principal amount of all Indebtedness
incurred under this clause (c) and clause (d) of this definition, does not
exceed $1,000,000 at any time outstanding;

          (d) Indebtedness permitted by clause (e) of the definition of
"Permitted Lien";

          (e) Indebtedness permitted under Section 8.02(e);

          (f) obligations of the Parent in respect of Hedging Agreements entered
into with any Agent-Related Person and with the prior written consent of each
Agent in order to manage existing or anticipated interest rate or exchange rate
risks and not for speculative purposes;

          (g) Contingent Obligations with respect to any Indebtedness described
in this definition;

          (h) Indebtedness in respect of performance bonds and surety or appeal
bonds entered into in the ordinary course of business;

          (i) Indebtedness arising from the honoring by a bank or other
financial institution of a check, draft or similar instrument inadvertently
(except in the case of daylight overdrafts) drawn against insufficient funds in
the ordinary course of business, provided that such Indebtedness is satisfied
within 3 Business Days of incurrence;

                                      -20-
<PAGE>
          (j) endorsements in the ordinary course of business of negotiable
instruments for deposit or collection;

          (k) Indebtedness owing to Xanodyne Pharmaceuticals, Inc. in respect of
the development costs of certain pipeline pharmaceutical products pursuant to
Section 8.4 of the Xanodyne Agreement in an aggregate principal amount not to
exceed $1,000,000 at any time outstanding; and

          (l) other Indebtedness not permitted under any of clauses (a) through
(j) of this definition in an aggregate principal amount not to exceed $1,000,000
at any time outstanding.

          "Permitted Investments" means (i) marketable direct obligations issued
or unconditionally guaranteed by the United States Government or issued by any
agency thereof and backed by the full faith and credit of the United States, in
each case, maturing within six months from the date of acquisition thereof; (ii)
commercial paper, maturing not more than 270 days after the date of issue rated
P-1 by Moody's or A-1 by Standard & Poor's; (iii) certificates of deposit
maturing not more than 270 days after the date of issue, issued by commercial
banking institutions and money market or demand deposit accounts maintained at
commercial banking institutions, each of which is a member of the Federal
Reserve System and has a combined capital and surplus and undivided profits of
not less than $500,000,000; (iv) repurchase agreements having maturities of not
more than 90 days from the date of acquisition which are entered into with major
money center banks included in the commercial banking institutions described in
clause (iii) above and which are secured by readily marketable direct
obligations of the United States Government or any agency thereof, (v) money
market accounts maintained with mutual funds having assets in excess of
$2,500,000,000; and (vi) tax exempt securities rated A or higher by Moody's or
A+ or higher by Standard & Poor's.

          "Permitted Liens" means:

          (a) Liens securing the Obligations;

          (b) Liens for taxes, assessments and governmental charges the payment
of which is not required under Section 8.01(c);

          (c) (i) Liens imposed by law or pursuant to customary reservations of
rights (other than retentions of title), such as landlords', carriers',
warehousemen's, mechanics', materialmen's and other similar Liens arising in the
ordinary course of business and securing obligations (other than Indebtedness
for borrowed money) that are not overdue by more than 30 days or are being
contested in good faith and by appropriate proceedings promptly initiated and
diligently conducted, or as to which payment and enforcement is stayed under the
Bankruptcy Code or pursuant to orders of the Bankruptcy Court, and a reserve or
other appropriate provision, if any, as shall be required by GAAP shall have
been made therefor (and as to which the assets or property subject to any such
Lien is not yet subject to foreclosure, sale or loss on account thereof) or (ii)
Liens constituting rights of return or rights to discounts, rebates and
chargebacks in the ordinary course of the business of, and consistent with the
industry

                                      -21-
<PAGE>
practices of, the Loan Parties and their Subsidiaries, to the extent that the
exercise of such rights could not reasonably be expected to have a Material
Adverse Effect;

          (d) Liens existing on the Filing Date, as described on Schedule
8.02(a) (other than the Liens described in clauses (j) and (p) below); provided,
that (i) no such Lien shall at any time be extended to cover any additional
property not subject thereto on the Filing Date and (ii) the principal amount of
the Indebtedness secured by such Liens shall not be extended, renewed, refunded
or refinanced;

          (e) (i) purchase money Liens on equipment acquired or held by any Loan
Party or any of its Subsidiaries after the Filing Date in the ordinary course of
its business to secure the purchase price of such equipment or Indebtedness
incurred solely for the purpose of financing the acquisition of such equipment
or (ii) Liens existing on such equipment at the time of its acquisition;
provided, however, that (A) no such Lien shall extend to or cover any other
property of any Loan Party or any of its Subsidiaries and (B) the aggregate
principal amount of Indebtedness secured by any or all such Liens shall not
exceed $1,000,000 at any time outstanding;

          (f) Liens (other than Liens created or imposed under ERISA the
creation or incurrence of which would result in an Event of Default under
Section 10.01(w) or (x)), deposits and pledges of cash securing (i) obligations
incurred in respect of workers' compensation, unemployment insurance or other
forms of governmental insurance or benefits, (ii) the performance of bids,
tenders, leases, contracts (other than for the payment of money) and statutory
obligations or (iii) obligations on surety or appeal bonds, but only to the
extent such Liens, deposits or pledges are made or otherwise arise in the
ordinary course of business and secure obligations not past due, or as to which
payment and enforcement is stayed under the Bankruptcy Code or pursuant to
orders of the Bankruptcy Court;

          (g) easements, zoning restrictions and similar encumbrances on real
property and minor irregularities in the title thereto that (i) in the case of
any Facility, are exceptions to the Title Insurance Policy with respect to such
Facility issued in connection with the Existing Credit Agreement or this
Agreement, as accepted by the Existing Agents or the Agents, as the case may be,
or (ii) in the case of any real property, do not (A) secure obligations for the
payment of money or (B) materially impair the value of such property or its use
by any Loan Party or any of its Subsidiaries in the normal conduct of such
Person's business;

          (h) Liens on real property or equipment securing Indebtedness
permitted by subsection (c) of the definition of Permitted Indebtedness;

          (i) Liens resulting from any judgment or award so long as such
judgment or award does not constitute an Event of Default under Section
10.01(q);

          (j) Liens securing the Senior Subordinated Notes, provided that such
Liens are subject to the Senior Subordinated Note Intercreditor Agreement;

          (k) leases or subleases granted to others not interfering in any
material respect with the business of any Loan Party;

                                      -22-
<PAGE>
          (l) any interest of title of a lessor or bailor under, and Liens
arising from Uniform Commercial Code financing statements (or equivalent
filings, registrations or agreements in foreign jurisdictions) relating to,
leases or bailee arrangements permitted by this Agreement;

          (m) normal and customary rights of setoff upon deposits of cash in
favor of banks or other depository institutions;

          (n) Liens of a collection bank arising under Section 4-210 of the
Uniform Commercial Code on items in the course of collection;

          (o) Liens in favor of customs and revenue authorities arising as a
matter of law to secure non-delinquent customs duties in connection with the
importation of goods;

          (p) Prior to the Final Facility Effective Date, Liens securing the
Pre-Petition Obligations;

          (q) Prior to the Final Facility Effective Date, replacement Liens on
the Collateral granted in favor of the Existing Agents to secure the
Indebtedness evidenced by the Existing Credit Agreement to the extent provided
in the Interim Bankruptcy Court Order;

          (r) replacement Liens on the Collateral granted in favor of the
Trustee under the Senior Subordinated Note Indenture to secure the Senior
Subordinated Notes to the extent provided in the Bankruptcy Court Orders;

          (s) Liens on insurance policies securing Indebtedness permitted by
clause (l) of the definition of Permitted Indebtedness to the extent such
Indebtedness is incurred in connection with financing insurance premiums for
such insurance policies; and

          (t) other Liens not permitted under any of clauses (a) through (r) of
this definition securing obligations of the Loan Parties and their Subsidiaries
in an aggregate amount not to exceed $300,000 at any time outstanding.

          "Permitted Priority Liens" means Liens permitted under clauses (d),
(e), (f), (g), (h), (k), (l), (m), (n) and (o) of the definition of the term
"Permitted Lien".

          "Person" means an individual, corporation, limited liability company,
partnership, association, joint-stock company, trust, unincorporated
organization, joint venture or other enterprise or entity or Governmental
Authority.

          "Pharma Purchase Agreement" means, collectively, one or more purchase
agreements with respect to the Pharma Sale in form and substance reasonably
satisfactory to the Agents (it being understood and agreed that the Xanodyne
Agreement (as in effect on the date hereof) is reasonably satisfactory to the
Agents).

          "Pharma Sale" means the marketing of, auction for, and sale of all or
substantially all of the "pharmaceuticals division" of the Borrowers' "product
sales business" (other than, in the case of the sale contemplated by the
Xanodyne Agreement, the Excluded Assets (as defined

                                      -23-
<PAGE>
in the Xanodyne Agreement)) (whether in one transaction or a series of related
transactions) pursuant to Section 363 of the Bankruptcy Code, on terms and
conditions reasonably satisfactory to, and pursuant to the Pharma Purchase
Agreement or other documentation approved by, the Agents and the Required
Lenders.

          "Plan" means any Employee Plan or Multiemployer Plan.

          "Pledge Agreement" means any pledge agreement or similar agreement or
instrument made by a Loan Party in favor of the Collateral Agent for the benefit
of the Agents, the L/C Issuer and the Lenders, in each case, in substantially
the same form and substance as the pledge agreements or similar agreements or
instruments that secure the Pre-Petition Obligations and otherwise in form and
substance reasonably satisfactory to the Collateral Agent.

          "Post-Default Rate" means a rate of interest per annum equal to the
rate of interest otherwise in effect from time to time pursuant to the terms of
this Agreement plus 2%, or, if a rate of interest is not otherwise in effect,
(i) in the case of the Term Loan and all Obligations with respect thereto
(including, without limitation, the principal thereof, the interest thereon, and
all fees, costs and expenses related thereto), the Reference Rate plus the Term
Loan Reference Rate Margin plus 2% and (ii) in the case of all other
Obligations, the Reference Rate plus the Revolving Loan Reference Rate Margin
plus 2%.

          "Pre-Petition Obligations" means all indebtedness, obligations
(including obligations in respect of any letters of credit) and liabilities of
the Borrowers to the Existing Agents and the Existing Lenders incurred prior to
the Filing Date arising from or related to the Existing Credit Agreement and the
other agreements, instruments and other documents related thereto plus fees,
premiums, expenses, indemnities and reimbursement obligations due thereunder and
interest thereon accruing both before and after the Filing Date, whether such
indebtedness, obligations or liabilities are direct or indirect, joint or
several, absolute or contingent, due or to become due, whether for payment or
performance, now existing or hereafter arising.

          "Priority Professional Expenses" means those Carve-Out Expenses
entitled to a priority as set forth in sub-clause (ii) of the clause "first" of
the definition of the term "Agreed Administrative Expense Priorities".

          "Product Recall Notice" means any written notice from the FDA stating
that any product or product line of any Loan Party or any of its Subsidiaries
has been or will be recalled.

          "Pro Rata Share" means:

               (a) with respect to a Lender's obligation to make Revolving Loans
and receive payments of interest, fees, and principal with respect thereto, the
percentage obtained by dividing (i) such Lender's Revolving Credit Commitment,
by (ii) the Total Revolving Credit Commitment, provided, that, if the Total
Revolving Credit Commitment has been reduced to zero, the numerator shall be the
aggregate unpaid principal amount of such Lender's Revolving Loans (including
Collateral Agent Advances) and its interest in the Letter of Credit Obligations
and the denominator shall be the aggregate unpaid principal amount of all
Revolving Loans (including Collateral Agent Advances) and Letter of Credit
Obligations,

                                      -24-
<PAGE>
               (b) with respect to a Lender's obligation to make the Term Loan
and receive payments of interest, fees, and principal with respect thereto, the
percentage obtained by dividing (i) such Lender's Term Loan Commitment, by (ii)
the Total Term Loan Commitment, provided that if the Total Term Loan Commitment
has been reduced to zero, the numerator shall be the aggregate unpaid principal
amount of such Lender's portion of the Term Loan and the denominator shall be
the aggregate unpaid principal amount of the Term Loan, and

               (c) with respect to all other matters (including, without
limitation, the indemnification obligations arising under Section 11.05), the
percentage obtained by dividing (i) the sum of such Lender's Revolving Credit
Commitment plus such Lender's Term Loan Commitment, by (ii) the sum of the Total
Revolving Credit Commitment plus the Total Term Loan Commitment, provided, that,
if such Lender's Revolving Credit Commitment or Term Loan Commitment shall have
been terminated or reduced to zero, such Lender's Revolving Credit Commitment or
Term Loan Commitment, as the case may be, shall be deemed to be the aggregate
unpaid principal amount of such Lender's Revolving Loans (including Collateral
Agent Advances) and its interest in the Letter of Credit Obligations or the
aggregate unpaid principal amount of such Lender's Term Loan, as the case may
be, and if the Total Revolving Credit Commitment or Total Term Loan Commitment
shall have been terminated or reduced to zero, the Total Revolving Credit
Commitment or Total Term Loan Commitment, as the case may be, shall be deemed to
be the aggregate unpaid principal amount of all Revolving Loans (including
Collateral Agent Advances) and Letter of Credit Obligations or the aggregate
unpaid principal amount of the Term Loan, as the case may be.

          "Professional Expense Cap" has the meaning specified therefor in
subclause (ii) of clause "first" of the definition of the term "Agreed
Administrative Expense Priorities".

          "Rating Agencies" has the meaning specified therefor in Section 2.07.

          "Reference Bank" means Bank of America, its successors or any other
commercial bank designated by the Administrative Agent to the Administrative
Borrower from time to time.

          "Reference Rate" means the greater of (x) the rate of interest
publicly announced by the Reference Bank in New York, New York from time to time
as its reference rate, base rate or prime rate and (y) the Federal Funds Rate
plus 0.50%. The reference rate, base rate or prime rate is determined from time
to time by the Reference Bank as a means of pricing some loans to its borrowers
and neither is tied to any external rate of interest or index nor necessarily
reflects the lowest rate of interest actually charged by the Reference Bank to
any particular class or category of customers. Each change in the Reference Rate
shall be effective from and including the date such change is publicly announced
as being effective.

          "Reference Rate Loan" means a Loan bearing interest calculated based
upon the Reference Rate.

          "Register" has the meaning specified therefor in Section 12.07(d).

          "Registered Loan" has the meaning specified therefor in Section
12.07(d).

                                      -25-
<PAGE>
          "Regulation T", "Regulation U" and "Regulation X" mean, respectively,
Regulations T, U and X of the Board or any successor, as the same may be amended
or supplemented from time to time.

          "Related Fund" means, with respect to any Person, an Affiliate of such
Person, or a fund or account managed by such Person or an Affiliate of such
Person.

          "Related Parties" means, with respect to an individual, spouses,
lineal ancestors or descendants, natural or adopted, and spouses of lineal
ancestors or descendants, or trusts for the sole benefit of any of such Persons.

          "Release" means any spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, seeping, migrating,
dumping or disposing of any Hazardous Material (including the abandonment or
discarding of barrels, containers and other closed receptacles containing any
Hazardous Material) into the indoor or outdoor environment, including, without
limitation, the movement of Hazardous Materials through or in the ambient air,
soil, surface or ground water, or property.

          "Remedial Action" means all actions taken to (i) clean up, remove,
remediate, contain, treat, monitor, assess, evaluate or in any other way address
Hazardous Materials in the indoor or outdoor environment; (ii) prevent or
minimize a Release or threatened Release of Hazardous Materials so they do not
migrate or endanger or threaten to endanger public health or welfare or the
indoor or outdoor environment; (iii) perform pre-remedial studies and
investigations and post-remedial operation and maintenance activities; or (iv)
perform any other actions authorized by 42 U.S.C. Section 9601.

          "Reportable Event" means an event described in Section 4043 of ERISA
(other than the commencement of the Chapter 11 Cases and any event not subject
to the provision for 30-day notice to the PBGC under the regulations promulgated
under such Section).

          "Required Lenders" means Lenders whose Pro Rata Shares aggregate at
least 50.1%.

          "Reserve Percentage" means, on any day, for any Lender, the maximum
percentage prescribed by the Board of Governors of the Federal Reserve System
(or any successor Governmental Authority) for determining the reserve
requirements (including any basic, supplemental, marginal, or emergency
reserves) that are in effect on such date with respect to eurocurrency funding
(currently referred to as "eurocurrency liabilities") of that Lender, but so
long as such Lender is not required or directed under applicable regulations to
maintain such reserves, the Reserve Percentage shall be zero.

          "Revolving Credit Commitment" means, with respect to each Lender, the
commitment of such Lender to make Revolving Loans to the Borrowers in the amount
set forth opposite such Lender's name in Schedule 1.01(A) hereto, as such amount
may be terminated or reduced from time to time in accordance with the terms of
this Agreement.

          "Revolving Loan" means a loan made by a Lender to the Borrowers
pursuant to Section 2.01(a)(i).

                                      -26-
<PAGE>
          "Revolving Loan Lender" means a Lender with a Revolving Credit
Commitment.

          "Revolving Loan LIBOR Rate Margin" means 5.00%; provided, that the
Revolving Loan LIBOR Rate Margin shall increase (a) by 0.50 percentage points
per annum on the earlier of (i) the date that is 3 months after the date of the
consummation of the Pharma Sale and (ii) the 6 month anniversary of the Interim
Facility Effective Date and (b) by an additional 0.50 percentage points per
annum on each 3 month anniversary of the Interim Facility Effective Date
thereafter.

          "Revolving Loan Reference Rate Margin" means 4.00%; provided, that the
Revolving Loan Reference Rate Margin shall increase (a) by 0.50 percentage
points per annum on the earlier of (i) the date that is 3 months after the date
of the consummation of the Pharma Sale and (ii) the 6 month anniversary of the
Interim Facility Effective Date and (b) by an additional 0.50 percentage points
per annum on each 3 month anniversary of the Interim Facility Effective Date
thereafter.

          "Rothschild Success Fee" means a success fee payable by the Parent to
Rothschild, Inc. in an aggregate amount not to exceed 1.5% of the gross proceeds
of the Pharma Sale.

          "Sale Procedure Motion" has the meaning specified therefor in Section
8.01(r).

          "Sale Procedure Order" has the meaning specified therefor in Section
8.01(r).

          "SEC" means the Securities and Exchange Commission or any other
similar or successor agency of the Federal government administering the
Securities Act.

          "Securities Act" means the Securities Act of 1933, as amended, or any
similar Federal statute, and the rules and regulations of the SEC thereunder,
all as the same shall be in effect from time to time.

          "Securitization" has the meaning specified therefor in Section 2.07.

          "Securitization Parties" has the meaning specified therefor in Section
2.07.

          "Security Agreement" means any security agreement or similar agreement
or instrument (including this Agreement) made by a Loan Party in favor of the
Collateral Agent for the benefit of the Agents, the L/C Issuer and the Lenders,
in each case, in substantially the same form and substance as the security
agreement or similar agreement or instrument that secures the Pre-Petition
Obligations and otherwise in form and substance satisfactory to the Collateral
Agent.

          "Senior Subordinated Note" means any one of the 11% Senior
Subordinated Notes due 2010, issued by the Parent in favor of the Senior
Subordinated Noteholders pursuant to the Senior Subordinated Note Indenture.

          "Senior Subordinated Note Indenture" means the Indenture, dated as of
March 28, 2002, by and among the Parent and the Trustee for the Senior
Subordinated Noteholders, as

                                      -27-
<PAGE>
amended by the Supplemental Indenture dated as of April 20, 2004 and the Second
Supplemental Indenture dated as of October 29, 2004.

          "Senior Subordinated Note Intercreditor Agreement" means the
Intercreditor Agreement, dated as of April 23, 2004, between the Collateral
Agent and the Trustee under the Senior Subordinated Note Indenture in its
capacity as collateral agent thereunder and acknowledged by the Borrowers.

          "Senior Subordinated Noteholder" means any one of the holders from
time to time of the Senior Subordinated Notes."

          "Settlement Period" has the meaning specified therefor in Section
2.02(d)(i).

          "Short Term Budget" means the rolling eight week cash requirements
forecast setting forth cash receipts and disbursements and Revolving Loans and
Letters of Credit of the Loan Parties for the periods covered thereby delivered
by the Parent to the Agents and the Lenders on or before the Interim Facility
Effective Date pursuant to Section 6.01(e)(x) hereto and each week thereafter
pursuant to Section 8.01(a)(vi) hereto, which are in form consistent with the
eight week cash requirement forecast heretofore delivered to the Agents and in
substance reasonably satisfactory to the Agents at the time of delivery thereof.

          "Silver Point" has the meaning specified therefor in the preamble
hereto.

          "Standard & Poor's" means Standard & Poor's Ratings Services, a
division of The McGraw-Hill Companies, Inc. and any successor thereto.

          "Subordinated Indebtedness" means Indebtedness of any Loan Party the
terms of which are satisfactory to the Collateral Agent and the Required Lenders
which has been expressly subordinated in right of payment to all Indebtedness of
such Loan Party under the Loan Documents (i) by the execution and delivery of a
subordination agreement, in form and substance satisfactory to the Collateral
Agent and the Required Lenders, or (ii) otherwise on terms and conditions
(including, without limitation, subordination provisions, payment terms,
interest rates, covenants, remedies, defaults and other material terms)
satisfactory to the Collateral Agent and the Required Lenders.

          "Subsidiary" means, with respect to any Person at any date, any
corporation, limited or general partnership, limited liability company, trust,
estate, association, joint venture or other business entity (i) the accounts of
which would be consolidated with those of such Person in such Person's
consolidated financial statements if such financial statements were prepared in
accordance with GAAP or (ii) of which more than 50% of (A) the outstanding
Capital Stock having (in the absence of contingencies) ordinary voting power to
elect a majority of the board of directors or other managing body of such
Person, (B) in the case of a partnership or limited liability company, the
interest in the capital or profits of such partnership or limited liability
company or (C) in the case of a trust, estate, association, joint venture or
other entity, the beneficial interest in such trust, estate, association or
other entity business is, at the time of determination, owned or controlled
directly or indirectly through one or more intermediaries, by such Person.

                                      -28-
<PAGE>
          "Success Fee" has the meaning specified therefor in the Fee Letter.

          "Supplemental Disclosure" has the meaning specified therefor in
Section 7.01(p).

          "Taxes" has the meaning specified therefor in Section 2.08(a).

          "Term Loan" means, collectively, the loans made by the Term Loan
Lenders to the Borrowers pursuant to Section 2.01(a)(ii).

          "Term Loan Commitment" means, with respect to each Lender, the
commitment of such Lender to make the Term Loan to the Borrowers in the amount
set forth in Schedule 1.01(A) hereto, as the same may be terminated or reduced
from time to time in accordance with the terms of this Agreement.

          "Term Loan Lender" means a Lender with a Term Loan Commitment.

          "Term Loan LIBOR Rate Margin" means 8.25%; provided, that the Term
Loan LIBOR Rate Margin shall increase (a) by 1.00 percentage point per annum on
the earlier of (i) the date that is 3 months after the date of the consummation
of the Pharma Sale and (ii) the 6 month anniversary of the Interim Facility
Effective Date and (b) by an additional 1.00 percentage point per annum on each
3 month anniversary of the Interim Facility Effective Date thereafter.

          "Term Loan Obligations" means any Obligations with respect to the Term
Loan (including without limitation, the principal thereof, the interest thereon,
and the fees, costs and expenses specifically related thereto).

          "Term Loan Reference Rate Margin" means 7.25%; provided, that the Term
Loan Reference Rate Margin shall increase (a) by 1.00 percentage point per annum
on the earlier of (i) the date that is 3 months after the date of the
consummation of the Pharma Sale and (ii) the 6 month anniversary of the Interim
Facility Effective Date and (b) by an additional 1.00 percentage point per annum
on each 3 month anniversary of the Interim Facility Effective Date thereafter.

          "Termination Event" means (i) a Reportable Event with respect to any
Employee Plan, (ii) any event that causes any Loan Party or any of its ERISA
Affiliates to incur liability under Section 409, 502(i), 502(l), 515, 4062,
4063, 4064, 4069, 4201, 4204 or 4212 of ERISA or Section 4971 or 4975 of the
Internal Revenue Code, (iii) the filing of a notice of intent to terminate an
Employee Plan or the treatment of an Employee Plan amendment as a termination
under Section 4041 of ERISA, (iv) the institution of proceedings by the PBGC to
terminate an Employee Plan, or (v) any other event or condition which might
constitute grounds under Section 4042 of ERISA for the termination of, or the
appointment of a trustee to administer, any Employee Plan; provided, however,
that no Termination Event shall be deemed to have occurred as a result of the
commencement of the Chapter 11 Cases.

          "Title Insurance Policy" means a mortgagee's loan policy, in form and
substance satisfactory to the Collateral Agent, together with all endorsements
made from time to time thereto, issued by or on behalf of a title insurance
company reasonably satisfactory to the Collateral Agent, insuring the Lien
created by a Mortgage in an amount and on terms reasonably satisfactory to the
Collateral Agent, delivered to the Collateral Agent (it being understood and

                                      -29-
<PAGE>
agreed that with respect to any Facility for which a title insurance policy was
obtained pursuant to the Existing Credit Agreement, a title insurance policy in
substantially the same form and substance as such title insurance policy (and
from the same title insurance company) shall be reasonably satisfactory to the
Collateral Agent).

          "Total Commitment" means the sum of the Total Revolving Credit
Commitment and the Total Term Loan Commitment.

          "Total Revolving Credit Commitment" means the sum of the amounts of
the Lenders' Revolving Credit Commitments.

          "Total Term Loan Commitment" means the sum of the amounts of the
Lenders' Term Loan Commitments.

          "Transferee" has the meaning specified therefor in Section 2.08(a).

          "Treasury Management Agreement" means any agreement governing the
provision of treasury or cash management services, including deposit accounts,
funds transfer, automated clearinghouse, zero balance accounts, returned check
concentration, controlled disbursement, lockbox, account reconciliation and
reporting.

          "UCP" has the meaning specified therefor in Section 3.01(h).

          "Uniform Commercial Code" has the meaning specified therefor in
Section 1.03.

          "Unused Line Fee" has the meaning specified therefor in Section
2.06(a).

          "WARN" has the meaning specified therefor in Section 7.01(y).

          "Xanodyne Agreement" means that certain Asset Purchase Agreement,
dated as of May 6, 2005, between Xanodyne Pharmaceuticals, Inc., the Parent and
Pharma LLC.

          Section 1.02 Terms Generally. The definitions of terms herein shall
apply equally to the singular and plural forms of the terms defined. Whenever
the context may require, any pronoun shall include the corresponding masculine,
feminine and neuter forms. The words "include", "includes" and "including" shall
be deemed to be followed by the phrase "without limitation". The word "will"
shall be construed to have the same meaning and effect as the word "shall".
Unless the context requires otherwise, (a) any definition of or reference to any
agreement, instrument or other document herein shall be construed as referring
to such agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (b) any reference
herein to any Person shall be construed to include such Person's successors and
assigns, (c) the words "herein", "hereof" and "hereunder", and words of similar
import, shall be construed to refer to this Agreement in its entirety and not to
any particular provision hereof, (d) all references herein to Articles,
Sections, Exhibits and Schedules shall be construed to refer to Articles and
Sections of, and Exhibits and Schedules to, this Agreement and (e) the words
"asset" and "property" shall be construed to have the same meaning and effect
and to refer to any right or interest in or to assets and properties of any kind

                                      -30-
<PAGE>
whatsoever, whether real, personal or mixed and whether tangible or intangible.
References in this Agreement to "determination" by any Agent include good faith
estimates by such Agent (in the case of quantitative determinations) and good
faith beliefs by such Agent (in the case of qualitative determinations).

          Section 1.03 Accounting and Other Terms. Unless otherwise expressly
provided herein, each accounting term used herein shall have the meaning given
it under GAAP applied on a basis consistent with those used in preparing the
Financial Statements. All terms used in this Agreement which are defined in
Article 8 or Article 9 of the Uniform Commercial Code as in effect from time to
time in the State of New York (the "Uniform Commercial Code") and which are not
otherwise defined herein shall have the same meanings herein as set forth
therein, provided that terms used herein which are defined in the Uniform
Commercial Code as in effect in the State of New York on the date hereof shall
continue to have the same meaning notwithstanding any replacement or amendment
of such statute except as any Agent may otherwise determine.

          Section 1.04 Time References. Unless otherwise indicated herein, all
references to time of day refer to Eastern Standard Time or Eastern daylight
saving time, as in effect in New York City on such day. For purposes of the
computation of a period of time from a specified date to a later specified date,
the word "from" means "from and including" and the words "to" and "until" each
means "to but excluding"; provided, however, that with respect to a computation
of fees or interest payable to any Agent, any Lender or the L/C Issuer, such
period shall in any event consist of at least one full day.

                                   ARTICLE II

                                    THE LOANS

          Section 2.01 Commitments. (a) Subject to the terms and conditions and
relying upon the representations and warranties herein set forth:

                    (i) each Revolving Loan Lender severally agrees to make
Revolving Loans to the Borrowers at any time and from time to time from the
Interim Facility Effective Date to the Final Maturity Date, or until the earlier
reduction of its Revolving Credit Commitment to zero in accordance with the
terms hereof, in an aggregate principal amount of Revolving Loans at any time
outstanding not to exceed the amount of such Lender's Revolving Credit
Commitment; and

                    (ii) each Term Loan Lender severally agrees to make the Term
Loan to the Borrowers on the Final Facility Effective Date in an aggregate
principal amount not to exceed the amount of such Lender's Term Loan Commitment.

               (b) Notwithstanding the foregoing:

                    (i) The aggregate principal amount of Revolving Loans
outstanding on any date to the Borrowers shall not exceed the difference between
(A) the Total Revolving Credit Commitment and (B) the sum of (1) the aggregate
Letter of Credit Obligations and (2) the aggregate amount of all reserves
established by the Administrative Agent in accordance with the definition of the
term "Availability".

                                      -31-
<PAGE>
                    (ii) The aggregate principal amount of Revolving Loans and
Letter of Credit Obligations outstanding at any time during any Budget Period to
the Borrowers shall not exceed the maximum aggregate principal amount of
Revolving Loans and Letter of Credit Obligations projected to be outstanding
during such Budget Period (with the exception of the Budget Period containing
the week ending September 30, 2005, as to which such maximum aggregate principal
amount of Revolving Loans and Letter of Credit Obligations shall exclude the
maximum aggregate principal amount of Revolving Loans and Letter of Credit
Obligations projected to be outstanding during the week ending September 30,
2005) as set forth in the Long-Term Budget (after giving effect to the Permitted
Deviation therefrom).

                    (iii) During the Interim Period, the aggregate principal
amount of Revolving Loans and Letter of Credit Obligations outstanding at any
time shall not exceed $15,000,000.

                    (iv) The Revolving Credit Commitment of each Lender (and the
letter of credit subfacility) shall automatically and permanently be reduced to
zero on the Final Maturity Date.

                    (v) Within the foregoing limits, the Borrowers may borrow,
repay and reborrow Revolving Loans, on or after the Interim Facility Effective
Date and prior to the Final Maturity Date, subject to the terms, provisions and
limitations set forth herein.

                    (vi) The aggregate principal amount of the Term Loan made on
the Final Facility Effective Date shall not exceed the Total Term Loan
Commitment. Any principal amount of the Term Loan which is repaid or prepaid may
not be reborrowed.

          Section 2.02 Making the Loans. (a) The Administrative Borrower shall
give the Agents prior written notice (in substantially the form of Exhibit A
hereto (a "Notice of Borrowing") not later than (x) in the case of a borrowing
consisting of a Reference Rate Loan, 11:00 a.m. (New York City time) on the date
of the proposed borrowing, and (y) in the case of a borrowing consisting of
LIBOR Rate Loans, 11:00 a.m. (New York City time) on a date that is three (3)
Business Days prior to the date of the proposed borrowing. Such Notice of
Borrowing shall be irrevocable and shall (i) specify (A) the principal amount of
the proposed Loan (which, in the case of a LIBOR Rate Loan, must be in a minimum
amount of $1,000,000 and in integral multiples of $100,000 in excess thereof),
(B) whether such Loan is requested to be a Reference Rate Loan or a LIBOR Rate
Loan and, in the case of a LIBOR Rate Loan, the initial Interest Period with
respect thereto, (C) in the case of Loans requested on the Final Facility
Effective Date, whether such Loan is requested to be a Revolving Loan or the
Term Loan, (D) the use of the proceeds of such proposed Loan, and (E) the
proposed borrowing date, which must be a Business Day, and, with respect to the
Term Loan, must be the Final Facility Effective Date, and (ii) include a
certification by an Authorized Officer of the Administrative Borrower that the
aggregate principal amount of Revolving Loans and Letter of Credit Obligations
outstanding on the date of the proposed Loan (after giving effect to the
proposed borrowing) shall not exceed the maximum aggregate principal amount of
Revolving Loans and Letter of Credit Obligations projected to be outstanding
during the then current Budget Period as set forth in the Long-Term Budget
(subject to the Permitted Deviation therefrom). The Agents and the Lenders may
act without liability upon the basis of written or telecopied notice believed by
the Agents in good

                                      -32-
<PAGE>
faith to be from the Administrative Borrower (or from any Authorized Officer
thereof designated in writing purportedly from the Administrative Borrower to
the Agents). Each Agent and each Lender shall be entitled to rely conclusively
on (xx) any Authorized Officer's authority to request a Loan on behalf of the
Borrowers until the Agents receive written notice to the contrary and (yy) any
Authorized Officer's certification with respect to the matters set forth in
clause (ii) above. The Agents and the Lenders shall have no duty to verify the
authenticity of the signature appearing on any written Notice of Borrowing.
Notwithstanding anything to the contrary herein, all Revolving Loans made prior
to the Final Facility Effective Date and all Revolving Loans and the Term Loan
made on the Final Facility Effective Date shall be Reference Rate Loans.
Thereafter all or any portion of the Loans may be converted into LIBOR Rate
Loans in accordance with the terms of Section 2.09.

               (b) Each Notice of Borrowing pursuant to this Section 2.02 shall
be irrevocable and the Borrowers shall be bound to make a borrowing in
accordance therewith. Each Revolving Loan shall be made in a minimum amount of
$250,000 and shall be in an integral multiple of $50,000.

               (c) (i) Except as otherwise provided in this Section 2.02(c), all
Loans under this Agreement shall be made by the Lenders simultaneously and
proportionately to their Pro Rata Shares of the Total Revolving Credit
Commitment and the Total Term Loan Commitment, as the case may be, it being
understood that no Lender shall be responsible for any default by any other
Lender in that other Lender's obligations to make a Loan requested hereunder,
nor shall the Commitment of any Lender be increased or decreased as a result of
the default by any other Lender in that other Lender's obligation to make a Loan
requested hereunder, and each Lender shall be obligated to make the Loans
required to be made by it by the terms of this Agreement regardless of the
failure by any other Lender.

                    (ii) Notwithstanding any other provision of this Agreement,
and in order to reduce the number of fund transfers among the Borrowers, the
Agents and the Lenders, the Borrowers, the Agents and the Lenders agree that the
Administrative Agent may (but shall not be obligated to), and the Borrowers and
the Lenders hereby irrevocably authorize the Administrative Agent to, fund, on
behalf of the Revolving Loan Lenders, Revolving Loans pursuant to Section 2.01,
subject to the procedures for settlement set forth in subsection 2.02(d);
provided, however, that (a) the Administrative Agent shall in no event fund any
such Revolving Loans if the Administrative Agent shall have received written
notice from the Collateral Agent or the Required Lenders on the Business Day
prior to the date of the proposed Revolving Loan that one or more of the
conditions precedent contained in Section 6.03 will not be satisfied at the time
of the proposed Revolving Loan, and (b) the Administrative Agent shall not
otherwise be required to determine that, or take notice whether, the conditions
precedent in Section 6.03 have been satisfied. If either (x) the Administrative
Borrower gives a Notice of Borrowing requesting a Revolving Loan that is a LIBOR
Rate Loan or (y) the Administrative Agent elects not to fund a requested
Revolving Loan that is a Reference Rate Loan on behalf of such Revolving Loan
Lenders, then promptly after receipt of the Notice of Borrowing requesting such
Revolving Loan, the Administrative Agent shall notify each Revolving Loan Lender
of the specifics of the requested Revolving Loan and that it will not fund the
requested Revolving Loan on behalf of the Revolving Loan Lenders. If the
Administrative Agent notifies the Revolving Loan Lenders that it will not fund a
requested Revolving Loan on behalf of the Revolving Loan Lenders, each

                                      -33-
<PAGE>
Revolving Loan Lender shall make its Pro Rata Share of the Revolving Loan
available to the Administrative Agent, in immediately available funds, in the
Administrative Agent's Account no later than 3:00 p.m. (New York City time)
(provided that the Administrative Agent requests payment from such Revolving
Loan Lender not later than 1:00 p.m. (New York City time)) on the date of the
proposed Revolving Loan. The Administrative Agent will make the proceeds of such
Revolving Loans available to the Borrowers on the day of the proposed Revolving
Loan by causing an amount, in immediately available funds, equal to the proceeds
of all such Revolving Loans received by the Administrative Agent in the
Administrative Agent's Account or the amount funded by the Administrative Agent
on behalf of the Revolving Loan Lenders to be deposited in an account designated
by the Administrative Borrower.

                    (iii) If the Administrative Agent has notified the Revolving
Loan Lenders that the Administrative Agent, on behalf of the Revolving Loan
Lenders, will fund a particular Revolving Loan pursuant to subsection
2.02(c)(ii), the Administrative Agent may assume that each such Revolving Loan
Lender has made such amount available to the Administrative Agent on such day
and the Administrative Agent, in its sole discretion, may, but shall not be
obligated to, cause a corresponding amount to be made available to the Borrowers
on such day. If the Administrative Agent makes such corresponding amount
available to the Borrowers and such corresponding amount is not in fact made
available to the Administrative Agent by any such Revolving Loan Lender, the
Administrative Agent shall be entitled to recover such corresponding amount on
demand from such Revolving Loan Lender together with interest thereon, for each
day from the date such payment was due until the date such amount is paid to the
Administrative Agent, at the Federal Funds Rate for three Business Days and
thereafter at the Reference Rate. During the period in which such Revolving Loan
Lender has not paid such corresponding amount to the Administrative Agent,
notwithstanding anything to the contrary contained in this Agreement or any
other Loan Document, the amount so advanced by the Administrative Agent to the
Borrowers shall, for all purposes hereof, be a Revolving Loan made by the
Administrative Agent for its own account. Upon any such failure by a Revolving
Loan Lender to pay the ADMINISTRATIVE Agent, the Administrative Agent shall
promptly thereafter notify the Administrative Borrower of such failure and the
Borrowers shall immediately pay such corresponding amount to the Administrative
Agent for its own account.

                    (iv) Nothing in this subsection 2.02(c) shall be deemed to
relieve any Revolving Loan Lender from its obligations to fulfill its Revolving
Credit Commitment hereunder or to prejudice any rights that the Administrative
Agent or the Borrowers may have against any Revolving Loan Lender as a result of
any default by such Revolving Loan Lender hereunder.

               (d) (i) With respect to each LIBOR Rate Loan, on the first and
the last date of each Interest Period, and with respect to all periods for which
the Administrative Agent, on behalf of the Revolving Loan Lenders, has funded
Revolving Loans that are Reference Rate Loans pursuant to subsection 2.02(c), on
Friday of each week, or if the applicable Friday is not a Business Day, then on
the following Business Day, or such shorter period as the Administrative Agent
may from time to time select (any such Interest Period, week or shorter period
being herein called a "Settlement Period"), the Administrative Agent shall
notify each Revolving Loan Lender of the unpaid principal amount of the
Revolving Loans outstanding as of the last day of each such Settlement Period.
In the event that such amount is greater than the

                                      -34-
<PAGE>
unpaid principal amount of the Revolving Loans outstanding on the last day of
the Settlement Period immediately preceding such Settlement Period (or, if there
has been no preceding Settlement Period, the amount of the Revolving Loans made
on the date of such Revolving Loan Lender's initial funding), each Revolving
Loan Lender shall promptly (and in any event not later than 2:00 p.m. (New York
City time) if the Administrative Agent requests payment from such Lender not
later than 12:00 noon (New York City time) on such day) make available to the
Administrative Agent its Pro Rata Share of the difference in immediately
available funds. In the event that such amount is less than such unpaid
principal amount, the Administrative Agent shall promptly pay over to each
Revolving Loan Lender its Pro Rata Share of the difference in immediately
available funds. In addition, if the Administrative Agent, at the direction of
the Collateral Agent, shall so request at any time when a Default or an Event of
Default shall have occurred and be continuing, or any other event shall have
occurred as a result of which the Collateral Agent shall determine that it is
desirable to present claims against the Borrowers for repayment, each Revolving
Loan Lender shall promptly remit to the Administrative Agent or, as the case may
be, the Administrative Agent shall promptly remit to each Revolving Loan Lender,
sufficient funds to adjust the interests of the Revolving Loan Lenders in the
then outstanding Revolving Loans to such an extent that, after giving effect to
such adjustment, each such Revolving Loan Lender's interest in the then
outstanding Revolving Loans will be equal to its Pro Rata Share thereof. The
obligations of the Administrative Agent and each Revolving Loan Lender under
this subsection 2.02(d) shall be absolute and unconditional. Each Revolving Loan
Lender shall only be entitled to receive interest on its Pro Rata Share of the
Revolving Loans which have been funded by such Revolving Loan Lender.

                    (ii) In the event that any Revolving Loan Lender fails to
make any payment required to be made by it pursuant to subsection 2.02(d)(i),
the Administrative Agent shall be entitled to recover such corresponding amount
on demand from such Revolving Loan Lender together with interest thereon, for
each day from the date such payment was due until the date such amount is paid
to the Administrative Agent, at the Federal Funds Rate for three Business Days
and thereafter at the Reference Rate. During the period in which such Revolving
Loan Lender has not paid such corresponding amount to the Administrative Agent,
notwithstanding anything to the contrary contained in this Agreement or any
other Loan Document, the amount so advanced by the Administrative Agent to the
Borrowers shall, for all purposes hereof, be a Revolving Loan made by the
Administrative Agent for its own account. Upon any such failure by a Revolving
Loan Lender to pay the Administrative Agent, the Administrative Agent shall
promptly thereafter notify the Administrative Borrower of such failure and the
Borrowers shall immediately pay such corresponding amount to the Administrative
Agent for its own account. Nothing in this subsection 2.02(d)(ii) shall be
deemed to relieve any Revolving Loan Lender from its obligation to fulfill its
Revolving Credit Commitment hereunder or to prejudice any rights that the
Administrative Agent or the Borrowers may have against any Revolving Loan Lender
as a result of any default by such Revolving Loan Lender hereunder.

          Section 2.03 Repayment of Loans; Evidence of Debt.

               (a) The outstanding principal of all Revolving Loans shall be due
and payable on the Final Maturity Date.

                                      -35-
<PAGE>
               (b) The outstanding principal of the Term Loan shall be repaid in
full on the earlier of (i) the date of the termination of the Total Revolving
Credit Commitment and (ii) the Final Maturity Date.

               (c) Each Lender shall maintain in accordance with its usual
practice an account or accounts evidencing the Indebtedness of the Borrowers to
such Lender resulting from each Loan made by such Lender, including the amounts
of principal and interest payable and paid to such Lender from time to time
hereunder.

               (d) The Administrative Agent shall maintain accounts in which it
shall record (i) the amount of each Loan made hereunder, (ii) the amount of any
principal or interest due and payable or to become due and payable from the
Borrowers to each Lender hereunder and (iii) the amount of any sum received by
the Administrative Agent hereunder for the account of the Lenders and each
Lender's share thereof.

               (e) The entries made in the accounts maintained pursuant to
paragraph (c) or (d) of this Section shall be prima facie evidence of the
existence and amounts of the obligations recorded therein; provided that the
failure of any Lender or the Administrative Agent to maintain such accounts or
any error therein shall not in any manner affect the obligation of the Borrowers
to repay the Loans in accordance with the terms of this Agreement.

               (f) Any Lender may request that Loans made by it be evidenced by
a promissory note. In such event, the Borrowers shall execute and deliver to
such Lender a promissory note payable to the order of such Lender (or, if
requested by such Lender, to such Lender and its registered assigns) in a form
furnished by the Collateral Agent and reasonably acceptable to the
Administrative Borrower. Thereafter, the Loans evidenced by such promissory note
and interest thereon shall at all times (including after assignment pursuant to
Section 12.07) be represented by one or more promissory notes in such form
payable to the order of the payee named therein (or, if such promissory note is
a registered note, to such payee and its registered assigns).

          Section 2.04 Interest.

               (a) Revolving Loans. Each Revolving Loan that is a Reference Rate
Loan shall bear interest on the principal amount thereof from time to time
outstanding, from the date of such Loan until such principal amount becomes due,
at a rate per annum equal to the Reference Rate plus the Revolving Loan
Reference Rate Margin. Each Revolving Loan that is a LIBOR Rate Loan shall bear
interest on the principal amount thereof from time to time outstanding, from the
date of such Loan until such principal amount is repaid, at a rate per annum
equal to the LIBOR Rate plus the Revolving Loan LIBOR Rate Margin.

               (b) Term Loan. Each portion of the Term Loan that is a Reference
Rate Loan shall bear interest on the principal amount thereof from time to time
outstanding, from the date of such Loan until such principal amount is repaid,
at a rate per annum equal to the Reference Rate plus the Term Loan Reference
Rate Margin. Each portion of the Term Loan that is a LIBOR Rate Loan shall bear
interest on the principal amount thereof from time to time

                                      -36-
<PAGE>
outstanding, from the date of such Loan until such principal amount is repaid,
at a rate per annum equal to the LIBOR Rate plus the Term Loan LIBOR Rate
Margin.

               (c) Default Interest. To the extent permitted by law, upon the
occurrence and during the continuance of an Event of Default, at the election of
the Collateral Agent or the Required Lenders, the principal of, and all accrued
and unpaid interest on, all Loans, fees, indemnities or any other Obligations of
the Loan Parties under this Agreement and the other Loan Documents, shall bear
interest, from the date such Event of Default occurred until the date such Event
of Default is cured or waived in writing in accordance herewith, at a rate per
annum equal at all times to the Post-Default Rate.

               (d) Interest Payment. Interest on each Loan shall be payable
monthly, in arrears, on the first day of each month, commencing on the first day
of the month following the month in which such Loan is made and at maturity
(whether upon demand, by acceleration or otherwise). Interest at the
Post-Default Rate shall be payable on demand. Each Borrower hereby authorizes
the Administrative Agent to, and the Administrative Agent may, from time to
time, charge the Loan Account pursuant to Section 5.02 with the amount of any
interest payment due hereunder.

               (e) General. All computations of interest for Reference Rate
Loans shall be made on the basis of a year of 365 or 366 days, as the case may
be, and the actual number of days elapsed. All other computations of interest
shall be made on the basis of a 360-day year and the actual number of days
elapsed (which results in more interest being paid than if computed on the basis
of a 365-day year).

          Section 2.05 Reduction of Commitment; Prepayment of Loans.

               (a) Reduction of Commitments.

                    (i) Revolving Credit Commitments. The Total Revolving Credit
Commitment shall terminate on the Final Maturity Date. The Borrowers may reduce
the Total Revolving Credit Commitment to an amount (which may be zero) not less
than the sum of (A) the aggregate unpaid principal amount of all Revolving Loans
then outstanding, (B) the aggregate principal amount of all Revolving Loans not
yet made as to which a Notice of Borrowing has been given by the Administrative
Borrower under Section 2.02, (C) the Letter of Credit Obligations at such time
and (D) the stated amount of all Letters of Credit not yet issued as to which a
request has been made and not withdrawn. Each such reduction (w) shall be in an
amount which is an integral multiple of $1,000,000 (unless the Total Revolving
Credit Commitment in effect immediately prior to such reduction is less than
$1,000,000), (x) shall be made by providing not less than five (5) Business
Days' prior written notice to the Administrative Agent and (y) shall be
irrevocable. Once reduced, the Total Revolving Credit Commitment may not be
increased. Each such reduction of the Total Revolving Credit Commitment shall
reduce the Revolving Credit Commitment of each Lender proportionately in
accordance with its Pro Rata Share thereof.

                    (ii) Term Loan. The Total Term Loan Commitment shall
terminate at 5:00 p.m. (New York City time) on the Final Facility Effective
Date.

                                      -37-
<PAGE>
               (b) Optional Prepayment.

                    (i) Revolving Loans. The Borrowers may at any time and from
time to time, prepay the principal of any Revolving Loan, in whole or in part.

                    (ii) Term Loan. The Borrowers may, at any time and from time
to time after the Final Facility Effective Date, upon at least 3 Business Days'
prior written notice to the Administrative Agent, prepay the principal of the
Term Loan, in whole or in part. Each prepayment made pursuant to this clause
(b)(ii) shall be accompanied by the payment of (A) accrued interest to the date
of such payment on the amount prepaid and (B) the Success Fee, if any, payable
in connection with such prepayment of the Term Loan

                    (iii) Prepayment In Full. The Borrowers may, upon at least 3
Business Days prior written notice to the Administrative Agent, terminate this
Agreement by paying to the Administrative Agent, in cash, the Obligations
(including either (A) providing cash collateral to be held by the Administrative
Agent for the benefit of the L/C Issuer and the other Revolving Loan Lenders in
an amount equal to 110% of the aggregate undrawn amount of all outstanding
Letters of Credit or (B) causing the original Letters of Credit to be returned
to the L/C Issuer), in full, together with the Success Fee, if any. If the
Administrative Borrower has sent a notice of termination pursuant to this clause
(iii), then the Lenders' obligations to extend credit hereunder shall terminate
on the date set forth as the date of termination of this Agreement in such
notice and the Borrowers shall be obligated to repay the Obligations (including
either (A) providing cash collateral to be held by the Administrative Agent for
the benefit of the L/C Issuer and the other Revolving Loan Lenders in an amount
equal to 110% of the aggregate undrawn amount of all outstanding Letters of
Credit or (B) causing the original Letters of Credit to be returned to the L/C
Issuer), in full, together with the Success Fee, if any, on the date set forth
as the date of termination of this Agreement in such notice.

               (c) Mandatory Prepayment.

                    (i) The Borrowers will immediately prepay the outstanding
principal amount of the Term Loan in the event that the Total Revolving Credit
Commitment is terminated for any reason.

                    (ii) The Borrowers will immediately prepay the Revolving
Loans on any date that the aggregate principal amount of all Revolving Loans and
Letter of Credit Obligations exceeds the lesser of (A) the difference between
(x) the Total Revolving Credit Commitment and (y) the aggregate amount of all
reserves established by the Administrative Agent prior to such date in
accordance with the definition of the term "Availability" and (B) the maximum
aggregate principal amount of Revolving Loans and Letter of Credit Obligations
projected to be outstanding during the then current Budget Period as set forth
in the Long-Term Budget (subject to the Permitted Deviation therefrom), to the
full extent of any such excess. On each day that any Revolving Loans or Letter
of Credit Obligations are outstanding, the Borrowers shall hereby be deemed to
represent and warrant to the Agents and the Lenders that (1) the difference
between (x) the Total Revolving Credit Commitment and (y) the aggregate amount
of all reserves established by the Administrative Agent prior to such day in
accordance with the definition of the term "Availability" equals or exceeds the
aggregate

                                      -38-
<PAGE>
principal amount of all Revolving Loans and Letter of Credit Obligations
outstanding on such day and (2) the aggregate principal amount of all Revolving
Loans and Letter of Credit Obligations outstanding on such day does not exceed
the maximum aggregate principal amount of Revolving Loans and Letter of Credit
Obligations projected to be outstanding during the then current Budget Period as
set forth in the Long-Term Budget (subject to the Permitted Deviation
therefrom). If at any time after the Borrowers have complied with the first
sentence of this Section 2.05(c)(ii), the aggregate principal amount of Letter
of Credit Obligations is greater than (A) the difference between (x) the Total
Revolving Credit Commitment and (y) the aggregate amount of all reserves
established by the Administrative Agent in accordance with the definition of the
term "Availability" or (B) the maximum aggregate principal amount of Revolving
Loans and Letter of Credit Obligations projected to be outstanding during the
then current Budget Period as set forth in the Long-Term Budget (subject to the
Permitted Deviation therefrom), the Borrowers shall provide cash collateral to
the Administrative Agent in an amount equal to 110% of such excess, and,
provided that no Event of Default shall have occurred and be continuing, such
cash collateral shall be returned by the Administrative Agent, at the direction
of the Collateral Agent, to the Borrowers on the first date and to the extent
that the aggregate principal amount of all outstanding Revolving Loans and
Letter of Credit Obligations (after giving effect to such return) no longer
exceeds the lesser of (A) the difference between (x) the Total Revolving Credit
Commitment and (y) the aggregate amount of all reserves established by the
Administrative Agent in accordance with the definition of the term
"Availability" and (B) the maximum aggregate principal amount of Revolving Loans
and Letter of Credit Obligations projected to be outstanding during the then
current Budget Period as set forth in the Long-Term Budget (subject to the
Permitted Deviation therefrom).

                    (iii) Within 3 days of any Disposition (other than the
Pharma Sale) by any Loan Party or any of its Subsidiaries pursuant to Section
8.02(c)(ii), the Borrowers shall prepay the outstanding principal amount of the
Loans in accordance with Section 2.05(d) in an amount equal to 100% of the Net
Cash Proceeds received by such Person in connection with such Disposition to the
extent that the aggregate amount of Net Cash Proceeds received by all Loan
Parties and their Subsidiaries (and not paid to the Administrative Agent as a
prepayment of the Loans) shall exceed for all such Dispositions $500,000 in the
aggregate during the term of this Agreement. Nothing contained in this clause
(iii) shall permit any Loan Party or any of its Subsidiaries to make a
Disposition of any property other than in accordance with Section 8.02(c)(ii).
Notwithstanding the foregoing, so long as no Event of Default has occurred and
is continuing on the date such Person receives Net Cash Proceeds in connection
with a Disposition of equipment, such Net Cash Proceeds (in an amount not to
exceed $500,000 in the aggregate during the term of this Agreement) received by
such Person may, at the option of the Borrowers, be applied to acquire
replacement equipment for the equipment so disposed of, provided, that (x) until
so applied, such Net Cash Proceeds shall either be (1) deposited into a cash
collateral account with a commercial bank designated by the Collateral Agent
(and when so deposited such Net Cash Proceeds shall constitute Collateral for
the Obligations then outstanding and shall remain in such cash collateral
account until such Net Cash Proceeds are applied in accordance with either of
clauses (y) or (z) of this clause (iii)) or (2) upon notification by the
Administrative Borrower to the Agents, applied to the Revolving Loans (and
concurrently with such application to the Revolving Loans, the Administrative
Agent shall, at the direction of the Collateral Agent, establish and maintain a
corresponding reserve to Availability in the amount so applied, which reserve
shall be released at such time as the Borrowers re-borrow funds in such amount
to be

                                      -39-
<PAGE>
used in accordance with either of clauses (y) or (z) of this clause (iii)), (y)
such Net Cash Proceeds must be applied and such equipment must be replaced
within 90 days after the date of receipt thereof, and (z) upon (1) the
occurrence and during the continuance of an Event of Default or (2) the
expiration of such 90 day period, such Net Cash Proceeds, if not so applied,
shall be applied to the prepayment of the Loans in accordance with Section
2.05(d).

                    (iv) Upon consummation of the Pharma Sale, the Borrowers
shall prepay the outstanding principal amount of the Loans in accordance with
Section 2.05(d) in an amount equal to 100% of the Net Cash Proceeds received by
the Borrowers in connection therewith.

                    (v) Within 3 days of the receipt by any Loan Party or any of
its Subsidiaries of any Extraordinary Receipts in excess of $500,000 in the
aggregate during the term of this Agreement, the Borrowers shall prepay the
outstanding principal of the Loans in accordance with Section 2.05(d) in an
amount equal to 100% of the Net Cash Proceeds of such Extraordinary Receipts.
Notwithstanding the foregoing, so long as no Event of Default has occurred and
is continuing on the date such Person receives Extraordinary Receipts consisting
of insurance proceeds from one or more policies covering, or proceeds from any
judgment, settlement, condemnation or other cause of action in respect of, the
loss, damage, taking or theft of any real property or equipment having an
aggregate market value of less than $1,500,000, such Extraordinary Receipts (in
an amount not to exceed $1,500,000) received by such Person may, at the option
of the Borrowers, be applied to repair or restore such real property or
equipment or acquire replacement real property or equipment for the real
property or equipment so lost, damaged or stolen or other real property or
equipment used or useful in the business of such Person for the real property or
equipment so lost, damaged or stolen, provided, that (x) until so applied, such
Extraordinary Receipts shall either be (1) deposited into a cash collateral
account with a commercial bank designated by the Collateral Agent (and when so
deposited such Extraordinary Receipts shall constitute Collateral for the
Obligations then outstanding and shall remain in such cash collateral account
until such Extraordinary Receipts are applied in accordance with either of
clauses (y) or (z) of this clause (v)) or (2) upon notification by the
Administrative Borrower to the Agents, applied to the Revolving Loans (and
concurrently with such application to the Revolving Loans, the Administrative
Agent shall, at the direction of the Collateral Agent, establish and maintain a
corresponding reserve to Availability in the amount so applied, which reserve
shall be released by the Administrative Agent upon the request of the
Administrative Borrower and at the direction of the Collateral Agent (which
direction shall be given upon such request by the Administrative Borrower
complying with this clause (v)) at such time as the Borrowers re-borrow funds in
such amount to be applied in accordance with either of clauses (y) or (z) of
this clause (v)), (y) such Extraordinary Receipts must be applied and such real
property or equipment must be repaired, restored or replaced within 180 days
after the date of receipt thereof, and (z) upon (1) the occurrence and during
the continuance of an Event of Default or (2) the expiration of such 180 day
period, such Extraordinary Receipts, if not so applied, shall be applied to the
prepayment of the Loans in accordance with Section 2.05(d).

                    (vi) In the event that the Lenders are required to repay or
disgorge to the Borrowers, or any representative of the Borrowers' estates, and
have repaid, all or any portion of the Pre-Petition Obligations authorized and
directed to be repaid pursuant to the Final Facility Bankruptcy Court Order, or
any payment on account of the Pre-Petition

                                      -40-
<PAGE>
Obligations made to any Lender is rescinded for any reason whatsoever,
including, but not limited to, as a result of any Avoidance Action, or any other
action, suit, proceeding or claim brought under any other provision of the
Bankruptcy Code or any applicable state law, or any other similar provisions
under any other state or federal statutory or common law (all such amounts being
hereafter referred to as the "Avoided Payments"), then, in such event, the
Borrowers shall prepay the outstanding principal amount of the Loans in
accordance with Section 2.05(d) in an amount equal to 100% of such Avoided
Payments immediately upon receipt of the Avoided Payments by the Borrowers or
any representative of the Borrowers' estates.

                    (vii) Without limiting any other provision of this Agreement
or any other Loan Document permitting or requiring prepayment of Loans in whole
or in part, the Borrowers shall prepay the Loans in full without premium or
penalty on the date which is 30 days following the entry of the Interim Facility
Bankruptcy Court Order in the event the Final Bankruptcy Court Order shall not
have been entered on or before such date.

               (d) Application of Payments. So long as no Event of Default shall
have occurred and be continuing, each prepayment pursuant to subsections
(c)(iii), (c)(iv), (c)(v) and (c)(vi) above shall be applied as follows:

                    (i) if the proceeds of any event set forth in subsection
(c)(iii) or (c)(v) above are from (A) any Disposition of any Account Receivable
or Inventory or (B) any Extraordinary Receipts arising from an insurance policy
or condemnation award solely with respect to Accounts Receivable or Inventory,
such proceeds shall be applied, first, ratably to the Revolving Loans, until
paid in full, second, to the Term Loan, until paid in full, and third, ratably
to all other Obligations, until paid in full;

                    (ii) if the proceeds of any event set forth in subsection
(c)(iii) or (c)(v) above are from any Disposition of any other assets of the
Loan Parties not described in clauses (i) or (iii) of this Section 2.05(d), such
proceeds shall be applied, first, to the Term Loan, until paid in full, second,
ratably to the Revolving Loans, until paid in full, and third, ratably to all
other Obligations, until paid in full;

                    (iii) if the proceeds of any event set forth in subsection
(c)(iii) or (c)(v) above are from a Disposition of all or substantially all of
the assets or Capital Stock of any Person or any Extraordinary Receipts arising
from insurance or casualty which Disposition or proceeds of insurance or
casualty includes both (x) Accounts Receivable or Inventory and (y) other
assets, such proceeds shall be applied as follows: (1) an amount equal to the
net book value of such Accounts Receivable and Inventory (determined at the time
of such Disposition or event resulting in such insurance or casualty proceeds)
shall be applied ratably to the Revolving Loans, until paid in full, and (2) the
remaining proceeds shall be applied, first, to the Term Loan, until paid in
full, second, ratably to the Revolving Loans, until paid in full, and third,
ratably to all other Obligations, until paid in full;

                    (iv) if the proceeds are from any event set forth in
subsection (c)(iv), (c)(v) (to the extent not applied pursuant to clauses (i) or
(iii) of this Section 2.05 (d)) or (c)(vi) above, such proceeds shall be
applied, first, to the Term Loan, until paid in full, second,

                                      -41-
<PAGE>
ratably to the Revolving Loans, until paid in full, and third, ratably to all
other Obligations, until paid in full.

Notwithstanding anything to the contrary contained in this Section 2.05 (d),
after the occurrence and during the continuance of an Event of Default, all
prepayments of the Loans pursuant to Section 2.05(c) shall be applied (or, in
the case of prepayments that have been temporarily applied to the Revolving
Loans pending final application thereof as permitted under the relevant
provisions of clauses (iii) and (iv) of Section 2.05(c), shall be re-credited)
in accordance with Section 5.04(b).

               (e) Interest and Fees. Any prepayment made pursuant to this
Section 2.05 (other than subsection (c)(ii) hereof) shall be accompanied by (i)
the payment of accrued interest on the principal amount being prepaid to the
date of prepayment, (ii) the payment of any applicable fees payable pursuant to
the terms of the Fee Letter, and (iii) if such prepayment would reduce the
amount of the outstanding Loans to zero at a time when the Total Revolving
Credit Commitment has been terminated, the payment of all other fees, costs and
expenses accrued to such date.

               (f) Cumulative Prepayments. Except as otherwise expressly
provided in this Section 2.05, payments with respect to any subsection of this
Section 2.05 are in addition to, but without duplication of, payments made or
required to be made under any other subsection of this Section 2.05.

          Section 2.06 Fees.

               (a) Unused Line Fee. From and after the Interim Facility
Effective Date and until the Final Maturity Date, the Borrowers shall pay to the
Administrative Agent for the account of the Revolving Loan Lenders, in
accordance with their Pro Rata Shares, an unused line fee (the "Unused Line
Fee"), which shall accrue at the rate per annum of 0.75% on the actual daily
excess, if any, of the Total Revolving Credit Commitment over the sum of the
principal amount of all Revolving Loans and Letter of Credit Obligations
outstanding from time to time and shall be payable quarterly in arrears on the
last Business Day of each calendar quarter commencing June 30, 2005.

               (b) Fee Letter Fees. The Borrowers shall pay to the
Administrative Agent, as and when due and payable under the terms of the Fee
Letter, the fees set forth in the Fee Letter.

          Section 2.07 Securitization. The Loan Parties hereby acknowledge that
the Lenders and their Affiliates may sell or securitize the Loans (a
"Securitization") through the pledge of the Loans as collateral security for
loans to the Lenders or their Affiliates or through the sale of the Loans or the
issuance of direct or indirect interests in the Loans, which loans to the
Lenders or their Affiliates or direct or indirect interests will be rated by
Moody's, Standard & Poor's or one or more other rating agencies (the "Rating
Agencies"). The Loan Parties shall cooperate with the Lenders and their
Affiliates to effect the Securitization including, without limitation, by (a)
amending this Agreement and the other Loan Documents, and executing such
additional documents, as reasonably requested by the Lenders in connection with
the

                                      -42-
<PAGE>
Securitization, provided that (i) any such amendment or additional documentation
does not impose costs in excess of $25,000 on the Loan Parties and (ii) any such
amendment or additional documentation does not adversely affect the rights, or
increase the obligations (other than ministerial obligations), of the Loan
Parties under the Loan Documents or change or affect in a manner adverse to the
Loan Parties the financial terms of the Loans, (b) providing such information as
may be reasonably requested by the Lenders in connection with the rating of the
Loans or the Securitization, and (c) providing in connection with any rating of
the Loans a certificate (i) agreeing to indemnify the Agents, the Lenders and
their Affiliates, any of the Rating Agencies, or any party providing credit
support or otherwise participating in the Securitization (collectively, the
"Securitization Parties") for any losses, claims, damages or liabilities (the
"Liabilities") to which the Agents, the Lenders, their Affiliates or such
Securitization Parties may become subject insofar as the Liabilities arise out
of or are based upon a violation of the representation set forth in Section
7.01(p)hereof, and such indemnity shall survive any transfer by the Lenders or
their successors or assigns of the Loans and (ii) agreeing to reimburse the
Agents, the Lenders and their Affiliates for any legal or other expenses
reasonably incurred by such Persons in connection with defending the
Liabilities.

          Section 2.08 Taxes. (a) Any and all payments by any Loan Party
hereunder shall be made free and clear of and without deduction for any and all
present or future taxes, levies, imposts, deductions, charges or withholdings,
and all liabilities with respect thereto, excluding taxes imposed on the net
income of any Agent, any Lender or the L/C Issuer (or any transferee or assignee
thereof, including a participation holder (any such entity, a "Transferee")) (i)
by the jurisdiction in which such Person is organized or has its principal
lending office or any political subdivision thereof or (ii) by reason of any
present or former connection between such Agent or such Lender or the L/C Issuer
and the jurisdiction of the Governmental Authority imposing such tax or any
political subdivision thereof, other than such a connection arising in whole or
in part (and to the extent arising) from such Agent or such Lender or the L/C
Issuer having executed, delivered or performed its obligations or received a
payment under, or enforced this Agreement or any other Loan Document (all such
nonexcluded taxes, levies, imposts, deductions, charges withholdings and
liabilities with respect to payments by any Loan Party hereunder, collectively
or individually, "Taxes"). If any Loan Party shall be required by law to deduct
any Taxes from or in respect of any sum payable hereunder to any Agent, any
Lender or the L/C Issuer (or any Transferee), (i) the sum payable shall be
increased by the amount (an "additional amount") necessary so that after making
all required deductions (including deductions applicable to additional sums
payable under this Section 2.08) such Agent, such Lender or the L/C Issuer (or
such Transferee) shall receive an amount equal to the sum it would have received
had no such deductions been made, (ii) such Loan Party shall make such
deductions and (iii) such Loan Party shall pay the full amount deducted to the
relevant Governmental Authority in accordance with applicable law.

               (b) In addition, each Loan Party agrees to pay to the relevant
Governmental Authority in accordance with applicable law any present or future
stamp or documentary taxes or any other excise or property taxes, charges or
similar levies that arise from any payment made hereunder or from the execution,
delivery or registration of, or otherwise with respect to, this Agreement
("Other Taxes"). Each Loan Party shall deliver to each Agent, each Lender and
the L/C Issuer official receipts in respect of any Taxes or Other Taxes payable
hereunder promptly after payment of such Taxes or Other Taxes.

                                      -43-
<PAGE>
               (c) The Loan Parties hereby jointly and severally indemnify and
agree to hold each Agent, each Lender and the L/C Issuer harmless from and
against Taxes and Other Taxes (including, without limitation, Taxes and Other
Taxes imposed on any amounts payable under this Section 2.08) paid by such
Person, whether or not such Taxes or Other Taxes were correctly or legally
asserted. Such indemnification shall be paid within 10 days from the date on
which any such Person makes written demand therefore specifying in reasonable
detail the nature and amount of such Taxes or Other Taxes.

               (d) Each Lender (or Transferee) that is organized under the laws
of a jurisdiction other than the United States, any State thereof or the
District of Columbia (a "Non-U.S. Lender") shall deliver to the Agents and the
Administrative Borrower two properly completed and duly executed copies of
either U.S. Internal Revenue Service Form W-8BEN or Form W-8ECI, or, in the case
of a Non-U.S. Lender claiming exemption from U.S. Federal withholding tax under
Section 871(h) or 881(c) of the Code with respect to payments of "portfolio
interest", a Form W-8BEN, or any subsequent versions thereof or successors
thereto (and, if such Non-U.S. Lender delivers a Form W-8, a certificate
representing that such Non-U.S. Lender is not a bank for purposes of Section
881(c) of the Internal Revenue Code, is not a 10-percent shareholder (within the
meaning of Section 871(h)(3)(B) of the Internal Revenue Code) of the Parent and
is not a controlled foreign corporation related to the Parent (within the
meaning of Section 864(d)(4) of the Internal Revenue Code)), in each case
claiming complete exemption from U.S. Federal withholding tax on payments by the
Loan Parties under this Agreement. Such forms shall be delivered by each
Non-U.S. Lender on or before the date it becomes a party to this Agreement (or,
in the case of a Transferee that is a participation holder, on or before the
date such participation holder becomes a Transferee hereunder) and on or before
the date, if any, such Non-U.S. Lender changes its applicable lending office by
designating a different lending office (a "New Lending Office"). In addition,
each Non-U.S. Lender shall deliver such forms within 20 days after receipt of a
written request therefor from the Administrative Borrower or any Agent.
Notwithstanding any other provision of this Section 2.08, a Non-U.S. Lender
shall not be required to deliver after the date hereof any form pursuant to this
Section 2.08 that such Non-U.S. Lender is not legally able to deliver.

               (e) The Loan Parties shall not be required to indemnify any
Non-U.S. Lender, or pay any additional amounts to any Non-U.S. Lender, in
respect of United States Federal withholding tax pursuant to this Agreement to
the extent that (i) the obligation to withhold amounts with respect to United
States Federal withholding tax existed on the date such Non-U.S. Lender became a
party to this Agreement (or, in the case of a Transferee that is a participation
holder, on the date such participation holder became a Transferee hereunder) or,
with respect to payments to a New Lending Office, the date such Non-U.S. Lender
designated such New Lending Office with respect to a Loan; provided, however,
that this clause (i) shall not apply to the extent the indemnity payment or
additional amounts any Transferee or any Lender (or Transferee) through a New
Lending Office, would be entitled to receive (without regard to this clause (i))
do not exceed the indemnity payment or additional amounts that the Person making
the assignment, participation or transfer to such Transferee or such Lender (or
Transferee) making the designation of such New Lending Office, would have been
entitled to receive in the absence of such assignment, participation, transfer
or designation, (ii) the obligation to pay such additional amounts would not
have arisen but for a failure by such Non-U.S. Lender to comply with the
provisions of clause (d) above, or (iii) any of the representations

                                      -44-
<PAGE>
or certifications made by a Non-U.S. Lender pursuant to clause (d) above are
incorrect at the time a payment hereunder is made, other than by reason of any
change in treaty, law or regulation having effect after the date such
representations or certifications were made.

               (f) Any Agent, any Lender or the L/C Issuer (or Transferee)
claiming any indemnity payment or additional payment amounts payable pursuant to
this Section 2.08 shall use reasonable efforts (consistent with legal and
regulatory restrictions) to file any certificate or document reasonably
requested in writing by the Administrative Borrower or to change the
jurisdiction of its applicable lending office if the making of such a filing or
change would avoid the need for or reduce the amount of any such indemnity
payment or additional amount which may thereafter accrue, would not require such
Agent, such Lender or the L/C Issuer (or Transferee) to disclose any information
such Agent, such Lender or the L/C Issuer (or Transferee) deems confidential and
would not, in the reasonable determination of such Agent, such Lender or the L/C
Issuer (or Transferee), be otherwise disadvantageous to such Agent, such Lender
or the L/C Issuer (or Transferee).

               (g) If any Agent or any Lender or the L/C Issuer (or any
Transferee) receives a refund of a tax for which a payment has been made by the
Loan Parties pursuant to this Agreement, which refund in the sole judgment of
such Agent or such Lender or the L/C Issuer (or Transferee) is attributable to
such payment made by the Loan Parties, then such Agent or such Lender or the L/C
Issuer (or Transferee) shall reimburse the Loan Parties for such amount. Nothing
contained in this clause (g) shall require any Agent or any Lender or the L/C
Issuer (or Transferee) to make available to any Loan Party or any other Person
any of its tax returns (or any other information that it deems to be
confidential in its sole discretion).

               (h) The obligations of the Loan Parties under this Section 2.08
shall survive the termination of this Agreement and the payment of the Loans and
all other amounts payable hereunder.

          Section 2.09 LIBOR Option. (a) In lieu of having interest charged at
the rate based upon the Reference Rate, the Borrowers shall have the option (the
"LIBOR Option") to have interest on all or a portion of the Loans be charged at
a rate of interest based upon the LIBOR Rate. Interest on LIBOR Rate Loans shall
be payable in accordance with Section 2.04(d). On the last day of each
applicable Interest Period, unless the Administrative Borrower properly has
exercised the LIBOR Option with respect thereto, the interest rate applicable to
such LIBOR Rate Loan automatically shall convert to the rate of interest then
applicable to Reference Rate Loans of the same type hereunder. At any time that
an Event of Default has occurred and is continuing, the Borrowers no longer
shall have the option to request that Loans bear interest at the LIBOR Rate.

               (b) (i) The Administrative Borrower may, at any time and from
time to time, so long as no Event of Default has occurred and is continuing,
elect to exercise the LIBOR Option by notifying Administrative Agent prior to
11:00 a.m. (New York time) at least 3 Business Days prior to the commencement of
the proposed Interest Period (the "LIBOR Deadline"). Notice of the
Administrative Borrower's election of the LIBOR Option for a permitted portion
of the Loans and an Interest Period pursuant to this Section shall be made by
delivery to the Administrative Agent of a LIBOR Notice received by the
Administrative Agent

                                      -45-
<PAGE>
before the LIBOR Deadline, or by telephonic notice received by the
Administrative Agent before the LIBOR Deadline (to be confirmed by delivery to
the Administrative Agent of a LIBOR Notice received by Administrative Agent
prior to 5:00 p.m. (New York time) on the same day). Promptly upon its receipt
of each such LIBOR Notice, the Administrative Agent shall provide a copy thereof
to each of the Lenders having a Revolving Credit Commitment.

                    (ii) Each LIBOR Notice shall be irrevocable and binding on
the Borrowers. In connection with each LIBOR Rate Loan, each Borrower shall
indemnify, defend, and hold the Agents and the Lenders harmless against any
loss, cost, or expense incurred by any Agent or any Lender as a result of (A)
the payment of any principal of any LIBOR Rate Loan other than on the last day
of an Interest Period applicable thereto (including as a result of an Event of
Default), (B) the conversion of any LIBOR Rate Loan other than on the last day
of the Interest Period applicable thereto, or (C) the failure to borrow,
convert, continue or prepay any LIBOR Rate Loan on the date specified in any
LIBOR Notice delivered pursuant hereto (such losses, costs, and expenses,
collectively, "Funding Losses"). Funding Losses shall, with respect to any Agent
or any Lender, be deemed to equal the amount determined by such Agent or such
Lender to be the excess, if any, of (1) the amount of interest that would have
accrued on the principal amount of such LIBOR Rate Loan had such event not
occurred, at the LIBOR Rate that would have been applicable thereto, for the
period from the date of such event to the last day of the then current Interest
Period therefor (or, in the case of a failure to borrow, convert or continue,
for the period that would have been the Interest Period therefor), minus (2) the
amount of interest that would accrue on such principal amount for such period at
the interest rate which such Agent or such Lender would be offered were it to be
offered, at the commencement of such period, Dollar deposits of a comparable
amount and period in the London interbank market. A certificate of an Agent or a
Lender delivered to the Administrative Borrower setting forth any amount or
amounts that such Agent or such Lender is entitled to receive pursuant to this
Section 2.09 shall be conclusive absent manifest error.

                    (iii) The Borrowers shall have not more than 8 LIBOR Rate
Loans in effect at any given time. The Borrowers only may exercise the LIBOR
Option for LIBOR Rate Loans of at least $1,000,000 and integral multiples of
$100,000 in excess thereof.

               (c) The Borrowers may prepay LIBOR Rate Loans at any time;
provided, however, that in the event that LIBOR Rate Loans are prepaid on any
date that is not the last day of the Interest Period applicable thereto,
including as a result of any automatic prepayment through the required
application by the Administrative Agent of proceeds of Collateral in accordance
with Section 5.04 or for any other reason, including early termination of the
term of this Agreement or acceleration of all or any portion of the Obligations
pursuant to the terms hereof, each Borrower shall indemnify, defend, and hold
the Agents and the Lenders and their participants harmless against any and all
Funding Losses in accordance with clause (b) above.

               (d) (i) The LIBOR Rate shall be adjusted by the Administrative
Agent with respect to any Lender on a prospective basis to take into account any
additional or increased costs to such Lender of maintaining or obtaining any
eurodollar deposits or increased costs due to changes in applicable law
occurring subsequent to the commencement of the then applicable Interest Period,
including changes in tax laws (except changes of general applicability

                                      -46-
<PAGE>
in corporate income tax laws) and changes in the reserve requirements imposed by
the Board of Governors of the Federal Reserve System (or any successor),
excluding the Reserve Percentage, which additional or increased costs would
increase the cost of funding loans bearing interest at the LIBOR Rate. In any
such event, the affected Lender shall give the Administrative Borrower and the
Administrative Agent notice of such a determination and adjustment and the
Administrative Agent promptly shall transmit the notice to each other Lender
and, upon its receipt of the notice from the affected Lender, the Administrative
Borrower may, by notice to such affected Lender (A) require such Lender to
furnish to the Administrative Borrower a statement setting forth the basis for
adjusting such LIBOR Rate and the method for determining the amount of such
adjustment, or (B) repay the LIBOR Rate Loans with respect to which such
adjustment is made (together with any amounts due under clause (b)(ii) above).

                    (ii) In the event that any change in market conditions or
any law, regulation, treaty, or directive, or any change therein or in the
interpretation of application thereof, shall at any time after the date hereof,
in the reasonable opinion of any Lender, make it unlawful or impractical for
such Lender to fund or maintain LIBOR Rate Loans or to continue such funding or
maintaining, or to determine or charge interest rates at the LIBOR Rate, such
Lender shall give notice of such changed circumstances to the Administrative
Agent and the Administrative Borrower and the Administrative Agent promptly
shall transmit the notice to each other Lender and (A) in the case of any LIBOR
Rate Loans of such Lender that are outstanding, the date specified in such
Lender's notice shall be deemed to be the last day of the Interest Period of
such LIBOR Rate Loans, and interest upon the LIBOR Rate Loans of such Lender
thereafter shall accrue interest at the rate then applicable to Loans that are
Reference Rate Loans, and (B) the Borrowers shall not be entitled to elect the
LIBOR Option until such Lender determines that it would no longer be unlawful or
impractical to do so.

               (e) Anything to the contrary contained herein notwithstanding,
neither any Agent, nor any Lender, nor any of their participants, is required
actually to acquire eurodollar deposits to fund or otherwise match fund any
Obligation as to which interest accrues at the LIBOR Rate. The provisions of
this Section shall apply as if each Lender or its participants had match funded
any Obligation as to which interest is accruing at the LIBOR Rate by acquiring
eurodollar deposits for each Interest Period in the amount of the LIBOR Rate
Loans.

                                   ARTICLE III

                                LETTERS OF CREDIT

          Section 3.01 Letters of Credit. (a) The Existing Letters of Credit
have previously been issued by the L/C Issuer prior to the Filing Date pursuant
to the Existing Credit Agreement and, subject to the terms and conditions hereof
and in reliance upon the representations and warranties set forth herein and the
agreements of the other Revolving Loan Lenders set forth in this Article III,
the L/C Issuer agrees to issue, and each Revolving Loan Lender severally agrees
to participate in the issuance by the L/C Issuer of, standby and trade Letters
of Credit in Dollars from time to time from the Final Facility Effective Date
until the date thirty (30) days prior to the Final Maturity Date as the
Administrative Borrower may request, in a form acceptable to the L/C Issuer;
provided, however, that (i) the Letter of Credit Obligations

                                      -47-
<PAGE>
outstanding shall not at any time exceed Two Million Five Hundred Thousand
Dollars ($2,500,000) (the "Letter of Credit Committed Amount"), and (ii) the sum
of the aggregate outstanding principal amount of Revolving Loans and Letter of
Credit Obligations outstanding on any date shall not exceed the lesser of (A)
the then current Availability and (B) the maximum aggregate principal amount of
Revolving Loans and Letter of Credit Obligations projected to be outstanding
during the then current Budget Period as set forth in the Long-Term Budget
(subject to the Permitted Deviation therefrom). No Letter of Credit shall (x)
have an original expiry date more than one hundred and eighty (180) days from
the date of issuance or (y) as originally issued or as extended, have an expiry
date extending beyond the date thirty (30) days prior to the Final Maturity
Date. Each Letter of Credit shall comply with the related Letter of Credit
Documents. The issuance date of each Letter of Credit shall be a Business Day.
All Existing Letters of Credit shall be deemed to have been issued pursuant
hereto, and from and after the Final Facility Effective Date shall be subject to
and governed by the terms and conditions hereof. The L/C Issuer shall be under
no obligation to issue any Letter of Credit if (A) any order, judgment or decree
of any Governmental Authority or arbitrator shall by its terms purport to enjoin
or restrain the L/C Issuer from issuing such Letter of Credit, or any
requirement of law applicable to the L/C Issuer or any request or directive
(whether or not having the force of law) from any Governmental Authority with
jurisdiction over the L/C Issuer shall prohibit, or request that the L/C Issuer
refrain from, the issuance of letters of credit generally or such Letter of
Credit in particular or shall impose upon the L/C Issuer with respect to such
Letter of Credit any restriction, reserve or capital requirement (for which the
L/C Issuer is not otherwise compensated hereunder) not in effect on the Interim
Facility Effective Date, or shall impose upon the L/C Issuer any unreimbursed
loss, cost or expense which was not applicable on the Interim Facility Effective
Date and which the L/C Issuer in good faith deems material to it or (B) the
issuance of such Letter of Credit would violate one or more policies of the L/C
Issuer applicable to all applicants for letters of credit of the L/C Issuer
generally.

               (b) The request for the issuance of a Letter of Credit (the
"Letter of Credit Application") shall be submitted by the Administrative
Borrower to the L/C Issuer, with a copy to the Administrative Agent, at least
three (3) Business Days prior to the requested date of issuance. Each Letter of
Credit Application shall be accompanied by a certification by an Authorized
Officer of the Administrative Borrower that the aggregate principal amount of
Revolving Loans and Letter of Credit Obligations outstanding on the date of
issuance of the proposed Letter of Credit (after giving effect to the issuance
thereof) shall not exceed the maximum aggregate principal amount of Revolving
Loans and Letter of Credit Obligations projected to be outstanding during the
then current Budget Period as set forth in the Long-Term Budget (subject to the
Permitted Deviation therefrom). Each Agent, each Lender and the L/C Issuer shall
be entitled to rely conclusively on any Authorized Officer's certification with
respect to the matters set forth in the immediately preceding sentence. The
Administrative Agent will, at least quarterly and more frequently upon request,
disseminate to each of the Revolving Loan Lenders a detailed report specifying
the Letters of Credit which are then issued and outstanding and any activity
with respect thereto which may have occurred since the date of the prior report,
and including therein, among other things, the beneficiary, the face amount and
the expiry date, as well as any payment or expirations which may have occurred.

               (c) Each Revolving Loan Lender, upon issuance of a Letter of
Credit, shall be deemed to have purchased without recourse a Participation
Interest from the L/C Issuer

                                      -48-
<PAGE>
in such Letter of Credit (including each Existing Letter of Credit) and the
obligations arising thereunder and any Collateral relating thereto, in each
case, in an amount equal to its Pro Rata Share of the obligations under such
Letter of Credit and shall absolutely, unconditionally and irrevocably assume
and be obligated to pay to the L/C Issuer through the Administrative Agent and
discharge when due, its Pro Rata Share of the obligations arising under such
Letter of Credit (including each Existing Letter of Credit). Without limiting
the scope and nature of each Revolving Loan Lender's Participation Interest in
any Letter of Credit, to the extent that the L/C Issuer has not been reimbursed
as required hereunder or under any such Letter of Credit, each such Revolving
Loan Lender shall pay to the L/C Issuer its Pro Rata Share of such unreimbursed
drawing in same day funds on the day of notification by the L/C Issuer of an
unreimbursed drawing pursuant to the provisions of Section 3.01(d) below. The
obligation of each Revolving Loan Lender to so reimburse the L/C Issuer shall be
absolute and unconditional and shall not be affected by the occurrence of a
Default, an Event of Default or any other occurrence or event. Any such
reimbursement shall not relieve or otherwise impair the obligation of the
Borrowers to reimburse the L/C Issuer under any Letter of Credit, together with
interest as hereinafter provided. Until each Revolving Loan Lender funds its
Revolving Loan advance pursuant to this Section 3.01(c) to reimburse the L/C
Issuer for any amount drawn under any Letter of Credit, interest in respect of
such Revolving Loan Lender's Pro Rata Share of such amount shall be solely for
the account of the L/C Issuer. If any Revolving Loan Lender fails to make
available to the Administrative Agent for the account of the L/C Issuer any
amount required to be paid by such Revolving Loan Lender pursuant to the
foregoing provisions of this Section 3.01(c), the L/C Issuer shall be entitled
to recover from such Revolving Loan Lender (acting through the Administrative
Agent), on demand, such amount with interest thereon for the period from the
date such payment is required to the date on which such payment is immediately
available to the L/C Issuer at a rate per annum equal to the Federal Funds Rate
from time to time in effect. A certificate of the L/C Issuer submitted to any
Revolving Loan Lender (through the Administrative Agent) with respect to any
amounts owing under this clause (c) shall be conclusive absent manifest error.

               (d) In the event of any drawing under any Letter of Credit, the
L/C Issuer will promptly notify the Administrative Borrower and the
Administrative Agent. Unless the Administrative Borrower shall immediately
notify the L/C Issuer that the Administrative Borrower intends to otherwise
reimburse the L/C Issuer for such drawing, the Administrative Borrower shall be
deemed to have requested that the Revolving Loan Lenders make a Revolving Loan
in the amount of the drawing as provided in Section 3.01(e)below on the related
Letter of Credit, the proceeds of which will be used to satisfy the related
reimbursement obligations. The Borrowers promise to reimburse the L/C Issuer on
the day of drawing under any Letter of Credit (either with the proceeds of a
Revolving Loan obtained hereunder or otherwise) in same day funds. If the
Borrowers shall fail to reimburse the L/C Issuer as provided hereinabove, the
Borrowers promise to pay the L/C Issuer interest on the unreimbursed amount of
such drawing on demand at a per annum rate equal to the Post-Default Rate. The
Borrowers' reimbursement obligations hereunder shall be absolute and
unconditional under all circumstances irrespective of any rights of setoff,
counterclaim or defense to payment any Borrower may claim or have against the
L/C Issuer, the Administrative Agent, the Revolving Loan Lenders, the
beneficiary of the Letter of Credit drawn upon or any other Person, including,
without limitation, any defense based on any failure of a Borrower or any other
Loan Party to receive consideration or the legality, validity, regularity or
unenforceability of the Letter of Credit. The Administrative

                                      -49-
<PAGE>
Agent will promptly notify the other Revolving Loan Lenders of the amount of any
unreimbursed drawing and each Revolving Loan Lender shall promptly pay to the
Administrative Agent for the account of the L/C Issuer in Dollars and in
immediately available funds, the amount of such Revolving Loan Lender's Pro Rata
Share of such unreimbursed drawing. Such payment shall be made on the day such
notice is received by such Revolving Loan Lender from the L/C Issuer if such
notice is received at or before 2:00 p.m. (New York City time), and otherwise
such payment shall be made at or before 12:00 noon (New York City time) on the
Business Day next succeeding the day such notice is received. If such Revolving
Loan Lender does not pay such amount to the L/C Issuer in full upon such
request, such Revolving Loan Lender shall, on demand, pay to the Administrative
Agent for the account of the L/C Issuer interest on the unpaid amount during the
period from the date of such drawing until such Revolving Loan Lender pays such
amount to the L/C Issuer in full at a rate per annum equal to, if paid within
two (2) Business Days of the date that such Revolving Loan Lender is required to
make payments of such amount pursuant to the preceding sentence, the Federal
Funds Rate and thereafter at a rate equal to the Reference Rate. Each Revolving
Loan Lender's obligation to make such payment to the L/C Issuer, and the right
of the L/C Issuer to receive the same, shall be absolute and unconditional,
shall not be affected by any circumstance whatsoever and without regard to the
termination of this Agreement or the Commitments hereunder, the existence of a
Default or Event of Default or the acceleration of the obligations of the
Borrowers hereunder and shall be made without any offset, abatement, withholding
or reduction whatsoever. Simultaneously with the making of each such payment by
a Revolving Loan Lender to the L/C Issuer, such Revolving Loan Lender shall,
automatically and without any further action on the part of the L/C Issuer or
such Revolving Loan Lender, acquire a Participation Interest in an amount equal
to such payment (excluding the portion of such payment constituting interest
owing to the L/C Issuer) in the related unreimbursed drawing portion of the
Letter of Credit Obligation and in the interest thereon and in the related
Letter of Credit Documents, and shall have a claim against the Borrowers with
respect thereto.

               (e) On any day on which the Administrative Borrower shall have
requested, or been deemed to have requested, a Revolving Loan to reimburse a
drawing under a Letter of Credit, the Administrative Agent shall give notice to
the Revolving Loan Lenders that a Revolving Loan has been requested or deemed
requested by the Administrative Borrower to be made in connection with a drawing
under a Letter of Credit, in which case a Revolving Loan comprised of Reference
Rate Loans shall be immediately made to the Borrowers by all Revolving Loan
Lenders (notwithstanding any termination of the Commitments pursuant to Section
10.01) based on the respective Pro Rata Shares of the Revolving Loan Lenders
(determined before giving effect to any termination of the Commitments pursuant
to Section 10.01) and the proceeds thereof shall be paid directly to the L/C
Issuer through the Administrative Agent for application to the respective Letter
of Credit Obligations. Each such Revolving Loan Lender hereby irrevocably agrees
to make its Pro Rata Share of each such Revolving Loan immediately upon any such
request or deemed request in the amount, in the manner and on the date specified
in the preceding sentence notwithstanding (i) the amount of such borrowing may
not comply with the minimum amount for Revolving Loans otherwise required
hereunder, (ii) whether any conditions specified in Section 6.03 or Section 6.04
are then satisfied, (iii) whether a Default or an Event of Default then exists,
(iv) failure for any such request or deemed request for Revolving Loan to be
made by the time otherwise required hereunder, (v) whether the date of such
borrowing is a date on which Revolving Loans are

                                      -50-
<PAGE>
otherwise permitted to be made hereunder or (vi) any termination of the
Commitments relating thereto immediately prior to or contemporaneously with such
borrowing. In the event that any Revolving Loan cannot for any reason be made on
the date otherwise required above (including, without limitation, as a result of
the commencement of a proceeding under the Bankruptcy Code with respect to any
Borrower or any other Loan Party), then each such Revolving Loan Lender hereby
agrees that it shall forthwith purchase (as of the date such borrowing would
otherwise have occurred, but adjusted for any payments received from the
Borrowers on or after such date and prior to such purchase) from the L/C Issuer
such Participation Interests in the outstanding Letter of Credit Obligations as
shall be necessary to cause each such Revolving Loan Lender to share in such
Letter of Credit Obligations ratably (based upon the respective Pro Rate Shares
of the Revolving Loan Lenders (determined before giving effect to any
termination of the Commitments pursuant to Section 10.01)), provided that at the
time any purchase of Participation Interests pursuant to this sentence is
actually made, the purchasing Revolving Loan Lender shall be required to pay to
the L/C Issuer, to the extent not paid to the L/C Issuer by the Borrowers in
accordance with the terms of Section 3.01(d) above, interest on the principal
amount of Participation Interests purchased for each day from and including the
day upon which such borrowing would otherwise have occurred to but excluding the
date of payment for such Participation Interests, at the rate equal to, if paid
within two (2) Business Days of the date of the Revolving Loan advance, the
Federal Funds Rate, and thereafter at a rate equal to the Reference Rate.

               (f) Notwithstanding anything to the contrary set forth in this
Agreement, including without limitation Section 3.01(a), a Letter of Credit
issued hereunder may be issued for the account of any Subsidiary of a Borrower,
provided that such Borrower shall be the actual account party for all purposes
of this Agreement for such Letter of Credit and such request shall not affect
the Borrowers' reimbursement obligations hereunder with respect to such Letter
of Credit shall not be affected.

               (g) The renewal or extension of any Letter of Credit shall, for
purposes hereof, be treated in all respects the same as the issuance of a new
Letter of Credit hereunder.

               (h) The L/C Issuer may have the Letters of Credit be subject to
The Uniform Customs and Practice for Documentary Credits (the "UCP") or the
International Standby Practices 1998 (the "ISP98"), in either case as published
as of the date of issue by the International Chamber of Commerce, in which case
the UCP or the ISP98, as applicable, may be incorporated therein and deemed in
all respects to be a part thereof.

               (i) (i) In addition to their other obligations under this Section
3.01, the Borrowers hereby agree to pay, and protect, indemnify and save each
Revolving Loan Lender harmless from and against, any and all claims, demands,
liabilities, damages, losses, costs, charges and expenses (including reasonable
attorneys' fees) that such Revolving Loan Lender may incur or be subject to as a
consequence, direct or indirect, of (A) the issuance of any Letter of Credit or
(B) the failure of such Revolving Loan Lender to honor a drawing under a Letter
of Credit as a result of any act or omission, whether rightful or wrongful, of
any present or future de jure or de facto government or Governmental Authority
(all such acts or omissions, herein called "Government Acts").

                                      -51-
<PAGE>
                    (ii) As between the Borrowers and the Revolving Loan Lenders
(including the L/C Issuer), the Borrowers shall assume all risks of the acts,
omissions or misuse of any Letter of Credit by the beneficiary thereof. No
Revolving Loan Lender (including the L/C Issuer) shall be responsible: (A) for
the form, validity, sufficiency, accuracy, genuineness or legal effect of any
document submitted by any party in connection with the application for and
issuance of any Letter of Credit, even if it should in fact prove to be in any
or all respects invalid, insufficient, inaccurate, fraudulent or forged; (B) for
the validity or sufficiency of any instrument transferring or assigning or
purporting to transfer or assign any Letter of Credit or the rights or benefits
thereunder or proceeds thereof, in whole or in part, that may prove to be
invalid or ineffective for any reason; (C) for errors, omissions, interruptions
or delays in transmission or delivery of any messages, by mail, cable,
telegraph, telex or otherwise, whether or not they be in cipher; (D) for any
loss or delay in the transmission or otherwise of any document required in order
to make a drawing under a Letter of Credit or of the proceeds thereof; and (E)
for any consequences arising from causes beyond the control of such Revolving
Loan Lender, including, without limitation, any Government Acts. None of the
above shall affect, impair, or prevent the vesting of the L/C Issuer's rights or
powers hereunder.

                    (iii) In furtherance and extension and not in limitation of
the specific provisions hereinabove set forth, any action taken or omitted by
any Revolving Loan Lender (including the L/C Issuer), under or in connection
with any Letter of Credit or the related certificates, if taken or omitted in
good faith, shall not put such Revolving Loan Lender under any resulting
liability to the Borrowers or any other Loan Party. It is the intention of the
parties that this Agreement shall be construed and applied to protect and
indemnify each Revolving Loan Lender (including the L/C Issuer) against any and
all risks involved in the issuance of the Letters of Credit, all of which risks
are hereby assumed by the Borrowers (on behalf of itself and each of the other
Loan Parties), including, without limitation, any and all Government Acts. No
Revolving Loan Lender (including the L/C Issuer) shall, in any way, be liable
for any failure by such Revolving Loan Lender or anyone else to pay any drawing
under any Letter of Credit as a result of any Government Acts or any other cause
beyond the control of such Revolving Loan Lender.

                    (iv) Nothing in this Section 3.01(i)is intended to limit the
reimbursement obligations of the Borrowers contained in Section 3.01 (d) above.
The obligations of the Borrowers under this Section 3.01 (i) shall survive the
termination of this Agreement. No act or omission of any current or prior
beneficiary of a Letter of Credit shall in any way affect or impair the rights
of the Revolving Loan Lenders (including the L/C Issuer) to enforce any right,
power or benefit under this Agreement.

                    (v) Notwithstanding anything to the contrary contained in
this Section 3.01 (i), the Borrowers shall have no obligation to indemnify any
Revolving Loan Lender (including the L/C Issuer) in respect of any liability
incurred by such Revolving Loan Lender (A) arising solely out of the gross
negligence or willful misconduct of the L/C Issuer, as finally determined by a
court of competent jurisdiction, or (B) caused by the L/C Issuer's failure to
pay under any Letter of Credit after presentation to it of a request strictly
complying with the terms and conditions of such Letter of Credit, as determined
by a court of competent jurisdiction, unless such payment is prohibited by any
law, regulation, court order or decree.

                                      -52-
<PAGE>
               (j) It is expressly understood and agreed that the obligations of
the L/C Issuer hereunder to the Revolving Loan Lenders are only those expressly
set forth in this Agreement and that the L/C Issuer shall be entitled to assume
that the conditions precedent set forth in Section 6.03 and, if applicable,
Section 6.04 have been satisfied unless it shall have acquired actual knowledge
that any such condition precedent has not been satisfied; provided, however,
that nothing set forth in this Section 3.01 shall be deemed to prejudice the
right of any Revolving Loan Lender to recover from the L/C Issuer any amounts
made available by such Revolving Loan Lender to the L/C Issuer pursuant to this
Section 3.01 in the event that it is determined by a court of competent
jurisdiction that the payment with respect to a Letter of Credit constituted
gross negligence or willful misconduct on the part of the L/C Issuer.

               (k) In the event of any conflict between this Agreement and any
Letter of Credit Application, this Agreement shall control.

               (l) Upon the request of the Administrative Agent, if, as of the
Final Maturity Date for Letters of Credit, any Letter of Credit may for any
reason remain outstanding and partially or wholly undrawn, the Borrowers shall
immediately Cash Collateralize the then outstanding Letter of Credit Obligations
(in an amount equal to such outstanding amount determined as of the date of such
borrowing or the expiry date, as the case may be). For purposes hereof, "Cash
Collateralize" means to pledge and deposit with or deliver to the Administrative
Agent, for the benefit of the L/C Issuer and the other Revolving Loan Lenders,
as collateral for the Letter of Credit Obligations, cash or deposit account
balances pursuant to documentation in form and substance satisfactory to the
Administrative Agent and the L/C Issuer (which documents are hereby consented to
by the Revolving Loan Lenders). Derivatives of such term have corresponding
meanings. Each Borrower hereby grants to the Administrative Agent, for the
benefit of the L/C Issuer and the other Revolving Loan Lenders, a security
interest in all such cash, deposit accounts and all balances therein and all
proceeds of the foregoing. Cash collateral shall be maintained in blocked,
non-interest bearing deposit accounts at Bank of America.

          Section 3.02 Letter of Credit Fees.

               (a) Letter of Credit Issuance Fee. In consideration of the
issuance of Letters of Credit hereunder, the Borrowers promise to pay to the
Administrative Agent for the account of each Revolving Loan Lender a fee (the
"Letter of Credit Fee") on such Revolving Loan Lender's Pro Rata Share of the
average daily maximum amount available to be drawn under each such Letter of
Credit computed at a per annum rate for each day from the date of issuance to
the date of expiration equal to the Revolving Loan LIBOR Rate Margin. The Letter
of Credit Fee will be payable quarterly in arrears on the last Business Day of
each March, June, September and December for the immediately preceding quarter
(or a portion thereof).

               (b) L/C Issuer Fees. In addition to the Letter of Credit Fee
payable pursuant to clause (a) above, the Borrowers promise to pay to the
Administrative Agent for the account of the L/C Issuer without sharing by the
other Revolving Loan Lenders (i) a letter of credit fronting fee of 0.125% on
the average daily maximum amount available to be drawn under each Letter of
Credit (other than the Existing Letters of Credit except in connection with
renewals, modifications or extensions of the Existing Letters of Credit)
computed at a per annum

                                      -53-
<PAGE>
rate for each day from the date of issuance to the date of expiration (which
fronting fee shall be payable quarterly in arrears on the first Business Day
following the last Business Day of each March, June, September and December for
the immediately preceding quarter (or a portion thereof)) and (ii) the customary
charges from time to time of the L/C Issuer with respect to the issuance,
amendment, transfer, administration, cancellation and conversion of, and
drawings under, such Letters of Credit.

                                   ARTICLE IV

                      SECURITY AND ADMINISTRATIVE PRIORITY

          Section 4.01 Pre-Petition Obligations. Each of the Loan Parties hereby
acknowledges, confirms and agrees that the Loan Parties are indebted to the
Existing Agents and the Existing Lenders for the Pre-Petition Obligations, as of
the Filing Date, (a) in an aggregate principal amount of not less than
$179,280,473.73 in respect of Pre-Petition Obligations constituting loans under
the Existing Credit Agreement and (b) in an aggregate amount of not less than
$34,981.45 in respect of Pre-Petition Obligations related to the Existing
Letters of Credit, in each case, together with interest, fees and premiums
accrued and accruing thereon in respect of such loans, and costs, expenses, fees
(including attorneys' fees), indemnities, reimbursement obligations and other
charges now or hereafter owed by the Loan Parties to the Existing Agents and the
Existing Lenders pursuant to the terms of the Existing Credit Agreement and the
other Loan Documents (as defined in the Existing Credit Agreement), all of which
are unconditionally owing by the Loan Parties to the Existing Agents and the
Existing Lenders, without offset, defense or counterclaim of any kind, nature
and description whatsoever.

          Section 4.02 Acknowledgment of Security Interests. As of the Filing
Date, each of the Loan Parties hereby acknowledges, confirms and agrees that (a)
the Existing Agents and the Existing Lenders have valid, enforceable and
perfected first priority and senior liens (subject only to Permitted Liens (as
defined in the Existing Credit Agreement) to the extent set forth in the
Existing Credit Agreement) upon and security interests in all of the Collateral
(as defined in the Existing Credit Agreement) granted pursuant to the Existing
Credit Agreement and the other Loan Documents (as defined in the Existing Credit
Agreement) as in effect on the Filing Date to secure all of the Pre-Petition
Obligations and (b) such Liens are not subject to avoidance, reduction,
disallowance, impairment or subordination pursuant to the Bankruptcy Code or
applicable non-bankruptcy law.

          Section 4.03 Binding Effect of Documents. Each of the Loan Parties
hereby acknowledges, confirms and agrees that: (a) each of the Existing Credit
Agreement and the other Loan Documents (as defined in the Existing Credit
Agreement) to which it is a party is in full force and effect as of the date
hereof, (b) the agreements and obligations of each of the Loan Parties contained
in the Existing Credit Agreement and the other Loan Documents (as defined in the
Existing Credit Agreement) constitute the legal, valid and binding obligations
of each of the Loan Parties enforceable against it in accordance with their
respective terms and the Loan Parties have no valid defense, offset or
counterclaim to the enforcement of such obligations and (c) the Existing Agents
and the Existing Lenders are and shall be entitled to all of the rights,
remedies and benefits provided for in the Existing Credit Agreement and the
other Loan Documents (as

                                      -54-
<PAGE>
defined in the Existing Credit Agreement), except as clauses (b) and (c) above
are subject to the automatic stay under the Bankruptcy Code upon commencement of
the Chapter 11 Cases.

          Section 4.04 Collateral; Grant of Lien and Security Interest.

               (a) As security for the full and timely payment and performance
of all of the Obligations, each Loan Party hereby, assigns, pledges and grants
to the Collateral Agent, for the benefit of the Agents, the Lenders and the L/C
Issuer, a security interest in and to and Lien on all of the property, assets or
interests in property or assets of such Person, of any kind or nature
whatsoever, real or personal, now existing or hereafter acquired or created,
including, without limitation, all property of the "estate" (within the meaning
of the Bankruptcy Code) of such Loan Party, and all accounts, inventory, goods,
contract rights, instruments, documents, chattel paper, patents, trademarks,
copyrights and licenses therefor, general intangibles, payment intangibles,
letters of credit, letter-of-credit rights, supporting obligations, machinery
and equipment, real property (including all Facilities), fixtures, leases, all
(or, in the case of a Foreign Subsidiary, 65%) of the issued and outstanding
Capital Stock entitled to vote (within the meaning of Treas. Reg. Section
1.956-2(c)(2)) and all of the issued and outstanding Capital Stock not entitled
to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) of each
Subsidiary of such Loan Party, all of the Capital Stock of all other Persons
that are not Subsidiaries directly owned by such Loan Party, money, investment
property, deposit accounts, all commercial tort claims and all causes of action
arising under the Bankruptcy Code or otherwise (excluding Avoidance Actions and
the proceeds thereof and all Avoided Payments), and all cash and non-cash
proceeds, rents, products and profits of any of collateral described above (all
property of the Loan Parties subject to the security interest referred to in
this Section 4.04(a) being hereinafter collectively referred to as the
"Collateral").

               (b) Upon entry of the Interim Bankruptcy Court Order or Final
Bankruptcy Court Order, as the case may be, the Liens and security interests in
favor of the Collateral Agent referred to in Section 4.04(a) hereof shall be
valid and perfected Liens and security interests in the Collateral, prior to all
other Liens and security interests in the Collateral, other than the Permitted
Priority Liens (subject to any action required under foreign law with respect to
the Capital Stock of Foreign Subsidiaries solely to the extent that such foreign
law is applicable). Such Liens and security interests and their priority shall
remain in effect until the Total Commitment shall have been terminated and all
Obligations shall have been repaid in cash in full and the outstanding Letters
of Credit shall have been terminated or cash collateralized.

               (c) Notwithstanding anything herein to the contrary (i) all
proceeds received by the Agents and the Lenders from the Collateral subject to
the Liens granted in this Section 4.04 and in each other Loan Document and by
the Bankruptcy Court Orders shall be subject to the prior payment of Carve-Out
Expenses to the extent set forth in clause "first" and the Rothschild Success
Fee to the extent set forth in clause "second", in each case, of the definition
of the term "Agreed Administrative Expense Priorities", and (ii) no Person
entitled to Carve-Out Expenses shall be entitled to sell or otherwise dispose,
or seek or object to the sale or other disposition, of any Collateral.

          Section 4.05 Administrative Priority. Each of the Loan Parties agrees
for itself that the Obligations of such Person shall constitute allowed
administrative expenses in the

                                      -55-
<PAGE>
Chapter 11 Cases, having priority over all administrative expenses of and
unsecured claims against such Person now existing or hereafter arising, of any
kind or nature whatsoever, including, without limitation, all administrative
expenses of the kind specified in, or arising or ordered under, Sections 105,
326, 328, 330, 331, 503(b), 506(c), 507(a), 507(b), 546(c), 726 and 1114 of the
Bankruptcy Code, subject only to the prior payment of Carve-Out Expenses to the
extent set forth in clause "first" and the Rothschild Success Fee to the extent
set forth in clause "second", in each case, of the definition of the term
"Agreed Administrative Expense Priorities".

          Section 4.06 Grants, Rights and Remedies. The Liens and security
interests granted pursuant to Section 4.04(a) hereof and the administrative
priority granted pursuant to Section 4.05 hereof may be independently granted by
the Loan Documents and by other Loan Documents hereafter entered into. This
Agreement, the Bankruptcy Court Orders and such other Loan Documents supplement
each other, and the grants, priorities, rights and remedies of the Agents and
the Lenders hereunder and thereunder are cumulative.

          Section 4.07 No Filings Required. The Liens and security interests
referred to herein shall be deemed valid and perfected by entry of the Interim
Bankruptcy Court Order or the Final Bankruptcy Court Order, as the case may be,
and entry of the Interim Bankruptcy Court Order shall have occurred on or before
the date of any Loan and entry of the Final Bankruptcy Court Order shall have
occurred on or before the date of the Term Loan or the issuance, renewal or
extension of any Letter of Credit. The Collateral Agent shall not be required to
file any financing statements, mortgages, notices of Lien or similar instruments
in any jurisdiction or filing office, take possession or control of any
Collateral, or take any other action in order to validate or perfect the Lien
and security interest granted by or pursuant to this Agreement, the Interim
Bankruptcy Court Order or the Final Bankruptcy Court Order, as the case may be,
or any other Loan Document.

          Section 4.08 Survival. The Liens, lien priority, administrative
priorities and other rights and remedies granted to the Agents and the Lenders
pursuant to this Agreement, the Bankruptcy Court Orders and the other Loan
Documents (specifically including, but not limited to, the existence, perfection
and priority of the Liens and security interests provided herein and therein,
and the administrative priority provided herein and therein) shall not be
modified, altered or impaired in any manner by any other financing or extension
of credit or incurrence of Indebtedness by any Loan Party (pursuant to Section
364 of the Bankruptcy Code or otherwise), or by any dismissal or conversion of
any of the Chapter 11 Cases, or by any other act or omission whatsoever. Without
limitation, notwithstanding any such order, financing, extension, incurrence,
dismissal, conversion, act or omission:

               (a) except for the Carve-Out Expenses to the extent set forth in
clause "first" and the Rothschild Success Fee to the extent set forth in clause
"second", in each case, of the definition of the term "Agreed Administrative
Expense Priorities" as set forth in Section 4.05, no costs or expenses of
administration which have been or may be incurred in the Chapter 11 Cases or any
conversion of the same or in any other proceedings related thereto, and no
priority claims, are or will be prior to or on parity with any claim of the
Agents and the Lenders against any Loan Party in respect of any Obligation;

                                      -56-
<PAGE>
               (b) the Liens in favor of the Agents and the Lenders set forth in
Section 4.04(a) hereof shall constitute valid and perfected first priority Liens
and security interests, subject only to Permitted Priority Liens to which such
Liens and security interests may be subordinate and junior, and shall be prior
to all other Liens and security interests, now existing or hereafter arising, in
favor of any other creditor or any other Person whatsoever (subject to any
action required under foreign law with respect to the Capital Stock of Foreign
Subsidiaries solely to the extent that such foreign law is applicable); and

               (c) the Liens in favor of the Agents and the Lenders set forth
herein and in the other Loan Documents shall continue to be valid and perfected
without the necessity that the Collateral Agent file financing statements or
mortgages, take possession or control of any Collateral, or otherwise perfect
its Lien under applicable non-bankruptcy law.

                                    ARTICLE V

                      FEES, PAYMENTS AND OTHER COMPENSATION

          Section 5.01 Audit and Collateral Monitoring Fees. The Borrowers
acknowledge that pursuant to Section 8.01(f), representatives of the Collateral
Agent may visit any or all of the Loan Parties and/or conduct audits,
inspections, appraisals, valuations and/or field examinations of any or all of
the Loan Parties or the Collateral at any time and from time to time in a manner
so as to not unduly disrupt the business of the Loan Parties. The Borrowers
agree to pay (i) $1,500 per day per examiner plus the examiner's out-of-pocket
costs and reasonable expenses incurred in connection with all such visits,
audits, inspections, appraisals, valuations and field examinations and (ii) the
actual out-of-pocket cost of all visits, audits, inspections, appraisals,
valuations and field examinations conducted by a third party on behalf of the
Collateral Agent. Notwithstanding the foregoing, if no Default or Event of
Default shall have occurred and be continuing, the Borrowers shall not be
obligated to pay the fees, costs and expenses for more than (x) 2 such audits,
inspections and/or field examinations (in the aggregate) of the Loan Parties in
any 12 month period during the term of this Agreement, and (y) 2 such appraisals
or valuations of the Collateral in any 12 month period during the term of this
Agreement.

          Section 5.02 Payments; Computations and Statements. (a) The Borrowers
will make each payment under this Agreement not later than 12:00 noon (New York
City time) on the day when due, in lawful money of the United States of America
and in immediately available funds, to the Administrative Agent's Account. All
payments received by the Administrative Agent after 12:00 noon (New York City
time) on any Business Day will be credited to the Loan Account on the next
succeeding Business Day. All payments shall be made by the Borrowers without
set-off, counterclaim, deduction or other defense to the Agents, the L/C Issuer
and the Lenders. Except as provided in Section 2.02, after receipt, the
Administrative Agent will promptly thereafter cause to be distributed like funds
relating to the payment of principal ratably to the Lenders in accordance with
their Pro Rata Shares and like funds relating to the payment of any other amount
payable to any Agent or Lender to such Agent or Lender, in each case to be
applied in accordance with the terms of this Agreement, provided that the
Administrative Agent will cause to be distributed all interest and fees received
from or for the account of the Borrowers not less than once each month and in
any event promptly after receipt thereof. The Lenders and

                                      -57-
<PAGE>
the Borrowers hereby authorize the Administrative Agent to, and the
Administrative Agent shall, at the direction of the Collateral Agent, from time
to time, charge the Loan Account of the Borrowers with any amount due and
payable by the Loan Parties under any Loan Document. Each of the Lenders and the
Borrowers agrees that the Administrative Agent, at the direction of the
Collateral Agent, shall have the right to make such charges whether or not any
Default or Event of Default shall have occurred and be continuing or whether any
of the conditions precedent in Section 6.03 have been satisfied. Any amount
charged to the Loan Account of the Borrowers shall be deemed a Revolving Loan
hereunder made by the Revolving Loan Lenders to the Borrowers, funded by the
Administrative Agent on behalf of the Revolving Loan Lenders and subject to
Section 2.02 of this Agreement. The Lenders and the Borrowers confirm that any
charges which the Administrative Agent may so make to the Loan Account of the
Borrowers as herein provided will be made as an accommodation to the Borrowers
and solely at the Collateral Agent's discretion as communicated to the
Administrative Agent. Whenever any payment to be made under any such Loan
Document shall be stated to be due on a day other than a Business Day, such
payment shall be made on the next succeeding Business Day and such extension of
time shall in such case be included in the computation of interest or fees, as
the case may be. All computations of interest for Reference Rate Loans shall be
made on the basis of a year of 365 or 366 days, as the case may be, and the
actual number of days elapsed. All other computations of interest shall be made
on the basis of a 360-day year and the actual number of days elapsed (which
results in more interest being paid than if computed on the basis of a 365-day
year). Each determination by the Administrative Agent of an interest rate or
fees hereunder shall be conclusive and binding for all purposes in the absence
of manifest error.

               (b) The Administrative Agent shall provide the Administrative
Borrower, promptly upon the request of the Administrative Borrower after the end
of any calendar month, a summary statement (in the form from time to time used
by the Administrative Agent) of the opening and closing daily balances in the
Loan Account of the Borrowers during such month, the amounts and dates of all
Loans made to the Borrowers during such month, the amounts and dates of all
payments on account of the Loans to the Borrowers during such month and the
Loans to which such payments were applied, the amount of interest accrued on the
Loans to the Borrowers during such month, any Letters of Credit issued by the
L/C Issuer for the account of the Borrowers during such month, specifying the
face amount thereof, the amount of charges to the Loan Account and/or Loans made
to the Borrowers during such month to reimburse the Revolving Loan Lenders for
drawings made under Letters of Credit, and the amount and nature of any charges
to the Loan Account made during such month on account of fees, commissions,
expenses and other Obligations. All entries on any such statement shall be
presumed to be correct and, thirty (30) days after the same is sent, shall be
final and conclusive absent manifest error or objection by the Administrative
Borrower prior to such date.

          Section 5.03 Sharing of Payments, Etc. Except as provided in Section
2.02 hereof, if any Lender shall obtain any payment (whether voluntary,
involuntary, through the exercise of any right of set-off, or otherwise) on
account of any Obligation in excess of its ratable share of payments on account
of similar obligations obtained by all the Lenders, such Lender shall forthwith
purchase from the other Lenders such participations in such similar obligations
held by them as shall be necessary to cause such purchasing Lender to share the
excess payment ratably with each of them; provided, however, that if all or any
portion of such excess payment is thereafter recovered from such purchasing
Lender, such purchase from each Lender shall be

                                      -58-
<PAGE>
rescinded and such Lender shall repay to the purchasing Lender the purchase
price to the extent of such recovery together with an amount equal to such
Lender's ratable share (according to the proportion of (i) the amount of such
Lender's required repayment to (ii) the total amount so recovered from the
purchasing Lender of any interest or other amount paid by the purchasing Lender
in respect of the total amount so recovered). The Borrowers agree that any
Lender so purchasing a participation from another Lender pursuant to this
Section 5.03 may, to the fullest extent permitted by law, exercise all of its
rights (including the Lender's right of set-off) with respect to such
participation as fully as if such Lender were the direct creditor of the
Borrowers in the amount of such participation.

          Section 5.04 Apportionment of Payments. Subject to Section 2.02 hereof
and to any written agreements among the Agents and/or the Lenders:

               (a) All payments of principal and interest in respect of
outstanding Loans, all payments in respect of the Letters of Credit, all
payments of fees (other than the fees set forth in Section 2.06 hereof, fees
with respect to Letters of Credit provided for in Section 3.02(b), and the audit
and collateral monitoring fee provided for in Section 5.01) and all other
payments in respect of any other Obligations, shall be allocated by the
Administrative Agent among such of the Lenders as are entitled thereto, in
proportion to their respective Pro Rata Shares or otherwise as provided herein
or, in respect of payments not made on account of Loans or Letter of Credit
Obligations, as designated by the Person making payment when the payment is
made.

               (b) After the occurrence and during the continuance of an Event
of Default, the Administrative Agent shall, upon the direction of the Collateral
Agent or the Required Lenders, apply all payments in respect of any Obligations
and all proceeds of the Collateral, subject to the provisions of this Agreement,
(i) first, ratably to pay the Obligations in respect of any fees, expense
reimbursements, indemnities and other amounts then due to the Agents or the L/C
Issuer, until paid in full; (ii) second, ratably to pay the Obligations in
respect of any fees and indemnities then due to the Lenders, until paid in full;
(iii) third, to pay interest due in respect of Collateral Agent Advances, until
paid in full; (iv) fourth, ratably to pay interest due in respect of the Loans
and Obligations consisting of scheduled or periodic payments with respect to
Hedging Agreements or Treasury Management Agreements, until paid in full; (v)
fifth, to pay principal of Collateral Agent Advances, until paid in full; (vi)
sixth, ratably to pay principal of the Loans and Letter of Credit Obligations
(or, to the extent such Obligations are contingent, to provide cash collateral
in respect of such Obligations) and Obligations consisting of termination or
other payments with respect to Hedging Agreements or Treasury Management
Agreements, until paid in full; and (vii) seventh, to the ratable payment of all
other Obligations then due and payable.

               (c) In each instance, so long as no Event of Default has occurred
and is continuing, Section 5.04(b) shall not be deemed to apply to any payment
by the Borrowers specified by the Administrative Borrower to the Administrative
Agent to be for the payment of Term Loan Obligations then due and payable under
any provision of this Agreement or the prepayment of all or part of the
principal of the Term Loan in accordance with the terms and conditions of
Section 2.05.

                                      -59-
<PAGE>
               (d) For purposes of Section 4.04(b), "paid in full" means payment
of all amounts owing under the Loan Documents according to the terms thereof,
including, without limitation, all loan fees, service fees, professional fees,
interest, default interest, interest on interest, and expense reimbursements.

               (e) In the event of a direct conflict between the priority
provisions of this Section 5.04 and other provisions contained in any other Loan
Document, it is the intention of the parties hereto that both such priority
provisions in such documents shall be read together and construed, to the
fullest extent possible, to be in concert with each other. In the event of any
actual, irreconcilable conflict that cannot be resolved as aforesaid, the terms
and provisions of this Section 5.04 shall control and govern.

          Section 5.05 Increased Costs and Reduced Return. (a) If any Lender,
any Agent or the L/C Issuer shall have determined that, after the Interim
Facility Effective Date, the adoption or implementation of, or any change in,
any law, rule, treaty or regulation, or any policy, guideline or directive of,
or any change in, the interpretation or administration thereof by, any court,
central bank or other administrative or Governmental Authority, or compliance by
any Lender, any Agent or the L/C Issuer or any Person controlling any such
Lender, any such Agent or the L/C Issuer with any directive of, or guideline
from, any central bank or other Governmental Authority or the introduction of,
or change in, any accounting principles applicable to any Lender, any Agent or
the L/C Issuer or any Person controlling any such Lender, any such Agent or the
L/C Issuer (in each case, whether or not having the force of law) (each a
"Change in Law"), shall (i) subject such Lender, such Agent or the L/C Issuer,
or any Person controlling such Lender, such Agent or the L/C Issuer to any tax,
duty or other charge with respect to any LIBOR Rate Loan made by such Lender or
such Agent or any Letter of Credit issued by the L/C Issuer, or change the basis
of taxation of payments to such Lender, such Agent or the L/C Issuer or any
Person controlling such Lender, such Agent or the L/C Issuer of any amounts
payable hereunder in respect of LIBOR Rate Loans (except for taxes on the
overall net income of such Lender, such Agent or the L/C Issuer or any Person
controlling such Lender, such Agent or the L/C Issuer), (ii) impose, modify or
deem applicable any reserve, special deposit or similar requirement (other than
the Reserve Percentage) against any LIBOR Rate Loan, any Letter of Credit or
against assets of or held by, or deposits with or for the account of, or credit
extended by, such Lender, such Agent or the L/C Issuer or any Person controlling
such Lender, such Agent or the L/C Issuer or (iii) impose on such Lender, such
Agent or the L/C Issuer or any Person controlling such Lender, such Agent or the
L/C Issuer any other condition regarding any LIBOR Rate Loan or Letter of
Credit, and the result of any event referred to in clauses (i), (ii) or (iii)
above shall be to increase the cost to such Lender, such Agent or the L/C Issuer
of making any LIBOR Rate Loan, issuing, guaranteeing or participating in any
Letter of Credit, or agreeing to make any Loan or issue, guaranty or participate
in any Letter of Credit, or to reduce any amount received or receivable by such
Lender, such Agent or the L/C Issuer hereunder in respect of LIBOR Rate Loans or
Letters of Credit, then, within 10 days of demand by such Lender, such Agent or
the L/C Issuer, the Borrowers shall pay to such Lender, such Agent or the L/C
Issuer such additional amounts as will compensate such Lender, such Agent or the
L/C Issuer for such increased costs or reductions in amount.

               (b) If any Lender, any Agent or the L/C Issuer shall have
determined that any Change in Law after the Interim Facility Effective Date
either (i) affects or would affect

                                      -60-
<PAGE>
the amount of capital required or expected to be maintained by such Lender, such
Agent or the L/C Issuer or any Person controlling such Lender, such Agent or the
L/C Issuer, and such Lender, such Agent or the L/C Issuer determines that the
amount of such capital is increased as a direct or indirect consequence of any
Loans made or maintained, Letters of Credit issued or any guaranty or
participation with respect thereto, such Lender's, such Agent's or the L/C
Issuer's or such other controlling Person's other obligations hereunder, or (ii)
has or would have the effect of reducing the rate of return on such Lender's,
such Agent's or the L/C Issuer's such other controlling Person's capital to a
level below that which such Lender, such Agent or the L/C Issuer or such
controlling Person could have achieved but for such circumstances as a
consequence of any Loans made or maintained, Letters of Credit issued, or any
guaranty or participation with respect thereto or any agreement to make Loans,
to issue Letters of Credit or such Lender's, such Agent's or the L/C Issuer's or
such other controlling Person's other obligations hereunder (in each case,
taking into consideration, such Lender's, such Agent's or the L/C Issuer's or
such other controlling Person's policies with respect to capital adequacy),
then, within 10 days of demand by such Lender, such Agent or the L/C Issuer, the
Borrowers shall pay to such Lender, such Agent or the L/C Issuer from time to
time such additional amounts as will compensate such Lender, such Agent or the
L/C Issuer for such cost of maintaining such increased capital or such reduction
in the rate of return on such Lender's, such Agent's or the L/C Issuer's or such
other controlling Person's capital.

               (c) All amounts payable under this Section 5.05 shall bear
interest from the date that is 10 days after the date of demand by any Lender,
any Agent or the L/C Issuer until payment in full to such Lender, such Agent or
the L/C Issuer at the Reference Rate. A certificate of such Lender, such Agent
or the L/C Issuer claiming compensation under this Section 5.05, specifying the
event herein above described and the nature of such event shall be submitted by
such Lender, such Agent or the L/C Issuer to the Administrative Borrower,
setting forth the additional amount due and an explanation of the calculation
thereof, and such Lender's, such Agent's or the L/C Issuer's reasons for
invoking the provisions of this Section 5.05, and shall be final and conclusive
absent manifest error.

               (d) The Borrowers shall not be required to compensate a Lender
pursuant to this Section 5.05 for any increased costs or reductions incurred
more than 180 days prior to the date that such Lender notifies the
Administrative Borrower of the change of law giving rise to such increased costs
or reductions and of such Lender's intention to claim compensation therefor;
provided, that, if the change of law giving rise to such increased costs or
reductions is retroactive, then such 180-day period referred to above shall be
extended to include the period of retroactive effect thereof.

          Section 5.06 Joint and Several Liability of the Borrowers. (a)
Notwithstanding anything in this Agreement or any other Loan Document to the
contrary, each of the Borrowers hereby accepts joint and several liability
hereunder and under the other Loan Documents in consideration of the financial
accommodations to be provided by the Agents, the L/C Issuer and the Lenders
under this Agreement and the other Loan Documents, for the mutual benefit,
directly and indirectly, of each of the Borrowers and in consideration of the
undertakings of the other Borrowers to accept joint and several liability for
the Obligations. Each of the Borrowers, jointly and severally, hereby
irrevocably and unconditionally accepts, not merely as a surety but also as a
co-debtor, joint and several liability with the other Borrowers, with respect to
the payment and

                                      -61-
<PAGE>
performance of all of the Obligations (including, without limitation, any
Obligations arising under this Section 5.06), it being the intention of the
parties hereto that all of the Obligations shall be the joint and several
obligations of each of the Borrowers without preferences or distinction among
them. If and to the extent that any of the Borrowers shall fail to make any
payment with respect to any of the Obligations as and when due or to perform any
of the Obligations in accordance with the terms thereof, then in each such
event, the other Borrowers will make such payment with respect to, or perform,
such Obligation. Subject to the terms and conditions hereof, the Obligations of
each of the Borrowers under the provisions of this Section 5.06 constitute the
absolute and unconditional, full recourse Obligations of each of the Borrowers,
enforceable against each such Person to the full extent of its properties and
assets, irrespective of the validity, binding effect or enforceability of this
Agreement, the other Loan Documents or any other circumstances whatsoever.

               (b) The provisions of this Section 5.06 are made for the benefit
of the Agents, the Lenders and their successors and assigns, and may be enforced
by them from time to time against any or all of the Borrowers as often as
occasion therefor may arise and without requirement on the part of the Agents,
the Lenders or such successors or assigns first to marshal any of its or their
claims or to exercise any of its or their rights against any of the other
Borrowers or to exhaust any remedies available to it or them against any of the
other Borrowers or to resort to any other source or means of obtaining payment
of any of the Obligations hereunder or to elect any other remedy. The provisions
of this Section 5.06 shall remain in effect until all of the Obligations shall
have been paid in full or otherwise fully satisfied.

               (c) Each of the Borrowers hereby agrees that it will not enforce
any of its rights of contribution or subrogation against the other Borrowers
with respect to any liability incurred by it hereunder or under any of the other
Loan Documents, any payments made by it to the Agents or the Lenders with
respect to any of the Obligations or any Collateral, until such time as all of
the Obligations have been paid in full in cash. Any claim which any Borrower may
have against any other Borrower with respect to any payments to the Agents or
the Lenders hereunder or under any other Loan Documents are hereby expressly
made subordinate and junior in right of payment, without limitation as to any
increases in the Obligations arising hereunder or thereunder, to the prior
payment in full in cash of the Obligations.

                                   ARTICLE VI

                               CONDITIONS TO LOANS

          Section 6.01 Conditions Precedent to Interim Facility. This Agreement
shall become effective as of the Business Day (the "Interim Facility Effective
Date") when each of the following conditions precedent shall have been satisfied
in a manner reasonably satisfactory to the Collateral Agent (and if so indicated
below, the Administrative Agent):

               (a) Interim Bankruptcy Court Order. The Interim Bankruptcy Court
Order shall have been entered by the Bankruptcy Court and the Agents shall have
received a true and complete copy of such order, and such order shall be in full
force and effect and shall not have been reversed, modified, amended, stayed or
vacated absent prior written consent of the Agents, the Required Lenders and the
Borrowers.

                                      -62-
<PAGE>
               (b) Payment of Fees, Etc. The Borrowers shall have paid on or
before the Interim Facility Effective Date, all fees, costs, expenses and taxes
then payable pursuant to Section 2.06 and Section 12.04.

               (c) Representations and Warranties; No Event of Default. The
following statements shall be true and correct: (i) the representations and
warranties contained in Section 2.05(c)(ii), ARTICLE VII and in each other Loan
Document are true and correct on and as of the Interim Facility Effective Date
as though made on and as of such date, except to the extent that any such
representation or warranty expressly relates solely to an earlier date (in which
case such representation or warranty shall be true and correct on and as of such
earlier date) and (ii) no Default or Event of Default shall have occurred and be
continuing on the Interim Facility Effective Date or would result from this
Agreement or the other Loan Documents becoming effective in accordance with its
or their respective terms.

               (d) Legality. The making of the initial Loans or the issuance of
any initial Letters of Credit shall not contravene any law, rule or regulation
applicable to any Agent, any Lender or the L/C Issuer.

               (e) Delivery of Documents. The Collateral Agent shall have
received on or before the Interim Effective Date the following, each in form and
substance reasonably satisfactory to the Collateral Agent (and in the case of
items (i), (v) and (xiii) below, the Administrative Agent) and, unless indicated
otherwise, dated on or as of the Interim Facility Effective Date:

                    (i) the Fee Letter;

                    (ii) a Pledge Agreement, duly executed by each Loan Party,
together with the original stock certificates (to the extent certificated)
representing all (or, in the case of a Foreign Subsidiary, 65%) of the issued
and outstanding Capital Stock entitled to vote (within the meaning of Treas.
Reg. Section 1.956-2(c)(2)) and all of the issued and outstanding Capital Stock
not entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2))
of each direct Subsidiary of such Loan Party and all intercompany promissory
notes of such Loan Party, accompanied by undated stock powers executed in blank
and other proper instruments of transfer; provided, that the possession by
Silver Point of such stock certificates, intercompany notes and related
documentation as collateral under the Existing Credit Agreement shall be deemed
to constitute delivery hereunder;

                    (iii) certified copies of request for copies of information
on Form UCC-11 in jurisdictions deemed necessary by the Collateral Agent,
listing all effective financing statements which name as debtor any Loan Party,
together with copies of such financing statements, none of which, except as
otherwise agreed in writing by the Collateral Agent, shall cover any of the
Collateral and the results of searches for any tax Lien and judgment Lien filed
against such Person or its property in jurisdictions deemed necessary by the
Collateral Agent, which results shall not show any such Liens, except Permitted
Liens;

                    (iv) a copy of the resolutions of each Loan Party, certified
as of the Interim Facility Effective Date by an Authorized Officer thereof,
authorizing (A) the

                                      -63-
<PAGE>
borrowings hereunder and the transactions contemplated by the Loan Documents to
which such Loan Party is or will be a party, and (B) the execution, delivery and
performance by such Loan Party of each Loan Document to which such Loan Party is
or will be a party and the execution and delivery of the other documents to be
delivered by such Person in connection herewith and therewith;

                    (v) a certificate of an Authorized Officer of each Loan
Party, certifying the names and true signatures of the representatives of such
Loan Party authorized to sign each Loan Document to which such Loan Party is or
will be a party and the other documents to be executed and delivered by such
Loan Party in connection herewith and therewith, together with evidence of the
incumbency of such authorized officers;

                    (vi) a certificate of the appropriate official(s) of (A) the
state of organization of each Loan Party and (B) each state of foreign
qualification of each Loan Party other than those states in which the failure to
be so qualified could not reasonably be expected to have a Material Adverse
Effect, in each case, certifying as of a recent date not more than 30 days prior
to the Interim Facility Effective Date as to the subsistence in good standing of
such Loan Party in such states;

                    (vii) a copy of the charter and by-laws, limited liability
company agreement, operating agreement, agreement of limited partnership or
other organizational document of each Loan Party, together with all amendments
thereto, certified as of the Interim Facility Effective Date by an Authorized
Officer of such Loan Party or a certificate of an Authorized Officer of such
Loan Party certifying that such documents delivered pursuant to the Existing
Credit Agreement remain in full force and effect and have not been amended or
otherwise modified;

                    (viii) (A) an opinion of in-house counsel for the Loan
Parties, substantially in the form of Exhibit C;

                    (ix) a certificate of an Authorized Officer of each Loan
Party, certifying as to the matters set forth in subsection (c) of this Section
6.01;

                    (x) a copy of (A) the Short-Term Budget and the Long-Term
Budget, (B) the Financial Statements and (C) the financial projections described
in Section 7.01(g)(ii)(B) and (C) hereof, certified as of the Interim Facility
Effective Date by an Authorized Officer of the Parent as complying with the
representations and warranties set forth in Section 7.01(g);

                    (xi) evidence of the insurance coverage required by Section
8.01, where requested by the Collateral Agent, with such endorsements as to the
named insureds or loss payees thereunder as the Collateral Agent may request and
providing that such policy may be terminated or canceled (by the insurer or the
insured thereunder) only upon 30 days' prior written notice to the Collateral
Agent and each such named insured or loss payee, together with evidence of the
payment of all premiums due in respect thereof for such period as the Collateral
Agent may request;

                                      -64-
<PAGE>
                    (xii) a certificate of an Authorized Officer of the
Administrative Borrower, certifying the names and true signatures of the persons
that are authorized to provide Notices of Borrowing, Letter of Credit
Applications, LIBOR Notices and all other notices under this Agreement and the
other Loan Documents; and

                    (xiii) such other agreements, instruments, approvals,
opinions and other documents, each satisfactory to the Collateral Agent in form
and substance, as the Collateral Agent may reasonably request.

               (f) Material Adverse Effect. No event or development shall have
occurred since April 29, 2005 which would have a Material Adverse Effect.

               (g) Priority. The Collateral Agent shall be satisfied that it has
been granted, and holds, for the benefit of the Agents, the Lenders, and the L/C
Issuer, a perfected, first priority Lien on, and security interest in, all of
the Collateral, subject only to Permitted Priority Liens (subject to any action
required under foreign law with respect to the Capital Stock of Foreign
Subsidiaries solely to the extent that such foreign law is applicable).

               (h) Approvals. All consents, authorizations and approvals of, and
filings and registrations with, and all other actions in respect of, any
Governmental Authority or other Person required in connection with the making of
the Loans during the Interim Period shall have been obtained and shall be in
full force and effect.

               (i) Retention of Professionals. The Borrowers shall have
continued the retention of FTI Consulting, Inc. and Rothschild, Inc. (or other
advisors reasonably acceptable to the Collateral Agent) and shall have filed
such first day motions as are necessary to obtain the approval thereof by the
Bankruptcy Court.

               (j) Existing Credit Agreement. The Existing Lenders shall have
received adequate protection in respect of the Liens securing the Pre-Petition
Obligations in the form of (i) replacement Liens on the Collateral, subject only
to the Liens securing the Obligations and the Permitted Priority Liens, (ii)
priority administrative expense claim status with respect to the Pre-Petition
Obligations, subject only to the super-priority administrative expense claim
status of the Obligations to the extent of any diminution in value of the
collateral securing the Pre-Petition Obligations caused by the Liens granted
hereunder and under the other Loan Documents, and (iii) an order approving
payment in cash of (A) on the Interim Facility Effective Date, all interest that
has accrued and all expenses that have been incurred under the Existing Credit
Agreement as of such date and (B) from and after the Interim Facility Effective
Date until the date on which all Pre-Petition Obligations shall have been paid
in full in cash, all outstanding letters of credit under the Existing Credit
Agreement shall have been terminated or cash collateralized and all commitments
under the Existing Credit Agreement shall have been terminated, all interest
accruing and all expenses incurred under the Existing Credit Agreement as and
when due and payable thereunder, in each case, at the rate of interest in effect
under the Existing Credit Agreement immediately prior to the Filing Date.

                                      -65-
<PAGE>
               (k) Purchase Agreement. The Agents shall have received on or
before the Interim Facility Effective Date, a fully executed copy of the Pharma
Purchase Agreement, which purchase agreement shall be in full force and effect.

               (l) First Day Motions. The Agents shall have received and be
reasonably satisfied with the first day motions filed by the Borrowers with the
Bankruptcy Court in the Chapter 11 Cases.

               (m) Commencement of Chapter 11 Cases. The Borrowers shall have
commenced the Chapter 11 Cases and no trustee, examiner or receiver shall have
been appointed or designated with respect to the Borrowers or their business,
properties or assets and no motion shall be pending seeking any such relief or
seeking any other relief in the Bankruptcy Court to exercise control over
Collateral with an aggregate fair market value in excess of $500,000.

               (n) Proceedings; Receipt of Documents. All proceedings in
connection with the making of the initial Loans or the issuance of the initial
Letters of Credit and the other transactions contemplated by this Agreement and
the other Loan Documents, and all documents incidental hereto and thereto, shall
be satisfactory to the Collateral Agent and its counsel, and the Collateral
Agent and such counsel shall have received all such information and such
counterpart originals or certified or other copies of such documents as the
Collateral Agent or such counsel may reasonably request.

          Section 6.02 Conditions Precedent to Final Facility Effectiveness. The
obligation of any Agent or any Lender to make any Loan or of the Administrative
Agent to assist the Borrowers in establishing or opening any Letter of Credit
during the Final Period shall commence as of the Business Day (the "Final
Facility Effective Date") when each of the following conditions precedent shall
have been satisfied in a manner satisfactory to the Collateral Agent:

               (a) Final Bankruptcy Court Order, Etc. The Final Bankruptcy Court
Order shall have been signed and entered by the Bankruptcy Court within a date
which is 30 days following the date of the entry of the Interim Facility
Bankruptcy Court Order, and the Collateral Agents shall have received a true and
complete copy of such order, and such order shall be in full force and effect
and shall not have been reversed, modified, amended, stayed or vacated absent
the prior written consent of the Agents, the Required Lenders and the Borrowers.

               (b) Payment of Fees, Etc. The Borrowers shall have paid on or
before such date all fees, costs, expenses and taxes then payable pursuant to
Section 2.06 and Section 12.04.

               (c) Representations and Warranties; No Event of Default. The
following statements shall be true and correct: (i) the representations and
warranties contained in Section 2.05(c)(ii), ARTICLE VII and in each other Loan
Document, certificate or other writing delivered to the Agents or the Lenders
pursuant hereto or thereto on or prior to the Final Facility Effective Date are
true and correct on and as of the Final Facility Effective Date as though made
on and as of such date, except to the extent that any such representation or
warranty expressly relates solely to an earlier date (in which case such
representation or warranty shall be true and

                                      -66-
<PAGE>
correct on and as of such earlier date) and (ii) no Default or Event of Default
shall have occurred and be continuing on the Final Facility Effective Date or
would result from the making of Loans or the issuance of any Letter of Credit on
such date.

               (d) Legality. The making of the Loans or the issuance of any
Letters of Credit on the Final Facility Effective Date shall not contravene any
law, rule or regulation applicable to any Agent, any Lender or the L/C Issuer.

               (e) Delivery of Documents. The Collateral Agent shall have
received on or before the Final Facility Effective Date the following, each in
form and substance reasonably satisfactory to the Collateral Agent and, unless
indicated otherwise, dated on or as of the Final Facility Effective Date:

                    (i) a modification to each Mortgage executed in connection
with the Existing Credit Agreement, duly executed by each applicable Loan Party,
with respect to each Facility;

                    (ii) evidence of the recording of the Modification to each
Mortgage in such office or offices as may be necessary or, in the reasonable
business judgment of the Collateral Agent, desirable to perfect the Lien
purported to be created thereby or to otherwise protect the rights of the
Agents, the L/C Issuer and the Lenders thereunder;

                    (iii) a Title Insurance Policy with respect to each
Mortgage;

                    (iv) an ALTA survey of each Facility, in form and substance
satisfactory to the Collateral Agent, certified to the Collateral Agent and to
the issuer of each Title Insurance Policy (which survey shall be waived to the
extent that the survey prepared in connection with the Existing Credit Agreement
with respect to such Facility is acceptable to the issuer of the relevant Title
Insurance Policy with respect to such Facility);

                    (v) (A) an appropriate pledge agreement, in form and
substance satisfactory to the Collateral Agent, with respect to a pledge of 65%
of the Capital Stock of Applied Analytical Industries Deutschland GmbH (the
"German Subsidiary"), (B) a legal opinion of foreign counsel of the German
Subsidiary in a form satisfactory to the Collateral Agent, which shall cover the
enforceability and perfection of the Collateral Agent's security interest in
such pledged shares of the German Subsidiary and (C) certificates evidencing any
such certificated Capital Stock, if any, together with stock powers, undated and
duly executed in blank (unless, such stock powers are deemed unnecessary by the
Collateral Agent in its reasonable discretion under the law of the jurisdiction
of such German Subsidiary);

                    (vi) an updated Short-Term Budget, together with a
certificate of an Authorized Officer stating that such Budget complies with the
representations and warranties set forth in Section 7.01(g); and

                    (vii) such depository account, blocked account, lockbox
account and similar agreements and other documents, each in form and substance
reasonably satisfactory to the Agents, as the Agents may reasonably request with
respect to the Borrowers' domestic cash management system (other than with
respect to fiduciary accounts of the Loan Parties and

                                      -67-
<PAGE>
deposit accounts of the Loan Parties exclusively used for payroll, payroll taxes
and other employee wage and benefit payments to or for the benefit of the
salaried employees of the Loan Parties).

               (f) Liens; Priority. The Collateral Agent shall be satisfied that
it has been granted, and still continues to hold, for the benefit of the Agents,
the Lenders, and the L/C Issuer a perfected, first priority Lien on and security
interest in all of the Collateral, subject only to Permitted Priority Liens
(subject to any action required under foreign law with respect to the Capital
Stock of Foreign Subsidiaries solely to the extent that such foreign law is
applicable). At the request of the Collateral Agent, the Collateral Agent shall
receive UCC, tax and judgment Lien searches and, title reports with respect to
all real property of the Borrowers and other appropriate evidence, evidencing
the absence of any Liens or mortgages on the Collateral, except Permitted Liens.

               (g) Pre-Petition Obligations. The Pre-Petition Obligations shall
have been repaid in full with the proceeds of the Term Loan (it being understood
that the Existing Letters of Credit shall be deemed to be issued under this
Agreement on the Final Facility Effective Date).

               (h) Material Adverse Effect. No event or development shall have
occurred since the Interim Facility Effective Date which would have a Material
Adverse Effect.

          Section 6.03 Conditions Precedent to All Loans and Letters of Credit.
The obligation of any Agent or any Lender to make any Loan or of the L/C Issuer
to issue any Letter of Credit after the Interim Facility Effective Date is
subject to the fulfillment, in a manner reasonably satisfactory to the
Administrative Agent, as certified to by the Administrative Borrower in the
applicable Notice of Borrowing, of each of the following conditions precedent:

               (a) Payment of Fees, Etc. The Borrowers shall have paid all fees,
costs, expenses and taxes then payable by the Borrowers pursuant to this
Agreement and the other Loan Documents, including, without limitation, Section
2.06 and Section 12.04 hereof.

               (b) Representations and Warranties; No Event of Default. The
following statements shall be true and correct, and the submission by the
Administrative Borrower to the Administrative Agent of a Notice of Borrowing
with respect to each such Loan, and the Borrowers' acceptance of the proceeds of
such Loan, or the submission by the Borrowers of a Letter of Credit Application
with respect to a Letter of Credit, and the issuance of such Letter of Credit,
shall each be deemed to be a representation and warranty by each Loan Party on
the date of such Loan or the date of issuance of such Letter of Credit that: (i)
the representations and warranties contained in Section 2.05(c)(ii), ARTICLE VII
and in each other Loan Document are true and correct on and as of such date as
though made on and as of such date, except to the extent that any such
representation or warranty expressly relates solely to an earlier date (in which
case such representation or warranty shall be true and correct on and as of such
earlier date), (ii) at the time of and after giving effect to the making of such
Loan and the application of the proceeds thereof or at the time of issuance of
such Letter of Credit, no Default or Event of Default has occurred and is
continuing or would result from the making of the Loan to be made,

                                      -68-
<PAGE>
or the issuance of such Letter of Credit to be issued, on such date and (iii)
the conditions set forth in this Section 6.03 have been satisfied as of the date
of such request.

               (c) Legality. The making of such Loan or the issuance of such
Letter of Credit shall not contravene any law, rule or regulation applicable to
any Agent, any Lender or the L/C Issuer.

               (d) Notices. The Administrative Agent shall have received (i) a
Notice of Borrowing pursuant to Section 2.02 hereof, (ii) a Letter of Credit
Application pursuant to Section 3.01, hereof, if applicable, and (iii) a LIBOR
Notice pursuant to Section 2.09 hereof, if applicable.

               (e) Delivery of Documents. The Collateral Agent shall have
received such other agreements, instruments, approvals, opinions and other
documents, each in form and substance reasonably satisfactory to the Collateral
Agent, as the Collateral Agent may reasonably request.

               (f) Proceedings; Receipt of Documents. All proceedings in
connection with the making of such Loan or the issuance of such Letter of Credit
and the other transactions contemplated by this Agreement and the other Loan
Documents, and all documents incidental hereto and thereto, shall be reasonably
satisfactory to the Collateral Agent and its counsel, and the Collateral Agent
and such counsel shall have received all such information and such counterpart
originals or certified or other copies of such documents, in form and substance
reasonably satisfactory to the Collateral Agent, as the Collateral Agent or such
counsel may reasonably request.

          Section 6.04 Conditions Subsequent to Effectiveness. The obligation of
the Agents or any Lender to maintain the Loans and Letters of Credit after the
Interim Facility Effective Date is subject to the fulfillment, on or before the
applicable date thereto (unless the Borrowers are diligently pursuing the
satisfaction of such condition subsequent and such date is extended in writing
by the Collateral Agent in its sole discretion), of each condition subsequent
set forth below (the failure by Borrowers to so perform or cause to be performed
constituting an Event of Default):

               (a) the Borrowers shall use commercially reasonable efforts to
deliver to the Collateral Agent, within 30 days of the Final Facility Effective
Date, a landlord waiver, in form and substance reasonably satisfactory to the
Collateral Agent, executed by each landlord with respect to each of the
locations at which Collateral with a book value in excess of $250,000 (when
aggregated with all other Collateral at the same location) is located (it
being understood that in the event the Borrowers are unable to obtain any such
landlord waiver, the Administrative Agent shall, at the direction of the
Collateral Agent using its reasonable discretion, establish such reserves
against Availability as the Collateral Agent deems reasonably necessary with
respect to the Collateral at such location).

               (b) the Borrowers shall use commercially reasonable efforts to
deliver to the Collateral Agent, within 30 days of the Final Facility Effective
Date, a collateral access agreement, in form and substance reasonably
satisfactory to the Collateral Agent, executed by each Person who possesses
Collateral of any Loan Party with a book value in an aggregate amount in excess
of $250,000 (it being understood that in the event the Borrowers are unable to
obtain any such collateral access agreement, the Administrative Agent shall, at
the direction of the Collateral Agent using its reasonable discretion,
establish such reserves against Availability as the Collateral Agent deems
reasonably necessary with respect to the Collateral in the possession of such
Person); and

               (c) the Borrowers shall use commercially reasonable efforts to
deliver to the Collateral Agent, within 30 days of the Final Facility Effective
Date, a copy of each letter issued by the applicable State Governmental
Authority, evidencing each Facility's compliance with all applicable building
codes, fire codes, other health and safety rules and regulations, parking,
density and height requirements and other building and zoning laws (it being
understood that in the event the Borrowers are unable to obtain any such letter
or such letter discloses a material impairment of the use of such Facility, the
Administrative Agent shall, at the direction of the Collateral Agent using its
reasonable discretion, establish such reserves against Availability as the
Collateral Agent deems reasonably necessary with respect to such Facility).

                                      -69-
<PAGE>
                                   ARTICLE VII

                         REPRESENTATIONS AND WARRANTIES

          Section 7.01 Representations and Warranties. Each Loan Party hereby
represents and warrants to the Agents, the Lenders and the L/C Issuer as
follows:

               (a) Organization, Good Standing, Etc. Each Loan Party (i) is a
corporation, limited liability company or limited partnership duly organized,
validly existing and in good standing under the laws of the state or
jurisdiction of its organization other than to the extent that the failure to be
in good standing in such state or jurisdiction could not reasonably be expected
to have a Material Adverse Effect, (ii) subject to the entry and the terms of
the Bankruptcy Court Orders, has all requisite corporate or limited liability
company power and authority to conduct its business as now conducted and as
presently contemplated and, in the case of the Borrowers, to make the borrowings
hereunder, and to execute and deliver each Loan Document to which it is a party,
and to consummate the transactions contemplated thereby, and (iii) is duly
qualified to do business and is in good standing in each jurisdiction in which
the character of the properties owned or leased by it or in which the
transaction of its business makes such qualification necessary other than in
such jurisdictions where the failure to be so qualified and in good standing
could not reasonably be expected to have a Material Adverse Effect.

               (b) Authorization, Etc. The execution, delivery and performance
by each Loan Party of each Loan Document to which it is or will be a party, (i)
subject to the entry and the terms of the Bankruptcy Court Orders, have been
duly authorized by all necessary action, (ii) do not and will not contravene its
charter or by-laws, its limited liability company or operating agreement or its
certificate of partnership or partnership agreement, as applicable, or any
applicable law, or any material term of any Material Contract (other than
conflicts, breaches and defaults the enforcement of which will be stayed by
virtue of the filing of the Chapter 11 Cases), or any order or decree of any
court or Governmental Authority (including, without limitation, any order
entered in the Chapter 11 Cases), (iii) do not and will not result in or require
the creation of any Lien (other than pursuant to any Loan Document) upon or with
respect to any of its properties, and (iv) do not and will not result in any
default, noncompliance, suspension, revocation, impairment, forfeiture or
nonrenewal of any permit, license, authorization or approval applicable to its
operations or any of its properties.

               (c) Governmental Approvals. Except for the entry of the
Bankruptcy Court Orders, no authorization or approval or other action by, and no
notice to or filing with, any Governmental Authority is required in connection
with the due execution, delivery and performance by any Loan Party of any Loan
Document to which it is or will be a party.

               (d) Enforceability of Loan Documents. Subject to the entry of the
Bankruptcy Court Orders, this Agreement is, and each other Loan Document to
which any Loan Party is or will be a party, when delivered hereunder, will be, a
legal, valid and binding obligation of such Person, enforceable against such
Person in accordance with its terms.

               (e) Subsidiaries. Schedule 7.01(e) is a complete and correct
description of the name, jurisdiction of incorporation and ownership of the
outstanding Capital

                                      -70-
<PAGE>
Stock of such Subsidiaries of the Parent in existence on the date hereof. All of
the issued and outstanding shares of Capital Stock of such Subsidiaries have
been validly issued and are fully paid and nonassessable, and the holders
thereof are not entitled to any preemptive, first refusal or other similar
rights. Except as indicated on such Schedule and as otherwise permitted by
Section 8.02(c)(i), all such Capital Stock is owned by the Parent or one or more
of its wholly-owned Subsidiaries, free and clear of all Liens (other than
Permitted Liens). There are no outstanding debt or equity securities of the
Parent or any of its Subsidiaries and no outstanding obligations of the Parent
or any of its Subsidiaries convertible into or exchangeable for, or warrants,
options or other rights for the purchase or acquisition from the Parent or any
of its Subsidiaries, or other obligations of any Subsidiary to issue, directly
or indirectly, any shares of Capital Stock of any Subsidiary of the Parent.

               (f) Litigation; Commercial Tort Claims. Except for pre-petition
litigation that is stayed by 11 U.S.C. Section 362 or as otherwise set forth in
Schedule 7.01(f) or in the Supplemental Disclosure, (i) there is no action, suit
or proceeding pending or threatened in writing affecting any Loan Party or any
of its properties before any court or other Governmental Authority or any
arbitrator that (A) if such action, suit or proceeding could reasonably be
expected to be adversely determined, could reasonably be expected to have a
Material Adverse Effect or (B) relates to this Agreement or any other Loan
Document or any transaction contemplated hereby or thereby (other than (1) any
action, suit or proceeding by any Person during the Interim Period objecting to
the entry by the Bankruptcy Court of the Final Bankruptcy Court Order or seeking
modification thereof from the terms contemplated in the Interim Bankruptcy Court
Order and (2) any action, suit or proceeding by any Person objecting to any
waiver or amendment of, or consent to the departure from, the terms of this
Agreement, in each case, to the extent that such action, suit or proceeding does
not result in the reversal, modification, amendment, stay or vacation of either
of the Bankruptcy Court Orders without the prior written consent of the Agents
and the Borrowers) and (ii) as of the Interim Facility Effective Date, none of
the Loan Parties holds any commercial tort claims in respect of which a claim
has been filed in a court of law or a written notice by an attorney has been
given to a potential defendant.

               (g) Financial Condition.

                    (i) Except to the extent set forth in Schedule 7.01(g)(i),
to the best knowledge of the Parent's management, as of the Interim Facility
Effective Date, the Financial Statements, copies of which have been delivered to
each Agent and each Lender, fairly present in all material respects the
consolidated financial condition of the Parent and its Subsidiaries as at the
respective dates thereof and the consolidated results of operations of the
Parent and its Subsidiaries for the fiscal periods ended on such respective
dates, all in accordance with GAAP, and since the Interim Facility Effective
Date no event or development has occurred that has had or could reasonably be
expected to have a Material Adverse Effect.

                    (ii) On or before the Interim Facility Effective Date, the
Parent has heretofore furnished to each Agent and each Lender (A) a Short-Term
Budget and a Long-Term Budget, (B) projected quarterly balance sheets, income
statements and statements of cash flows of the Parent and its Subsidiaries for
the period from April 1, 2005, through December 31, 2005, and (C) projected
annual balance sheets, income statements and statements of cash flows

                                      -71-
<PAGE>
of the Parent and its Subsidiaries for the Fiscal Years ending in 2005 through
2006, which Budgets and projected financial statements shall be updated from
time to time pursuant to Section 8.01(a)(vi). Such Budgets and projections when
delivered will be, prepared in good faith by the management of the Parent, based
on assumptions believed by the management of the Parent to be reasonable at the
time made and upon information believed by the management of the Parent to have
been accurate based upon the information available to the management of Parent
at the time such Budgets and projections were furnished.

               (h) Compliance with Law, Etc. No Loan Party is in violation of
(i) its organizational documents, (ii) except as set forth on Schedule 7.01(h),
any material law, rule, regulation (including, without limitation, the FDA
Regulations and the HHS Regulations), judgment or order of any Governmental
Authority applicable to it or any of its property or assets (other than
immaterial violations for which no penalty or fine in excess of $250,000 is
payable, or which are being contested in good faith by proper proceedings which
stay the imposition of any penalty, fine or Lien resulting from such violation
and with respect to which adequate reserves have been set aside for the payment
of any penalty or fine arising therefrom in accordance with GAAP, or the
enforcement of which are stayed by virtue of the Chapter 11 Cases), or (iii)
other than violations occurring as a result of the filing of the Chapter 11
Cases, and other than violations the enforcement of which are stayed by virtue
of the filing of the Chapter 11 Cases, any material term of any Material
Contract, and no Default or Event of Default has occurred and is continuing.

               (i) ERISA. Except as set forth on Schedule 7.01(i), (i) each
Employee Plan is in substantial compliance with ERISA and the Internal Revenue
Code, (ii) no Termination Event has occurred nor is reasonably expected to occur
with respect to any Employee Plan, (iii) the most recent annual report (Form
5500 Series) with respect to each Employee Plan, including any required Schedule
B (Actuarial Information) thereto, copies of which have been filed with the
Internal Revenue Service and, if requested by any Agent pursuant to Section
8.01(a)(x), delivered to the Agents, is complete and correct in all material
respects and fairly presents the funding status of such Employee Plan, and since
the date of such report there has been no material adverse change in such
funding status, (iv) copies of each agreement entered into with the PBGC, the
U.S. Department of Labor or the Internal Revenue Service with respect to any
Employee Plan have been delivered to the Agents, (v) no Employee Plan had an
accumulated or waived funding deficiency or permitted decrease which would
create a deficiency in its funding standard account or has applied for an
extension of any amortization period within the meaning of Section 412 of the
Internal Revenue Code at any time during the previous 60 months, and (vi) no
Lien imposed under the Internal Revenue Code or ERISA exists or is likely to
arise on account of any Employee Plan within the meaning of Section 412 of the
Internal Revenue Code. Except as set forth on Schedule 7.01(i), no Loan Party or
any of its ERISA Affiliates has incurred any withdrawal liability under ERISA
with respect to any Multiemployer Plan, or is aware of any facts indicating that
it or any of its ERISA Affiliates may in the future incur any such withdrawal
liability. No Loan Party or any of its ERISA Affiliates nor any fiduciary of any
Employee Plan has (i) engaged in a nonexempt prohibited transaction described in
Sections 406 of ERISA or 4975 of the Internal Revenue Code, (ii) failed to pay
any required installment or other payment required under Section 412 of the
Internal Revenue Code on or before the due date for such required installment or
payment, (iii) engaged in a transaction within the meaning of Section 4069 of
ERISA or (iv) incurred any liability to the PBGC which

                                      -72-
<PAGE>
remains outstanding other than the payment of premiums, and there are no premium
payments which have become due which are unpaid. Except as set forth on Schedule
7.01(i), there are no pending or, to the best knowledge of any Loan Party,
threatened claims, actions, proceedings or lawsuits (other than claims for
benefits in the normal course) asserted or instituted against (i) any Employee
Plan or its assets, (ii) any fiduciary with respect to any Employee Plan, or
(iii) any Loan Party or any of its ERISA Affiliates with respect to any Employee
Plan, in each case, that could reasonably be expected to result in a liability
to any Loan Party or any of its ERISA Affiliates in an amount in excess of
$500,000. Except as required by Section 4980B of the Internal Revenue Code, no
Loan Party or any of its ERISA Affiliates maintains an employee welfare benefit
plan (as defined in Section 3(1) of ERISA) which provides health or welfare
benefits (through the purchase of insurance or otherwise) for any retired or
former employee of any Loan Party or any of its ERISA Affiliates or coverage
after a participant's termination of employment.

               (j) Taxes, Etc. All Federal, state and local tax returns and
other reports required by applicable law to be filed by any Loan Party have been
filed, or extensions have been obtained, and all taxes, assessments and other
governmental charges imposed upon any Loan Party or any property of any Loan
Party and which have become due and payable on or prior to the date hereof have
been paid, except (i) as of the Interim Facility Effective Date, for amounts
contested in good faith by proper proceedings which stay the imposition of any
penalty, fine or Lien resulting from the non-payment thereof and with respect to
which adequate reserves have been set aside for the payment thereof on the
Financial Statements in accordance with GAAP (or to the extent that such payment
or any enforcement action is stayed as a result of the Chapter 11 Cases) and
(ii) after the Interim Facility Effective Date, as permitted by Section 8.01(c).

               (k) Regulations T, U and X. No Loan Party is or will be engaged
in the business of extending credit for the purpose of purchasing or carrying
margin stock (within the meaning of Regulation T, U or X), and no proceeds of
any Loan will be used to purchase or carry any margin stock or to extend credit
to others for the purpose of purchasing or carrying any margin stock.

               (l) Nature of Business. No Loan Party is engaged in any business
other than specialty pharmaceutical services with comprehensive drug development
capabilities with focus in fee-for-service pharmaceutical services, drug product
sales, pharmaceutical product development, pharmaceutical product manufacturing
and product life cycle management and ancillary businesses.

               (m) Adverse Agreements, Etc. No Loan Party is a party to any
agreement or instrument, or subject to any charter, limited liability company
agreement, partnership agreement or other corporate, partnership or limited
liability company restriction or any judgment, order, regulation, ruling or
other requirement of a court or other Governmental Authority, other than any
agreement, instrument, judgment, order, regulation, ruling or other requirement
(i) the enforcement of which is stayed by virtue of the Chapter 11 Cases or (ii)
which does not have, or in the future could not reasonably be expected to have,
a Material Adverse Effect.

                                      -73-
<PAGE>
               (n) Permits, Etc. Each Loan Party has, and is in compliance with,
all permits, licenses, authorizations, approvals, entitlements and
accreditations required for such Person lawfully to own, lease, manage or
operate, or to acquire, each business currently owned, leased, managed or
operated, or to be acquired, by such Person except for such non-compliance and
such permits, licenses, authorizations, entitlements and accelerations, as to
which (individually or in the aggregate) a Loan Party or its Subsidiary's
failure to maintain or so comply could not reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect. No condition
exists or event has occurred which, in itself or with the giving of notice or
lapse of time or both, would result in the suspension, revocation, impairment,
forfeiture or non-renewal of any such permit, license, authorization, approval,
entitlement or accreditation, and there is no claim that any thereof is not in
full force and effect.

               (o) Properties. (i) Each Loan Party has good and marketable title
to, valid leasehold interests in, or valid licenses to use, all property and
assets material to its business, free and clear of all Liens, except Permitted
Liens. All such properties and assets are in good working order and condition,
ordinary wear and tear excepted.

                    (ii) Schedule 7.01(o) sets forth a complete and accurate
list, as of the Interim Facility Effective Date, of the location, by state and
street address, of all real property owned or leased by each Loan Party and
identifies the interest (fee or leasehold) of such Loan Party therein. Except as
set forth on Schedule 7.01(o), each Loan Party has, as of the Interim Facility
Effective Date, valid leasehold interests in the Leases described on Schedule
7.01(o) to which it is a party. True, complete and correct copies of each such
Lease, as in effect on the Interim Facility Effective Date, have been made
available to the Collateral Agent prior to the Interim Facility Effective Date.
Schedule 7.01(o) sets forth with respect to each such Lease, as in effect on the
Interim Facility Effective Date, the commencement date, termination date,
renewal options (if any) and annual base rents. Each such Lease that is a
Material Contract is valid and enforceable in accordance with its terms and is
in full force and effect (except to the extent that any such Lease is terminated
or rejected by a Loan Party or any of its Subsidiaries upon a determination by
such Person in its reasonable business judgment that such Lease is no longer
material and useful to the conduct of the business of the Parent and its
Subsidiaries, taken as a whole). No consent or approval of any landlord or other
third party in connection with any such Lease is necessary for any Loan Party to
enter into and execute the Loan Documents to which it is a party, except as set
forth on Schedule 7.01(o). To the best knowledge of any Loan Party, no other
party to any such Lease is in default of its obligations thereunder. Except as
set forth on Schedule 7.01(o), no Loan Party (or any other party to any such
Lease) has at any time delivered or received any notice of default which remains
uncured under any such Lease, except in respect of any default occurring as a
result of the filing of the Chapter 11 Cases. As of the Interim Facility
Effective Date, no event has occurred which, with the giving of notice or the
passage of time or both, would constitute a default under any such Lease, except
any such default the enforcement of which is stayed by virtue of the filing of
the Chapter 11 Cases.

               (p) Full Disclosure. To the best knowledge of management of each
Loan Party, (i) all written information (including, without limitation, all
information disclosed in the Parent's public filings with the SEC) and other
materials (other than (x) the projections referred to below and (y) any
discrepancies between (1) the information disclosed in prior public filings by
the Parent with the SEC and (2) the information disclosed by the Parent under
the titled

                                      -74-
<PAGE>
sections set forth in Schedule 1.01(G) hereto of the Annual Report on Form 10-K
for the fiscal year ended December 31, 2004 (the information described in this
clause (2), the "Supplemental Disclosure"), concerning the Loan Parties and
their Subsidiaries (collectively, the "Information") which has been, or is
hereafter, made available by, or on behalf of the Loan Parties when furnished
was, or delivered will be, when considered as a whole, complete and correct in
all material respects and, to the best knowledge of management of the Loan
Parties, does not, or will not when delivered, when taken as a whole, contain
any untrue statement of material fact, or, when taken as a whole, omit to state
a material fact necessary in order to make the statements contained therein not
misleading in light of the circumstances under which such statements has been
made and (ii) all financial projections concerning the Loan Parties and their
Subsidiaries that have been or are hereafter made available to the Lenders were,
or when delivered will be, prepared in good faith on the basis of (A)
assumptions believed by the management of the Loan Parties to be reasonable and
(B) information believed by the management of the Loan Parties to have been
accurate based upon the information available to the management of the Loan
Parties at the time such projections were furnished to the Lenders.

               (q) Intentionally Omitted.

               (r) Environmental Matters. Except as set forth on Schedule
7.01(r), (i) the operations of each Loan Party are in material compliance with
all Environmental Laws; (ii) there has been no Release at any of the properties
owned or operated by any Loan Party or a predecessor in interest, or at any
disposal or treatment facility which received Hazardous Materials generated by
any Loan Party or any predecessor in interest which could reasonably be expected
to have a Material Adverse Effect; (iii) no Environmental Action has been
asserted against any Loan Party or any predecessor in interest nor does any Loan
Party have knowledge or notice of any threatened or pending Environmental Action
against any Loan Party or any predecessor in interest which could reasonably be
expected to have a Material Adverse Effect; (iv) no Environmental Actions have
been asserted against any facilities that may have received Hazardous Materials
generated by any Loan Party or any predecessor in interest which could
reasonably be expected to have a Material Adverse Effect; (v) no property now or
formerly owned or operated by a Loan Party has been used as a treatment or
disposal site for any Hazardous Material other than in material compliance with
Environmental Laws; (vi) no Loan Party has failed to report to the proper
Governmental Authority any Release which is required to be so reported by any
Environmental Laws which could reasonably be expected to have a Material Adverse
Effect; (vii) each Loan Party holds all licenses, permits and approvals required
under any Environmental Laws in connection with the operation of the business
carried on by it, except for such licenses, permits and approvals as to which a
Loan Party's failure to maintain or comply with could not reasonably be expected
to have a Material Adverse Effect; and (viii) no Loan Party has received any
notification pursuant to any Environmental Laws that (A) any work, repairs,
construction or Capital Expenditures are required to be made in respect as a
condition of continued compliance with any Environmental Laws, or any license,
permit or approval issued pursuant thereto or (B) any license, permit or
approval referred to above is about to be reviewed, made, subject to limitations
or conditions, revoked, withdrawn or terminated, in each case, except as could
not reasonably be expected to have a Material Adverse Effect. This Section
7.01(r) contains the sole representations and warranties of the Loan Parties
with regard to matters arising under Environmental Laws.

                                      -75-
<PAGE>
               (s) Insurance. Each Loan Party keeps its property adequately
insured and maintains (i) insurance to such extent and against such risks,
including fire, as is customary with companies in the same or similar
businesses, (ii) workmen's compensation insurance in the amount required by
applicable law, (iii) public liability insurance, which shall include product
liability insurance, in the amount customary with companies in the same or
similar business against claims for personal injury or death on properties
owned, occupied or controlled by it, and (iv) such other insurance as may be
required by law or as may be reasonably required by the Collateral Agent
(including, without limitation, against larceny, embezzlement or other criminal
misappropriation). Schedule 7.01(s) sets forth a list of all insurance
maintained by each Loan Party on the Interim Facility Effective Date.

               (t) Use of Proceeds. The proceeds of the Loans shall be used (i)
in the case of the Loans made on the Interim Facility Effective Date and the
Final Facility Effective Date, (A) to pay for the fees, costs and expenses
incurred in connection with the transactions contemplated hereby and (B) for
general corporate purposes and to fund ongoing working capital requirements of
the Borrowers (including, without limitation, payments of Carve-Out Expenses and
administrative expenses of the kind specified in Section 503(b) of the
Bankruptcy Code incurred in the ordinary course of business of the Borrowers or
otherwise approved by the Bankruptcy Court (and not otherwise prohibited under
this Agreement), subject to the priorities set forth in the definition of
"Agreed Administrative Expense Priorities" herein) and (ii) in the case of Loans
made on the Final Facility Effective Date, to repay the Pre-Petition Obligations
in full. The Letters of Credit will be used for general corporate and working
capital purposes.

               (u) Location of Bank Accounts. Schedule 7.01(u) sets forth a
complete and accurate list as of the Interim Facility Effective Date of all
deposit, checking and other bank accounts, all securities and other accounts
maintained with any broker dealer and all other similar accounts maintained by
each Loan Party, together with a description thereof (i.e., the bank or broker
dealer at which such deposit or other account is maintained and the account
number and the purpose thereof).

               (v) Intellectual Property. Except as set forth on Schedule
7.01(v), each Loan Party owns or licenses or otherwise has the right to use all
licenses, permits, patents, patent applications, trademarks, trademark
applications, service marks, tradenames, copyrights, copyright applications,
franchises, authorizations, non-governmental licenses and permits for
intellectual property rights and other intellectual property rights that are
necessary for the operation of its business, without infringement upon or
conflict with the rights of any other Person with respect thereto, except for
such infringements and conflicts which, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect. Set forth on
Schedule 7.01(v) is a complete and accurate list as of the Interim Facility
Effective Date of all such material licenses, permits, patents, patent
applications, registered trademarks, trademark applications, registered service
marks, tradenames, registered copyrights, and copyright applications of each
Loan Party. No slogan or other advertising device, product, process, method,
substance, part or other material now employed, or now contemplated to be
employed, by any Loan Party infringes upon or conflicts with any rights owned by
any other Person, and no claim or litigation regarding any of the foregoing is
pending or threatened, except for such infringements, conflicts, claims and
litigation which could not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect. To the best knowledge of each Loan
Party, no patent, invention, device,

                                      -76-
<PAGE>
application, principle or any statute, law, rule, regulation, standard or code
is pending or proposed, which, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect.

               (w) Material Contracts. Set forth on Schedule 7.01(w) is a
complete and accurate list as of the Interim Facility Effective Date of all
Material Contracts (other than the Loan Documents) of each Loan Party, showing
the parties and subject matter thereof and amendments and modifications thereto.
Each such Material Contract (i) is in full force and effect and is binding upon
and enforceable against each Loan Party that is a party thereto and, to the best
knowledge of such Loan Party, all other parties thereto in accordance with its
terms (except to the extent that any such Material Contract is terminated by a
Loan Party or any of its Subsidiaries upon a determination by such Person in its
reasonable business judgment that such Material Contract is no longer material
and useful to the conduct of the business of the Parent and its Subsidiaries,
taken as a whole), (ii) has not been otherwise amended or modified (other than
in accordance with Section 8.02(s)), and (iii) is not in default in any material
respect due to the action of any Loan Party or, to the best knowledge of any
Loan Party, any other party thereto, except any such default, the enforcement of
which is stayed by virtue of the filing of the Chapter 11 Cases.

               (x) Holding Company and Investment Company Acts. None of the Loan
Parties is (i) a "holding company" or a "subsidiary company" of a "holding
company" or an "affiliate" of a "holding company", as such terms are defined in
the Public Utility Holding Company Act of 1935, as amended, or (ii) an
"investment company" or an "affiliated person" or "promoter" of, or "principal
underwriter" of or for, an "investment company", as such terms are defined in
the Investment Company Act of 1940, as amended.

               (y) Employee and Labor Matters. Except as could not reasonably be
expected to have a Material Adverse Effect, there is (i) no unfair labor
practice complaint pending or, to the best knowledge of any Loan Party,
threatened against any Loan Party before any Governmental Authority and no
grievance or arbitration proceeding pending or, to the best knowledge of any
Loan Party, threatened against any Loan Party which arises out of or under any
collective bargaining agreement, (ii) no strike, labor dispute, slowdown,
stoppage or similar action or grievance pending or, to the best knowledge of any
Loan Party, threatened against any Loan Party or (iii) to the best knowledge of
any Loan Party, no union representation question existing with respect to the
employees of any Loan Party and no union organizing activity taking place with
respect to any of the employees of any Loan Party. No Loan Party or any of its
ERISA Affiliates has incurred any liability or obligation under the Worker
Adjustment and Retraining Notification Act ("WARN") or similar state law, which
remains unpaid or unsatisfied. The hours worked and payments made to employees
of any Loan Party have not been in violation of the Fair Labor Standards Act or
any other applicable legal requirements, except to the extent such violations
could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect. All material payments due from any Loan Party on
account of wages and employee health and welfare insurance and other benefits
have been paid or accrued as a liability on the books of such Loan Party other
than payments in respect of severance, employment or consulting agreements that
have been rejected by the Loan Parties in the Chapter 11 Cases with the approval
of the Bankruptcy Court.

               (z) [Intentionally Omitted]

                                      -77-
<PAGE>
               (aa) Name; Jurisdiction of Organization; Organizational ID
Number; Chief Place of Business; Chief Executive Office; FEIN. Schedule 7.01(aa)
sets forth a complete and accurate list as of the date hereof of (i) the exact
legal name of each Loan Party, (ii) the jurisdiction of organization of each
Loan Party, (iii) the organizational identification number of each Loan Party
(or indicates that such Loan Party has no organizational identification number),
(iv) each place of business of each Loan Party, (v) the chief executive office
of each Loan Party and (vi) the federal employer identification number of each
Loan Party.

               (bb) Tradenames. Schedule 7.01(bb) hereto sets forth a complete
and accurate list as of the Interim Facility Effective Date of all tradenames,
business names or similar appellations used by each Loan Party or any of its
divisions or other business units during the past five years.

               (cc) Locations of Collateral. There is no location at which any
Loan Party has any Collateral (except for Inventory in transit) other than (i)
those locations listed on Schedule 7.01(cc), (ii) any other locations in the
United States for which such Loan Party has provided notice to the Agents in
accordance with Section 8.01(l) and (iii) any other locations at which any Loan
Party has Collateral with a fair market value of less than $50,000, individually
for any location, and $500,000, for all such locations. Schedule 7.01(cc) hereto
contains a true, correct and complete list, as of the Interim Facility Effective
Date, of the legal names and addresses of each warehouse at which Collateral of
each Loan Party is stored. None of the receipts received by any Loan Party from
any warehouse states that the goods covered thereby are to be delivered to
bearer or to the order of a named Person or to a named Person and such named
Person's assigns.

               (dd) Administrative Priority; Lien Priority.

                    (i) After the Interim Bankruptcy Court Order Entry Date or
the Final Bankruptcy Court Order Entry Date, as the case may be, the Obligations
of the Loan Parties will constitute allowed administrative expenses in the
Chapter 11 Cases, having priority in payment over all other administrative
expenses and unsecured claims against the Loan Parties now existing or hereafter
arising, of any kind or nature whatsoever, including, without limitation, all
administrative expenses of the kind specified in, or arising or ordered under,
Sections 105, 326, 328, 330, 331, 503(b), 506(c), 507(a), 507(b), 546(c), 726
and 1114 of the Bankruptcy Code, subject only to the prior payment of Carve-Out
Expenses to the extent set forth in clause "first" and the Rothschild Success
Fee to the extent set forth in clause "second", in each case, of the definition
of the term "Agreed Administrative Expense Priorities".

                    (ii) Upon entry of the Interim Bankruptcy Court Order or the
Final Bankruptcy Court Order, as the case may be, the Lien and security interest
of the Collateral Agent on the Collateral shall be a valid and perfected first
priority Lien, subject only to Permitted Priority Liens (subject to any action
required under foreign law with respect to the Capital Stock of Foreign
Subsidiaries solely to the extent that such foreign law is applicable).

                    (iii) On or after the Interim Bankruptcy Court Order Entry
Date and prior to the Final Bankruptcy Court Order Entry Date, the Interim
Bankruptcy Court Order is in full force and effect, and has not been reversed,
modified, amended, stayed or vacated absent

                                      -78-
<PAGE>
the written consent of the Agents, the Required Lenders and the Borrowers, and
after the Final Bankruptcy Court Order Entry Date, the Final Bankruptcy Court
Order is in full force and effect, and has not been reversed, modified, amended,
stayed or vacated absent the written consent of the Agents, the Required Lenders
and the Borrowers.

               (ee) Appointment of Trustee or Examiner; Liquidation. No order
has been entered in any Chapter 11 Case (i) for the appointment of a Chapter 11
trustee, (ii) for the appointment of an examiner with enlarged powers (beyond
those set forth in Sections 1106(a)(3) and (4) of the Bankruptcy Code) under
Section 1106(b) of the Bankruptcy Code or (iii) to convert any Chapter 11 Case
to a Chapter 7 case or to dismiss any Chapter 11 Case.

               (ff) FDA Compliance; Notices, etc. Except as set forth in
Schedule 7.01(ff) hereto, each Loan Party and each of its Subsidiaries are, and
the products sold by each Loan Party and each of its Subsidiaries are, in
compliance with all current applicable statutes, rules, regulations, guidelines,
policies, orders or directives administered or issued by the FDA and the Food
and Drug Act, except (i) where in such Person's reasonable opinion, such Person
and its Subsidiaries will not ultimately be found by the FDA or under the Food
and Drug Act to be out of compliance with such statutes, rules, regulations,
guidelines, policies, orders or directives, (ii) where failure to so comply
could not reasonably be expected to have a Material Adverse Effect, or (iii)
with respect to any FDA Form 483-s or warning letters issued by the FDA or
pursuant to the Food and Drug Act (the foregoing, together with any such notices
as any Loan Party or any of its Subsidiaries may at any time hereafter receive,
collectively, the "FDA Notices"), so long as such Person is diligently pursuing
corrective action with respect to the same.

               (gg) Schedules. All of the information which is required to be
scheduled to this Agreement is set forth on the Schedules attached hereto, is
correct and accurate and does not omit to state any information material
thereto.

               (hh) Representations and Warranties in Documents; No Default. All
representations and warranties set forth in this Agreement and the other Loan
Documents are true and correct in all respects at the time as of which such
representations were made and on the Interim Facility Effective Date. No Event
of Default has occurred and is continuing and no condition exists which
constitutes a Default or an Event of Default.

                                  ARTICLE VIII

                          COVENANTS OF THE LOAN PARTIES

          Section 8.01 Affirmative Covenants. So long as any principal of or
interest on any Loan, Letter of Credit Obligation or any other Obligation
(whether or not due) shall remain unpaid or any Lender shall have any Commitment
hereunder, each Loan Party will, unless the Required Lenders shall otherwise
consent in writing:

                                      -79-
<PAGE>
               (a) Reporting Requirements. Furnish to each Agent and, if
requested by any Agent, each Lender:

                    (i) as soon as available and in any event within 45 days
after the end of each fiscal quarter of the Parent and its Subsidiaries
commencing with the first fiscal quarter of the Parent and its Subsidiaries
ending after the Interim Facility Effective Date, either (A) a copy of a report
on Form 10-Q, or any successor form, and any amendments thereto, filed by the
Parent with the SEC with respect to the immediately preceding fiscal quarter or
(B) consolidated and consolidating balance sheets, consolidated and
consolidating statements of operations and retained earnings and consolidated
and consolidating statements of cash flows of the Parent and its Subsidiaries as
at the end of such quarter, and for the period commencing at the end of the
immediately preceding Fiscal Year and ending with the end of such quarter,
setting forth in each case in comparative form the figures for the corresponding
date or period of the immediately preceding Fiscal Year, all in reasonable
detail (and to include, in the case of the consolidated statements of
stockholders' equity and cash flows, revenue and volume data for any products
acquired and/or marketed by a Loan Party or any of its Subsidiaries to the
extent that such product accounts for 7% or more of net revenues of the Parent
and its Subsidiaries on a consolidated basis) by product line (to the extent
available and in any event including profit and loss information by product line
to the gross margin level) and reasonably acceptable to the Collateral Agent and
certified by an Authorized Officer of the Parent as fairly presenting, in all
material respects, the financial position of the Parent and its Subsidiaries as
of the end of such quarter and the results of operations and cash flows of the
Parent and its Subsidiaries for such quarter, in accordance with GAAP applied in
a manner consistent with that of the most recent audited financial statements of
the Parent and its Subsidiaries furnished to the Agents and the Lenders, subject
to the absence of footnotes and normal year-end adjustments;

                    (ii) as soon as available, and in any event within 90 days
after the end of each Fiscal Year of the Parent and its Subsidiaries, commencing
with Fiscal Year ending December 31, 2005, either (A) a copy of a report on Form
10-K, or any successor form, and any amendments thereto, filed by the Parent
with the SEC with respect to the immediately preceding Fiscal Year or (B)
consolidated and consolidating balance sheets, consolidated and consolidating
statements of operations and retained earnings and consolidated and
consolidating statements of cash flows of the Parent and its Subsidiaries as at
the end of such Fiscal Year, setting forth in each case in comparative form the
figures for the corresponding date or period set forth in the financial
statements for the immediately preceding Fiscal Year, all in reasonable detail
and prepared in accordance with GAAP, and accompanied by a report prepared in
accordance with generally accepted auditing standards, of independent certified
public accountants of recognized standing selected by the Parent and reasonably
satisfactory to the Collateral Agent (which opinion shall be without any
qualification or exception as to the scope of such audit);

                    (iii) as soon as available, and in any event within 30 days
after the end of each fiscal month of the Parent and its Subsidiaries commencing
with the first fiscal month of the Parent and its Subsidiaries ending after the
Interim Facility Effective Date, internally prepared consolidated and
consolidating balance sheets, consolidated and consolidating statements of
operations and retained earnings and consolidated and consolidating statements
of cash flows as at the end of such fiscal month, and for the period commencing
at the

                                      -80-
<PAGE>
end of the immediately preceding Fiscal Year and ending with the end of such
fiscal month, all in reasonable detail and certified by an Authorized Officer of
the Parent as fairly presenting, in all material respects, the financial
position of the Parent and its Subsidiaries as at the end of such fiscal month
and the results of operations, retained earnings and cash flows of the Parent
and its Subsidiaries for such fiscal month, in accordance with GAAP applied in a
manner consistent with that of the most recent audited financial statements
furnished to the Agents and the Lenders, subject to the absence of footnotes and
normal year-end adjustments;

                    (iv) simultaneously with the delivery of the financial
statements of the Parent and its Subsidiaries required by clauses (i) and (ii)
of this Section 8.01(a), a certificate of an Authorized Officer of the Parent
(1) stating that such Authorized Officer has reviewed the provisions of this
Agreement and the other Loan Documents and has made or caused to be made under
his or her supervision a review of the condition and operations of the Parent
and its Subsidiaries during the period covered by such financial statements with
a view to determining whether the Parent and its Subsidiaries were in compliance
with all of the provisions of this Agreement and such Loan Documents at the
times such compliance is required hereby and thereby, and that such review has
not disclosed, and such Authorized Officer has no knowledge of, the existence
during such period of an Event of Default or Default or, if an Event of Default
or Default existed, describing the nature and period of existence thereof and
the action which the Parent and its Subsidiaries propose to take or have taken
with respect thereto.

                    (v) (A) as soon as available and in any event within 15 days
after the end of each fiscal month of the Parent and its Subsidiaries commencing
with the first fiscal month of the Parent and its Subsidiaries ending after the
Interim Facility Effective Date, reports in form and detail satisfactory to the
Collateral Agent and certified by an Authorized Officer of the Administrative
Borrower as being accurate and complete (1) listing all Accounts Receivable of
the Loan Parties as of such day (including an aging thereof) and such other
information with respect to such Accounts Receivable as the Collateral Agent may
reasonably request and (2) listing all accounts payable of the Loan Parties as
of each such day (including an aging thereof) and such other information with
respect to such accounts payable as the Collateral Agent may reasonably request,
and

                    (B) as soon as available and in any event within 15 days
after the end of each fiscal quarter of the Parent and its Subsidiaries
commencing with the first fiscal quarter of the Parent and its Subsidiaries
ending after the Interim Facility Effective Date, reports in form and detail
satisfactory to the Collateral Agent and certified by an Authorized Officer of
the Administrative Borrower as being accurate and complete listing all Inventory
of the Loan Parties as of each such day, and containing a breakdown of such
Inventory in a form reasonably satisfactory to the Collateral Agent and such
other information with respect to such Inventory as the Collateral Agent may
reasonably request;

                    (vi) (A) as soon as available and in any event not later
than the end of each Fiscal Year, financial projections, supplementing and
superseding the financial projections referred to in Section 7.01(g)(ii)(B),
prepared on a quarterly basis and otherwise in form and substance reasonably
satisfactory to the Collateral Agent, for the immediately succeeding Fiscal Year
for the Parent and its Subsidiaries, (B) as soon as available and in any event
not later than July 31st of each year, financial projections, supplementing and
superseding

                                      -81-
<PAGE>
the financial projections referred to in Section 7.01(g)(ii)(C), prepared on a
quarterly basis and otherwise in form and substance reasonably satisfactory to
the Collateral Agent, for the remaining six-month period in such Fiscal Year,
(C) as soon as available and in any event not later than the date of the Pharma
Sale, a Long-Term Budget, supplementing and superceding the Long-Term Budget
attached hereto as Schedule 1.01(C), in form consistent with the Long-Term
Budget attached hereto as Schedule 1.01(C) and substance reasonably satisfactory
to the Agents at the time of delivery thereof, for the remainder of the term of
the Agreement, setting forth the cash receipts and disbursements and Revolving
Loan and Letter of Credit projections of the Loan Parties after giving effect to
the Pharma Sale, (D) on Wednesday of each week, commencing with the Wednesday of
the first full week following the Interim Facility Effective Date, a Short-Term
Budget, supplementing and superseding the Short-Term Budget previously delivered
pursuant to this clause (D) for the prior week, showing actual performance and
any variances of actual performance from projected performance, and (E) as soon
as available and in any event within 3 Business Days after the end of each
Budget Period, a reconciliation, in form and substance reasonably satisfactory
to the Agents, of the actual total payments and cash generation/use of the Loan
Parties and the actual maximum aggregate principal amount of Revolving Loans and
Letter of Credit Obligations for such Budget Period to the budgeted line item
amounts set forth in the Long-Term Budget for such Budget Period; all such
financial projections to be prepared in good faith on the basis of (1)
assumptions believed by the management of the Parent to be reasonable and (2)
information believed by the management of the Parent to have been accurate based
upon the information available to the management of the Parent at the time such
projections are furnished to the Agents and the Lenders;

                    (vii) promptly after submission to any Governmental
Authority, to the fullest extent permitted by applicable law, all documents and
information furnished to such Governmental Authority (other than to the extent
that provision of such documents or information to the Agents and the Lenders
would invalidate any privileged status granted by such Governmental Authority
with respect to such documents or information, in which case, the Loan Parties
shall furnish a summary of the documents or information so provided that does
not invalidate such privilege) in connection with any investigation of any Loan
Party other than routine inquiries by such Governmental Authority;

                    (viii) promptly, and in any event within 5 Business Days
after the occurrence of an Event of Default or Default or the occurrence of any
event or development that could reasonably be expected to have a Material
Adverse Effect, the written statement of an Authorized Officer of the
Administrative Borrower setting forth the details of such Event of Default or
Default or other such event or development and the action which the affected
Loan Party proposes to take with respect thereto;

                    (ix) promptly, and in any event within 5 Business Days after
any Loan Party knows or has reason to know of any material violation, claim,
complaint, charge or receipt of any material violation, claim, complaint or
charge of or under the Food and Drug Act or any material applicable statutes,
rules, regulations, guidelines, policies orders or directives administered or
issued by the FDA, including without limitation receipt by any Loan Party or any
of its Subsidiaries of any Product Recall Notice, or any other FDA Notice or
amendment to a previous Product Recall Notice or FDA Notice, a statement of an
Authorized Officer of the Administrative Borrower setting forth the details of
such occurrence and the actions, if any,

                                      -82-
<PAGE>
which such Loan Party proposes to take with respect thereto, and in the case of
a written document evidencing such event, together with a true, correct and
complete copy of such Product Recall Notice, FDA Notice or amendment or other
notice, as the case may be.

                    (x) (A) promptly and in any event within 10 Business Days
after any Loan Party or any ERISA Affiliate thereof knows or has reason to know
that (1) any Reportable Event with respect to any Employee Plan has occurred,
(2) any other Termination Event with respect to any Employee Plan has occurred,
or (3) an accumulated funding deficiency has been incurred or an application has
been made to the Secretary of the Treasury for a waiver or modification of the
minimum funding standard (including installment payments) or an extension of any
amortization period under Section 412 of the Internal Revenue Code with respect
to an Employee Plan, a statement of an Authorized Officer of the Administrative
Borrower setting forth the details of such occurrence and the action, if any,
which such Loan Party or such ERISA Affiliate proposes to take with respect
thereto, (B) promptly and in any event within 10 Business Days after receipt
thereof by any Loan Party or any ERISA Affiliate thereof from the PBGC, copies
of each notice received by any Loan Party or any ERISA Affiliate thereof of the
PBGC's intention to terminate any Plan or to have a trustee appointed to
administer any Plan, (C) promptly and in any event within 10 Business Days after
the filing thereof with the Internal Revenue Service if requested by any Agent,
copies of each Schedule B (Actuarial Information) to the annual report (Form
5500 Series) with respect to each Employee Plan and Multiemployer Plan, (D)
promptly and in any event within 10 Business Days after any Loan Party or any
ERISA Affiliate thereof knows or has reason to know that a required installment
within the meaning of Section 412 of the Internal Revenue Code has not been made
when due with respect to an Employee Plan, (E) promptly and in any event within
10 Business Days after receipt thereof by any Loan Party or any ERISA Affiliate
thereof from a sponsor of a Multiemployer Plan or from the PBGC, a copy of each
notice received by any Loan Party or any ERISA Affiliate thereof concerning the
imposition or amount of withdrawal liability under Section 4202 of ERISA or
indicating that such Multiemployer Plan may enter reorganization status under
Section 4241 of ERISA, and (F) promptly and in any event within 10 Business Days
after any Loan Party or any ERISA Affiliate thereof sends notice of a plant
closing or mass layoff (as defined in WARN) to employees, copies of each such
notice sent by such Loan Party or such ERISA Affiliate thereof;

                    (xi) promptly after the commencement thereof but in any
event not later than 5 Business Days after service of process with respect
thereto on, or the obtaining of knowledge thereof by, any Loan Party, notice of
each action, suit or proceeding before any court or other Governmental Authority
or other regulatory body or any arbitrator which, if adversely determined, could
reasonably be expected to have a Material Adverse Effect;

                    (xii) [Intentionally Omitted]

                    (xiii) promptly, and in any event within 5 Business Days
after execution, receipt or delivery thereof, copies of any material notices
that any Loan Party executes or receives in connection with the sale or other
Disposition of the Capital Stock (other than pursuant to a stock option plan or
stock incentive plan approved by the Board of Directors of the Parent) of, or
all or substantially all of the assets of, any Loan Party;

                                      -83-
<PAGE>
                    (xiv) promptly after the sending or filing thereof, copies
of all statements, reports and other information any Loan Party sends to any
holders of its Indebtedness (other than (A) any statements, reports and other
information any Loan Party sends to any holders of intercompany Indebtedness,
Capitalized Lease Obligations or purchase money Indebtedness and (B) any
statements, reports and other information any Loan Party sends to any holders of
Indebtedness incurred by it prior to the Filing Date and not required to be
delivered to the Agents and the Lenders pursuant to clause (xvii) below) or its
securities or files with the SEC or any national (domestic or foreign)
securities exchange;

                    (xv) promptly upon receipt thereof, copies of all financial
reports (including, without limitation, management letters), if any, submitted
to any Loan Party by its auditors in connection with any annual or interim audit
of the books thereof;

                    (xvi) promptly after the filing thereof, copies of all
pleadings, motions, applications, financial information and other papers and
documents filed by any Loan Party in the Chapter 11 Cases, which papers and
documents shall also be given or served on each Agent's counsel;

                    (xvii) promptly after the sending thereof, copies of all
written reports given by any Loan Party to any official or unofficial creditors'
committee in the Chapter 11 Cases related to the operations, business, assets,
properties or financial condition of the Loan Parties or any of their
Subsidiaries (including, without limitation, audits, appraisals, valuations,
projections and other financial reports) other than any written reports subject
to privilege, provided that such Person may redact any confidential information
contained in any such written report if it provides a summary of the nature of
the information redacted to each Agent; and

                    (xviii) promptly upon request, such other information
concerning the condition or operations, financial or otherwise, of any Loan
Party as any Agent may from time to time may reasonably request.

               (b) Additional Guaranties and Collateral Security. Cause:

                    (i) each Domestic Subsidiary of any Loan Party not in
existence on the Interim Facility Effective Date, to execute and deliver to the
Collateral Agent promptly and in any event within 10 Business Days (or, in the
case of clause (D) below, 15 Business Days) after the formation, acquisition or
change in status thereof (A) a Guaranty guaranteeing the Obligations, (B) a
Security Agreement, (C) if such Subsidiary has any Subsidiaries, a Pledge
Agreement, together with (x) certificates, if any, evidencing all (or, in the
case of a first-tier Foreign Subsidiary of such Subsidiary, 65%) (or such
greater percentage that, due to a change in applicable law after the Interim
Facility Effective Date, (1) could not reasonably be expected to cause the
undistributed earnings of such Foreign Subsidiary as determined for United
States federal income tax purposes to be treated as a deemed dividend to such
Foreign Subsidiary's United States parent or (2) could not reasonably be
expected to cause any material adverse tax consequences) of the issued and
outstanding Capital Stock entitled to vote (within the meaning of Treas. Reg.
Section 1.956-2(c)(2)) and 100% of the issued and outstanding Capital Stock not
entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) of

                                      -84-
<PAGE>
the Capital Stock of any Person owned by such Subsidiary, (y) undated stock
powers executed in blank with signature guaranteed, and (z) such opinion of
counsel and such approving certificate of such Subsidiary as the Collateral
Agent may reasonably request in respect of complying with any legend on any such
certificate or any other matter relating to such shares, (D) one or more
Mortgages creating on any real property of such Subsidiary with a fair market
value in excess of $500,000 (which, in the case of a leasehold interest in real
property, shall be on a commercially reasonable efforts basis), a perfected,
first priority Lien on such real property, a Title Insurance Policy covering
such real property, a current ALTA survey thereof and a surveyor's certificate,
each in form and substance satisfactory to the Collateral Agent, together with
such other agreements, instruments and documents as the Collateral Agent may
reasonably require whether comparable to the documents required under Section
8.01(n) or otherwise, and (E) such other agreements, instruments, approvals,
legal opinions or other documents reasonably requested by the Collateral Agent
in order to create, perfect, establish the first priority of or otherwise
protect any Lien purported to be covered by any such Security Agreement, Pledge
Agreement or Mortgage or otherwise to effect the intent that such Subsidiary
shall become bound by all of the terms, covenants and agreements contained in
the Loan Documents and that substantially all property and assets of such
Subsidiary shall become Collateral for the Obligations; and

                    (ii) each owner of the Capital Stock of any such Domestic
Subsidiary to execute and deliver promptly and in any event within 10 Business
Days after the formation or acquisition of such Subsidiary a Pledge Agreement,
together with (A) certificates evidencing all of the Capital Stock of such
Subsidiary, (B) undated stock powers or other appropriate instruments of
assignment executed in blank with signature guaranteed, (C) such opinion of
counsel and such approving certificate of such Subsidiary as the Collateral
Agent may reasonably request in respect of complying with any legend on any such
certificate or any other matter relating to such shares and (D) such other
agreements, instruments, approvals, legal opinions or other documents reasonably
requested by the Collateral Agent relating to such shares.

               (c) Compliance with Laws, Etc. Comply, and cause each of its
Subsidiaries to comply, with all applicable material laws, rules, regulations
(including, without limitation, the FDA Regulations and the HHS Regulations),
orders, judgments and awards (including any settlement of any claim that, if
breached, could give rise to any of the foregoing), other than (i) any
non-compliance for which no penalty or fine in excess of $250,000 is payable, or
which is being contested in good faith by proper proceedings which stay the
imposition of any penalty, fine or Lien resulting from such non-compliance and
with respect to which adequate reserves have been set aside for the payment of
any penalty or fine arising therefrom in accordance with GAAP, or for which
enforcement action is stayed by virtue of the filing of the Chapter 11 Cases and
(ii) any non-compliance existing on the Filing Date and set forth on Schedule
7.01(h), to the extent that such non-compliance, individually and in the
aggregate, could not reasonably be expected to have a Material Adverse Effect.

               (d) Preservation of Existence, Etc. Maintain and preserve, and
cause each of its Subsidiaries to (i) maintain and preserve, (A) its existence
and (B) its other rights and privileges other than such rights and privileges
the failure to so maintain and preserve could not reasonably be expect to have a
Material Adverse Effect, and (ii) become or remain, and cause each of its
Subsidiaries to become or remain, duly qualified and in good standing in each

                                      -85-
<PAGE>
jurisdiction in which the character of the properties owned or leased by it or
in which the transaction of its business makes such qualification necessary
other than in such jurisdictions where the failure to be so qualified and in
good standing could not reasonably be expected to have a Material Adverse
Effect.

               (e) Keeping of Records and Books of Account. Keep, and cause each
of its Subsidiaries to keep, adequate records and books of account, with
complete entries made to permit the preparation of financial statements in
accordance with GAAP.

               (f) Inspection Rights. Permit, and cause each of its Subsidiaries
to permit, the agents and representatives of any Agent at any time and from time
to time during normal business hours, and, so long as no Default or Event of
Default shall have occurred and be continuing, upon reasonable prior notice and
in a manner that does not materially interfere with the business or operations
of the Loan Parties, to examine and make copies of and abstracts from its
records and books of account, to visit and inspect its properties, to verify
materials, leases, notes, accounts receivable, deposit accounts and its other
assets, to conduct audits, physical counts, valuations, appraisals, Phase I
Environmental Site Assessments (and, if reasonably requested by the Collateral
Agent based upon the results of any such Phase I Environmental Site Assessment,
a Phase II Environmental Site Assessment) or examinations and to discuss its
affairs, finances and accounts with any of its directors, officers, managerial
employees, independent accountants or any of its other representatives. In
furtherance of the foregoing, each Loan Party hereby authorizes its independent
accountants, and the independent accountants of each of its Subsidiaries, to
discuss the affairs, finances and accounts of such Person (independently or
together with representatives of such Person) with the agents and
representatives of any Agent in accordance with this Section 8.01(f).

               (g) Maintenance of Properties, Etc. Maintain and preserve, and
cause each of its Subsidiaries to maintain and preserve, all of its properties
which are material to its business in good working order and condition, ordinary
wear and tear excepted, and comply, and cause each of its Subsidiaries to
comply, at all times with the provisions of all leases material to its business
to which it is a party as lessee or under which it occupies property, so as to
prevent any loss or forfeiture thereof or thereunder, except any non-compliance
resulting in a default, the enforcement of which is stayed by the Chapter 11
Cases.

               (h) Maintenance of Insurance. Maintain, and cause each of its
Subsidiaries to maintain, insurance with responsible and reputable insurance
companies or associations (including, without limitation, comprehensive general
liability, hazard, rent and business interruption insurance) with respect to its
properties (including all real properties leased or owned by it) and business,
in such amounts and covering such risks as is required by any Governmental
Authority having jurisdiction with respect thereto or as is carried generally in
accordance with sound business practice by companies in similar businesses
similarly situated and in any event in amount, adequacy and scope reasonably
satisfactory to the Collateral Agent. All policies covering the Collateral are
to be made payable to the Collateral Agent for the benefit of the Agents, the
L/C Issuer and the Lenders, as its interests may appear, in case of loss, under
a standard non-contributory "lender" or "secured party" clause and are to
contain such other provisions as the Collateral Agent may reasonably require to
fully protect the Lenders' interest in the Collateral and to any payments to be
made under such policies. All certificates of insurance

                                      -86-
<PAGE>
are to be delivered to the Collateral Agent within 10 Business Days after
receipt thereof and the policies are to be premium prepaid, with the loss
payable and additional insured endorsement in favor of the Collateral Agent and
such other Persons as the Collateral Agent may designate from time to time, and
shall provide for not less than 30 days' prior written notice to the Collateral
Agent of the exercise of any right of cancellation. If any Loan Party or any of
its Subsidiaries fails to maintain such insurance, the Collateral Agent may
arrange for such insurance, but at the Borrowers' expense and without any
responsibility on the Collateral Agent's part for obtaining the insurance, the
solvency of the insurance companies, the adequacy of the coverage, or the
collection of claims. Upon the occurrence and during the continuance of an Event
of Default, the Collateral Agent shall have the sole right, in the name of the
Lenders, any Loan Party and its Subsidiaries, to file claims under any insurance
policies, to receive, receipt and give acquittance for any payments that may be
payable thereunder, and to execute any and all endorsements, receipts, releases,
assignments, reassignments or other documents that may be necessary to effect
the collection, compromise or settlement of any claims under any such insurance
policies.

               (i) Obtaining of Permits, Etc. Obtain, maintain and preserve, and
cause each of its Subsidiaries to obtain, maintain and preserve, and take all
necessary action to timely renew, all permits, licenses, authorizations,
approvals, entitlements and accreditations which are necessary or useful in the
proper conduct of its business other than those permits, licenses,
authorizations, approvals, entitlements and accreditations the lack of which
could not reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect.

               (j) Environmental. (i) Keep any property either owned or operated
by it or any of its Subsidiaries free of any Environmental Liens; (ii) comply,
and cause each of its Subsidiaries to comply, in all material respects with
Environmental Laws and provide to the Collateral Agent any documentation of such
compliance which the Collateral Agent may reasonably request; (iii) provide the
Agents written notice within 5 Business Days of any notice of Release of a
Hazardous Material in excess of any reportable quantity from or onto property at
any time owned or operated by it or any of its Subsidiaries and take any
Remedial Actions required to abate said Release; and (iv) provide the Agents
with written notice promptly and in any event within 10 Business Days of the
receipt of any of the following: (A) notice that an Environmental Lien has been
filed against any property of any Loan Party or any of its Subsidiaries; (B)
commencement of any Environmental Action or notice that an Environmental Action
will be filed against any Loan Party or any of its Subsidiaries; and (C) notice
of a violation, citation or other administrative order which could have a
Material Adverse Effect. This Section 8.01(j) and Section 8.02(r) contain the
sole covenants of each Loan Party with regard to matters arising under
Environmental Laws.

               (k) Further Assurances. Subject to the terms of the Bankruptcy
Court Orders and the requirements of the Bankruptcy Court and applicable law,
take such action and execute, acknowledge and deliver, and cause each of its
Subsidiaries to take such action and execute, acknowledge and deliver, at its
sole cost and expense, such agreements, instruments or other documents as any
Agent may reasonably require from time to time in order (i) to carry out more
effectively the purposes of this Agreement and the other Loan Documents, (ii) to
subject to valid and perfected first priority Liens (subject only to Permitted
Liens) any of the Collateral or any other property of any Loan Party and its
Subsidiaries (to the extent consistent with the terms

                                      -87-
<PAGE>
of this Agreement and the other Loan Documents), (iii) to establish and maintain
the validity and effectiveness of any of the Loan Documents and the validity,
perfection and priority of the Liens intended to be created thereby, and (iv) to
better assure, convey, grant, assign, transfer and confirm unto each Agent, each
Lender and the L/C Issuer the rights now or hereafter intended to be granted to
it under this Agreement or any other Loan Document. In furtherance of the
foregoing, to the maximum extent permitted by applicable law and subject to the
terms of the Bankruptcy Court Orders and the requirements of the Bankruptcy
Court, each Loan Party (i) authorizes each Agent to execute any such agreements,
instruments or other documents in such Loan Party's name and to file such
agreements, instruments or other documents in any appropriate filing office,
(ii) authorizes each Agent to file any financing statement required hereunder or
under any other Loan Document, and any continuation statement or amendment with
respect thereto, in any appropriate filing office without the signature of such
Loan Party, and (iii) ratifies the filing of any financing statement, and any
continuation statement or amendment with respect thereto, filed without the
signature of such Loan Party prior to the date hereof. The assurances
contemplated by this Section 8.01(k) shall be given under applicable
non-bankruptcy law (to the extent not inconsistent with the Bankruptcy Code and
the Bankruptcy Court Orders and not in violation of applicable non-bankruptcy
law) as well as the Bankruptcy Code, it being the intention of the parties that
any Agent may request assurances under applicable non-bankruptcy law, and such
request shall be complied with (if otherwise made in good faith by such Agent)
whether or not any of the Bankruptcy Court Orders are in force and whether or
not dismissal of the Chapter 11 Cases or any other action by the Bankruptcy
Court is imminent, likely or threatened.

               (l) Change in Collateral; Collateral Records. (i) Give the
Collateral Agent not less than 10 days' prior written notice of any change in
the location of any Collateral (other than Collateral in transit), other than
with respect to (A) locations set forth on Schedule 7.01(cc) and (B) locations
of any Collateral with an aggregate fair market value of less than $50,000,
individually for any location, and $500,000, for all such locations, (ii) advise
the Collateral Agent promptly, in sufficient detail, of any material adverse
change relating to the type, quantity or quality of the Collateral or the Lien
granted thereon and (iii) execute and deliver, and cause each of its
Subsidiaries to execute and deliver, to the Collateral Agent for the benefit of
the Agents, the L/C Issuer and the Lenders from time to time, solely for the
Collateral Agent's convenience in maintaining a record of Collateral, such
written statements and schedules as the Collateral Agent may reasonably require,
designating, identifying or describing the Collateral.

               (m) Subordination. Cause all Indebtedness now or hereafter owed
by it to any other Loan Party or any of its Subsidiaries to be Subordinated
Indebtedness.

               (n) After Acquired Real Property. Upon the acquisition by it or
any of its Domestic Subsidiaries after the date hereof of any interest (whether
fee or leasehold) in any real property (wherever located) (each such interest
being an "After Acquired Property") (x) with a Current Value (as defined below)
in excess of $250,000 in the case of a fee interest, or (y) requiring the
payment of annual rent exceeding in the aggregate $100,000 in the case of
leasehold interest, promptly so notify the Collateral Agent, setting forth with
specificity a description of the interest acquired, the location of the real
property, any structures or improvements thereon and, in the case of a fee
interest in After Acquired Property, either an

                                      -88-
<PAGE>
appraisal or such Loan Party's good-faith estimate of the current value of such
After Acquired Property (for purposes of this Section, the "Current Value"). The
Collateral Agent shall notify such Loan Party whether it intends to require a
Mortgage and the other documents referred to below or in the case of leasehold,
a leasehold Mortgage. Within 15 Business Days of receipt of such notice
requesting a Mortgage, the Person which has acquired such After Acquired
Property shall furnish to the Collateral Agent the following, each in form and
substance satisfactory to the Collateral Agent: (i) a Mortgage with respect to
such After Acquired Property and related assets located at the After Acquired
Property (which, in the case of a leasehold interest in After Acquired Property,
shall be on a commercially reasonable efforts basis), each duly executed by such
Person and in recordable form; (ii) evidence of the recording of the Mortgage
referred to in clause (i) above in such office or offices as may be necessary
or, in the opinion of the Collateral Agent, desirable to create and perfect a
valid and enforceable first priority lien on the property purported to be
covered thereby or to otherwise protect the rights of the Agents, the L/C Issuer
and the Lenders thereunder, (iii) a Title Insurance Policy, (iv) a survey of
such After Acquired Property, certified to the Collateral Agent and to the
issuer of the Title Insurance Policy by a licensed professional surveyor
reasonably satisfactory to the Collateral Agent, (v) Phase I Environmental Site
Assessments with respect to such After Acquired Property, certified to the
Collateral Agent by a company reasonably satisfactory to the Collateral Agent,
(vi) in the case of a leasehold interest, a certified copy of the lease between
the landlord and such Person with respect to such real property in which such
Person has a leasehold interest, and (vii) such other documents or instruments
(including opinions of counsel) as the Collateral Agent may reasonably require.
The Borrowers shall pay all fees, costs and expenses, including reasonable
attorneys' fees, costs and expenses, and all title insurance charges and
premiums, in connection with each Loan Party's obligations under this Section
8.01(n).

               (o) Fiscal Year. Cause the Fiscal Year of the Parent and its
Subsidiaries to end on December 31st of each calendar year unless the Agents
consent to a change in such Fiscal Year (and appropriate related changes to this
Agreement).

               (p) Payments Current. Make (i) all royalty and other payments due
and payable under each Licensing Agreement prior to the time when the other
party thereto may terminate any such Licensing Agreement and (ii) all deferred
payments when due in connection with any Acquisition, in each case, except for
payments contested in good faith and with respect to which adequate reserves
have been set aside for the payment thereof in accordance with GAAP and payments
with respect to which enforcement action is stayed by virtue of the filing of
the Chapter 11 Cases.

               (q) Retention of Advisors. Continue at all times the retention of
FTI Consulting, Inc. and Rothschild, Inc. pursuant to the agreements between
such financial advisors and the Parent entered into prior to the Filing Date (or
other financial advisors reasonably acceptable to the Collateral Agent).

               (r) Pharma Sale.

                    (i) Within 1 day of the Interim Facility Effective Date,
provide the Agents with a draft motion (the "Sale Procedure Motion") to be filed
with the Bankruptcy Court for approval of a sale procedure reasonably acceptable
to the Agents with respect to the

                                      -89-
<PAGE>
Pharma Sale. The Sale Procedure Motion, and the order approving such procedure
(the "Sale Procedure Order"), shall be in form and substance reasonably
satisfactory to the Agents. Without limiting the generality of the foregoing,
the sale and bidding procedure sought by the Sale Procedure Motion and approved
by the Sale Procedure Order shall expressly provide that the Net Cash Proceeds
of the Pharma Sale shall be paid to the Administrative Agent for the benefit of
the Agents, the Lenders and the L/C Issuer at the close of the Pharma Sale in
accordance with the terms of this Agreement.

                    (ii) Within 5 days of the Interim Facility Effective Date,
file the Sale Procedure Motion with the Bankruptcy Court for approval of the
Pharma Sale.

                    (iii) Within 45 days of the Interim Facility Effective Date
(or such longer period as may otherwise be agreed to in writing by the
Collateral Agent), obtain entry of the Sale Procedure Order approving the Sale
Procedure Motion.

                    (iv) Not later than September 30, 2005, receive the Net Cash
Proceeds of the Pharma Sale.

                    (v) Take all commercially reasonable steps necessary or
desirable to obtain any and all required regulatory and/or third party approvals
for the Pharma Sale.

               (s) Landlord Waivers; Collateral Access Agreements. (i) At any
time any Collateral with a book value in excess of 250,000 (when aggregated
with all other Collateral at the same location) is located on any real property
of a Loan Party (whether such real property is now owned or is acquired after
the Interim Facility Effective Date) which is not owned by a Loan Party, use
commercially reasonable efforts to obtain written subordinations or waivers, in
form and substance reasonably satisfactory to the Collateral Agent, of all
present and future Liens to which the owner or lessor of such premises may be
entitled to assert against the Collateral (it being understood that in the
event the Loan Parties are unable to obtain any such written subordination or
waiver the Administrative Agent shall, at the direction of the Collateral Agent
using its reasonable discretion, establish such reserves against Availability as
the Collateral Agent deems necessary with respect to any such Collateral); and

                    (ii) At any time any Collateral with a book value in excess
of 250,000 (when aggregated with all other Collateral at the same location) is
located on any premises not owned by a Loan Party, use commercially reasonable
efforts to obtain written access agreements, in form and substance reasonably
satisfactory to the Collateral Agent, providing access to Collateral located on
such premises in order to remove such Collateral from such premises during an
Event of Default (it being understood that in the event the Loan Parties are
unable to obtain any such written access agreements, the Administrative Agent
shall, at the direction of the Collateral Agent using its reasonable discretion,
establish such reserves against Availability as the Collateral Agent deems
necessary with respect to any such Collateral).

          Section 8.02 Negative Covenants. So long as any principal of or
interest on any Loan, Letter of Credit Obligation or any other Obligation
(whether or not due) shall remain unpaid or any Lender shall have any Commitment
hereunder, each Loan Party shall not, unless the Required Lenders shall
otherwise consent in writing:

               (a) Liens, Etc. Create, incur, assume or suffer to exist, or
permit any of its Subsidiaries to create, incur, assume or suffer to exist, any
Lien upon or with respect to any of its properties, whether now owned or
hereafter acquired; file or suffer to exist under the Uniform Commercial Code or
any similar law or statute of any jurisdiction, a financing statement (or the
equivalent thereof) that names it or any of its Subsidiaries as debtor; sign or
suffer to exist any security agreement authorizing any secured party thereunder
to file such financing statement (or the equivalent thereof); sell any of its
property or assets subject to an understanding or agreement, contingent or
otherwise, to repurchase such property or assets (including sales of accounts
receivable) with recourse to it or any of its Subsidiaries or assign or
otherwise transfer, or permit any of its Subsidiaries to assign or otherwise
transfer, any account or other right to receive income; other than, as to all of
the above, Permitted Liens. For the avoidance of doubt, this Section 8.02(a)
does not prohibit an assignment or transfer permitted by Section 8.02(c)(ii).

               (b) Indebtedness. Create, incur, assume, guarantee or suffer to
exist, or otherwise become or remain liable with respect to, or permit any of
its Subsidiaries to create, incur, assume, guarantee or suffer to exist or
otherwise become or remain liable with respect to, any Indebtedness other than
Permitted Indebtedness.

               (c) Fundamental Changes; Dispositions. Wind-up, liquidate or
dissolve, or merge, consolidate or amalgamate with any Person, or convey, sell,
lease or

                                      -90-
<PAGE>
sublease, transfer or otherwise dispose of, whether in one transaction or a
series of related transactions, all or any part of its business, property or
assets, whether now owned or hereafter acquired (or agree to do any of the
foregoing), or purchase or otherwise acquire, whether in one transaction or a
series of related transactions, all or substantially all of the assets of any
Person (or any division thereof) (or agree to do any of the foregoing), or
permit any of its Subsidiaries to do any of the foregoing; provided, however,
that

                    (i) (A) any Borrower may be merged into or consolidated
with, or may convey, sell or transfer all of its business, property or assets
to, another Borrower and (B) any direct or indirect wholly-owned Subsidiary of
any Loan Party (other than a Borrower) may be merged into, or may convey, sell
or transfer all of its business, property or assets to, such Loan Party or
another direct or indirect wholly-owned Subsidiary of such Loan Party, or may
consolidate with, or may convey, sell or transfer all of its business, property
or assets to, another direct or indirect wholly-owned Subsidiary of such Loan
Party, or may be liquidated with its assets contributed to such Loan Party or
another direct or indirect wholly-owned Subsidiary of such Loan Party, so long
as (1) no other provision of this Agreement would be violated thereby, (2) such
Loan Party gives the Agents at least 20 days' prior written notice of such
merger or consolidation, (3) no Default or Event of Default shall have occurred
and be continuing either before or after giving effect to such transaction, (4)
the Lenders' rights in any Collateral, including, without limitation, the
existence, perfection and priority of any Lien thereon, are not adversely
affected by such merger or consolidation and (5) if either Subsidiary is a Loan
Party, the surviving Subsidiary, if any, is joined as a Loan Party hereunder and
is a party to a Security Agreement and the Capital Stock of which Subsidiary is
the subject of a Pledge Agreement, in each case, which is in full force and
effect on the date of and immediately after giving effect to such merger or
consolidation;

                    (ii) any Loan Party and its Subsidiaries may (A) sell
Inventory in the ordinary course of business, (B) sell or license intellectual
property, know-how, developed pharmaceutical products, drug delivery
technologies and pharmaceutical product development, research and testing
results in the ordinary course of business, (C) dispose of equipment in the
ordinary course of business, (D) sell, lease, license or otherwise transfer
property or assets to any Loan Party, provided that the Loan Parties shall cause
to be executed and delivered such documents, instruments and certificates in
connection therewith as the Collateral Agent may reasonably request, (E) sell,
lease, license or otherwise transfer property or assets in exchange transactions
in which a Loan Party or any of its Subsidiaries receives consideration with a
fair market value at least equal (as determined by the Parent's board of
directors) to the fair market value of the property or assets sold, leased,
licensed or otherwise transferred, which consideration consists of property or
assets that are used or useful in the same or a similar line of business as the
Loan Parties; provided that (1) if the transferring Person is a Loan Party, a
Loan Party shall be the party receiving the property or assets comprising such
consideration, (2) with respect to the consideration received, the Loan Parties
shall cause to be executed and delivered such documents, instruments and
certificates in connection therewith as the Collateral Agent may reasonably
request, (3) if the property or assets being transferred constitutes Collateral,
the property or assets received as consideration shall also become Collateral in
accordance with Section 8.01(k) and (4) if the property or assets being
transferred in any such transaction has a fair market value in excess of
$500,000, then, prior to the consummation of such transaction, the
Administrative Borrower shall have received the prior consent of the Required
Lenders, (F) sell

                                      -91-
<PAGE>
or otherwise dispose of other property or assets for cash in an aggregate amount
not less than the fair market value of such property or assets, (G) in the case
of any direct or indirect Foreign Subsidiary of any Loan Party, sell, lease,
license or otherwise transfer property or assets to any other direct or indirect
wholly-owned Foreign Subsidiary of any Loan Party, and (H) make Investments
permitted by Section 8.02(e); provided that, in the case of clauses (C) and (F)
above, the Net Cash Proceeds of such Dispositions (x) do not exceed $500,000 in
the aggregate during the term of this Agreement and (y) are paid to the
Administrative Agent for the benefit of the Agents, the L/C Issuer and the
Lenders if required pursuant to the terms of Section 2.05(c)(iii); and

                    (iii) the Borrowers may consummate the Pharma Sale on terms
no less favorable than the terms set forth in the Pharma Purchase Agreement and
otherwise in accordance with the terms of the Sale Procedure Motion and the Sale
Procedure Order, provided that the Net Cash Proceeds received by the Borrowers
as a result thereof are not less than the amount calculated as the "Potential
Net Deal Proceeds" on the schedule entitled "Estimated Sources and Uses of
Proceeds Analysis - Proposed Pharmaceuticals Sales Transaction" provided by the
Borrowers to the Agents on May 8, 2005 (subject to the contingencies described
in Footnote 1 thereto to the extent that such contingencies actually occur).

               (d) Change in Nature of Business. Make, or permit any of its
Subsidiaries to make, any change in the nature of its business as described in
Section 7.01(l).

               (e) Loans, Advances, Investments, Etc. Make or commit or agree to
make any loan, advance, guarantee of obligations, other extension of credit or
capital contributions to, or hold or invest in or commit or agree to hold or
invest in, or purchase or otherwise acquire or commit or agree to purchase or
otherwise acquire any shares of the Capital Stock, bonds, notes, debentures or
other securities of, or make or commit or agree to make any other investment in,
any other Person, or purchase or own any futures contract or otherwise become
liable for the purchase or sale of currency or other commodities at a future
date in the nature of a futures contract, or permit any of its Subsidiaries to
do any of the foregoing, except for: (i) Investments existing on the date
hereof, as set forth on Schedule 8.02(e) hereto, but not any increase in the
amount thereof as set forth in such Schedule or any other modification of the
terms thereof, (ii) loans, advances or other Investments by (A) a Loan Party or
a Foreign Subsidiary to or in a Loan Party, in each case, made in the ordinary
course of business, and (B) a Loan Party to or in the German Subsidiary made in
the ordinary course of business and not exceeding in the aggregate for all Loan
Parties to the German Subsidiary at any one time outstanding $500,000 (excluding
advances of payroll in the ordinary course of business, which advances are
permitted hereunder), (iii) loans and advances by a Loan Party or any of its
Subsidiaries to its officers, directors, employees, agents, customers, suppliers
or manufacturers for moving, entertainment, travel and other expenses in the
ordinary course of business and not exceeding in the aggregate for all Loan
Parties and their Subsidiaries at any one time outstanding (A) prior to the
consummation of the Pharma Sale, $750,000 and (B) thereafter, $350,000, (iv)
Permitted Investments, (v) Investments consisting of Capital Stock, obligations,
securities or other property received by any Loan Party in settlement of
accounts receivable or other Indebtedness (created in the ordinary course of
business) from bankrupt obligors, (vi) Investments consisting of Indebtedness
permitted by Section 8.02(b), and (vii) other Investments by a Loan Party not
permitted under any of clauses (i) through (vi) of this

                                      -92-
<PAGE>
Section 8.02(e) in an aggregate amount for all Loan Parties and their
Subsidiaries not to exceed $500,000 at any time.

               (f) Lease Obligations. Create, incur or suffer to exist, or
permit any of its Subsidiaries to create, incur or suffer to exist, any
obligations as lessee (i) for the payment of rent for any real or personal
property in connection with any sale and leaseback transaction or (ii) for the
payment of rent for any real or personal property under leases or agreements to
lease other than (A) Capitalized Lease Obligations which would not cause the
aggregate amount of all obligations under Capitalized Leases entered into after
the Interim Facility Effective Date owing by all Loan Parties and their
Subsidiaries in any Fiscal Year to exceed the amounts set forth in subsection
(g) of this Section 8.02, and (B) Operating Lease Obligations which would not
cause the aggregate amount of all Operating Lease Obligations owing by all Loan
Parties and their Subsidiaries in any Fiscal Year to exceed $5,000,000.

               (g) Capital Expenditures. Make or commit or agree to make, or
permit any of its Subsidiaries to make or commit or agree to make, any Capital
Expenditure (by purchase made or Capitalized Lease entered into after the Filing
Date) that would cause the aggregate amount of all such Capital Expenditures
arising from purchases made or Capitalized Leases entered into by the Loan
Parties and their Subsidiaries during the period from and after the Filing Date
through each date set forth below to exceed the amount set forth opposite such
date:

<TABLE>
<CAPTION>
 Period Ending       Amount
---------------   ----------
<S>               <C>
August 31, 2005   $2,500,000
May 11, 2006      $5,000,000
</TABLE>

               (h) Restricted Payments. (i) Declare or pay any dividend or other
distribution, direct or indirect, on account of any Capital Stock of any Loan
Party or any of its Subsidiaries, now or hereafter outstanding, (ii) make any
repurchase, redemption, retirement, defeasance, sinking fund or similar payment,
purchase or other acquisition for value, direct or indirect, of any Capital
Stock of any Loan Party or any direct or indirect parent of any Loan Party, now
or hereafter outstanding, (iii) make any payment to retire, or to obtain the
surrender of, any outstanding warrants, options or other rights for the purchase
or acquisition of shares of any class of Capital Stock of any Loan Party, now or
hereafter outstanding, (iv) return any Capital Stock to any shareholders or
other equity holders of any Loan Party or any of its Subsidiaries, or make any
other distribution of property, assets, shares of Capital Stock, warrants,
rights, options, obligations or securities thereto as such or (v) pay any
management fees or any other fees or expenses (including the reimbursement
thereof by any Loan Party or any of its Subsidiaries) pursuant to any
management, consulting or other services agreement (other than employment or
consulting agreements with shareholders or other equity holders of any Loan
Party or any of its Subsidiaries that are approved by the Board of Directors of
the Parent) to any of the shareholders or other equityholders of any Loan Party
or any of its Subsidiaries or other Affiliates, or to any other Subsidiaries or
Affiliates of any Loan Party; provided, however, (A) any Subsidiary of any
Borrower may pay dividends to such Borrower or any wholly-owned

                                      -93-
<PAGE>
Subsidiary of such Borrower and (B) the Parent may pay dividends in the form of
common Capital Stock, provided that, at the election of the Collateral Agent,
which the Collateral Agent may and, upon the direction of the Required Lenders,
shall make by notice to the Administrative Borrower, no such payment shall be
made if an Event of Default shall have occurred and be continuing or would
result from the making of any such payment.

               (i) Federal Reserve Regulations. Permit any Loan or the proceeds
of any Loan under this Agreement to be used for any purpose that would cause
such Loan to be a margin loan under the provisions of Regulation T, U or X of
the Board.

               (j) Transactions with Affiliates. Enter into, renew, extend or be
a party to, or permit any of its Subsidiaries to enter into, renew, extend or be
a party to, any transaction or series of related transactions (including,
without limitation, the purchase, sale, lease, transfer or exchange of property
or assets of any kind or the rendering of services of any kind) with any
Affiliate, except (i) in the ordinary course of business in a manner and to an
extent consistent with past practice and necessary or desirable for the prudent
operation of its business, for fair consideration and on terms no less favorable
to it or its Subsidiaries than would be obtainable in a comparable arm's length
transaction with a Person that is not an Affiliate thereof, (ii) transactions
with another Loan Party, (iii) intercompany transactions among the Loan Parties
and their Subsidiaries expressly permitted by this Agreement, (iv) compensation
and benefits to officers and directors to the extent approved by the Board of
Directors of the Parent (or a committee of independent members thereof), and (v)
the transactions set forth on Schedule 8.02(j).

               (k) Limitations on Dividends and Other Payment Restrictions
Affecting Subsidiaries. Create or otherwise cause, incur, assume, suffer or
permit to exist or become effective any consensual encumbrance or restriction of
any kind on the ability of any Subsidiary of any Loan Party (i) to pay dividends
or to make any other distribution on any shares of Capital Stock of such
Subsidiary owned by any Loan Party or any of its Subsidiaries, (ii) to pay or
prepay or to subordinate any Indebtedness owed to any Loan Party or any of its
Subsidiaries, (iii) to make loans or advances to any Loan Party or any of its
Subsidiaries or (iv) to transfer any of its property or assets to any Loan Party
or any of its Subsidiaries, or permit any of its Subsidiaries to do any of the
foregoing; provided, however, that nothing in any of clauses (i) through (iv) of
this Section 8.02(k) shall prohibit or restrict compliance with:

                    (A) this Agreement and the other Loan Documents;

                    (B) any agreements in effect on the date of this Agreement
and described on Schedule 8.02(k);

                    (C) any applicable law, rule or regulation (including,
without limitation, applicable currency control laws and applicable state
corporate statutes restricting the payment of dividends in certain
circumstances) or order of the Bankruptcy Court;

                    (D) in the case of clause (iv) any agreement setting forth
customary restrictions on the subletting, assignment or transfer of any property
or asset that is a lease, license, conveyance or contract of similar property or
assets; or

                                      -94-
<PAGE>
                    (E) in the case of clause (iv) any agreement, instrument or
other document evidencing a Permitted Lien (or the Indebtedness secured thereby)
from restricting on customary terms the transfer of any property or assets
subject thereto.

               (l) Limitation on Issuance of Capital Stock. Issue or sell or
enter into any agreement or arrangement for the issuance and sale of, or permit
any Subsidiary of the Parent to issue or sell or enter into any agreement or
arrangement for the issuance and sale of any shares of its Capital Stock, any
securities convertible into or exchangeable for its Capital Stock or any
warrants.

               (m) Modifications, Organizational Documents and Certain Other
Agreements; Etc.

                    (i) amend, modify or otherwise change its name, jurisdiction
of organization, organizational identification number or FEIN, except that a
Loan Party may (A) change its name, jurisdiction of organization, organizational
identification number or FEIN in connection with a transaction permitted by
Section 8.02(c) and (B) change its name upon at least 30 days prior written
notice by the Administrative Borrower to the Agents of such change and so long
as, at the time of such written notification, such Person provides any financing
statements or fixture filings necessary to perfect and continue perfected the
Collateral Agent's Liens; or

                    (ii) amend, modify or otherwise change its certificate of
incorporation or bylaws (or other similar organizational documents), including,
without limitation, by the filing or modification of any certificate of
designation, or any agreement or arrangement entered into by it, with respect to
any of its Capital Stock (including any shareholders' agreement), or enter into
any new agreement with respect to any of its Capital Stock, except any such
amendments, modifications or changes or any such new agreements or arrangements
pursuant to this clause (v) that either individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect.

               (n) Investment Company Act of 1940. Engage in any business, enter
into any transaction, use any securities or take any other action or permit any
of its Subsidiaries to do any of the foregoing, that would cause it or any of
its Subsidiaries to become subject to the registration requirements of the
Investment Company Act of 1940, as amended, by virtue of being an "investment
company" or a company "controlled" by an "investment company" not entitled to an
exemption within the meaning of such Act.

               (o) Compromise of Accounts Receivable. Compromise or adjust any
Account Receivable (or extend the time of payment thereof) or grant any
discounts, allowances or credits or permit any of its Subsidiaries to do so
other than (i) as set forth on Schedule 8.02(o) or (ii) in the ordinary course
of its business and consistent with industry practice.

               (p) Properties. Permit any property (other than property with an
aggregate fair market value of less than $500,000) to become a fixture with
respect to real property or to become an accession with respect to other
personal property with respect to which

                                      -95-
<PAGE>
real or personal property the Collateral Agent does not have a valid and
perfected first priority Lien.

               (q) ERISA. (i) Engage, or permit any ERISA Affiliate to engage,
in any transaction described in Section 4069 of ERISA; (ii) engage, or permit
any ERISA Affiliate to engage, in any prohibited transaction described in
Section 406 of ERISA or 4975 of the Internal Revenue Code for which a statutory
or class exemption is not available or a private exemption has not previously
been obtained from the U.S. Department of Labor; (iii) adopt or permit any ERISA
Affiliate to adopt any employee welfare benefit plan within the meaning of
Section 3(1) of ERISA which provides benefits to employees after termination of
employment other than as required by Section 601 of ERISA or applicable law;
(iv) fail to make any contribution or payment to any Multiemployer Plan which it
or any ERISA Affiliate may be required to make under any agreement relating to
such Multiemployer Plan, or any law pertaining thereto; or (v) fail, or permit
any ERISA Affiliate to fail, to pay any required installment or any other
payment required under Section 412 of the Internal Revenue Code on or before the
due date for such installment or other payment.

               (r) Environmental. Permit the use, handling, generation, storage,
treatment, Release or disposal of Hazardous Materials at any property owned or
leased by it or any of its Subsidiaries, except in compliance in all material
respects with Environmental Laws.

               (s) Certain Agreements. Agree to any material amendment or other
material change to or material waiver of any of its rights under the Xanodyne
Agreement, any other Pharma Purchase Agreement or any other Material Contract
that is materially adverse to the Agents, the L/C Issuer and the Lenders.

               (t) Excess Cash. Accumulate or maintain cash in bank accounts (in
excess of checks outstanding against such accounts and amounts necessary to meet
minimum balance requirements), cash equivalents or Permitted Investments of the
Loan Parties and their Subsidiaries in an aggregate amount in excess of
$1,000,000 (excluding amounts deposited into accounts subject to a control
agreement in favor of the Collateral Agent, fiduciary accounts of the Parent or
any of its Subsidiaries and deposit accounts exclusively used for payroll,
payroll taxes and other employee wage and benefit payments to or for the benefit
of a Loan Party's or any of its Subsidiaries' salaried employees) for a period
of more than 3 consecutive Business Days.

               (u) Bankruptcy Court Orders; Administrative Priority; Lien
Priority; Payment of Claims.

                    (i) At any time, seek, consent to or suffer to exist any
reversal, modification, amendment, stay or vacation of any of the Bankruptcy
Court Orders, except for modifications and amendments agreed to by the Agents
and the Required Lenders;

                    (ii) at any time, suffer to exist a priority for any
administrative expense or unsecured claim against any of the Loan Parties (now
existing or hereafter arising of any kind or nature whatsoever, including
without limitation any administrative expenses of the kind specified in, or
arising or ordered under, Sections 105, 326, 328, 330, 331, 503(b), 506(c),

                                      -96-
<PAGE>
507(a), 507(b), 546(c), 726 and 1114 of the Bankruptcy Code equal or superior to
the priority of the Agent and the Lenders in respect of the Obligations, except
as provided in Section 4.05 and for the Carve-Out Expenses having priority of
payment over the Obligations to the extent set forth in clause "first" and the
Rothschild Success Fee to the extent set forth in clause "second", in each case,
of the definition of the term "Agreed Administrative Expense Priorities";

                    (iii) at any time, suffer to exist any Lien on the
Collateral having a priority equal or superior to the Lien in favor of the
Collateral Agent for the benefit of the Agents, the Lenders and the L/C Issuer
in respect of the Collateral, except for Permitted Priority Liens; and

                    (iv) prior to the date on which the Obligations have been
paid in full in cash, the Loan Parties shall not pay any administrative expense
claims except (A) (1) the Priority Professional Expenses then due and payable
and (2) other payments then due and payable to the extent set forth in
sub-clause (i) of clause "first" of the definition of the term "Agreed
Administrative Expense Priorities", (B) the Rothschild Success Fee then due and
payable to the extent set forth in clause "second" of the definition of the term
"Agreed Administrative Expense Priorities", (C) the Obligations then due and
payable hereunder, and (D) Carve-Out Expenses (other than Priority Professional
Expenses) and other administrative expense and professional claims then due and
payable in the ordinary course of the business of the Loan Parties or their
respective Chapter 11 Cases, in each case, to the extent and having the order of
priority set forth in the definition of the term "Agreed Administrative Expense
Priorities". Notwithstanding the order of priority set forth in the definition
of the term "Agreed Administrative Expense Priorities", the Borrowers may pay
the administrative expense and professional claims described in clause (D) of
this Section 8.02(u)(iv) in the ordinary course of the business of the Loan
Parties or their respective Chapter 11 Cases so long as no Event of Default
under this Agreement or a default by any Loan Party in any of its obligations
under any of the Bankruptcy Court Orders shall have occurred and be continuing
either before or after giving effect to such payment.

                    (v) Payments. Make any payment of principal or interest or
otherwise on account of any Indebtedness or trade payable incurred prior to the
Filing Date other than (i) to the Existing Agents and the Existing Lenders in
respect of the Pre-Petition Obligations and (ii) to the Persons and in respect
of the obligations set forth in Schedule 8.02(v), in the case of this clause
(ii), after prior written notice of any payment made pursuant to item 2 or 3 of
Schedule 8.02(v) has been given by the Loan Parties to the Collateral Agent and
subject to the approval of the Bankruptcy Court.

                                   ARTICLE IX

                      MANAGEMENT, COLLECTION AND STATUS OF
                    ACCOUNTS RECEIVABLE AND OTHER COLLATERAL

          Section 9.01 Collection of Accounts Receivable; Management of
Collateral. (a) On or prior to the Interim Facility Effective Date, the Loan
Parties shall assist the Administrative Agent in (i) establishing, and, during
the term of this Agreement, maintaining one or more lockboxes in the name of the
Administrative Agent and identified on Schedule 9.01

                                      -97-
<PAGE>
hereto (collectively, the "Lockboxes") with the financial institutions set forth
on Schedule 9.01 hereto or such other financial institutions selected by the
Loan Parties and acceptable to the Administrative Agent in its sole discretion
(each being referred to as a "Lockbox Bank"), and (ii) establishing, and during
the term of this Agreement, maintaining an account (a "Collection Account" and,
collectively, the "Collection Accounts") in the name of the Administrative Agent
with each Lockbox Bank. The Loan Parties shall irrevocably instruct their
Account Debtors, with respect to Accounts Receivable of the Loan Parties, to
remit all payments to be made by checks or other drafts to the Lockboxes and to
remit all payments to be made by wire transfer or by Automated Clearing House,
Inc. payment as directed by the Administrative Agent and shall instruct each
Lockbox Bank to deposit all amounts received in its Lockbox to the Collection
Account at such Lockbox Bank on the day received or, if such day is not a
Business Day, on the next succeeding Business Day. Until the Administrative
Agent has advised the Loan Parties to the contrary after the occurrence and
during the continuance of an Event of Default, the Loan Parties may and will
enforce, collect and receive all amounts owing on the Accounts Receivable of the
Loan Parties for the Administrative Agent's benefit and on the Administrative
Agent's behalf, but at the Loan Parties' expense; such privilege shall
terminate, at the election of any Agent, upon the occurrence and during the
continuance of an Event of Default. All checks, drafts, notes, money orders,
acceptances, cash and other evidences of Indebtedness received directly by the
Loan Parties from any of their Account Debtors, as proceeds from Accounts
Receivable of the Loan Parties, or as proceeds of any other Collateral, shall be
held by the Loan Parties in trust for the Agents, the L/C Issuer and the Lenders
and upon receipt be deposited by the Loan Parties in original form and no later
than the next Business Day after receipt thereof into a Collection Account. The
Loan Parties shall not commingle such collections with the Loan Parties' own
funds or the funds of any of their Subsidiaries or Affiliates or with the
proceeds of any assets not included in the Collateral. Prior to the occurrence
of an Event of Default, all funds received in the Collection Accounts shall be
processed by the respective Lockbox Banks in accordance with the instructions of
officers or agents of the Borrowers in accordance with prior practice. After the
occurrence and during the continuance of an Event of Default, the Collateral
Agent may give notice to the respective Lockbox Banks that all funds received in
the Collection Account shall be sent by wire transfer or Automated Clearing
House, Inc. payment to the Administrative Agent's Account for application at the
end of each Business Day to reduce the then outstanding Obligations, conditional
upon final payment to the Administrative Agent. No checks, drafts or other
instruments received by the Administrative Agent shall constitute final payment
to the Administrative Agent unless and until such checks, drafts or instruments
have actually been collected.

               (b) After the occurrence and during the continuance of an Event
of Default, the Collateral Agent or its designee may, and at the request of the
Required Lenders, the Collateral Agent shall, send a notice of assignment and/or
notice of the Collateral Agent's security interest to any and all Account
Debtors or third parties holding or otherwise concerned with any of the
Collateral, and thereafter the Collateral Agent or its designee shall have the
sole right to collect the Accounts Receivable and/or take possession of the
Collateral and the books and records relating thereto. The Loan Parties shall
not, without prior written consent of the Collateral Agent, grant any extension
of time of payment of any Account Receivable, compromise or settle any Account
Receivable for less than the full amount thereof, release, in whole or in part,
any Person or property liable for the payment thereof, or allow any credit or

                                      -98-
<PAGE>
discount whatsoever thereon, except, in the absence of a continuing Event of
Default, as permitted by Section 8.02(o).

               (c) Subject to the entry and the terms of the Bankruptcy Court
Orders, each Loan Party hereby appoints the Collateral Agent or its designee on
behalf of the Collateral Agent as the Loan Parties' attorney-in-fact with power
exercisable during the continuance of an Event of Default to endorse any Loan
Party's name upon any notes, acceptances, checks, drafts, money orders or other
evidences of payment relating to the Accounts Receivable, to sign any Loan
Party's name on any invoice or bill of lading relating to any of the Accounts
Receivable, drafts against Account Debtors with respect to Accounts Receivable,
assignments and verifications of Accounts Receivable and notices to Account
Debtors with respect to Accounts Receivable, to send verification of Accounts
Receivable, and to notify the Postal Service authorities to change the address
for delivery of mail addressed to any Loan Party to such address as the
Collateral Agent or such designee may designate and to do all other acts and
things necessary to carry out this Agreement. All acts of said attorney or
designee are hereby ratified and approved, and said attorney or designee shall
not be liable for any acts of omission or commission (other than acts of
omission or commission constituting gross negligence or willful misconduct as
determined by a final judgment of a court of competent jurisdiction), or for any
error of judgment or mistake of fact or law not constituting gross negligence or
willful misconduct as determined by a final judgment of a court of competent
jurisdiction; this power being coupled with an interest is irrevocable until all
of the Loans, Letter of Credit Obligations and other Obligations under the Loan
Documents are paid in full and all of the Loan Documents are terminated.

               (d) Nothing herein contained shall be construed to constitute any
Agent as agent of any Loan Party for any purpose whatsoever, and the Agents
shall not be responsible or liable for any shortage, discrepancy, damage, loss
or destruction of any part of the Collateral wherever the same may be located
and regardless of the cause thereof (other than from acts of omission or
commission constituting gross negligence or willful misconduct as determined by
a final judgment of a court of competent jurisdiction). The Agents shall not,
under any circumstance or in any event whatsoever, have any liability for any
error or omission or delay of any kind occurring in the settlement, collection
or payment of any of the Accounts Receivable or any instrument received in
payment thereof or for any damage resulting therefrom (other than acts of
omission or commission constituting gross negligence or willful misconduct as
determined by a final judgment of a court of competent jurisdiction). The
Agents, by anything herein or in any assignment or otherwise, do not assume any
of the obligations under any contract or agreement assigned to any Agent and
shall not be responsible in any way for the performance by any Loan Party of any
of the terms and conditions thereof.

               (e) If any Account Receivable includes a charge for any tax
payable to any Governmental Authority, each Agent is hereby authorized (but in
no event obligated) in its discretion to pay the amount thereof to the proper
taxing authority for the Loan Parties' account and to charge the Loan Parties
therefor. The Loan Parties shall notify the Agents if any Account Receivable
includes any taxes due to any such Governmental Authority and, in the absence of
such notice, the Agents shall have the right to apply the full proceeds of such
Account Receivable and shall not be liable for any taxes that may be due by
reason of the sale and delivery creating such Account Receivable.

                                      -99-
<PAGE>
               (f) Notwithstanding any other terms set forth in the Loan
Documents, the rights and remedies of the Agents, the L/C Issuer and the Lenders
herein provided, and the obligations of the Loan Parties set forth herein, are
cumulative of, may be exercised singly or concurrently with, and are not
exclusive of, any other rights, remedies or obligations set forth in any other
Loan Document or as provided by law.

          Section 9.02 Accounts Receivable Documentation. The Loan Parties will
at such intervals as the Collateral Agent may reasonably require, execute and
deliver confirmatory written assignments of the Accounts Receivable to the
Agents and furnish such further schedules and/or information as any such Agent
may reasonably require relating to the Accounts Receivable. The items to be
provided under this Section 9.02 are to be in form reasonably satisfactory to
the Collateral Agent and are to be executed and delivered to the Agents from
time to time solely for their convenience in maintaining records of the
Collateral. The Loan Parties' failure to give any of such items to the Agents
shall not affect, terminate, modify or otherwise limit the Collateral Agent's
Lien on the Collateral. The Loan Parties shall not re-date any invoice or sale
or make sales on extended dating beyond that customary in the Loan Parties'
industry, and shall not re-bill any Accounts Receivable, except in the ordinary
course of business, without promptly disclosing the same to the Agents and
providing the Agents with a copy of such re-billing, identifying the same as
such. If the Loan Parties become aware of anything materially detrimental to any
of the Loan Parties' material customers' credit, the Loan Parties will promptly
advise the Agents thereof.

          Section 9.03 Status of Accounts Receivable and Other Collateral. With
respect to Collateral of any Loan Party at the time the Collateral becomes
subject to the Collateral Agent's Lien, each Loan Party covenants, represents
and warrants: (a) such Loan Party shall be the sole owner, free and clear of all
Liens (except for Permitted Liens), and shall be fully authorized to sell,
transfer, pledge and/or grant a security interest in each and every item of said
Collateral; (b) to the best knowledge of any Loan Party, each Account Receivable
with an invoice amount in excess of $250,000 shall be a good and valid account
representing a bona fide indebtedness incurred or an amount owed by the Account
Debtor therein named; (c) none of the transactions underlying or giving rise to
any Account Receivable shall violate any applicable state or federal laws or
regulations, and all documents relating thereto shall be legally sufficient
under such laws or regulations and shall be legally enforceable in accordance
with their terms (subject to applicable bankruptcy, insolvency, moratorium and
similar laws affecting creditor's rights generally); (d) except as set forth on
Schedule 8.02(o), no agreement under which any deduction or offset of any kind,
other than normal trade discounts, may be granted or shall have been made by
such Loan Party at or before the time such Account Receivable is created; (e)
all agreements, instruments and other documents relating to any Account
Receivable shall be true and correct and in all material respects what they
purport to be; (f) such Loan Party shall maintain books and records pertaining
to said Collateral in such detail, form and scope as the Agents shall reasonably
require; (g) such Loan Party shall promptly notify the Collateral Agent if any
Account Receivable with an invoice amount in excess of $250,000 arises out of
contracts with any Governmental Authority, and will execute any instruments and
take any steps required by the Collateral Agent in order that all monies due or
to become due under any such contract shall be assigned to the Collateral Agent
and notice thereof given to such Governmental Authority under the Federal
Assignment of Claims Act or any similar state or local law; (h) such Loan Party
will, immediately upon learning thereof, report to the Agents any material loss
or

                                     -100-
<PAGE>
destruction of, or substantial damage to, any of the Collateral, and any other
matters affecting the value, enforceability or collectibility of any of the
Collateral with a value in excess of $250,000; (i) if any amount payable under
or in connection with any Account Receivable with an invoice amount in excess of
$250,000 is evidenced by a promissory note or other instrument, such promissory
note or instrument shall be immediately pledged, endorsed, assigned and
delivered to the Collateral Agent for the benefit of the Agents, the L/C Issuer
and the Lenders as additional Collateral; (j) such Loan Party shall conduct a
physical count of its Inventory at such intervals as any Agent reasonably may
request (but, absent an Event of Default, not more than 2 times in any 12 month
period during the term of this Agreement) and such Loan Party shall promptly
supply the Agents with a copy of such count accompanied by a report of the value
(based on the lower of cost (on a first in first out basis) and market value) of
such Inventory; and (k) such Loan Party is not and shall not be entitled to
pledge any Agent's or any Lender's credit on any purchases or for any purpose
whatsoever.

          Section 9.04 Collateral Custodian. Upon the occurrence and during the
continuance of any Default or Event of Default, the Collateral Agent or its
designee may at any time and from time to time employ and maintain on the
premises of any Loan Party a custodian selected by the Collateral Agent or its
designee who shall have full authority to do all acts necessary to protect the
Agents' and the Lenders' interests. Each Loan Party hereby agrees to, and to
cause its Subsidiaries to, cooperate with any such custodian and to do whatever
the Collateral Agent or its designee may reasonably request to preserve the
Collateral. All costs and expenses incurred by the Collateral Agent or its
designee by reason of the employment of the custodian shall be the
responsibility of the Borrowers and charged to the Loan Account.

                                   ARTICLE X

                                EVENTS OF DEFAULT

          Section 10.01 Events of Default. If any of the following Events of
Default shall occur and be continuing:

               (a) any Borrower shall fail to pay any principal of or interest
on any Loan, any Collateral Agent Advance, or any fee, indemnity or other amount
payable under this Agreement or any other Loan Document when due (whether by
scheduled maturity, required prepayment, acceleration, demand or otherwise);

               (b) any representation or warranty made or deemed made by or on
behalf of any Loan Party or by any officer of the foregoing under or in
connection with any Loan Document shall have been incorrect in any material
respect when made or deemed made;

               (c) any Loan Party shall:

                    (i) fail to perform or comply with any covenant or agreement
contained in Section 6.04, Section 8.01(a)(vi)(D), Section 8.01(a)(viii),
Section 8.01(a)(xvi), Section 8.01(a)(xvii), Section 8.01(c), Section
8.01(d)(i)(A), Section 8.01(f), Section 8.01(h) (other than with respect to the
delivery of insurance policies thereunder), Section 8.01(o), or Section 8.01(q),
Section 8.01(r), Section 8.02 or ARTICLE IX, or any Loan Party shall fail to

                                     -101-
<PAGE>
perform or comply with any covenant or agreement contained in any Security
Agreement to which it is a party, any Pledge Agreement to which it is a party,
or any Mortgage to which it is a party;

                    (ii) fail to perform or comply with any covenant or
agreement contained in Section 8.01(a) (other than Section 8.01(a)(vi)(D),
Section 8.01(a)(viii), Section 8.01(a)(xvi) and Section 8.01(a)(xvii)), Section
8.01(g), Section 8.01(i), Section 8.01(j), Section 8.01(k), Section 8.01(l),
Section 8.01(n) or Section 8.01(p), and such failure continues for 5 Business
Days; or

                    (iii) fail to perform or comply with any covenant or
agreement contained in Section 8.01(b), Section 8.01(d)(i)(B), Section
8.01(d)(ii), Section 8.01(e), Section 8.01(h) (with respect to the delivery of
insurance policies thereunder), Section 8.01(m) or Section 8.01(s) and such
failure continues for 10 Business Days;

               (d) any Loan Party shall fail to perform or comply with any other
term, covenant or agreement contained in any Loan Document to be performed or
observed by it and, except as set forth in subsections (a), (b) and (c) of this
Section 10.01, such failure continues for 15 Business Days;

               (e) an order with respect to any of the Chapter 11 Cases shall be
entered by the Bankruptcy Court appointing, or any Loan Party shall file an
application for an order with respect to any Chapter 11 Case seeking the
appointment of, (i) a trustee under Section 1104, or (ii) an examiner with
enlarged powers relating to the operation of the business (powers beyond those
set forth in Section 1106(a)(3) and (4) of the Bankruptcy Code) under Section
1106(b) of the Bankruptcy Code;

               (f) an order with respect to any of the Chapter 11 Cases shall be
entered by the Bankruptcy Court converting such Chapter 11 Case to a Chapter 7
case;

               (g) an application shall be made by any Borrower for an order by
the Bankruptcy Court, or an order shall be entered by the Bankruptcy Court,
confirming a plan of reorganization in any of the Chapter 11 Cases which does
not (i) contain a provision for termination of the Total Commitment and payment
in full in cash of all Obligations of the Borrowers hereunder and under the
other Loan Documents and the termination or cash collateralization of the
outstanding Letters of Credit on or before the effective date of such plan or
plans upon entry thereof and (ii) provide for the continuation of the Liens and
security interests granted to the Collateral Agent for the benefit of the
Agents, the Lenders and the L/C Issuer and priorities until such plan effective
date;

               (h) an order shall be entered by the Bankruptcy Court dismissing
any of the Chapter 11 Cases which does not contain a provision for termination
of the Total Commitment, and payment in full in cash of all Obligations of the
Borrowers hereunder and under the other Loan Documents upon entry thereof and
the termination or cash collateralization of the outstanding Letters of Credit;

               (i) an order with respect to any of the Chapter 11 Cases shall be
entered by the Bankruptcy Court without the express prior written consent of the
Agents and the

                                     -102-
<PAGE>
Lenders, (i) to revoke, reverse, stay, modify, supplement or amend any of the
Bankruptcy Court Orders, (ii) to permit any administrative expense or any claim
(now existing or hereafter arising, of any kind or nature whatsoever) to have
administrative priority as to the Loan Parties equal or superior to the priority
of the Agents and the Lenders in respect of the Obligations, except for allowed
administrative expenses to the extent set forth in clause "first" and the
Rothschild Success Fee to the extent set forth in clause "second", in each case,
of the definition of the term "Agreed Administrative Expense Priorities", or
(iii) to grant or permit the grant of a Lien on the Collateral other than a
Permitted Lien;

               (j) an application for any of the orders described in clauses (e)
through (i) above shall be made by a Person other than the Borrowers and such
application is not contested by the Borrowers in good faith and the relief
requested is granted in an order that is not stayed pending appeal;

               (k) an order shall be entered by the Bankruptcy Court that is not
stayed pending appeal granting relief from the automatic stay to any creditor of
any Loan Party with respect to any claim in an amount equal to or exceeding
$500,000 in the aggregate;

               (l) (i) any Loan Party shall attempt to invalidate, reduce or
otherwise impair the Liens or security interests of any Agent and/or the
Lenders, claims or rights against such Person or to subject any Collateral to
assessment pursuant to Section 506(c) of the Bankruptcy Code, (ii) any Lien or
security interest created by this Agreement or the Bankruptcy Court Orders
shall, for any reason, cease to be valid or (iii) any action is commenced by any
Loan Party which contests the validity, perfection or enforceability of any of
the Liens and security interests of any Agent and/or the Lenders created by any
of the Bankruptcy Court Orders, this Agreement, any Mortgage, any Security
Agreement, and any Pledge Agreement or any other security agreement;

               (m) the determination of any Loan Party, whether by vote of such
Person's board of directors or otherwise, to suspend the operation of such
Person's business in the ordinary course, liquidate all or substantially all of
such Person's assets, or to conduct any sales of all or substantially all of
such Person's assets, or the filing of a motion or other application in the
Chapter 11 Cases, seeking authority to do any of the foregoing, in each case,
other than in connection with the Pharma Sale;

               (n) the Bankruptcy Court Orders or any Security Agreement, any
Pledge Agreement, any Mortgage or any other security document, after delivery
thereof pursuant hereto, shall for any reason fail or cease to create a valid,
perfected and first priority Lien (subject to any action required under foreign
law with respect to the Capital Stock of Foreign Subsidiaries solely to the
extent that such foreign law is applicable) in favor of the Collateral Agent for
the benefit of the Agents, the L/C Issuer and the Lenders on any Collateral
purported to be covered thereby, except to the extent permitted by the terms
thereof;

               (o) any provision of any Loan Document shall at any time for any
reason (other than pursuant to the express terms thereof) cease to be valid and
binding on or enforceable against any Loan Party intended to be a party thereto,
or the validity or enforceability thereof shall be contested by any party
thereto, or a proceeding shall be

                                     -103-
<PAGE>
commenced by any Loan Party or any Governmental Authority having jurisdiction
over any of them, other than the US Trustee for the Chapter 11 Cases, seeking to
establish the invalidity or unenforceability thereof, or any Loan Party shall
deny in writing that it has any liability or obligation purported to be created
under any Loan Document;

               (p) except to the extent permitted by the terms of any Loan
Document, any bank (other than any Agent) at which any deposit account, blocked
account, or lockbox account of any Loan Party containing deposits in excess of
$100,000 is maintained shall fail to comply with any of the terms of any deposit
account, blocked account, lockbox account or similar agreement to which such
bank is a party or any securities intermediary, commodity intermediary or other
financial institution at any time in custody, control or possession of any
investment property of any Loan Party shall fail to comply with any of the terms
of any investment property control agreement to which such Person is a party;

               (q) one or more judgments, orders or awards (or any settlement of
any claim that, if breached, could result in a judgment, order or award) for the
payment of money exceeding $500,000 in the aggregate shall be rendered against
any Loan Party or any of its Subsidiaries and remain unsatisfied and either (i)
enforcement proceedings shall have been commenced by any creditor upon any such
judgment, order, award or settlement that have not been stayed by the automatic
stay in the Chapter 11 Cases, or (ii) there shall be a period of 20 consecutive
days after entry thereof during which a stay of enforcement of any such
judgment, order, award or settlement, by reason of a pending appeal or
otherwise, shall not be in effect; provided, however, that any such judgment,
order, award or settlement shall not give rise to an Event of Default under this
subsection (q) if and for so long as (A) the amount of such judgment, order,
award or settlement is covered by a valid and binding policy of insurance
between the defendant and the insurer covering full payment thereof and (B) such
insurer has been notified, and has not disputed the claim made for payment, of
the amount of such judgment, order, award or settlement;

               (r) the Loan Parties and their Subsidiaries are enjoined,
restrained or in any way prevented by the order of any court or any Governmental
Authority from conducting all or any material part of their business, taken as a
whole, for more than fifteen (15) days;

               (s) any material damage to, or loss, theft or destruction of, any
Collateral, whether or not insured, or any strike, lockout, labor dispute,
embargo, condemnation, act of God or public enemy, or other casualty which
causes, for more than fifteen (15) consecutive days, the cessation or
substantial curtailment of revenue producing activities at any facility of any
Loan Party, if any such event or circumstance could reasonably be expected to
have a Material Adverse Effect;

               (t) any cessation of a substantial part of the business (other
than the business of the Pharmaceuticals Division of the Loan Parties as a
result of the Pharma Sale) of the Loan Parties and their Subsidiaries, taken as
a whole, for a period which materially and adversely affects the ability of such
Person to continue its business on a profitable basis;

               (u) the loss, suspension or revocation of, or failure to renew,
any license or permit now held or hereafter acquired by any Loan Party or any of
its Subsidiaries, if

                                     -104-
<PAGE>
such loss, suspension, revocation or failure to renew could reasonably be
expected to have a Material Adverse Effect;

               (v) the indictment of any Loan Party or any of its Subsidiaries
under any criminal statute, or commencement of criminal or civil proceedings
against any Loan Party, pursuant to which statute or proceedings the penalties
or remedies sought or available include forfeiture to any Governmental Authority
of any material portion of the property of the Loan Parties and their
Subsidiaries, taken as whole;

               (w) any Loan Party or any of its ERISA Affiliates shall have made
a complete or partial withdrawal from a Multiemployer Plan, and, as a result of
such complete or partial withdrawal, any Loan Party or any of its ERISA
Affiliates incurs a withdrawal liability in an annual amount exceeding $500,000;
or a Multiemployer Plan enters reorganization status under Section 4241 of
ERISA, and, as a result thereof any Loan Party's or any of its ERISA Affiliates'
annual contribution requirements with respect to such Multiemployer Plan
increases in an annual amount exceeding $500,000;

               (x) any Termination Event with respect to any Employee Plan shall
have occurred, and, 30 days after notice thereof shall have been given to any
Loan Party by any Agent, (i) such Termination Event (if correctable) shall not
have been corrected, and (ii) the then current value of such Employee Plan's
vested benefits exceeds the then current value of assets allocable to such
benefits in such Employee Plan by more than $500,000 (or, in the case of a
Termination Event involving liability under Section 409, 502(i), 502(l), 515,
4062, 4063, 4064, 4069, 4201, 4204 or 4212 of ERISA or Section 4971 or 4975 of
the Internal Revenue Code, the liability is in excess of such amount);

               (y) any Loan Party or any of its Subsidiaries shall be liable for
any Environmental Liabilities and Costs the payment of which could reasonably be
expected to have a Material Adverse Effect;

               (z) any Loan Party or any of its Subsidiaries shall (i) receive a
Product Recall Notice or (ii) fail to be in substantial compliance with the Food
and Drug Act and all current applicable statutes, rules, regulations,
guidelines, policies, orders or directives administered or issued by the FDA, to
the extent that such failure could reasonably be expected to (a) have a Material
Adverse Effect or (b) result in or account for a 10% or greater decrease in the
Parent's and its Subsidiaries' total sales from the preceding Fiscal Year;

               (aa) a Change of Control shall have occurred;

               (bb) an event or development occurs which could reasonably be
expected to have a Material Adverse Effect; or

               (cc) a Material Adverse Deviation shall have occurred;

          then, and in any such event, the Collateral Agent may, and shall at
the request of the Required Lenders, by notice to the Administrative Borrower
and subject to the terms of the Bankruptcy Court Orders, (i) terminate or reduce
all Commitments, whereupon all Commitments shall immediately be so terminated or
reduced, (ii) declare all or any portion of the Loans and

                                     -105-
<PAGE>
Obligations then outstanding to be due and payable, whereupon all or such
portion of the aggregate principal of all Loans and Obligations, all accrued and
unpaid interest thereon, all fees and all other amounts payable under this
Agreement and the other Loan Documents shall become due and payable immediately,
without further order of, or application to, the Bankruptcy Court (except as
otherwise expressly provided in the Bankruptcy Court Orders), presentment,
demand, protest or further notice of any kind, all of which are hereby expressly
waived by each Loan Party and (iii) exercise any and all of its other rights and
remedies under applicable law (including, but not limited to, the Bankruptcy
Code and the Uniform Commercial Code, hereunder and under the other Loan
Documents. Subject to Section 5.04(b), the L/C Issuer may, after the occurrence
and during the continuation of any Event of Default, require the Borrowers to
deposit with the Administrative Agent with respect to each Letter of Credit then
outstanding cash in an amount equal to 110% of the greatest amount for which
such Letter of Credit may be drawn. Such deposits shall be held by the
Administrative Agent as security for, and to provide for the payment of, the
Letter of Credit Obligations.

                                   ARTICLE XI

                                     AGENTS

          Section 11.01 Appointment. (a) Each Lender (and each subsequent maker
of any Loan by its making thereof) hereby irrevocably appoints and authorizes
the Administrative Agent and the Collateral Agent to perform the duties of each
such Agent as set forth in this Agreement including: (i) to receive on behalf of
each Lender any payment of principal of or interest on the Loans outstanding
hereunder and all other amounts accrued hereunder for the account of the Lenders
and paid to such Agent, and, subject to Section 2.02 of this Agreement, to
distribute promptly to each Lender its Pro Rata Share of all payments so
received; (ii) to distribute to each Lender copies of all material notices and
agreements received by such Agent and not required to be delivered to each
Lender pursuant to the terms of this Agreement, provided that the Agents shall
not have any liability to the Lenders for any Agent's inadvertent failure to
distribute any such notices or agreements to the Lenders; (iii) to maintain, in
accordance with its customary business practices, ledgers and records reflecting
the status of the Obligations, the Loans, and related matters and to maintain,
in accordance with its customary business practices, ledgers and records
reflecting the status of the Collateral and related matters; (iv) to execute or
file any and all financing or similar statements or notices, amendments,
renewals, supplements, documents, instruments, proofs of claim, notices and
other written agreements with respect to this Agreement or any other Loan
Document; (v) to make the Loans and Collateral Agent Advances, for such Agent or
on behalf of the applicable Lenders as provided in this Agreement or any other
Loan Document; (vi) to perform, exercise, and enforce any and all other rights
and remedies of the Lenders with respect to the Loan Parties, the Obligations,
or otherwise related to any of same to the extent reasonably incidental to the
exercise by such Agent of the rights and remedies specifically authorized to be
exercised by such Agent by the terms of this Agreement or any other Loan
Document; (vii) to incur and pay such fees necessary or appropriate for the
performance and fulfillment of its functions and powers pursuant to this
Agreement or any other Loan Document; and (viii) subject to Section 11.03 of
this Agreement, to take such action as such Agent deems appropriate on its
behalf to administer the Loans and the Loan Documents and to exercise such other
powers delegated to such Agent by the terms hereof or the other Loan Documents
(including, without limitation, the power to

                                     -106-
<PAGE>
give or to refuse to give notices, waivers, consents, approvals and instructions
and the power to make or to refuse to make determinations and calculations)
together with such powers as are reasonably incidental thereto to carry out the
purposes hereof and thereof. As to any matters not expressly provided for by
this Agreement and the other Loan Documents (including, without limitation,
enforcement or collection of the Loans), the Agents shall not be required to
exercise any discretion or take any action, but shall be required to act or to
refrain from acting (and shall be fully protected in so acting or refraining
from acting) upon the instructions of the Required Lenders, and such
instructions of the Required Lenders shall be binding upon all Lenders and all
makers of Loans; provided, however, that the L/C Issuer shall not be required to
refuse to honor a drawing under any Letter of Credit and the Agents shall not be
required to take any action which, in the reasonable opinion of any Agent,
exposes such Agent to liability or which is contrary to this Agreement or any
other Loan Document or applicable law.

               (b) The L/C Issuer shall act on behalf of the Lenders with
respect to any Letters of Credit issued by it and the documents associated
therewith, and the L/C Issuer shall have all of the benefits and immunities (i)
provided to the Agents in this Article X with respect to any acts taken or
omissions suffered by the L/C Issuer in connection with Letters of Credit issued
by it or proposed to be issued by it and the applications and agreements for
letters of credit pertaining to such Letters of Credit as fully as if the term
"Administrative Agent", "Collateral Agent" or "Agents" as used in this Article
XI and in the definition of "Agent-Related Person" included the L/C Issuer with
respect to such acts or omissions, and (ii) as additionally provided herein with
respect to the L/C Issuer.

          Section 11.02 Nature of Duties. The Agents shall have no duties or
responsibilities except those expressly set forth in this Agreement or in the
other Loan Documents. The duties of the Agents shall be mechanical and
administrative in nature. The Agents shall not have by reason of this Agreement
or any other Loan Document a fiduciary relationship in respect of any Lender.
Nothing in this Agreement or any other Loan Document, express or implied, is
intended to or shall be construed to impose upon the Agents any obligations in
respect of this Agreement or any other Loan Document except as expressly set
forth herein or therein. Each Lender shall make its own independent
investigation of the financial condition and affairs of the Loan Parties in
connection with the making and the continuance of the Loans hereunder and shall
make its own appraisal of the creditworthiness of the Loan Parties and the value
of the Collateral, and the Agents shall have no duty or responsibility, either
initially or on a continuing basis, to provide any Lender with any credit or
other information with respect thereto, whether coming into their possession
before the initial Loan hereunder or at any time or times thereafter, provided
that, upon the reasonable request of a Lender, each Agent shall provide to such
Lender any documents or reports delivered to such Agent by the Loan Parties
pursuant to the terms of this Agreement or any other Loan Document. If any Agent
seeks the consent or approval of the Required Lenders to the taking or
refraining from taking any action hereunder, such Agent shall send notice
thereof to each Lender. Each Agent shall promptly notify each Lender any time
that the Required Lenders have instructed such Agent to act or refrain from
acting pursuant hereto.

          Section 11.03 Rights, Exculpation, Etc. No Agent-Related Person shall
be liable for any action taken or omitted to be taken by them under or in
connection with this Agreement or the other Loan Documents, except for their own
gross negligence or willful

                                     -107-
<PAGE>
misconduct as determined by a final judgment of a court of competent
jurisdiction. Without limiting the generality of the foregoing, the
Agent-Related Persons (i) may treat the payee of any Loan as the owner thereof
until the Collateral Agent receives written notice of the assignment or transfer
thereof, pursuant to Section 12.07 hereof, signed by such payee and in form
satisfactory to the Collateral Agent; (ii) may consult with legal counsel
(including, without limitation, counsel to any Agent or counsel to the Loan
Parties), independent public accountants, and other experts selected by any of
them and shall not be liable for any action taken or omitted to be taken in good
faith by any of them in accordance with the advice of such counsel or experts;
(iii) make no warranty or representation to any Lender and shall not be
responsible to any Lender for any statements, certificates, warranties or
representations made in or in connection with this Agreement or the other Loan
Documents; (iv) shall not have any duty to ascertain or to inquire as to the
performance or observance of any of the terms, covenants or conditions of this
Agreement or the other Loan Documents on the part of any Person, the existence
or possible existence of any Default or Event of Default, or to inspect the
Collateral or other property (including, without limitation, the books and
records) of any Person; (v) shall not be responsible to any Lender for the due
execution, legality, validity, enforceability, genuineness, sufficiency or value
of this Agreement or the other Loan Documents or any other instrument or
document furnished pursuant hereto or thereto; and (vi) shall not be deemed to
have made any representation or warranty regarding the existence, value or
collectibility of the Collateral, the existence, priority or perfection of the
Collateral Agent's Lien thereon, or any certificate prepared by any Loan Party
in connection therewith, nor shall the Agents be responsible or liable to the
Lenders for any failure to monitor or maintain any portion of the Collateral.
The Agent-Related Persons shall not be liable for any apportionment or
distribution of payments made in good faith pursuant to Section 5.04, and if any
such apportionment or distribution is subsequently determined to have been made
in error the sole recourse of any Lender to whom payment was due but not made,
shall be to recover from other Lenders any payment in excess of the amount which
they are determined to be entitled. The Agent-Related Persons may at any time
request instructions from the Lenders with respect to any actions or approvals
which by the terms of this Agreement or of any of the other Loan Documents the
Agent-Related Persons are permitted or required to take or to grant, and if such
instructions are promptly requested, the Agent-Related Persons shall be
absolutely entitled to refrain from taking any action or to withhold any
approval under any of the Loan Documents until they shall have received such
instructions from the Required Lenders. Without limiting the foregoing, no
Lender shall have any right of action whatsoever against any Agent-Related
Person as a result of such Agent-Related Person acting or refraining from acting
under this Agreement or any of the other Loan Documents in accordance with the
instructions of the Required Lenders.

          Section 11.04 Reliance. Each Agent shall be entitled to rely upon any
written notices, statements, certificates, orders or other documents or any
telephone message believed by it in good faith to be genuine and correct and to
have been signed, sent or made by the proper Person, and with respect to all
matters pertaining to this Agreement or any of the other Loan Documents and its
duties hereunder or thereunder, upon advice of counsel selected by it.

          Section 11.05 Indemnification. To the extent that any Agent-Related
Person or the L/C Issuer is not reimbursed and indemnified by any Loan Party,
the Lenders will reimburse and indemnify such Agent-Related Person and the L/C
Issuer from and against any and all liabilities, obligations, losses, damages,
penalties, actions, judgments, suits, costs, expenses,

                                     -108-
<PAGE>
advances or disbursements of any kind or nature whatsoever which may be imposed
on, incurred by, or asserted against such Agent or the L/C Issuer in any way
relating to or arising out of this Agreement or any of the other Loan Documents
or any action taken or omitted by such Agent-Related Person or the L/C Issuer
under this Agreement or any of the other Loan Documents, in proportion to each
Lender's Pro Rata Share, including, without limitation, advances and
disbursements made pursuant to Section 11.08; provided, however, that no Lender
shall be liable for any portion of such liabilities, obligations, losses,
damages, penalties, actions, judgments, suits, costs, expenses, advances or
disbursements for which there has been a final judicial determination that such
liability resulted from such Agent-Related Person's or the L/C Issuer's gross
negligence or willful misconduct. The obligations of the Lenders under this
Section 11.05 shall survive the payment in full of the Loans and the termination
of this Agreement.

          Section 11.06 Agents Individually. With respect to its Pro Rata Share
of the Total Commitment hereunder and the Loans made by it, each Agent shall
have and may exercise the same rights and powers hereunder and is subject to the
same obligations and liabilities as and to the extent set forth herein for any
other Lender or maker of a Loan. The terms "Lenders" or "Required Lenders" or
any similar terms shall, unless the context clearly otherwise indicates, include
each Agent in its individual capacity as a Lender or one of the Required
Lenders. Each Agent and its Affiliates may accept deposits from, lend money to,
and generally engage in any kind of banking, trust or other business with any
Borrower as if it were not acting as an Agent pursuant hereto without any duty
to account to the other Lenders.

          Section 11.07 Successor Agent. (a) Each Agent may resign from the
performance of all its functions and duties hereunder and under the other Loan
Documents at any time by giving at least thirty (30) Business Days' prior
written notice to the Administrative Borrower and each Lender. Such resignation
shall take effect upon the acceptance by a successor Agent of appointment
pursuant to clauses (b) and (c) below or as otherwise provided below. Any
resignation by Bank of America as Administrative Agent shall also constitute its
resignation as L/C Issuer.

               (b) Upon any such notice of resignation, the Required Lenders
shall appoint a successor Agent; provided, that, so long as no Event of Default
shall have occurred and be continuing, if such successor Agent is not the other
Agent hereunder (or any of its Affiliates or Related Funds), such appointment
shall be made with the consent of the Administrative Borrower (which consent
shall not be unreasonably withheld, delayed or conditioned). Upon the acceptance
of any appointment as Agent hereunder by a successor Agent, such successor Agent
shall thereupon succeed to and become vested with all the rights, powers,
privileges and duties of the retiring Agent, and the retiring Agent shall be
discharged from its duties and obligations under this Agreement and the other
Loan Documents. After any Agent's resignation hereunder as an Agent, the
provisions of this ARTICLE XI shall inure to its benefit as to any actions taken
or omitted to be taken by it while it was an Agent under this Agreement and the
other Loan Documents.

               (c) If a successor Agent shall not have been so appointed within
said thirty (30) Business Day period, the retiring Agent, with the consent of
the other Agent shall then appoint a successor Agent who shall serve as an Agent
until such time, if any, as the Required Lenders, with the consent of the other
Agent, appoint a successor Agent as provided above;

                                     -109-
<PAGE>
provided, that, so long as no Event of Default shall have occurred and be
continuing, if such successor Agent is not the other Agent hereunder (or any of
its Affiliates or Related Funds), such appointment shall be made with the
consent of the Administrative Borrower (which consent shall not be unreasonably
withheld, delayed or conditioned).

               (d) In the case of the resignation of the Administrative Agent
from the performance of all its functions and duties hereunder and under the
other Loan Documents, if no successor Administrative Agent accepts appointment
as Administrative Agent within said thirty (30) Business Day period, the
retiring Administrative Agent's resignation shall nevertheless thereupon become
effective and the Collateral Agent shall perform all of the duties of the
Administrative Agent hereunder until such time, if any, as a successor
Administrative Agent is appointed in accordance with this Section 11.07.

          Section 11.08 Collateral Matters.

               (a) The Collateral Agent may from time to time make such
disbursements and advances ("Collateral Agent Advances") which the Collateral
Agent, in its reasonable business judgment, deems necessary or desirable to
preserve, protect, prepare for sale or lease or dispose of the Collateral or any
portion thereof, to enhance the likelihood or maximize the amount of repayment
by the Borrowers of the Loans, Letter of Credit Obligations and other
Obligations or to pay any other amount chargeable to the Borrowers pursuant to
the terms of this Agreement, including, without limitation, fees, costs and
expenses as described in Section 12.04. The Collateral Agent Advances shall be
repayable on demand and be secured by the Collateral and shall bear interest at
a rate per annum equal to the rate of interest then applicable to the Loans,
except that no such Collateral Agent Advance shall be eligible to be a LIBOR
Rate Loan. The Collateral Agent Advances shall constitute Obligations hereunder
which may be charged to the Loan Account in accordance with Section 5.02. The
Collateral Agent shall notify the Administrative Agent, each Lender and the
Administrative Borrower in writing of each such Collateral Agent Advance, which
notice shall include a description of the purpose of such Collateral Agent
Advance. Without limitation to its obligations pursuant to Section 11.05, each
Lender agrees that it shall make available to the Collateral Agent, upon the
Collateral Agent's demand, in Dollars in immediately available funds, the amount
equal to such Lender's Pro Rata Share of each such Collateral Agent Advance. If
such funds are not made available to the Collateral Agent by such Lender, the
Collateral Agent shall be entitled to recover such funds on demand from such
Lender, together with interest thereon for each day from the date such payment
was due until the date such amount is paid to the Collateral Agent, at the
Federal Funds Rate for three Business Days and thereafter at the Reference Rate.

               (b) The Lenders hereby irrevocably authorize the Collateral
Agent, at its option and in its discretion, to release any Lien granted to or
held by the Collateral Agent upon any Collateral upon termination of the Total
Commitment and payment and satisfaction of all Loans, Letter of Credit
Obligations, and all other Obligations which have matured and which the
Collateral Agent has been notified in writing are then due and payable; or
constituting property being sold or disposed of in compliance with the terms of
this Agreement and the other Loan Documents; or constituting property in which
the Loan Parties owned no interest at the time the Lien was granted or at any
time thereafter; or (subject to Section 12.02) if approved, authorized or
ratified in writing by the Required Lenders; or to subordinate any Lien on any

                                     -110-
<PAGE>
property granted to the Collateral Agent to the holder of any Lien on such
property permitted by clauses (e) or (h) of the definition of Permitted Liens.
Upon request by the Collateral Agent at any time, the Lenders will confirm in
writing the Collateral Agent's authority to release particular types or items of
Collateral pursuant to this Section 11.08(b).

               (c) Without in any manner limiting the Collateral Agent's
authority to act without any specific or further authorization or consent by the
Lenders (as set forth in Section 11.08(b)), each Lender agrees to confirm in
writing, upon request by the Collateral Agent, the authority to release
Collateral conferred upon the Collateral Agent under Section 11.08(b). Upon
receipt by the Collateral Agent of confirmation from the Lenders of its
authority to release any particular item or types of Collateral, and upon prior
written request by any Loan Party, the Collateral Agent shall (and is hereby
irrevocably authorized by the Lenders to) execute such documents as may be
necessary to evidence the release of the Liens granted to the Collateral Agent
for the benefit of the Agents, the L/C Issuer and the Lenders upon such
Collateral; provided, however, that (i) the Collateral Agent shall not be
required to execute any such document on terms which, in the Collateral Agent's
reasonable business judgment, would expose the Collateral Agent to liability or
create any obligations or entail any consequence other than the release of such
Liens without recourse or warranty, and (ii) such release shall not in any
manner discharge, affect or impair the Obligations or any Lien upon (or
obligations of any Loan Party in respect of) all interests in the Collateral
retained by any Loan Party.

               (d) The Collateral Agent shall have no obligation whatsoever to
any Lender to assure that the Collateral exists or is owned by the Loan Parties
or is cared for, protected or insured or has been encumbered or that the Lien
granted to the Collateral Agent pursuant to this Agreement or any other Loan
Document has been properly or sufficiently or lawfully created, perfected,
protected or enforced or is entitled to any particular priority, or to exercise
at all or in any particular manner or under any duty of care, disclosure or
fidelity, or to continue exercising, any of the rights, authorities and powers
granted or available to the Collateral Agent in this Section 11.08 or in any
other Loan Document, it being understood and agreed that in respect of the
Collateral, or any act, omission or event related thereto, the Collateral Agent
may act in any manner it may deem appropriate, in its sole discretion, given the
Collateral Agent's own interest in the Collateral as one of the Lenders and that
the Collateral Agent shall have no duty or liability whatsoever to any other
Lender, except as otherwise provided herein.

          Section 11.09 Agency for Perfection. Each Agent and each Lender hereby
appoints each other Agent and each other Lender as agent and bailee for the
purpose of perfecting the security interests in and liens upon the Collateral in
assets which, in accordance with Article 9 of the Uniform Commercial Code, can
be perfected only by possession or control (or where the security interest of a
secured party with possession or control has priority over the security interest
of another secured party) and each Agent and each Lender hereby acknowledges
that it holds possession of or otherwise controls any such Collateral for the
benefit of the Agents, the L/C Issuer and the Lenders as secured party. Should
the Administrative Agent, the L/C Issuer or any Lender obtain possession or
control of any such Collateral, the Administrative Agent, the L/C Issuer or such
Lender shall notify the Collateral Agent thereof, and, promptly upon the
Collateral Agent's request therefor shall deliver possession or control of such
Collateral to the Collateral Agent or in accordance with the Collateral Agent's
instructions. In addition, the

                                     -111-
<PAGE>
Collateral Agent shall also have the power and authority hereunder to appoint
such other sub-agents as may be necessary or required under applicable state law
or otherwise to perform its duties and enforce its rights with respect to the
Collateral and under the Loan Documents. Each Loan Party by its execution and
delivery of this Agreement hereby consents to the foregoing.

          Section 11.10 Senior Subordinated Note Intercreditor Agreement. The
Administrative Agent and each Lender hereby grants to the Collateral Agent all
requisite authority to enter into or otherwise become bound by the Senior
Subordinated Note Intercreditor Agreement and to bind the Administrative Agent
and the Lenders thereto by the Collateral Agent's entering into or otherwise
becoming bound thereby, and no further consent or approval on the part of the
Administrative Agent or any Lender is or will be required in connection with the
performance of the Senior Subordinated Note Intercreditor Agreement.

          Section 11.11 Other Agents; Arrangers and Manager. None of the Lenders
or other Persons identified on the facing page or signature pages of this
Agreement as a "syndication agent," "documentation agent," "co-agent," "book
manager," "lead manager," "arranger," "lead arranger," or "co-arranger" shall
have any right, power, obligation, liability, responsibility or duty under this
Agreement other than, in the case of such Lenders, those applicable to all
Lenders as such. Without limiting the foregoing, none of the Lenders or other
Persons so identified shall have or be deemed to have any fiduciary relationship
with any Lender. Each Lender acknowledges that it has not relied, and will not
rely, on any of the Lenders or other Persons so identified in deciding to enter
into this Agreement or in taking or not taking action hereunder.

                                  ARTICLE XII

                                 MISCELLANEOUS

          Section 12.01 Notices, Etc. All notices and other communications
provided for hereunder shall be in writing and shall be mailed, telecopied or
delivered, if to any Loan Party, at the following address:

          aaiPharma Inc.
          2320 Scientific Park Drive
          Wilmington, North Carolina 28405
          Attention: Chief Financial Officer
          Telephone: 704-254-7000
          Telecopier: 910-815-2387

          with a copy to:

          Robinson, Bradshaw & Hinson, P.A.
          101 North Tryon Street, Suite 1990
          Charlotte, North Carolina 28246
          Attention: Matthew S. Churchill, Esq.
          Telephone: 704-377-2536
          Telecopier: 704-373-3988

                                     -112-
<PAGE>
          if to the Administrative Agent, to it at the following addresses:

          for payments and requests for credit extensions:

          Bank of America, N.A.
          Mail Code: TX1-492-14-12
          90 Main Street, 14th Floor
          Dallas, Texas 75202-3714
          Attention: Stephen Keilers
          Telephone: 214-209-2627
          Telecopier: 214-290-8367

          for copies of executed Assignment and Acceptances:

          Bank of America, N.A.
          Mail Code: NC1-001-15-01
          One Independence Center
          101 North Tryon Street
          Charlotte, North Carolina 28255
          Attention: GCIB Assignment Desk
          Telephone: 704-386-7259
          Telecopier: 704-409-0080

          payment instructions:

          Bank of America, N.A.
          Mail Code: TX1-492-14-12
          90 Main Street, 14th Floor
          Dallas, Texas 75202-3714
          ABA#: 111-000-012
          Account #: 129-100-0883
          Attention: Credit Services / Stephen Keilers
          Ref: aaiPharma

          for all other notices:

          Bank of America, N.A.
          Mail Code: CA5-701-05-19
          1455 Market Street, 5th Floor
          San Francisco, California 94103
          Attention: Annie Cuenco
          Telephone: 415-436-4008
          Telecopier: 415-503-5007

                                     -113-
<PAGE>
          if to the Collateral Agent, to it at the following address:

          Silver Point Finance, LLC
          Two Greenwich Plaza
          Greenwich, Connecticut 06830
          Attention: David Sawyer
          Telephone: 203-542-4206
          Telecopier: 203-542-4306

          with copies to:

          in the case of any Agent:

          Schulte Roth & Zabel LLP
          919 Third Avenue
          New York, New York 10022
          Attention: Frederic L. Ragucci, Esq.
          Telephone: 212-756-2000
          Telecopier: 212-593-5955

          in the case of the Administrative Agent:

          Moore & Van Allen, PLLC
          100 N. Tryon Street, Suite 4700
          Charlotte, North Carolina 28202
          Attention: C. Wayne McKinzie, Esq.
          Telephone: 704-331-1061
          Telecopier: 704-331-1159

          if to the L/C Issuer, to it at the following address:

          Bank of America, N.A.
          Mail Code: CA9-703-19-23
          333 South Beaudry Avenue, 19th Floor
          Los Angeles, California 90017-1466
          Attention: Sandra Leon
          Telephone: 213-345-5231
          Telecopier: 213-345-0265

          with a copy to:

          Moore & Van Allen, PLLC
          100 N. Tryon Street, Suite 4700
          Charlotte, North Carolina 28202
          Attention: C. Wayne McKinzie, Esq.
          Telephone: 704-331-1061
          Telecopier: 704-331-1159

                                     -114-
<PAGE>
          if to any Lender, to it at such address as shall be designated by it
          in a written notice to the other parties complying as to delivery with
          the terms of this Section 12.01

or, as to each party, at such other address as shall be designated by such party
in a written notice to the other parties complying as to delivery with the terms
of this Section 12.01. All such notices and other communications shall be
effective, (i) if mailed, when received or three days after deposited in the
mails, whichever occurs first, (ii) if telecopied, when transmitted and
confirmation received, or (iii) if delivered, upon delivery, except that notices
to any Agent or the L/C Issuer pursuant to ARTICLE II, ARTICLE III or Section
12.07 shall not be effective until received by such Agent or the L/C Issuer, as
the case may be.

Nothing in this Agreement or in any other Loan Document shall be construed to
limit or affect the obligation of the Borrowers or any other Person to serve
upon the Agents and the Lenders in the manner prescribed by the Bankruptcy Code
any pleading or notice required to be given to the Agents and the Lenders
pursuant to the Bankruptcy Code.

          Section 12.02 Amendments, Etc. No amendment or waiver of any provision
of this Agreement, and no consent to any departure by any Loan Party therefrom,
shall in any event be effective unless the same shall be in writing and signed
by the Required Lenders or by the Collateral Agent with the consent of the
Required Lenders, and then such waiver or consent shall be effective only in the
specific instance and for the specific purpose for which given, provided,
however, that no amendment, waiver or consent shall (i) increase the Commitment
of any Lender, reduce the principal of, or interest on, the Loans or Obligations
payable to any Lender (provided that only the consent of the Required Lenders
shall be required to waive the applicability of any post-default increase in
interest rates), reduce the amount of any fee payable for the account of any
Lender, or postpone or extend any date fixed for any scheduled payment of
principal of, or any payment of interest or fees on, the Loans or Letter of
Credit Obligations payable to any Lender, in each case without the written
consent of such Lender, (ii) change the percentage of the Commitments or of the
aggregate unpaid principal amount of the Loans that is required for the Lenders
or any of them to take any action hereunder, (iii) amend the definition of
"Required Lenders", "Pharma Sale" or "Pro Rata Share", (iv) release all or a
substantial portion of the Collateral or subordinate any Lien granted in favor
of the Collateral Agent for the benefit of the Lenders (except as otherwise
provided in this Agreement and the other Loan Documents as in effect on the date
hereof), or release any Borrower or any Guarantor, (v) amend, modify or waive
Section 2.05(c)(iv), Section 2.05(d)(iv), Section 5.04, Section 8.02(c)(iii) or
this Section 12.02 of this Agreement, or (vi) modify, waive, release or
subordinate the superpriority claim status of the Obligations (except as
permitted in this Agreement and the Loan Documents), in each case, without the
written consent of each Lender. Notwithstanding the foregoing (a) no amendment,
waiver or consent shall, unless in writing and signed by an Agent, affect the
rights or duties of such Agent (but not in its capacity as a Lender) under this
Agreement or the other Loan Documents and (b) no amendment, waiver or consent
shall, unless in writing and signed by the L/C Issuer, affect the rights or
duties of the L/C Issuer (but not in its capacity as a Lender) under this
Agreement or the other Loan Documents.

          Section 12.03 No Waiver; Remedies, Etc. No failure on the part of any
Agent, the L/C Issuer or any Lender to exercise, and no delay in exercising, any
right hereunder or

                                     -115-
<PAGE>
under any other Loan Document shall operate as a waiver thereof; nor shall any
single or partial exercise of any right under any Loan Document preclude any
other or further exercise thereof or the exercise of any other right. The rights
and remedies of the Agents, the L/C Issuer and the Lenders provided herein and
in the other Loan Documents are cumulative and are in addition to, and not
exclusive of, any rights or remedies provided by law. The rights of the Agents,
the L/C Issuer and the Lenders under any Loan Document against any party thereto
are not conditional or contingent on any attempt by the Agents, the L/C Issuer
and the Lenders to exercise any of their rights under any other Loan Document
against such party or against any other Person.

          Section 12.04 Expenses; Taxes; Attorneys' Fees. The Borrowers will pay
on demand, all out-of-pocket costs and expenses incurred by or on behalf of each
Agent (and, in the case of clauses (c) through (m) below, each Lender) (other
than the fees and out-of-pocket costs and expenses incurred by Silver Point
prior to the Filing Date in connection with its retention of Capstone Corporate
Recovery LLC, which out-of-pocket costs and expenses shall be paid by the
Borrowers to the extent required by the Fee/Expense Side Letter, dated as of
April 29, 2005, between the Parent and Silver Point), regardless of whether the
transactions contemplated hereby are consummated, including, without limitation,
reasonable out-of-pocket fees, costs, client charges and expenses of counsel for
each Agent (and, in the case of clauses (c) through (m) below, each Lender),
accounting, due diligence, periodic field audits, physical counts, valuations,
investigations, searches and filings, monitoring of assets, appraisals of
Collateral, title searches and reviewing environmental assessments,
miscellaneous disbursements, examination, travel, lodging and meals (it being
understood that, to the extent applicable with respect to visits, audits,
inspections, valuations and field examinations, the limitations set forth in
Section 5.01 shall apply to this Section 12.04), arising from or relating to:
(a) the negotiation, preparation, execution, delivery, performance and
administration of this Agreement and the other Loan Documents (including,
without limitation, the preparation of any additional Loan Documents pursuant to
Section 8.01(b) or the review of any of the agreements, instruments and
documents referred to in Section 8.01(f) and the use of Intralinks or other
similar information transmission systems in connection with the Loan Documents),
(b) any requested amendments, waivers or consents to this Agreement or the other
Loan Documents whether or not such documents become effective or are given, (c)
the preservation and protection of any of the Lenders' rights under this
Agreement or the other Loan Documents, (d) the defense of any claim or action
asserted or brought against any Agent, the L/C Issuer or any Lender by any
Person that arises from or relates to this Agreement, any other Loan Document,
the Agents' or the Lenders' claims against any Loan Party, or any and all
matters in connection therewith, (e) the commencement or defense of, or
intervention in, any court proceeding arising from or related to this Agreement
or any other Loan Document, (f) the filing of any petition, complaint, answer,
motion or other pleading by any Agent, the L/C Issuer or any Lender, or the
taking of any action in respect of the Collateral or other security, in
connection with this Agreement or any other Loan Document, (g) the protection,
collection, lease, sale, taking possession of or liquidation of, any Collateral
or other security in connection with this Agreement or any other Loan Document,
(h) any attempt to enforce any Lien or security interest in any Collateral or
other security in connection with this Agreement or any other Loan Document, (i)
any attempt to collect from any Loan Party, (j) all liabilities and costs
arising from or in connection with the past, present or future operations of any
Loan Party involving any damage to real or personal property or natural
resources or harm or injury alleged to have resulted from any Release of
Hazardous Materials on, upon or into such property, (k) any Environmental
Liabilities and Costs incurred in connection with the

                                     -116-
<PAGE>
investigation, removal, cleanup and/or remediation of any Hazardous Materials
present or arising out of the operations of any facility owned or operated by
any Loan Party, (l) any Environmental Liabilities and Costs incurred in
connection with any Environmental Lien, or (m) the receipt by any Agent, the L/C
Issuer or any Lender of any advice from professionals with respect to any of the
foregoing. Without limitation of the foregoing or any other provision of any
Loan Document: (w) the Borrowers agree to pay all stamp, document, transfer,
recording or filing taxes or fees and similar impositions now or hereafter
determined by any Agent, the L/C Issuer or any Lender to be payable in
connection with this Agreement or any other Loan Document, and the Borrowers
agree to save each Agent and each Lender harmless from and against any and all
present or future claims, liabilities or losses with respect to or resulting
from any omission to pay or delay in paying any such taxes, fees or impositions,
(x) the Borrowers agree to pay all broker fees that may become due in connection
with the transactions contemplated by this Agreement and the other Loan
Documents, (y) the Borrowers agree to pay all fees and reasonable out-of-pocket
expenses incurred by the Collateral Agent after the Filing Date in connection
with its retention of Capstone Corporate Recovery LLC, and (z) if the Borrowers
fail to perform any covenant or agreement contained herein or in any other Loan
Document, any Agent may itself perform or cause performance of such covenant or
agreement, and the expenses of such Agent incurred in connection therewith shall
be reimbursed on demand by the Borrowers.

          Section 12.05 Right of Set-off. Upon the occurrence and during the
continuance of any Event of Default, any Agent, the L/C Issuer or any Lender
may, and is hereby authorized to, at any time and from time to time, without
notice to any Loan Party (any such notice being expressly waived by the Loan
Parties) and to the fullest extent permitted by law, set off and apply any and
all deposits (general or special, time or demand, provisional or final) at any
time held and other Indebtedness at any time owing by such Agent, the L/C Issuer
or such Lender to or for the credit or the account of any Loan Party against any
and all obligations of the Loan Parties either now or hereafter existing under
any Loan Document, irrespective of whether or not such Agent, the L/C Issuer or
such Lender shall have made any demand hereunder or thereunder and although such
obligations may be contingent or unmatured. Each Agent and each Lender agrees to
notify such Loan Party promptly after any such set-off and application made by
such Agent, the L/C Issuer or such Lender provided that the failure to give such
notice shall not affect the validity of such set-off and application. The rights
of the Agents, the L/C Issuer and the Lenders under this Section 12.05 are in
addition to the other rights and remedies (including other rights of set-off)
which the Agents, the L/C Issuer and the Lenders may have under this Agreement
or any other Loan Documents of law or otherwise.

          Section 12.06 Severability. Any provision of this Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining portions hereof or affecting the validity or
enforceability of such provision in any other jurisdiction.

          Section 12.07 Assignments and Participations.

               (a) This Agreement and the other Loan Documents shall be binding
upon and inure to the benefit of each Loan Party and each Agent and each Lender
and their respective successors and assigns (including, except for the right to
request Loans, any trustee

                                     -117-
<PAGE>
succeeding to the rights of the Loan Parties pursuant to Chapter 11 of the
Bankruptcy Code or pursuant to any conversion to a case under Chapter 7 of the
Bankruptcy Code); provided, however, that none of the Loan Parties may assign or
transfer any of its rights hereunder without the prior written consent of each
Lender and any such assignment without the Lenders' prior written consent shall
be null and void.

               (b) Each Lender may assign to one or more other lenders or other
entities all or a portion of its rights and obligations under this Agreement
(including, without limitation, all or a portion of its Commitments, the Loans
made by it and its Pro Rata Share of Letter of Credit Obligations); provided,
however, that (i) such assignment is in an amount which is at least $5,000,000
or a multiple of $1,000,000 in excess thereof (or the remainder of such Lender's
Commitment) (except such minimum amount shall not apply to an assignment by a
Lender to (x) an Affiliate of such Lender or a Related Fund of such Lender or
(y) a group of new Lenders, each of whom is an Affiliate or Related Fund of each
other to the extent the aggregate amount to be assigned to all such new Lenders
is at least $5,000,000 or a multiple of $1,000,000 in excess thereof), (ii) the
parties to each such assignment shall execute and deliver to the Collateral
Agent (and, in the case of an assignment by a Lender of all or a portion of its
Revolving Credit Commitment and its Revolving Loans, the Administrative Agent),
for its acceptance, an Assignment and Acceptance, together with any promissory
note subject to such assignment and such parties shall deliver to the Collateral
Agent a processing and recordation fee of $5,000 (except the payment of such fee
shall not be required in connection with an assignment by a Lender to an
Affiliate of such Lender or Related Fund of such Lender), (iii) except as
provided in Section 12.07(b)(iv), any such assignment shall be made with the
written consent of (x) in the case of an assignment by a Lender to one or more
other lenders or other entities of all or a portion of its Term Loan Commitment
and the Term Loan made by it, the Collateral Agent and (y) in the case of an
assignment by a Lender to one or more other lenders or other entities of all or
a portion of its Revolving Credit Commitment and the Revolving Loans made by it,
each Agent, in each case, which consent shall not be unreasonably withheld, and
(iv) no written consent of any Agent shall be required in connection with any
assignment by a Lender to an Affiliate of such Lender or a Related Fund of such
Lender. Upon such execution, delivery and acceptance, from and after the
effective date specified in each Assignment and Acceptance, which effective date
shall be at least three Business Days after the delivery thereof to the
Collateral Agent (and the Administrative Agent, if applicable) (or such shorter
period as shall be agreed to by the Collateral Agent (and the Administrative
Agent, if applicable) and the parties to such assignment), (A) the assignee
thereunder shall become a "Lender" hereunder and, in addition to the rights and
obligations hereunder held by it immediately prior to such effective date, have
the rights and obligations hereunder that have been assigned to it pursuant to
such Assignment and Acceptance and (B) the assigning Lender thereunder shall, to
the extent that rights and obligations hereunder have been assigned by it
pursuant to such Assignment and Acceptance, relinquish its rights and be
released from its obligations under this Agreement (and, in the case of an
Assignment and Acceptance covering all or the remaining portion of an assigning
Lender's rights and obligations under this Agreement, such Lender shall cease to
be a party hereto). The Collateral Agent shall provide to the Administrative
Agent and the Parent a copy of any Assignment and Acceptance accepted by it
under this Section 12.07(b). Notwithstanding anything contained to the contrary
in this Section 12.07(b) or any Assignment and Acceptance, the Administrative
Agent shall not be required to recognize any assignee lender as a Lender under
this Agreement until the second Business Day following the date of its receipt

                                     -118-
<PAGE>
of a copy of such Assignment and Acceptance from the Collateral Agent in
accordance with Section 12.01. Notwithstanding anything contained to the
contrary in this Section 12.07(b), a Lender may assign any or all of its rights
under the Loan Documents to an Affiliate of such Lender or a Related Fund of
such Lender without delivering an Assignment and Acceptance to the Collateral
Agent (and the Administrative Agent, if applicable); provided, that (x) the
Borrowers and the Agents may continue to deal solely and directly with such
assigning Lender in connection with the interest so assigned until such Lender
and its assignee shall have executed and delivered an Assignment and Acceptance
to the Collateral Agent (and the Administrative Agent, if applicable) for
recordation and (y) the failure of such assigning Lender to deliver an
Assignment and Acceptance to the Collateral Agent (and the Administrative Agent,
if applicable) or any other Person shall not affect the legality, validity or
binding effect of such assignment.

               (c) By executing and delivering an Assignment and Acceptance, the
assigning Lender and the assignee thereunder confirm to and agree with each
other and the other parties hereto as follows: (i) other than as provided in
such Assignment and Acceptance, the assigning Lender makes no representation or
warranty and assumes no responsibility with respect to any statements,
warranties or representations made in or in connection with this Agreement or
any other Loan Document or the execution, legality, validity, enforceability,
genuineness, sufficiency or value of this Agreement or any other Loan Document
furnished pursuant hereto; (ii) the assigning Lender makes no representation or
warranty and assumes no responsibility with respect to the financial condition
of any Loan Party or any of its Subsidiaries or the performance or observance by
any Loan Party of any of its obligations under this Agreement or any other Loan
Document furnished pursuant hereto; (iii) such assignee confirms that it has
received a copy of this Agreement and the other Loan Documents, together with
such other documents and information it has deemed appropriate to make its own
credit analysis and decision to enter into such Assignment and Acceptance; (iv)
such assignee will, independently and without reliance upon the assigning
Lender, any Agent or any Lender and based on such documents and information as
it shall deem appropriate at the time, continue to make its own credit decisions
in taking or not taking action under this Agreement and the other Loan
Documents; (v) such assignee appoints and authorizes the Agents to take such
action as agents on its behalf and to exercise such powers under this Agreement
and the other Loan Documents as are delegated to the Agents by the terms hereof
and thereof, together with such powers as are reasonably incidental hereto and
thereto; and (vi) such assignee agrees that it will perform in accordance with
their terms all of the obligations which by the terms of this Agreement and the
other Loan Documents are required to be performed by it as a Lender.

               (d) The Collateral Agent shall, on behalf of the Borrowers,
maintain, or cause to be maintained at the Payment Office, a copy of each
Assignment and Acceptance delivered to and accepted by it and a register (the
"Register") for the recordation of the names and addresses of the Lenders and
the Commitments of, and principal amount of the Loans (the "Registered Loans")
and Letter of Credit Obligations owing to each Lender from time to time. Other
than in connection with an assignment by a Lender to an Affiliate of such Lender
or a Related Fund of such Lender, the entries in the Register shall be
conclusive and binding for all purposes, absent manifest error, and the
Borrowers, the Agents and the Lenders shall treat each Person whose name is
recorded in the Register as a Lender hereunder for all purposes of this
Agreement. The Register shall be available for inspection by the Administrative
Borrower and

                                     -119-
<PAGE>
any Lender at any reasonable time and from time to time upon reasonable prior
notice. In the case of any assignment by a Lender to an Affiliate of such Lender
or a Related Fund of such Lender, and which assignment is not recorded in the
Register, the assigning Lender shall maintain a comparable register.

               (e) Upon its receipt of an Assignment and Acceptance executed by
an assigning Lender and an assignee, together with any promissory notes subject
to such assignment, the Collateral Agent shall, if the Collateral Agent (and the
Administrative Agent, if applicable) consents to such assignment and if such
Assignment and Acceptance has been completed (i) accept such Assignment and
Acceptance and (ii) record the information contained therein in the Register.

               (f) A Registered Loan (and the registered note, if any,
evidencing the same) may be assigned or sold in whole or in part only by
registration of such assignment or sale on the Register (and each registered
note shall expressly so provide). Any assignment or sale of all or part of such
Registered Loan (and the registered note, if any, evidencing the same) may be
effected only by registration of such assignment or sale on the Register,
together with the surrender of the registered note, if any, evidencing the same
duly endorsed by (or accompanied by a written instrument of assignment or sale
duly executed by) the holder of such registered note, whereupon, at the request
of the designated assignee(s) or transferee(s), one or more new registered notes
in the same aggregate principal amount shall be issued to the designated
assignee(s) or transferee(s). Prior to the registration of assignment or sale of
any Registered Loan (and the registered note, if any, evidencing the same), the
Agents shall treat the Person in whose name such Registered Loan (and the
registered note, if any, evidencing the same) is registered as the owner thereof
for the purpose of receiving all payments thereon and for all other purposes,
notwithstanding notice to the contrary.

               (g) In the event that any Lender sells participations in a
Registered Loan, such Lender shall maintain a register on which it enters the
name of all participants in the Registered Loans held by it (the "Participant
Register"). A Registered Loan (and the registered note, if any, evidencing the
same) may be participated in whole or in part only by registration of such
participation on the Participant Register (and each registered note shall
expressly so provide). Any participation of such Registered Loan (and the
registered note, if any, evidencing the same) may be effected only by the
registration of such participation on the Participant Register.

               (h) Any foreign Person who purchases or is assigned or
participates in any portion of such Registered Loan shall comply with Section
2.08(d).

               (i) Each Lender may sell participations to one or more banks or
other entities in or to all or a portion of its rights and obligations under
this Agreement and the other Loan Documents (including, without limitation, all
or a portion of its Commitments, the Loans made by it and its Pro Rata Share of
the Letter of Credit Obligations); provided, that (i) such Lender's obligations
under this Agreement (including without limitation, its Commitments hereunder)
and the other Loan Documents shall remain unchanged; (ii) such Lender shall
remain solely responsible to the other parties hereto for the performance of
such obligations, and the Borrowers, the Agents and the other Lenders shall
continue to deal solely and directly with such

                                     -120-
<PAGE>
Lender in connection with such Lender's rights and obligations under this
Agreement and the other Loan Documents; and (iii) a participant shall not be
entitled to require such Lender to take or omit to take any action hereunder
except (A) action directly effecting an extension of the maturity dates or
decrease in the principal amount of the Loans or Letter of Credit Obligations,
(B) action directly effecting an extension of the due dates or a decrease in the
rate of interest payable on the Loans or the fees payable under this Agreement,
or (C) actions directly effecting a release of all or a substantial portion of
the Collateral or any Loan Party (except as set forth in Section 11.08 of this
Agreement or any other Loan Document). The Loan Parties agree that each
participant shall be entitled to the benefits of Section 2.08 and Section 5.05
of this Agreement with respect to its participation in any portion of the
Commitments and the Loans as if it was a Lender.

               (j) In the event (i) any Lender delivers to the Administrative
Borrower any notice in accordance with Section 2.08(c), Section 2.09(d), or
Section 5.05(b), (ii) any Lender defaults in its obligations to fund a Revolving
Loan pursuant to this Agreement, or (iii) any Lender (a "Non-Consenting Lender")
refuses to consent to an amendment, modification or waiver of this Agreement
that, pursuant to Section 12.02, requires the consent of all of the Lenders or
all of the Lenders directly affected thereby, then, provided that no Default or
Event of Default has occurred and is continuing at such time, the Borrowers may,
at their own expense (such expense to include any transfer fee payable to the
Collateral Agent under Section 12.07(b) ), require such Lender to transfer and
assign in whole or in part, without recourse (in accordance with and subject to
the terms and conditions of Section 12.07), all or part of its interests, rights
and obligations under this Agreement to any assignee which shall assume such
assigned obligations, provided that (A) such assignee shall be acceptable to the
Collateral Agent (and in the case of an assignment of a Revolving Credit
Commitment or Revolving Loans, the Administrative Agent), (B) such assignment
shall not conflict with any law, rule or regulation or order of any court or
other Governmental Authority, (C) the Borrowers or such assignee shall have paid
to the assigning Lender in immediately available funds the principal of and
interest accrued to the date of such payment on the Loans made by it hereunder
and all other amounts owed to it hereunder (including, without limitation, any
amounts owing pursuant to Section 2.09(d), or Section 5.05(b)) and (D) in the
event such Lender is a Non-Consenting Lender, each assignee shall consent, at
the time of such assignment, to each matter in respect of which such Lender was
a Non-Consenting Lender and the Borrowers also require each other Lender that is
a Non-Consenting Lender to assign its interests, rights and obligations under
this.

          Section 12.08 Counterparts. This Agreement may be executed in any
number of counterparts and by different parties hereto in separate counterparts,
each of which shall be deemed to be an original, but all of which taken together
shall constitute one and the same agreement. Delivery of an executed counterpart
of this Agreement by telecopier or electronic transmission shall be equally as
effective as delivery of an original executed counterpart of this Agreement. Any
party delivering an executed counterpart of this Agreement by telecopier or
electronic transmission also shall deliver an original executed counterpart of
this Agreement but the failure to deliver an original executed counterpart shall
not affect the validity, enforceability, and binding effect of this Agreement.
The foregoing shall apply to each other Loan Document mutatis mutandis.

                                     -121-
<PAGE>
          Section 12.09 GOVERNING LAW. THIS AGREEMENT AND THE OTHER LOAN
DOCUMENTS (UNLESS EXPRESSLY PROVIDED TO THE CONTRARY IN ANOTHER LOAN DOCUMENT IN
RESPECT OF SUCH OTHER LOAN DOCUMENT) SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE
AND TO BE PERFORMED IN THE STATE OF NEW YORK, EXCEPT AS GOVERNED BY THE
BANKRUPTCY CODE.

          Section 12.10 CONSENT TO JURISDICTION; SERVICE OF PROCESS AND VENUE.
ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN
DOCUMENT SHALL BE BROUGHT IN THE BANKRUPTCY COURT, AND, BY EXECUTION AND
DELIVERY OF THIS AGREEMENT, EACH LOAN PARTY HEREBY IRREVOCABLY ACCEPTS IN
RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE JURISDICTION OF THE
BANKRUPTCY COURT. EACH LOAN PARTY HEREBY IRREVOCABLY CONSENTS TO THE SERVICE OF
PROCESS OUT OF THE BANKRUPTCY COURT AND IN ANY SUCH ACTION OR PROCEEDING BY THE
MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO
THE ADMINISTRATIVE BORROWER AT ITS ADDRESS FOR NOTICES AS SET FORTH IN SECTION
12.01. THE LOAN PARTIES AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR
PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY
SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING HEREIN
SHALL AFFECT THE RIGHT OF THE AGENTS, THE L/C ISSUER AND THE LENDERS TO SERVICE
OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO COMMENCE LEGAL PROCEEDINGS
OR OTHERWISE PROCEED AGAINST ANY LOAN PARTY IN ANY OTHER JURISDICTION. EACH LOAN
PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED
BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE JURISDICTION OR
LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN SUCH COURT AND ANY CLAIM THAT
ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT
THAT ANY LOAN PARTY HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION
OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE,
ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH
RESPECT TO ITSELF OR ITS PROPERTY, EACH LOAN PARTY HEREBY IRREVOCABLY WAIVES
SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS AGREEMENT AND THE OTHER
LOAN DOCUMENTS.

          Section 12.11 WAIVER OF JURY TRIAL, ETC. EACH LOAN PARTY, EACH AGENT
AND EACH LENDER HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION,
PROCEEDING OR COUNTERCLAIM CONCERNING ANY RIGHTS UNDER THIS AGREEMENT OR THE
OTHER LOAN DOCUMENTS, OR UNDER ANY AMENDMENT, WAIVER, CONSENT, INSTRUMENT,
DOCUMENT OR OTHER AGREEMENT DELIVERED OR WHICH IN THE FUTURE MAY BE DELIVERED IN
CONNECTION THEREWITH, OR ARISING FROM ANY FINANCING RELATIONSHIP EXISTING IN
CONNECTION WITH THIS AGREEMENT, AND AGREES THAT ANY

                                     -122-
<PAGE>
SUCH ACTION, PROCEEDINGS OR COUNTERCLAIM SHALL BE TRIED BEFORE A COURT AND NOT
BEFORE A JURY. EACH LOAN PARTY CERTIFIES THAT NO OFFICER, REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY AGENT, THE L/C ISSUER OR ANY LENDER HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT ANY AGENT, THE L/C ISSUER OR ANY LENDER WOULD NOT,
IN THE EVENT OF ANY ACTION, PROCEEDING OR COUNTERCLAIM, SEEK TO ENFORCE THE
FOREGOING WAIVERS. EACH LOAN PARTY HEREBY ACKNOWLEDGES THAT THIS PROVISION IS A
MATERIAL INDUCEMENT FOR THE AGENTS, THE L/C ISSUER AND THE LENDERS ENTERING INTO
THIS AGREEMENT.

          Section 12.12 Consent by the Agents, the L/C Issuer and Lenders.
Except as otherwise expressly set forth herein or in any other Loan Document to
the contrary, if the consent, approval, satisfaction, determination, judgment,
acceptance or similar action (an "Action") of any Agent, the L/C Issuer or any
Lender shall be permitted or required pursuant to any provision hereof or any
provision of any other agreement to which any Loan Party is a party and to which
any Agent, the L/C Issuer or any Lender has succeeded thereto, such Action shall
be required to be in writing and may be withheld or denied by such Agent, the
L/C Issuer or such Lender, in its sole discretion, with or without any reason,
and without being subject to question or challenge on the grounds that such
Action was not taken in good faith.

          Section 12.13 No Party Deemed Drafter. Each of the parties hereto
agrees that no party hereto shall be deemed to be the drafter of this Agreement.

          Section 12.14 Reinstatement; Certain Payments. If any claim is ever
made upon any Agent, any Lender or the L/C Issuer for repayment or recovery of
any amount or amounts received by such Agent, such Lender or the L/C Issuer in
payment or on account of any of the Obligations, such Agent, such Lender or the
L/C Issuer shall give prompt notice of such claim to each other Agent and Lender
and the Administrative Borrower, and if such Agent, such Lender or the L/C
Issuer repays all or part of such amount by reason of (i) any judgment, decree
or order of any court or administrative body having jurisdiction over such
Agent, such Lender or the L/C Issuer or any of its property, or (ii) any good
faith settlement or compromise of any such claim effected by such Agent, such
Lender or the L/C Issuer with any such claimant, then and in such event each
Loan Party agrees that (A) any such judgment, decree, order, settlement or
compromise shall be binding upon it notwithstanding the cancellation of any
Indebtedness hereunder or under the other Loan Documents or the termination of
this Agreement or the other Loan Documents, and (B) it shall be and remain
liable to such Agent, such Lender or the L/C Issuer hereunder for the amount so
repaid or recovered to the same extent as if such amount had never originally
been received by such Agent, such Lender or the L/C Issuer.

          Section 12.15 Indemnification.

               (a) General Indemnity. In addition to each Loan Party's other
Obligations under this Agreement, each Loan Party agrees to, jointly and
severally, defend, protect, indemnify and hold harmless each Agent, each Lender
and the L/C Issuer and all of their respective officers, directors, employees,
attorneys, consultants and agents (collectively called the "Indemnitees") from
and against any and all losses, damages, liabilities, obligations, penalties,
fees, reasonable costs and expenses (including, without limitation, reasonable

                                     -123-
<PAGE>
attorneys' fees, costs and expenses) incurred by such Indemnitees, whether prior
to or from and after the Interim Facility Effective Date, whether direct,
indirect or consequential, as a result of or arising from or relating to or in
connection with any of the following: (i) the negotiation, preparation,
execution or performance or enforcement of this Agreement, any other Loan
Document or of any other document executed in connection with the transactions
contemplated by this Agreement, (ii) any Agent's or any Lender's furnishing of
funds to the Borrowers or the L/C Issuer's issuing of Letters of Credit for the
account of the Borrowers under this Agreement or the other Loan Documents,
including, without limitation, the management of any such Loans, or the Letter
of Credit Obligations, (iii) any matter relating to the financing transactions
contemplated by this Agreement or the other Loan Documents or by any document
executed in connection with the transactions contemplated by this Agreement or
the other Loan Documents, or (iv) any claim, litigation, investigation or
proceeding relating to any of the foregoing, whether or not any Indemnitee is a
party thereto (collectively, the "Indemnified Matters"); provided, however, that
the Loan Parties shall not have any obligation to any Indemnitee under this
subsection (a) for any Indemnified Matter caused by the gross negligence or
willful misconduct of such Indemnitee, as determined by a final judgment of a
court of competent jurisdiction.

               (b) Environmental Indemnity. Without limiting Section 12.15(a)
hereof, each Loan Party agrees to, jointly and severally, defend, indemnify, and
hold harmless the Indemnitees against any and all Environmental Liabilities and
Costs, arising out of (i) any Releases or threatened Releases (x) at any
property presently or formerly owned or operated by any Loan Party or any
Subsidiary of any Loan Party, or any predecessor in interest, or (y) of any
Hazardous Materials generated and disposed of by any Loan Party or any
Subsidiary of any Loan Party, or any predecessor in interest; (ii) any
violations of Environmental Laws; (iii) any Environmental Action relating to any
Loan Party or any Subsidiary of any Loan Party, or any predecessor in interest;
(iv) any personal injury (including wrongful death) or property damage (real or
personal) arising out of exposure to Hazardous Materials used, handled,
generated, transported or disposed by any Loan Party or any Subsidiary of any
Loan Party, or any predecessor in interest; and (v) any breach of any warranty
or representation regarding environmental matters made by the Loan Parties in
Section 7.01(r) or the breach of any covenant made by the Loan Parties in
Section 8.01(j). Notwithstanding the foregoing, the Loan Parties shall not have
any obligation to any Indemnitee under this subsection (b) regarding any
potential environmental matter covered hereunder which is caused by the gross
negligence or willful misconduct of such Indemnitee, as determined by a final
judgment of a court of competent jurisdiction.

               (c) The indemnification for all of the foregoing losses, damages,
fees, costs and expenses of the Indemnitees are chargeable against the Loan
Account. To the extent that the undertaking to indemnify, pay and hold harmless
set forth in this Section 12.15 may be unenforceable because it is violative of
any law or public policy, each Loan Party shall, jointly and severally,
contribute the maximum portion which it is permitted to pay and satisfy under
applicable law, to the payment and satisfaction of all Indemnified Matters
incurred by the Indemnitees. The indemnities set forth in this Section 12.15
shall survive the repayment of the Obligations and discharge of any Liens
granted under the Loan Documents.

          Section 12.16 Parent as Agent for Borrowers. Each Borrower hereby
irrevocably appoints Parent as the borrowing agent and attorney-in-fact for the
Borrowers (the

                                     -124-
<PAGE>
"Administrative Borrower") which appointment shall remain in full force and
effect unless and until the Agents shall have received prior written notice
signed by all of the Borrowers that such appointment has been revoked and that
another Borrower has been appointed Administrative Borrower. Each Borrower
hereby irrevocably appoints and authorizes the Administrative Borrower (i) to
provide to the Agents and receive from the Agents all notices with respect to
Loans obtained for the benefit of any Borrower and all other notices and
instructions under this Agreement and (ii) to take such action as the
Administrative Borrower deems appropriate on its behalf to obtain Loans and to
exercise such other powers as are reasonably incidental thereto to carry out the
purposes of this Agreement. It is understood that the handling of the Loan
Account and Collateral of the Borrowers in a combined fashion, as more fully set
forth herein, is done solely as an accommodation to the Borrowers in order to
utilize the collective borrowing powers of the Borrowers in the most efficient
and economical manner and at their request, and that neither the Agents, the L/C
Issuer nor the Lenders shall incur liability to the Borrowers as a result
hereof. Each of the Borrowers expects to derive benefit, directly or indirectly,
from the handling of the Loan Account and the Collateral in a combined fashion
since the successful operation of each Borrower is dependent on the continued
successful performance of the integrated group. To induce the Agents, the L/C
Issuer and the Lenders to do so, and in consideration thereof, each of the
Borrowers hereby jointly and severally agrees to indemnify the Indemnitees and
hold the Indemnitees harmless against any and all liability, expense, loss or
claim of damage or injury, made against such Indemnitee by any of the Borrowers
or by any third party whosoever, arising from or incurred by reason of (a) the
handling of the Loan Account and Collateral of the Borrowers as herein provided,
(b) the Agents, the L/C Issuer and the Lenders relying on any instructions of
the Administrative Borrower, or (c) any other action taken by any Agent, the L/C
Issuer or any Lender hereunder or under the other Loan Documents.
Notwithstanding the foregoing, the Loan Parties shall not have any obligation to
any Indemnitee under this Section 12.16 for any liability, expense, loss or
claim of damage or injury which is caused by the gross negligence or willful
misconduct of such Indemnitee, as determined by a final judgment of a court of
competent jurisdiction.

          Section 12.17 Records. The unpaid principal of and interest on the
Loans, the interest rate or rates applicable to such unpaid principal and
interest, the duration of such applicability, the Commitments, and the accrued
and unpaid fees payable pursuant to Section 2.06 hereof, including, without
limitation, the Letter of Credit Fee, the Unused Line Fee and the fees set forth
in the Fee Letter, shall at all times be ascertained from the records of the
Agents, which shall be conclusive and binding absent manifest error.

          Section 12.18 Binding Effect. This Agreement shall become effective
when it shall have been executed by each Loan Party, each Agent, the L/C Issuer
and each Lender and when the conditions precedent set forth in Section 6.01
hereof have been satisfied or waived in writing by the Agents, and thereafter
shall be binding upon and inure to the benefit of each Loan Party, each Agent,
the L/C Issuer and each Lender, and their respective successors and assigns
(including, except for the right to request Loans, any trustee succeeding to the
rights of the Loan Parties pursuant to Chapter 11 of the Bankruptcy Code or
pursuant to any conversion to a case under Chapter 7 of the Bankruptcy Code),
except that the Loan Parties shall not have the right to assign their rights
hereunder or any interest herein without the prior written consent of the
Agents, the L/C Issuer and each Lender, and any assignment by any Lender shall
be governed by Section 12.07 hereof.

                                     -125-
<PAGE>
          Section 12.19 Interest. It is the intention of the parties hereto that
each Agent and each Lender shall conform strictly to usury laws applicable to
it. Accordingly, if the transactions contemplated hereby or by any other Loan
Document would be usurious as to any Agent, the L/C Issuer or any Lender under
laws applicable to it (including the laws of the United States of America and
the State of New York or any other jurisdiction whose laws may be mandatorily
applicable to such Agent, the L/C Issuer or such Lender notwithstanding the
other provisions of this Agreement), then, in that event, notwithstanding
anything to the contrary in this Agreement or any other Loan Document or any
agreement entered into in connection with or as security for the Obligations, it
is agreed as follows: (i) the aggregate of all consideration which constitutes
interest under law applicable to any Agent, the L/C Issuer or any Lender that is
contracted for, taken, reserved, charged or received by such Agent, the L/C
Issuer or such Lender under this Agreement or any other Loan Document or
agreements or otherwise in connection with the Obligations shall under no
circumstances exceed the maximum amount allowed by such applicable law, any
excess shall be canceled automatically and if theretofore paid shall be credited
by such Agent, the L/C Issuer or such Lender on the principal amount of the
Obligations (or, to the extent that the principal amount of the Obligations
shall have been or would thereby be paid in full, refunded by such Agent, the
L/C Issuer or such Lender, as applicable, to the Borrowers); and (ii) in the
event that the maturity of the Obligations is accelerated by reason of any Event
of Default under this Agreement or otherwise, or in the event of any required or
permitted prepayment, then such consideration that constitutes interest under
law applicable to any Agent, the L/C Issuer or any Lender may never include more
than the maximum amount allowed by such applicable law, and excess interest, if
any, provided for in this Agreement or otherwise shall be canceled automatically
by such Agent, the L/C Issuer or such Lender, as applicable, as of the date of
such acceleration or prepayment and, if theretofore paid, shall be credited by
such Agent, the L/C Issuer or such Lender, as applicable, on the principal
amount of the Obligations (or, to the extent that the principal amount of the
Obligations shall have been or would thereby be paid in full, refunded by such
Agent, the L/C Issuer or such Lender to the Borrowers). All sums paid or agreed
to be paid to any Agent, the L/C Issuer or any Lender for the use, forbearance
or detention of sums due hereunder shall, to the extent permitted by law
applicable to such Agent, the L/C Issuer or such Lender, be amortized, prorated,
allocated and spread throughout the full term of the Loans until payment in full
so that the rate or amount of interest on account of any Loans hereunder does
not exceed the maximum amount allowed by such applicable law. If at any time and
from time to time (x) the amount of interest payable to any Agent, the L/C
Issuer or any Lender on any date shall be computed at the Highest Lawful Rate
applicable to such Agent, the L/C Issuer or such Lender pursuant to this Section
12.19 and (y) in respect of any subsequent interest computation period the
amount of interest otherwise payable to such Agent, the L/C Issuer or such
Lender would be less than the amount of interest payable to such Agent, the L/C
Issuer or such Lender computed at the Highest Lawful Rate applicable to such
Agent, the L/C Issuer or such Lender, then the amount of interest payable to
such Agent, the L/C Issuer or such Lender in respect of such subsequent interest
computation period shall continue to be computed at the Highest Lawful Rate
applicable to such Agent, the L/C Issuer or such Lender until the total amount
of interest payable to such Agent, the L/C Issuer or such Lender shall equal the
total amount of interest which would have been payable to such Agent, the L/C
Issuer or such Lender if the total amount of interest had been computed without
giving effect to this Section 12.19.

                                     -126-
<PAGE>
          For purposes of this Section 12.19, the term "applicable law" shall
mean that law in effect from time to time and applicable to the loan transaction
between the Borrowers, on the one hand, and the Agents, the L/C Issuer and the
Lenders, on the other, that lawfully permits the charging and collection of the
highest permissible, lawful non-usurious rate of interest on such loan
transaction and this Agreement, including laws of the State of New York and, to
the extent controlling, laws of the United States of America.

          The right to accelerate the maturity of the Obligations does not
include the right to accelerate any interest that has not accrued as of the date
of acceleration.

          Section 12.20 Confidentiality. Each Agent and each Lender agrees (on
behalf of itself and each of its affiliates, directors, officers, employees and
representatives) to use reasonable precautions to keep confidential, in
accordance with its customary procedures for handling confidential information
of this nature and in accordance with safe and sound practices of comparable
commercial finance companies, any non-public information supplied to it by the
Loan Parties pursuant to this Agreement or the other Loan Documents which is
identified in writing by the Loan Parties as being confidential at the time the
same is delivered to such Person (and which at the time is not, and does not
thereafter become, publicly available or available to such Person from another
source not known to be subject to a confidentiality obligation to such Person
not to disclose such information), provided that nothing herein shall limit the
disclosure of any such information (i) to the extent required by statute, rule,
regulation or judicial process, (ii) to counsel for any Agent, the L/C Issuer or
any Lender (it being understood that such Person will be informed of the
confidential nature of such information and instructed to keep it confidential),
(iii) to examiners, auditors, accountants or Securitization Parties, (iv) in
connection with any litigation to which any Agent, the L/C Issuer or any Lender
is a party or (v) to any assignee or participant (or prospective assignee or
participant) so long as such assignee or participant (or prospective assignee or
participant) first agrees, in writing, to be bound by confidentiality provisions
similar in substance to this Section 12.20. Each Agent, the L/C Issuer and each
Lender agrees that, upon receipt of a request or identification of the
requirement for disclosure pursuant to clause (iv) hereof, it will make
reasonable efforts to keep the Loan Parties informed of such request or
identification; provided that each Loan Party acknowledges that each Agent and
each Lender may make disclosure as required or requested by any Governmental
Authority having or asserting jurisdiction over such Agent, the L/C Issuer or
Lender or representative thereof and that each Agent and each Lender may be
subject to review by Securitization Parties or other regulatory agencies and may
be required to provide to, or otherwise make available for review by, the
representatives of such parties or agencies any such non-public information (it
being understood that such Person will be informed of the confidential nature of
such information and instructed to keep it confidential).

          Section 12.21 Integration. This Agreement, together with the other
Loan Documents, reflects the entire understanding of the parties with respect to
the transactions contemplated hereby and shall not be contradicted or qualified
by any other agreement, oral or written, before the date hereof.

                                     -127-
<PAGE>
          Section 12.22 USA Patriot Act Notice.

          Each Lender, the Collateral Agent (for itself and not on behalf of any
Lender) and the Administrative Agent (for itself and not on behalf of any
Lender) hereby notifies the Borrowers that pursuant to the requirements of the
USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26,
2001)), it is required to obtain, verify and record information that identifies
the Borrowers, which information includes the name and address of the Borrowers
and other information that will allow such Lender, the Collateral Agent or the
Administrative Agent, as applicable, to identify the Borrowers in accordance
therewith.

                [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

                                     -128-
<PAGE>
          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their respective officers thereunto duly authorized, as of the
date first above written.

                                    BORROWERS:

                                    AAIPHARMA INC., as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Ludo J. Reynders
                                        ----------------------------------------
                                    Name: Ludo J. Reynders
                                    Title: President and Chief Executive Officer

                                    APPLIED ANALYTICAL INDUSTRIES LEARNING
                                    CENTER, INC., as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAI TECHNOLOGIES, INC., as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAI PROPERTIES, INC., as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAI JAPAN, INC., as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                      S-1
<PAGE>
                                    KANSAS CITY ANALYTICAL SERVICES, INC.,
                                    as a debtor and a debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAI DEVELOPMENT SERVICES, INC., as a debtor
                                    and a debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAIPHARMA LLC, as a debtor and a
                                    debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                    AAI DEVELOPMENT SERVICES, INC., as a debtor
                                    and a debtor-in-possession

                                    By: /s/ Gregory S. Bentley
                                        ----------------------------------------
                                    Name: Gregory S. Bentley
                                    Title: Vice President

                                      S-2
<PAGE>
                                    COLLATERAL AGENT:

                                    SILVER POINT FINANCE, LLC,
                                    as Collateral Agent

                                    By: /s/ Frederick H. Fogel
                                        ----------------------------------------
                                    Name: Frederick H. Fogel
                                          --------------------------------------
                                    Title: Authorized Signatory
                                           -------------------------------------

                                    ADMINISTRATIVE AGENT:

                                    BANK OF AMERICA, N.A.,
                                    as Administrative Agent

                                    By: /s/ Annie Cuenco
                                        ----------------------------------------
                                    Name: Annie Cuenco
                                          --------------------------------------
                                    Title: Assistant Vice President
                                           -------------------------------------

                                      S-3
<PAGE>
                                    LENDERS:

                                    BANK OF AMERICA, N.A.,
                                    as L/C Issuer

                                    By: /s/ Timothy L. Ison
                                        ----------------------------------------
                                    Name: Timothy L. Ison
                                          --------------------------------------
                                    Title: Vice President
                                           -------------------------------------

                                    BANK OF AMERICA, N.A.,
                                    as a Lender

                                    By: /s/ Jonathan M. Barnes
                                        ----------------------------------------
                                    Name: Jonathan M. Barnes
                                          --------------------------------------
                                    Title: Associate
                                           -------------------------------------

                                    SEA PINES FUNDING LLC,
                                    as a Lender

                                    By: /s/ Meredith J. Koslick
                                        ----------------------------------------
                                    Name: Meredith J. Koslick
                                          --------------------------------------
                                    Title: Assistant Vice President
                                           -------------------------------------

                                    TRS THEBE LLC,
                                    as a Lender

                                    By: /s/ Alice L. Wagner
                                        ----------------------------------------
                                    Name: Alice L. Wagner
                                          --------------------------------------
                                    Title: Vice President
                                           -------------------------------------

                                    SIL LOAN FUNDING LLC,
                                    as a Lender

                                    By: /s/ Jennifer M. Parker
                                        ----------------------------------------
                                    Name: Jennifer M. Parker
                                          --------------------------------------
                                    Title: Attorney in Fact
                                           -------------------------------------

                                      S-4
<PAGE>
                                    SPCP GROUP LLC,
                                    as a Lender

                                    By: /s/ Frederick H. Fogel
                                        ----------------------------------------
                                    Name: Frederick H. Fogel
                                          --------------------------------------
                                    Title: Authorized Signatory
                                           -------------------------------------

                                    SPF CDO I, LLC,
                                    as a Lender

                                    By: /s/ Frederick H. Fogel
                                        ----------------------------------------
                                    Name: Frederick H. Fogel
                                          --------------------------------------
                                    Title: Authorized Signatory
                                           -------------------------------------

                                    GOLDMAN SACHS CREDIT PARTNERS L.P.,
                                    as a Lender

                                    By: /s/ Mark DeNotale
                                        ----------------------------------------
                                    Name: Mark DeNotale
                                          --------------------------------------
                                    Title: Authorized Signatory
                                           -------------------------------------

                                      S-5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]